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Abstract 
Prolonged therapy required to effectively treat mycobacterial infection frequently results in 
severe dose-limiting side-effects and drug resistance due to patient non-compliance with 
protracted dosage regimens. Biodegradable poly-a-hydroxy acid microspheres and 
microcapsules containing rifampicin (RIF) and isoniazid (INH) respectively have been 
prepared with the intention of providing high sustained site-specific concentrations to 
overcome some of the shortcomings of existing oral treatments. Due to the high dose, 
hydrophilicity and instability of both drugs, formulation strategies to attain high drug 
loading and methodologies to characterize in vitro drug release during ongoing 
decomposition were required. Stability indicating HPLC assays to quantify drug release 
have been developed, validated and applied to monitor drug release based on cumulative 
quantification of drug and degradates. A mathematical correction for serial 
decompositions associated with RIF was made based on the terminal pseudo equilibrium 
observed during stability studies. An isocratic HPLC assay was prospectively developed 
for the quantification of both drugs and their major metabolites in biological samples. 
Further preformulation studies confirmed the absence of significant polymorphs for both 
drugs when recrystallized from solvents later used in formulation development. 
Furthermore, thermal analysis revealed only modest interaction between the drugs and 
Resomer®. The high and moderate water solubilities of INH (145 mgmL-1) and RIF (1 
mgmL-1) determined the selection of spray-drying (SD) and emulsion solvent evaporation 
(ESE) for RIF, whereas preparation of INH microcapsules relied solely on the former 
technique. Examination of the effects of varying RIF: polymer ratio, phase volumes and 
continuum presaturation with selected poly(L-lactide) and poly(D, L-lactide-co-glycolide) 
(PDLGA) Resomer® identified optimum conditions to maximize drug loading during a 
comparison of aqueous ESE with spray-drying with a range of nine further amorphous 
Resomer® polymers. Although yields were generally higher with ESE (85-90 %), SD (45- 
75 %) was considered a superior preparation technique on the basis of the rapid 
production of microspheres of high and predictable drug loading (100 % of that 
attempted), with monodisperse granulometry and superior morphology. Release profiles 
were typically asymptotic characterized by a rapid `burst' of release followed by a slow 
release of residual entrapped RIF, irrespective of the preparative technique or polymer 
used. Poor yields (7.2 %) when SD low molecular weight (MW) PDLGA (8 kD) were 
greatly enhanced (74.8 %) by reduction in drying temperature and substitution of 
chloroform: dichloromethane (CFM: DCM) (1: 1) cosolvent with DCM. These conditions 
were adopted as the optimum parameters for further studies of blends of low (2 kD, 
R104) and moderate (11 kD, R202H) MW poly(D, L-lactide) (PDLLA); materials which 
demonstrated excellent sprayability and dramatically modulated the release of drug when 
combined compared to their use alone. Drug release showed a remarkable dependence 
on blend, dramatic acceleration being observed between 44 and 48 %w/w R104. Release 
over this range showed a marked dependence on medium temperature and led to the 
proposal of an autohydration mechanism linked to the hydrophilicity and glass transition 
(T9) of the blend which accounted for the sigmoidal profiles observed. First order 
dependence of release allowed calculation of Arrhenius derived activation energies of 
drug release in glassy anhydrous and rubbery plastic matrices of 630 and 320 J mol-1. 
Hydration and thermal studies supported the postulated diffusion mechanism, whereas 
granulometric and morphological examinations demonstrated that erosion did not 
contribute significantly. The criticality of matrix composition was further highlighted when 
interchange with nominally identical polymer, R202H, shifted the critical composition to 30 
%w/w R104. Moreover, this observation contested the batch-to-batch reproducibility of 
commercial polymer. Substitution of DCM with halothane (HAL) and acetone (ACT) had a 
profound influence on the properties of compositionally identical ('R104: R202'H, 30: 70) 
microspheres, particularly release kinetics. This was attributed to the more rapid drying 
kinetics with the poor solvent, ACT, and the generation of a porous matrix. Consequently, 
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drug was largely released during the 'burst' phase. Superior solvents, HAL and DCM 
resulted in enhanced matrix coherence at the expense of considerable residual solvent 
burdens (6 - 12.5 %), which allowed extensive matrix relaxation as solvent was lost with 
first order kinetics. This ageing process was followed by the development of an 
endotherm associated with the Tg as the matrix stabilized with a resultant increase in the 
induction period and a general retardation of drug release. Extension of the concept of 
blending R104 as release 'initiator' to a range of MW PDLGA of 50: 50 and 75: 25 
comonomer ratio as release 'modulator' was of limited success generating release 
profiles reminiscent of each polymer when used alone. The magnitude of the 'burst' 
correlated to the precipitation kinetics of the predominant complementary PDLGA 
polymer as determined by cloud-point titration. Due to the more hydrophilic nature of the 
copolymers, at the critical concentration uncontrolled hydration resulted in a single rapid 
release phase. Spray-dried biodegradable INH microcapsules were prepared by a two 
stage process whereby SD cores of drug or in combination with biodegradable albumin or 
casein were subsequently coated with PDLGA by SD. The highly crystalline, aggregated 
and irregular morphology of SD drug resulted in poor coating efficiency and a rapid 
release of encapsulated drug. Protein microspheres of superior sphericity allowed more 
effective coating and hence slower INH release. It is concluded that SD has excellent 
industrial potential for the preparation of biodegradable poly-a-hydroxy acid microspheres 
for high dose drugs to be delivered directly to their site of action, e. g., intra-pulmonary. 
Indeed, the granulometry of these particles and, in particular, the hydrophilic character of 
blends of PDLLA described have considerable potential for the sustained delivery of 
drugs in the low volumes of fluid that prevails in the lung. These formulations might offset 
some of the limitations of current oral antimycobacterial therapy. 
Abstract 
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1. Introduction 
Earliest examples of polymers for parenteral administration included silicone rubber and 
polyethylene. The major disadvantage of these inert polymers implants was their non- 
biodegradability, which necessitated surgical removal of the implants after drug 
exhaustion (Jalil & Nixon, 1990f). The development of biodegradable polymers was 
initially heralded as a major. advance in medicine due to their potential as bioerodible and 
biocompatible sutures, the removal of which would no longer require surgery (Lewis, 
1990). Biodegradable polymers may be defined as synthetic or natural polymers which 
degrade in vivo either enzymatically or non-enzymatically to produce biocompatible or 
non-toxic by-products, which themselves can be eliminated via normal physiological 
processes (Jalil & Nixon, 1990f). Since their inception, biodegradable materials have 
found use in dentistry and orthopaedics (Wood, 1980), but have been more extensively 
investigated as pharmaceutical excipients in the field of drug delivery (Lewis, 1990; 
Brannon-Peppas, 1995). A plethora of natural (Magee et al., 1993) and synthetic 
polymers (Whateley, 1992) to achieve prolonged or site-specific delivery of drugs have 
been reported. However, the thermoplastic (co)polymers based on lactic (PLA) and 
glycolic acid (PGA) are the most extensively employed: poly(L-lactic acid) (PLLA), 
poly(DL-iactic acid) (PDLLA) and poly(DL-lactic-co-glycolic acid) (PDLGA) being 
representative examples. Notwithstanding their biocompatibility and biodegradability, their 
utility is derived from the versatility and their popularity from their approval for use in 
formulation by the Food and Drug Administration of the USA (Tice & Cowsar, 1984). Their 
commercial availability further accounts for the proliferation of published work in the last 
decade describing their use in drug delivery systems (DDS). 
1.1 Poly-a-hydroxy acids 
1.1.1 Synthesis 
The low molecular weight (MW) products of direct condensation of poly-a-hydroxy acid 
monomers were traditionally considered unsuitable for biomedical application because of 
their poor mechanical strength and rapid degradation (Wu, 1995). MW of 10 kD have 
been reported for PDLGA with the use of antimony oxide and temperatures of 120 °C, 
whereas efficient removal of water is the rate-limiting step at higher temperatures 
required for the reaction in the absence of catalyst. Because of these practical difficulties, 
intermediate to high MW homo- and copolymers of lactic acid and glycolic acid - 
chemical structures of which are shown in Figure 1.1 -are synthesized by ring-opening 
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melt condensation of the cyclic dimers, dilactide and diglycolide. The significant 
advantage of this procedure is that no dehydration step is required and that the cyclized 
monomers and linear polymer can be readily purified (Wu, 1995). Synthesis typically 
involves heating (130 - 200 °C) reactant dimers under vacuum (0.1 mmHg) in the 
presence of catalyst (and chain control agent) (Kulkarni et al., 1966,1971; Deasy et al., 
1989). Optically active PLA can be derived from L (+) and D (-) isomers of lactic acid, 
which upon polycondensation of the corresponding diester, give rise to optically active 
polymers of opposite birefringence to that of the starting isomer (Boehringer Ingleheim, 
1992). In contrast, the polymerization of optically inactive D, L-racemate yields optically 
inactive PDLLA. The potential range can be further multiplied where glycolide is 
incorporated. Furthermore, the wide range of synthetic conditions described has 
produced polymers of variable MW distribution, composition and polymeric sequencing, 
parameters shown to be sensitive to the reaction conditions (Gilding & Reed, 1979; Rak 
et al., 1985; Gohel et al., 1996). 
--H 
O 
1 11 
HO C-C-O 
H 
H 
n 
HO 
CH3 O 
1 II 
CH-C-O 
polyglycolide polylactide 
H 
n 
Figure 1.1 Chemical structures of polyglycolide and polylactide homopolymers. 
In a study of the synthesis of PLLGA and PDLGA, Gilding & Reed (1979) demonstrated 
that glycolide was preferentially incorporated at low conversions, with accelerated 
polymerization of lactide as glycolide was depleted. Consequently, block glycolide 
copolymers separated by lactide units were generated initially. Changes in the initial 
reactant monomeric ratio altered the preferential polymerisation mechanism and thus the 
polymeric product, whereby MW increased, whereas polydispersity fell, with increased 
glycolide content. Deasy et al. (1989) observed similar trends, albeit not as pronounced. 
These differences may be attributed to the different reaction temperatures in both studies, 
as glycolide incorporation is favoured at higher temperatures, whereby Deasy et al. 
(1989) used reaction temperatures 20 °C below those of Gilding & Reed (1979). Higher 
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MW polymers are generally produced at lower temperatures (Avgoustakis & Nixon, 1991) 
and with longer synthetic times (Deasy et al., 1989). Rak et al. (1985) favoured a two- 
step process of 4h at 180 °C followed by 2h at 200 °C to maximize PDLLA chain length. 
Initiation of a greater number of chain reactions was assigned to the reduction in MW 
observed as catalyst, stannous octoate, levels increased (Deasy et al., 1989). There is 
additional controversy in relation to the preferred catalyst employed. Tetraphenyl tin has 
been favoured by some on the basis of ease of handling (Kulkarni et al., 1966) and 
catalytic efficiency (Gohel et al., 1996). Schindler et al. (1977), however, favoured 
catalysts free of carbon metal bonds, such as stannous octoate or chloride. What is 
known, however, is that residual catalyst can render PDLLA biologically incompatible, 
efficient removal being a prerequisite of their biocompatibility (Asano et al., 1990) and 
long-term stability (Jamshidi et al., 1988). 
The sensitivity of final polymer characteristics, i. e., comonomer sequence, MW, 
polydispersity to the many synthetic variables has confounded interpretation and 
elucidation of the optimum conditions for their preparation. Furthermore, the fact that 
these characteristics determine material behaviour, it follows that small changes in the 
synthetic protocol can have a profound effect on the final performance of formulations on 
which they are based (Deasy et al., 1989). This situation has been alleviated in the last 
decade by the widespread commercial availability of adequately characterized 
reproducible polymers, e. g., Resomer®. Some of the pertinent characteristics for drug 
delivery of these materials are now considered. 
1.1.2 Physical, Chemical and Biological Properties 
1.1.2.1 Solubility 
Polymer solubility is a critical factor to the preparation of poly-a-hydroxy acid-based 
formulations as most manufacturing methodologies rely on solubilization and hence 
mobilization of the polymer phase in an effort to homogenize the drug throughout the 
excipient matrix. Stereochemical factors influence crystallinity, which, in turn, determines 
the solubility of poly-a-hydroxy acids in organic solvents. In general, solubility decreases 
as chain length (Jalil & Nixon, 1990b; Bodmeier et al, 1989) and glycolide content 
increases (Mehta et al., 1996). For comparable MW, PDLLA has greatest solubility in 
common organic solvents including acetone (ACT), tetrahydrofuran and most chlorinated 
solvents (Boehringer Ingelheim, 1992). PDLGA, however, has limited solubility in 
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chloroform (CFM), whereas PLLA solubilizes in chloroform, dichloromethane (DCM) and 
benzene often only after heating at 50 - 60 T. PGA solubility is limited to fluorinated 
solvents, such as hexafluoro-propan-2-ol, the prohibitive expense of which is one factor 
which has limited its investigation as a pharmaceutical excipient (Sato et at., 1988; 
Whateley, 1992). 
1.1.2.2 Crystallinity, Hydrophilicity and Thermal behaviour 
Comonomer composition and ratio, chain linearity and copolymer MW are principal 
determinants of polymer crystallinity, thermal character and water uptake, all of which are 
inextricably linked (Lewis, 1990). Hydrophilicity is the key parameter, since all 
biodegradable devices are in intimate contact with an aqueous environment and 
biodegradation occurs through hydrolysis (Wood, 1980). Therefore, any factor which 
affects water uptake will have a huge bearing on biodegradation. In addition, crystallinity 
is also critical, as it not only affects water uptake and thus biodegradation, but also drug 
diffusion, the latter occurring predominantly through the amorphous regions of the 
polymeric matrix (Peterlin, 1983). 
X-ray analysis of PLLA and PDLLA disclosed the crystalline and amorphous nature of 
these respective polymers (Kulkarni et al., 1971). Gilding & Reed (1979) studied the 
thermal behaviour of a range of homo- and copolymers. PLLA, PGA and PLLGA 
containing greater than 90 % lactide showed recrystallization exotherms, subsequent to 
glass transition (Tg), and prior to melting endotherms. X-ray analysis revealed that the 
crystalline region of PLLGA lay outwith proportions of glycolide < 25 % and > 67 %. 
Substitution with the D, L-lactide isomer extended the amorphous region for the copolymer 
from 0- 70 %. Crystallinities of homopolymers were 46 - 52 % and 37 % for PGA and 
PLLA, respectively, whilst PDLLA was amorphous. The amorphous character of the latter 
material arises through the disruptive effect of asymmetric methyl carbon on the relatively 
long and aligned stereoregular chains (Wood, 1980). Gilding & Reed, (1979) showed 
equilibrium water uptake correlated well with polymeric crystallinity, with the exception 
that PGA was more hydrophilic than PLLA, due to stereoactive methyl substituent on the 
backbone of the latter rendering the polymer hydrophobic. For copolymers, however, 
water content increased with hydrophilicity to 20 - 30 %w/w in the amorphous region, 
then fell again corresponding to the onset of crystallinity. Similar recrystallization 
behaviour of quench-cooled samples was due to a stress-relaxation phenomena (Kalb & 
Pennings, 1980). Polymer MW per se does not particularly affect the permeability of 
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polymers unless oligomers are present. In contrast, polydispersity can modify crystallinity, 
Tg and mechanical strength, and thus change degradation characteristics of a given drug 
/ polymer system (Reed & Gilding, 1981) due to preferential degradation and dissolution 
of the amorphous domains. 
The magnitude of Tg temperature also has implications for mechanical properties and 
also drug diffusivity (Pitt et al., 1979). Kalb & Pennings (1980) studied the diffusion 
parameters of a series of steroids in crystalline poly-s-caprolactone, PDLLA and 
copolymers thereof. The thousand-fold reduction in diffusivity of progesterone in PDLLA 
relative to poly-E-caprolactone was at odds with their respective polymer crystallinities. 
However, the increase in free volume, molecular mobility and hence permeability of poly- 
E-caprolactone in excess of its glass transition of -65 °C, compared with 57 °C for PDLLA 
accounted for these differences. Water frequently acts as a potent plasticizer for 
amorphous solids (Hancock & Zografi, 1994) and poly-a-hydroxy acids are no exception 
(Omelczuk & McGinity, 1992). Siemann (1985) observed approximately 12 °C reductions 
in PDLLA Tg upon hydration which the author cautioned might have a profound effect on 
thermomechanical and diffusive properties of implanted drug-polymer composites. 
Elsewhere, differential hydration behaviour of poly-a-hydroxy acids in the glassy and 
rubbery states has precluded the use of Arrhenius derived activation energies for the 
prediction of the long-term stability of these materials from data derived at elevated 
temperatures (Schellhorn & Buchholz, 1996). 
1.1.2.3 Biocompatibility 
Biocompatibility refers to the ability of a material to perform with an appropriate host 
response: histo- and pathologic damage, immunogenicity, carcinogenicity and 
thrombogenicity representing indications of lack of compatibility (Vert et al., 1992). 
Biocompatibility of excipient polymers is generally an essential prerequisite for their use in 
drug delivery applications intended for compartmental implantation. Herrman et at. (1970) 
represents one of the earliest studies of biocompatibility where PGA sutures showed a 
minimal inflammatory response, when compared with absorbable cat-gut materials. 
However, Kulkarni et al. (1971) later described a progression of cellular events 
characterized by accumulation of polymorphonuclear leukocytes; infiltration of foreign 
body giant cells, then finally, dense fibrotic tissue growth following implantation of films 
and powders of PDLLA. Yamaguchi & Anderson (1993) observed a similar mitotic 
sequence which could be correlated to the granulometry of the studied microspheres and 
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their sequential phagocytosis. This phagocytic response has been effectively suppressed 
by precoating PDLLA with hydrophilic bovine serum albumin (Tabata & Ikada, 1988). 
Moderate and comparable tissue responses following chemoembolization of PDLGA 
microspheres have been related to release of hydro-soluble oligomers, which, in turn, 
was related to polymer MW and comonomer ratio (Spienlehauer et al., 1989). 
Presence of medicament can have a variable effect on polymer-tissue response. Steroid 
incorporation was thought to pharmacologically alter the intra-articular intolerance of 
PDLLA (Ratcliffe et al., 1984). Elsewhere, encapsulation of drug loaded PDLLA 
microspheres have been shown to reduce clarithromycin-induced tissue irritation (Gupta 
et al., 1993), whereby I. M. administration of PDLLA microspheres revealed only minor 
swelling persisting for 12 - 24 h, whereas bulk drug caused dogs to limp for 2-3d. 
Visscher et al. (1988) observed a comparable tissue response following 1. M. implantation 
of PDLGA ergot and placebo microcapsules. Others workers found no destructive or 
inflammatory changes in vessel walls with PDLGA microspheres upon 
chemoembolization (Grandfils et al., 1992). Further, blank PDLGA microspheres 
implanted in rats brains were biocompatible and degraded totally within two months 
(Langer, 1991). 
There are, however, conflicting data on the biocompatibility of poly-a-hydroxy acids 
raising questions of their candidature for certain applications. Comparative studies of the 
biodegradation of crystalline PLLA and the same material processed to eliminate 
crystallinity revealed differential behaviour in vivo (Pistner et al., 1993). Crystalline 
material remained intact producing a minimal cellular response over the 116 week study 
period. In contrast, degradation of amorphous material produced surface roughening in 
the first week, which evolved to sizeable lacunae after 50 weeks. Thereafter, connective 
tissue deformed the remaining mass. Elsewhere, poly-a-hydroxy acids have induced 
intra-articular (Ratcliffe et al., 1984) and acute pulmonary inflammatory reactions 
(Armstrong et al., 1991; 1992; 1996). In the latter studies, significant incidence of 
haemorrhage and neutrophil proliferation in groups treated with blank and fluorescein 
microspheres, compared with saline control, indicated pulmonary 
incompatibility of poly- 
lactic acid. However, intra-pulmonary steroid delivery has been cited as the 
therapeutic 
basis for preparation of PDLLA-hydrocortisone microspheres (Giunchedi et al., 
1995). 
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1.1.2.4 Biodegradability 
1.1.2.4.1 Polymer factors 
In general chemical terms, degradation occurs via random hydrolytic cleavage of 
accessible ester bonds, and subsequent solubilization of oligomeric fractions below a 
critical level (15 kD) with accompanied weight loss (Schindler et al., 1977; Wang et al., 
1990; Shah et al., 1992); so-called homogeneous degradation. Mechanisms of 
degradation have evolved and been refined. Chu & Campbell (1982) suggested a 
mechanism initiated on the surface, growing inwards based on the appearance of surface 
cracks on polyglycolic acid sutures. However, the model of Heller (1980) supported the 
bulk mechanism, whereby hydrolysis proceeded uniformly throughout the polymer mass, 
and was for some time universally accepted. 
Early investigations of the dependence of degradation rate on monomeric ratio 
erroneously attributed variations in relative rates to selective metabolic pathways of PLA 
and PGA (Miller et al., 1977). The significance of crystallinity through its dependence on 
copolymer ratio upon polymer degradation rate was recognized by Reed & Gilding 
(1981). Thus, a two-stage mechanism of semi-crystalline polymer degradation has been 
proposed by Chu (1985); initiated in the amorphous regions whilst terminating in adjoining 
crystalline domains. Freed from restricted motion, accelerated degradation of previously 
less dense crystalline regions occurred subsequent to preferential degradation of 
accessible amorphous zones. Preferential hydrolytic attack of glycolide bonds has 
resulted in analogous crystallization of lactide enriched zones (Li et al., 1990). Thus, 
variation in comonomer ratio, and, an attendant change in crystallinity and hydrophilicity, 
modulates the contribution of each stage to polymer degradation and thus modifies the 
composite rate and pattern of degradation. The relationship between copolymer 
composition and degradation of Miller et al. (1977), mirrored that of composition and 
crystallinity of Gilding & Reed (1979). These features confer considerable versatility on 
PDLGA as a material of variable degradation and thus release character in the design of 
delivery systems. Asano et al. (1990) stated that crystallinity, biodegradability and 
hydrophilicity of the copolymer can be freely controlled by altering monomeric co-ratio. In 
the same study, optimal biodegradability in the amorphous region occurred at a 
copolymer ratio of 70 % glycolic acid, in accord with the maximal hydrophilicity observed 
by Gilding & Reed (1979). 
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A further geometry-dependent heterogeneous mechanism has recently gained popularity, 
whereby entrapped oligomeric fractions promotes internal acidosis and autocatalytic 
degradation (Vert, et al., 1991; Witschi & Doelker, 1998), but in a size dependent manner 
(Flandroy et al., 1997). This mechanism has a particularly pronounced effect on 
degradation where a fraction of oligomers have been purposely incorporated (Park, 1994; 
Reich & Bernickel, 1998). 
Within a polymer class, MW is another factor available to modulate degradation and 
release character. Degradation increases due to the higher content of autocatalytic 
COOH end-groups as MW decreases. Asano et al. (1989) observed the time for 100 % in 
vivo degradation of PDLGA (70: 30) acid increased linearly with number average MW 
(Mn). Total degradation times of 10 weeks and 20 weeks were observed for copolymers 
of Mn = 1.6 and 3.3 kD respectively. Further examination of poly-D, L-lactic acid and poly- 
D, L-lactide in the Mn range 1.4 to 16.9 kD revealed two in vivo degradation patterns for 
these amorphous polymers. Below Mn 1.6 kD, a parabolic degradation profile emerged, 
characterized by a rapid degradation. Those above 2 kD, in contrast, exhibited an 
sigmoidal profile consequent of an initial lag phase before the onset of the acceleratory 
and terminal phases. During this lag period, water uptake and hydrophilicity concomitantly 
increase as the polymer fragmented, exposing alkoxylic and carboxylic groups (Hutchison 
& Furr, 1990). The duration of the lag or induction period was proportional to Mn above 
the critical level. Schindler et al. (1977) identified a threshold intrinsic viscosity of 0.5 dL g- 
1 for PDLLA, corresponding to a MW of 15 kD, below which dramatic weight loss 
occurred. Copolymer degradation has also been correlated with Tg (Avgoustakis & Nixon 
(1991), whereby the latter increased in parallel with MW and lactide content (Jamshidi et 
al., 1988). 
1.1.2.4.2 Environmental factors 
Since biodegradable systems are intended for use in physiological systems, a number of 
studies have examined the effect of biochemical factors on polymer degradation, i. e., pH, 
ionic strength, enzymatic activity of the degradation environment. The effects of pH and 
ionic strength have been extensively examined by Makino et al. (1985; 1986a, b). The 
rate of hydrolytic deesterification and polymer mass loss was most rapid at pH 9.6 and 
slowest at pH 5.0 (Makino et al., 1986a). The effect of pH appeared to change the 
mechanism of degradation based on polydispersity and lactic acid generation 
measurements (Makino et at., 1986b). At high pH, random chain scission was apparent, 
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in contrast to an `unzipping' mechanism at lower pH values (Makino et al., 1985). In 
contrast, Belbella et al. (1996) have proposed a random scission at low pH and 
sequential cleavage from the chain ends in alkaline medium. The complex effect of pH 
and rejection of the simple acid-base hydrolysis mechanism was first identified by Chu 
and coworkers. Chu (1981 a) observed a 20% retention of PGA suture strength after 21 d 
at pH 5.25 and 7.44, whereas no traces of sutures were evident at pH 10.09 after the 
same time. The variation in degradation rate was explained on the basis of the `cage- 
effect', a process, specific to low pH, where reactive species can recombine following 
acid hydrolysis. Removal of the acidic products of polymer degradation by disodium 
hydrogen orthophosphate and a potential catalytic effect of buffer salts explained the 
increased degradation rate in buffered media (Chu, 1981b). Degradate removal by buffer 
salts was the proposed mechanism by which increases in buffer concentration caused 
parallel increases in degradation rate (Makino et al., 1986a) of PLLA microcapsules. 
Conflicting behaviour is probably a consequence of complex anionic and cationic specific 
catalytic effects reported recently for PDLLA/PDLGA films (Reich & Bernickel, 1998). 
1.1.2.4.3 Physiological factors 
Brady et al. (1973) demonstrated the bioresorptivity of 14C-labelled PDLLA implanted 
blocks. They found 36.8 % of original radioactivity was lost from the implant after 168 d. 
However, only 7.7 % of the cumulative loss could be reconciled as radioactivity in faeces, 
urine and tissues, that unaccounted fraction being lost as expired C02- 
The role of enzymes in poly-a-hydroxy acid degradation is unclear. Herrman et al. (1970) 
suggested an enzymatic contribution in favour of the phagocytic mechanism to the 
resorption of PGA acid sutures. However, phagocytosis contributes significantly to 
microsphere resorption of diameter <2 . tm (Tabata & lkada, 1988). Under non- 
standardized conditions, Williams & Mort (1977) observed selective activity of a series of 
15 enzymes on PGA sutures. Differences were probably a reflection of the substrate 
specificity of enzymes studied. Makino et al. (1985) demonstrated increased levels of 
carboxylic esterase increased degradation of PDLLA due to an effect confined initially to 
the material surface. The coherence of surface was considered to restrict the penetration 
of the large enzyme (96 kD). According to Splenlehauer et al. 
(1989) in vivo 
administration of poly-a-hydroxy acids accelerated their degradation 
by a factor of two, 
highlighting the failure of in vitro studies to mimic the biological conditions. 
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1.2 Drug delivery systems based on poly-a-hydroxy acids 
The potential to readily alter polymer physicochemistry confers significant versatility on 
the poly-a-hydroxy acids. This is best highlighted by the volume of articles which describe 
the preparation and characterization of biodegradable delivery systems of a multitude of 
designs: implants (Yolles et al, 1975; Wise et al., 1978; Phillips & Gresser, 1984; 
Bodmeier & Chen, 1988; Scmitt et at., 1993; Deasy et al., 1993; Kader & Jalil, 1998a, b); 
fibres (Eenink et al., 1987); microparticles (Smith & Hunneyball, 1986); nanoparticles (Le 
Ray et al., 1994; Belbella at el., 1996); beads (Schwope et al., 1975); pellets (Bodmeier & 
Chen, 1989); rods (Wise et al., 1976); and, the most extensively examined, 
microspheres. The diversity of reported microencapsulation techniques is further 
testament to their versatility, allowing the formulator considerable flexibility in the design 
and fabrication of these systems. A suitable technique must achieve suitable drug 
loading, drug stability and release kinetics (Iwata & McGinity, 1992), the selection of 
which, will principally depend on the solubility of the polymer and drug to be incorporated 
(Jalil & Nixon, 1990f), the intended use and duration of therapy (Lewis, 1990). Although, 
emulsion solvent extraction (Sato et al., 1988; Arshady, 1991; Pavanetto et al., 1992); 
phase separation (Vidmar et al., 1984,1985; Ruiz et al., 1989; Owusu-Ababio & Rogers, 
1996); solvent partition (Leelarasamee et al., 1986; 1988a, b); interfacial deposition 
(Makino et al., 1985); and, in situ polymerization (Speiser & Hijsnsbroek, 1979) have 
been reported, microencapsulation based on solvent evaporation has been the most 
comprehensively examined, i. e., emulsion-solvent-evaporation (ESE) and spray-drying. 
1.2.1 Emulsion-solvent-evaporation 
In general terms, microsphere preparation by the ESE process involves three stages. The 
drug to be encapsulated is dissolved (or dispersed) in a suitable water-immiscible and 
volatile organic solvent. This solution (or suspension) is then dispersed in a hydrophilic 
phase containing emulsifier or viscosity enhancer to form stable microdroplets. 
Microsphere formation is induced by solvent evaporation by application of heat and/or 
vacuum which causes a phase separation process in which the polymer solution is 
converted into precipitated, solid microspheres (Grandfils et al., 1992). Although 
conceptually simple, the final physical characteristics of the product are a complex 
interplay between the disperse phase (i. e. drug, polymer and solvent), emulsifier, 
continuum and process specific factors (Watts et al., 1990). A multitude of configurations 
have been described, modifications often being made to compensate for unfavourable 
drug physicochemistry and thus to maximize loading efficiency. 
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1.2.1.1 Disperse phase 
1.2.1.1.1 Drug 
Using aqueous emulsion techniques, high encapsulation efficiencies can only be attained 
if 1) the drug is successfully retained within the polymeric matrix or 2), partitioning of the 
drug from the disperse phase is suppressed. Drug physicochemistry and drug loading, 
which themselves are inextricably linked, have a dramatic influence on the characteristics 
of the microspheres thus formed. Therefore, aqueous emulsification procedures are more 
amenable to drugs with low aqueous solubility. Fong et al. (1986) cited a solubility 
criterion of <_ 0.023 gL-1 for efficient encapsulation. Accordingly, nifedipine, which 
complies with this solubility specification (0.010 gL-1), gave encapsulation efficiencies of 
80 - 100 % within the attempted range of 23 - 7.4 %w/w, respectively (Sansdrap & Möes, 
1993). Conversely, water soluble drugs such as theophylline, salicylic acid and caffeine 
could not be entrapped due to complete migration into the aqueous phase (Bodmeier & 
McGinity, 1987c), whereas highly efficient encapsulation of lipophilic steroids (Beck et al., 
1979; Zhifang et al., 1993), diazepam (Bodmeier & McGinity, 1987c), and hydrocortisone 
(Cavalier et al., 1986) have been described. In relation to solubility, incorporation 
efficiencies of a series of bases have been shown to be directly related to their octanol- 
water partition coefficients (Cha & Pitt, 1989). The relative coincidence of the values for 
thioridazine of 82 % (Maulding et at., 1987) and 88.8 % (Fong et at., 1986) prepared 
according to different protocols, highlights the relative insignificance of processing 
parameters, and, the criticality of inherent drug properties to successful drug entrapment 
at the extremes of aqueous solubility. 
Efficiency of encapsulation has repeatedly been shown to be a function of attempted 
loading, the former generally decreasing as the latter increases (Splen'lehauer et al., 
1988; Polard et al., 1996; Celebi et al., 1996). This trend is theoretically reversed in the 
situation where sufficient drug transfer from the internal phase to attain saturation 
solubility of a poorly soluble drug in the continuum occurs. Here a lower mass of drug 
dispersed should result in reduced encapsulation efficiency, and vice versa. In support of 
this, Jalil & Nixon (1990d, e) found encapsulation efficiencies in PDLLA of 90.9 % and 
72.6 % when attempting core loadings of 66.6 %w/w and 20 %w/w, respectively. 
Comparable observations were made by others (Cavalier et al., 1986; Ramtoola et al., 
1991). Parabolic dependence of encapsulation efficiency has been reported for cisplatin 
(Splenlehauer et al., 1986a) and nifedipine (Sandrap & Möes, 1993), presumably due to 
continuum saturation being attained at intermediate attempted loadings. 
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1.2.1.1.2 Solvent 
For efficient drug encapsulation the ideal characteristics of the polymer solvent include an 
ability to dissolve both drug and polymer; immiscibility with the continuum; lower boiling 
point than the continuum and low toxicity (Watts et al., 1990). Bodmeier & McGinity 
(1986; 1988b) in studies evaluating solvent selection, identified that a degree of water 
miscibility was required to ensure the preparation of smooth spherical spheres. The 
water-immiscible solvent-, DCM, which also possesses measurable water solubility, 
achieved highest drug loading at 23 %w/w of an attempted 30 %w/w. However, CFM, 
which has a water solubility of 0.8 %w/w, and benzene, produced microspheres of 
minimal quinidine sulphate content. The authors also reported that ACT and 
dimethysulphoxide when used alone did not emulsify but produced large polymer 
agglomerates. However, inclusion of 30 %v/v ACT in DCM did form discrete 
microspheres (Bodmeier & McGinity, 1988a), of improved loading. These observations 
were explained on the basis of diffusion of solvent from the disperse phase and 
subsequent evaporation at the air/water interface (Bodmeier & McGinity, 1988b). An 
optimum rate of evaporation, and thus co-solvent ratio should theoretically exist for every 
ESE procedure. The optimum should induce phase separation rapidly, but in a controlled 
manner to achieve satisfactory densification and avoid interfacial perturbation leading to 
agglomerates. 
Chlorinated solvents are generally considered hazardous to the environment and 
undesirable for manufacturing processes. Accordingly, their complete substitution for 
methyl (Wakiyama et al., 1981) and ethyl acetate (Wakiyama et al., 1981; Chern et al., 
1996) and methyl ethyl ketone (MEK) (Sah et al., 1995) or partial substitution with water 
miscible ACT (Grandfils et al., 1992; Cowsar, 1985; Coombes et al., 1994) and methanol 
(Polard et al., 1996) has been described on both toxicological and technological grounds. 
Conversely, Splenlehauer et al. (1986b) included water-immiscible cyclohexane to reduce 
solvent residue. This was ascribed to increased porosity due to the sequential 
evaporation of DCM followed by the pockets of cyclohexane. Others have incubated 
microspheres in a polymer non-solvent, heptane, to extract residual DCM (Leelarasamee 
et al., 1988b). 
1.2.1.1.3 Polymer 
The granulometric, yield, loading and morphological characteristics can all be affected by 
the MW of the polymer (Jalil & Nixon, 1990b, c); its stereochemistry and concentration; 
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disperse volume; as well as core drug characteristics. Dispersion of greater volumes of a 
fixed disperse composition dramatically decreased quinidine sulphate content (Bodmeier 
& McGinity, 1986). Continuum-solvent saturation and thus reduced rates of polymer 
precipitation which promoted drug diffusion outwards, explained this trend. Optimal 
disperse viscosities corresponding to 7.16 %w/w, that inhibited internal crystal movement 
and therefore maintained spherical integrity and drug payload, were identified for cisplatin 
microspheres (Splenlehauer et al., 1986b). In the same study, microsphere size and size 
distribution increased in line with disperse viscosity. In contrast, successful microsphere 
formation was reported from a homogenous solution in the range 1.7 to 10 %w/v polymer, 
where a linear inverse dependence of mean diameter on disperse volume in the range 20 
to 60 mL was observed (Sansdrap & Wes, 1993). However, the report contained no 
process yield or morphological data on the particles thus formed. Grandfils et al. (1992) 
concluded that disperse phase modification was the best parameter to achieve 
chemobolic particles with a narrow size range and perfect sphericity. 
Microsphere properties are more dependent on polymer stereochemistry than MW. 
Morphology, density and phenobarbitone content of PDLLA microspheres were 
independent of polymer MW, although mean diameter increased within the range 5.2 to 
20.5 kD (Jalll & Nixon, 1990d). Despite viscosity differences, the amorphous character of 
this polymer group efficiently encapsulated phenobarbitone crystals, inhibiting crystal 
diffusion, and thus accounted for comparable polymer performance. In contrast, PLLA of 
61.3 and 43.2 kD produced large porous particles, porosity and size increasing with 
respect to MW and core loading. Conversely, low MW PLLA (2.4 kD) polymers yielded 
microspheres with uniform, smooth morphology when prepared at low drug content. 
Increasing core loading met with surface deterioration, porosity and a greater propensity 
to aggregate. Particle size showed a complex parabolic behaviour with respect to core 
loading reaching a minimum at a drug: polymer (D: P) ratio of unity (Jalil & Nixon, 1990b). 
These observations were assigned to faster polymer deposition as polymer solubility 
decreased in the disperse with increases in MW and crystallinity. 
1.2.1.2 Emulsifier 
Judicious selection of aqueous emulsifier should produce a stable emulsion which upon 
solvent evaporation yields small, uniform and discrete particles which deaggregate with 
minimal agitation (Arshady, 1991). Hydrophilic colloids are most frequently employed 
such as gelatin (Wakiyama et al., 1981; 1982a, b); polyvinyl alcohol (PVA) (Zhifang et 
Introduction 13 
Development and characterization of biodegradable microspheres containing selected antimycobacterials David F. Bain 
al., 1993; Le Corre et al., 1994b; Sah et at., 1995; Chern et al., 1996); and, 
methylcellulose (Benita et al., 1984; Cavalier et al., 1986; Maulding et al., 1987). PVA is 
most frequently used, generally alone (Beck et al., 1979; Maulding et at., 1986), or, 
alternatively, with viscosity enhancers, e. g., methylcellulose (Splenlehauer et at., 1986a, 
Bissery et al., 1984). Others have used anionic surfactants, e. g., sodium lauryl sulphate 
(Suzuki & Price, 1985); polyoxyethylene sorbitan mono-oleate (Bodmeier & McGinity, 
1986); sodium oleate (Fong et al., 1986) and hydroxymethylcellulose (Sansdrap & Wes, 
1993). Bodmeier & McGinity (1987b) have, however, prepared satisfactory yields of 
microspheres at pH 12 without emulsifier. The authors considered electrostatic repulsion 
of deprotonated polymer COO- end-groups at high pH maintained emulsion stability. 
The choice of emulsifying agent has a significant influence on particle size of 
microspheres. Microsphere aggregation may be avoided by increasing the viscosity grade 
of PVA used (Splenlehauer et al., 1986a). This effect was considered to be due to the 
longer polymeric chains of a higher grade emulsifying agent, and enhanced steric 
repulsion of droplets within the more viscous aqueous phase. Successful preparation of 
microspheres using PVA at concentrations as low as 0.01 % (Le Corre et al., 1994b) and 
at levels as high as 10 % (Boisdron-Celle et al., 1995) can be found. These low levels 
were presumably sufficient because disperse phase volume was small, i. e., 5 mL. Benita 
et al. (1984), found that microsphere size increased as the PVA concentration increased 
due to an increase in the viscosity of the aqueous phase in the range 0.27 to 5.0 %w/v, 
while further increases from 5- 10 % have been shown to reduce particle size from 100 
to 20 µm by others (Boisdron-Celle et al., 1995). However, other workers found no 
correlation of PVA concentration with particle size between the range 0.5 and 0.1 %w/v 
(Celebi et al., 1996). The variety of results reported are a result of the non-standardized 
conditions under which these observations were made. Singh et al. (1996) have 
demonstrated that compliance of residual PVA limits is best achieved by using minimal 
volumes and concentrations of emulsifier during preparation, which, in turn, minimizes the 
need for tedious successive microsphere washings. 
Production of large coarse particles indicated emulsion instability using 1 %w/v gelatin 
solution due to viscosity limitations (Wakiyama et al., 1981) which were eliminated at 2 
%. 
Inclusion of dibasic sodium phosphate further disrupted the viscosity of 1% gelatin 
producing a blend of spherical and non-spherical particles. The inclusion of 
baffles in the 
emulsion vessel can significantly alter fluid dynamics resulting in reduced microsphere 
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particle diameter (Crossan & Whateley, 1994), polydispersity and increased yield 
(Bodmeier & McGinity, 1987a). 
Emulsifier has been identified as the cause of crystal deposition at the microsphere- 
continuum interface. Consequently, interrupted solvent evaporation strategies have been 
developed, in which the original continuum is replaced in-process with emulsifier-free 
medium (Beck et al., 1979; Benita et al., 1984). Benita et al. (1984) considered an 
optimum time for continuum exchange existed, before which, immature particles could 
agglomerate due to matrix plasticity conferred by residual solvent. Bissery et al. (1984) 
used a two-stage protocol whereby initial emulsification was performed in 0.25 %w/v 
PVA, followed by dilution in 1 %w/v methylcelIulose. Aggregation noted was probably 
consequent of the low polymer (2 %w/v) and primary emulsifier concentrations. 
1.2.1.3 Continuum 
Strategies intended to minimize drug partitioning from microdroplets during hardening 
have comprised continuum modification in terms of volume (Sansdrap & Möes, 1993), pH 
(Bodmeier & McGinity, 1987a, b) and composition (Jalil & Nixon, 1989; 1990a-h). Such 
modifications are not always, however, without detriment to other microsphere 
characteristics. 
Continuum volume affects the rate and extent of disperse solvent partitioning which was 
identified by Bodmeier & McGinity (1986) as a critical determinant of drug loading 
efficiency. Increasing the volume of continuum from 1.0 to 1.8 L resulted in a increased 
quinidine loading in the range 18.9 to 25.0 %w/w. Owing to the small disperse: continuum 
phase ratio, solvent extraction, not evaporation was the predominant phase separation 
mechanism. Larger continuum volumes, however, were also associated with an increase 
in particle size which has been shown also to increase drug loading (Zhifang et al., 1993; 
Sanchez et al., 1993; Boisdron-Celle et al., 1995). On the contrary, insignificant 
granulometric changes were evident elsewhere upon a five-fold increase in continuum 
volume (Sansdrap & Möes, 1993). 
Bodmeier & McGinity (1987a, b) showed pH manipulation of the continuum to high values, 
suppressed ionization of the base quinidine sulphate, thus minimizing drug partition from 
the dispersed droplets. For an attempted drug loading of 30 %w/w, negligible drug levels 
were attained at acidic pH, whereas 23.6 %w/w loading was observed at pH 
13. Surface 
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layer peeling and the exposure of a porous substructure occurred at extreme pH, but 
were absent at pH < 10, with minimal effect on drug loading. Higher osmotic pressures 
generated by quinidine sulphate, which promoted surface degradation, explained the 
superior morphology seen with microspheres prepared with free base. In a further study 
(Bodmeier & McGinity, 1987b), rapid pH change between 12 and 7 (and vice versa) had 
no effect on drug loading beyond two minutes. This time was considered optimal, allowing 
the use of short exposure times thus protecting the polymer coat without compromising 
loading. The authors postulated that sufficient solvent rapidly diffused into the large 
continuum volume (1.4 L) creating a coherent membrane, thus hindering further drug 
partitioning. In the same report, a `partition method' was devised, whereby saturated 
solutions of quinidine sulphate at pH 8 (high drug solubility) were prepared, into which 
drug free polymeric solutions were dispersed. A linear relationship between the quantity 
of drug dissolved and final loading was observed. These observations verified the ideas 
of rapid solvent-drug exchange and that ultimate loading was a function of the total drug 
in the system. Comparable improvements in microsphere loading of morphine (Polard et 
al., 1996) and local anaesthetic (Wakiyama et al., 1981; Le Corre et al., 1994b) have 
been attained on the basis of the pH-partition principle. 
On the one hand, presaturation of the continuum with incipient drug has been repeatedly 
demonstrated to improve loading efficiency: tetracaine (Wakiyama et al., 1981), 
phenobarbitone (Jalil & Nixon, 1989), cisplatin (Splenlehauer et al., 1986a, b; 1988), 
quinidine (Bodmeier & McGinity, 1987c) and diazepam (Pavanetto et al., 1994a); on the 
other hand, micrbspheres with substantial embedded surface crystals are associated with 
continuum presaturation (Jalil & Nixon, 1989). Others have successfully attempted to 
prevent drug partition by equalization of disperse: continuum osmotic potential by addition 
of salts to the continuum (Joly et al., 1994; Esposito et al., 1997). 
A number of anhydrous encapsulation procedures have been described in an attempt to 
improve the inherent limitations of encapsulation of hydrophilic substances using the 
aqueous ESE procedure. Tsai et al. (1986) pioneered a non-aqueous o/oI ESE technique, 
whereby a solution of mitomycin-C and PLLA was dispersed in light liquid paraffin (LLP) 
containing, as emulsion stabilizer, Span 65. Subsequent evaporation of acetonitrile at 55 
°C resulted in the precipitation of polymer and drug as coherent, spherical microparticles 
with a particle average size of 95 µm. Jalil & Nixon (1989; 1990a-e, g, h; ) have extensively 
investigated this technique using phenobarbitone as core reference. The authors have 
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reported that both encapsulation efficiency and microsphere yield improved significantly 
using the o/o1, opposed to a conventional aqueous emulsion procedure (Jalil & Nixon, 
1989). Poor solubility of phenobarbitone in LLP relative to aqueous media explained this 
observation. However, microspheres produced by the o/ol were large and irregular in 
shape compared with those prepared using the o/w procedure and required large 
volumes of organic solvent to remove residual oil and emulsifier. High speed 
homogenization has recently generated particles of substantially smaller granulometry 
(Atkins et al., 1998). Aqueous substitution for silicone oil increased encapsulation 
efficiency of cisplatin from 10 to 80 % of an unspecified attempted loading (Wada et al., 
1988b). Other workers have investigated glycerin-water combinations (Gupta et al., 
1993) and glycerin alone (Pavanetto et al., 1994a) as alternative continuous phases. 
1.2.1.4 Process 
The effect of continuum viscosity is a function of the manufacturing technique and the 
manner by which viscosity modification arise. Jalil & Nixon (1990e) attributed reduced 
particle size at elevated temperatures to a reduction in continuum and disperse viscosity 
which facilitated dispersion. However, the same cause, but opposite effect was described 
by Wakiyama et al., (1981), whereby processing at 40 °C, using 1 %w/v gelatin, produced 
larger microspheres than those obtained at room temperature under vacuum due to 
droplet coalescence. Higher viscosity of 1 %w/v Na alginate, compared to 1% w/v gelatin, 
produced smaller microspheres under equivalent conditions. It has also been reported 
that increasing levels of gelatin produced progressively smaller microspheres (Wakiyama 
et al., 1981; Juni et al., 1985a). 
Generally, increased stirring rates are associated with a decrease in mean particle size 
and distribution breadth (Benita et al., 1984, Splenlehauer et al., 1986a; Sanchez et at., 
1993; Zhifang et al., 1993; Sansdrap & Möes, 1993). With these changes, encapsulation 
efficiencies typically decrease in parallel with an increase in particle specific area 
(Splenlehauer et at., 1986a). Exceptions to these trends do however exist. For example, 
despite a 30-fold reduction in mean microsphere size to 1 µm at 3000 rpm compared with 
1000 rpm, Sanchez et al. (1993) assigned the invariant and high encapsulation efficiency 
to the affinity of cyclosporin A for the disperse phase. Conti et al. (1995a) observed an 
anomalous increase in particle size as the rate of high speed homogenization increased 
at 0.5 %w/v PVA level, but size was invariant above 2 %w/v PVA. 
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A study of the effect of temperature of evaporation concluded that the observed reduction 
in microcapsule size with increased temperature of solvent evaporation was due to 
viscosity reduction of both the disperse and continuous phases (Jalil & Nixon, 1990e). 
Rapid phase separation, induced by excessive temperatures, accounted for the disrupted 
surface of microcapsules prepared at 85 °C. Furthermore, morphologically smooth 
microcapules were prepared from amorphous PDLLA, independent of polymer MW, in 
contrast to the highly porous and textured products of semi-crystalline PLLA. Evaporation 
of acetonitrile at temperatures above the Tg temperature of PDLLA probably facilitated 
the film-forming character of the polymer (Jalil & Nixon, 1990e). Amorphous PLLA 
matrices can be readily formed by more rapid solvent evaporation induced by application 
of vacuum to the emulsion during microsphere hardening (Izumikawa et al., 1991). 
Overall, the extensive and occasionally contradictory results from ESE highlight the need 
for empirical studies because of the complex interaction between the drug substance and 
the polymer matrix, as well as the manufacturing technology. 
1.2.2 Spray-drying 
The aforementioned preparative techniques are often time-consuming and dependent on 
many variables. Ideally, microsphere preparation should be simple, reproducible, rapid 
(Takada et at., 1995) and easy to scale-up (Bodmeier & Chen, 1988); criteria which are 
arguably best satisfied by spray-drying. Most research laboratories use the same 
apparatus; the Mini-spray Büchi 190/1 (Bitz & Doelker, 1995; Bodmeier & Chen, 1988; 
Bruhn & Müller, 1991; Castelli et at., 1994; Clarke et at., 1998; Conte et at., 1994a, b; 
Conti et al., 1991,1994,1997; Genta et al., 1991,1994; Giunchedi et al., 1994a, b, 1995, 
1998; Gupta et at., 1993; Mathiowitz et al., 1992; Pavanetto et at., 1992; 1994a, b; Rafler 
& Jobmann, 1994; Volland et al., 1994; Wagenaar & Müller, 1994), a schematic of which 
is shown in Figure 1.2. The codissolved or suspended feed (A) is fed at a controlled rate 
(B) through the nozzle (C). Flow rate - which controls the characteristics of the 
microdroplet aerosol (D) - and aspiration (F) - which draws the air through the 
glassware assembly - when balanced, ensure efficient separation of product from the 
drying air at the level of the cyclone (G). This, in turn, promotes deposition of product in 
the collector (1). Whereas the inlet temperature is preset, the temperature of air detected 
by the thermocouple (H) is a function of the inlet temperature, flow rate, and the drying 
load. The latter factor is determined by the heat capacity of the liquid being processed 
and the feed rate of same. 
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Figure 1.2 Schematic of the two-fluid nozzle co-current Büchi® Minispray 191 spray-drier. 
Arrows indicate the idealized directions of both air and product flow 
1.2.2.1 Drug 
Unlike other microencapsulation strategies, efficient encapsulation can be achieved with 
little dependence on the solubility of the drug or_ polymer using spray-drying (Bruhn & 
Müller, 1991). The earliest report of spray-dried biodegradable particles described the 
preparation of antimalarial PDLGA (25: 75) microspheres (Wise et al., 1976). 
Encapsulation of 2,4-diamino-6-(2-naphthylsulphonyl)-quinazoline at levels of 16.7 % and 
33.3 %w/w drug produced finely divided particles of < 125 µm although no other physical 
characteristics were presented. Presumably, the unusual cosolution of 1,1,1,3,3,3- 
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hexafluoro-2-propanol and benzene was employed to promote polymer solubility, 
although no rationale was specified. Bodmeier & Chen (1988) illustrated the effects of 
drug characteristics on spray-dried microsphere formation. Drug was either dissolved 
(progesterone) or suspended (theophylline) in PDLLA prior to spray-drying. The 
polymorphic form of progesterone varied with spray conditions, whereby entrapment 
within PDLLA promoted formation of the ß-form. Although morphology was not discussed, 
retarded dissolution indicated that theophylline was in part encapsulated; dissolution rate 
increasing with respect drug payload. In the same study, caffeine produced rod-like 
particles indicative of a drug-polymer incompatibility. 
Considering all the drug and the polymer are sprayed and no drug can be lost to the 
continuum as it is hot air (Bodmeier & Chen, 1988), encapsulation efficiencies of < 100 % 
have quite surprisingly been reported (Pavanetto et al., 1993; 1994a). For vitamin D3, this 
effect was drug load dependent which the authors stated erroneously was analogous to 
partitioning observed in emulsion technology (Pavanetto et al., 1993). Stereospecific 
PLLA achieved highest loadings, whereas, racemic polymers of low and medium Mn 
produced lower but comparable drug levels. Again no explanation was offered, although 
polymer dependent drug decomposition is inferred owing to the instability of vitamin D3. In 
general, actual and theoretical loadings have shown good correspondence (Conti et al., 
1994; Wagenaar & Müller, 1994). 
1.2.2.2 Polymer 
Polymer MW is a critical factor to successful microsphere formation using the Büchi 190/1 
equipment (Bodmeier & Chen, 1988; Pavanetto et al., 1993; Rafler & Jobmann, 1994). 
Bodmeier & Chen (1988) encountered the problem of fibre formation owing to insufficient 
forces to break the liquid into droplets, consistent with the fibrous recrystallization 
behaviour observed for PLLA by Kalb & Pennings (1980). Filament formation was 
strongly dependent on the stereochemistry of the polymer used and to a lesser degree its 
viscosity. Higher solution viscosity of PLLA, when compared with optically inactive 
PDLLA, arose as a result of the chain-stiffening effect of isotactically arranged methyl 
groups. Accordingly, the optimal MW range and the concentration at which PLLA inclines 
towards fibre formation are both lower than for PDLLA of equivalent MW. Solvent choice 
appeared to have no influence on fibre formation (Rafler & Jobmann, 1994). Pavanetto et 
al. (1993) identified optimal concentrations and polymer MW in the ranges 0.5 - 2.5 %w/v 
and 16 - 209 kD, respectively; which where 
highly stereospecific. 
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Another important determinant of particle morphology is D: P ratio (Conte et al., 1994b; 
Pavanetto et al., 1993). Pavanetto et al. (1993) did not comment on the morphological 
consequences of increasing vitamin D3 payload from 5- 30 % (an increase in D: P ratio of 
1: 19 to 1: 3.33. Conte et al. (1994b), however, described a smooth spherical product at 
D: P ratio of 1: 2, whereas a deterioration in sphericity coincided with the onset of 
agglomeration at a D: P ratio of 2: 1. For polyanhydrides, spray-drying had the effect of 
reducing or eliminating polymer crystallinity which, in turn, affected morphology. 
Crystalline polymers, such as poly (sebacic anhydride) gave microspheres with a porous 
and crenelated surface. In contrast, copolymers of carboxyphenoxypropane and sebacic 
acid which possess low crystallinity, yielded microspheres with a smooth exterior 
(Mathiowitz et al., 1992). 
In a general sense, PDLLA appears to produce superior morphologies (Pavanetto et al, 
1993; Wagenaar & Müller, 1994) compared with both PLLA and PDLGA. Small craters 
(Wagenaar & Müller, 1994), surface concavities (Gupta et al., 1993) particle collapse 
(Thoma et al., 1992) have more frequently been described with the latter two polymer 
types. These observations can only partially be explained on the basis of crystallinity (see 
1.1.2.2). In addition, PDLLA is solubilized under moderate conditions, that may favour 
solubilization and thus entrapment of drugs over a broader solubility range. The superior 
film-forming character of PDLLA compared with PLLA might also be influential (Arshady, 
1991) 
1.2.2.3 Solvent 
Pavanetto et al. (1993) obtained superior morphology with a 1: 1 cosolvent of DCM: CFM, 
when DCM, CFM and 1,2 dichloro-ethylene and mixtures thereof were compared. 
However, comparable morphologies have been attained using DCM alone using PDLLA 
of equivalent MW at elevated inlet temperatures (60 compared with 51 °C) and feed 
rates (800 compared with 225 mLh") (Wagenaar & Müller, 1994). Others have advocated 
the complete or partial substitution of ACT on toxicological grounds, which did not seem 
to adversely affect particle morphology in their studies (Rafler-& Jobmann, 1994). 
1.2.2.4 Process 
Limited systematic assessment of the influence of process parameters have been 
reported using diazepam and PDLLA as model drug and polymer, respectively (Conte et 
al., 1994a). At a fixed D: P ratio of 3: 7, whilst 3 %w/w total solid gave good microsphere 
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morphology, 1.25 % gave incomplete microspheres, whereas 5% promoted 
agglomeration. A temperature increase from 44 to 63 °C dramatically reduced particle 
size. The effect of feed rate, however, appeared complex and dependent on inlet 
temperature. Overall, at higher temperatures, increased feed rate reduced particle size, 
while the effect on particle size distribution was reversed at lower temperatures. No 
explanation for these observations was offered by the authors. 
A major advantage of spray-drying is the short preparation times (Pavanetto et al., 1992; 
Takada et al., 1995). Pavanetto et al. (1992) estimated a four-fold increase in production 
rate when compared with traditional emulsion methods. Comparison of spray-drying with 
w/o/w gave profound decreases in preparation time for 10 g batches; 3 min compared 
with 24 h, respectively (Takada et al., 1995). 
Yields as low as 30 % (Giunchedi et al., 1998; Pavanetto et al., 1993) are not uncommon, 
and as high as 60 % (Conti et al., 1994; Wagenaar & Müller, 1994) have been reported. 
Bodmeier & Chen (1988) identified polymer T9, and residual solvent as potential 
determinants of yield. An optimum spray-air flow pattern, which minimizes particle-wall 
collision and restricts product loss via the exhaust, was thought to exist (Bodmeier & 
Chen, 1988). Indeed, polymer MW and concentration had little influence on the yield of 
vitamin D3, highlighting the criticality of process parameters (Pavanetto et al., 1993). Yield 
does, however, appear to be more strongly influenced by the character of the feed; 10 - 
40 % for emulsions (Takada et al., 1995); 50 % for solutions (Conti et al., 1994b) being 
representative. When clarification using spray-drying of solvent-evaporated microspheres 
was employed very low yields were reported, although no data were presented (Gupta et 
al., 1993). No explanation was offered by the authors, but factors such as the small 
particle size produced by microfluidization of immature microspheres which could more 
easily be exhausted; low solid content of the feed (2 -6x 10-3 gmL-1); and, low 
temperature of recovery whereby residual moisture would promote glassware adherence, 
undoubtedly made a contribution. Takada et al., (1995) demonstrated a double nozzle 
method whereby formed particles were coated with mannitol in-process. This modification 
was reported to greatly improve yield by minimizing particle-glassware adherence. 
Particle size distribution, morphology and particle formation are a function of different 
process and material factors: polymer used, i. e., concentration, stereochemistry, MW 
(Pavanetto et al., 1993; Bodmeier & Chen, 1988) and its solubility; apparatus design 
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(Wise, 1976); and, the proportion and nature of drug (Rafler & Jobmann, 1994). 
Generally, particle size distributions reported are typically in the range 1- 10 µm and with 
little variation. Different designs have yielded smaller particles of range 0.5 - 2.0 µm 
(Wang et at., 1990) and considerably larger particles (Wise et al., 1976), although no 
detail of the atomization principle for the latter two was given. At low concentrations, 
spray-dried PDLLA piroxicam microspheres exhibited a constant mean volume diameter 
of 5 µm, whereas increasing D90% values, was ascribed to fibre formation at polymer 
concentrations exceeding 2% (Wagenaar & Müller, 1994). Rafler & Jobmann, (1994) 
observed small increases in size and distribution of drug-loaded when compared with 
blank microspheres, corresponding to a greater solid content of the feed. Generally, 
particle size will increase with respect to polymer concentration in the feed and polymer 
MW (Pavanetto et al., 1993) but not necessarily with a linear dependence (Wagenaar & 
Müller, 1994). 
There is evidently a complex interplay between process-specific (e. g. inlet temperature, air 
flow rate, aspiration) and feed specific (e. g. drug, polymer concentration, solvent choice) 
variables which influence particle morphology and, in turn, release kinetics. A detailed 
account of the factors influencing release from poly-a-hydroxy polyesters is presented 
later. Here, process factors, and their inter-relationships with polymer feed will be 
reviewed. Rafler & Jobmann (1994) stated with a constant feed, different release profiles 
utilizing spray-drying parameters could only be achieved to a limited extent, probably 
owing to their minimal effect on particle granulometry. Conte et al. (1994a) compared the 
release of particles collected from the cyclone and product collector. For each batch, 
particles from the collector released drug faster than those from the cyclone, in 
agreement with their smaller diameter. However, when different batches from the same 
location were compared, those collected from the cyclone with smaller diameters 
released diazepam more slowly. The authors concluded only that process parameters 
had an influence. Possible reasons for this behaviour might have been a surface curing in 
the hotter region of the cyclone. Curing of microparticles has been previously described 
as a means of retarding drug release (Zhou & Chang, 1988). 
Spray-drying with poly-a-hydroxy acids has been used elsewhere for product recovery 
(Gupta et at., 1993; Wichert & Rohdewald, 1990), excipient preparation (Avgoustakis & 
Nixon, 1993a, b) and more recently, spray-coating (Lee et al., 1997). Wichert & 
Rohdewald (1990) compared a solvent evaporation-extraction procedure with a `melting- 
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method' for the preparation of vinpocetine-loaded PDLLA microspheres. This novel 
method involved emulsification of a pre-molten blend of drug and polymer in an aqueous 
continuum, in which polvinylpyrrolidone (PVP) had been dissolved to prevent 
agglomeration. Spray-drying of the hot emulsion (50 - 95 °C) resulted in discrete 
microparticles with a porous microinterior embedded in PVP. Particle morphology was 
dependent on MW of the polymer and preparative technique. Spray-dried particles of 
polymer, MW 2 kD, were smooth and regular, whereas those of polymer, MW 16 kD, 
were rod-like and more irregular in size. Irregular particles were probably a result of the 
high viscosity of the polymer-drug melt which required higher temperatures and the 
inclusion of plasticizer polyethylene glycol (PEG) to facilitate emulsification. Sam et al. 
(1994) have reported a related spray desolvation technique which also avoids the use of 
toxic chlorinated solvents. 
Finally, notwithstanding the fact size distribution manipulation is restricted (using the 
Büchi apparatus) and limitations of the feed exist, it can be concluded that spray-drying 
has considerable potential in microencapsulation. Advantages include general 
applicability, concerning both the drugs (heat sensitive and heat resistant materials can 
be used) and polymers (hydrophilic and hydrophobic); one-stage continuous operation; 
and, its adaptability on an industrial scale. 
1.3 Characterization of biodegradable microspheres 
Characterization techniques should be appropriately selected so as to adequately 
examine desired characteristics, particularly those sensitive to manufacturing variables 
whose constancy is critical to the preparation of a reproducible and effective product. 
Characterization should allow an understanding and eventual prediction of the system's 
behaviour (Hausberger & DeLuca, 1995). Techniques selected should also consider the 
reliability of the measurements made, ease of measurement and availability. 
1.3.1 Microscopy 
The utility of light microscopy is generally limited to subjective assessment of microsphere 
shape, general granulometry and presence of aggregates (Jalil & Nixon, 1989), although 
modern image analysis allows rapid objective measurement of the same attributes. 
Scanning electron microscopy (SEM) affords high magnification and definition images for 
direct visualization of microsphere morphology and topography (Watts et al., 1990) and 
correlation with other characteristics such as drug release profile (Wakiyama et al., 
1981), 
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surface area and bulk density (Hausberger & DeLuca, 1995). Surface continuity, pores, 
pitting and surface crystals can be readily assessed after microsphere preparation, during 
degradation (Jalil & Nixon, 1990c) and long-term storage (Jalil & Nixon, 1990h). Sample 
drying is crucial, as cursory misinterpretation of disintegrated microspheres as a result of 
polymer degradation was later found to be due to internal volatilization of residual 
moisture which fractured particles not adequately dried before coating (Bodmeier & 
McGinity, 1988a). Freeze fracture SEM of microspheres (Jalil & Nixon, 1990d; Wagenaar 
& Müller, 1994; Esposito et al., 1997) allows characterization of internal architecture. 
Sophisticated microscopic techniques, such as atomic force microscopy and image 
analysis have recently been applied to the characterization of adsorbed emulsifier (Boury 
et al., 1997). 
1.3.2 Particle size 
The size of the microsphere and particle size distribution of the encapsulated product are 
important parameters to control in microparticle delivery systems to ensure syringeability 
(Beck et al., 1985) and efficient organ targeting, particularly for products intended for 
chemoembolization (Grandfils et al., 1992; Flandroy et al., 1997) and intrapulmonary 
delivery (Armstrong et al., 1994,1995; Guiziou et at., 1996). Therefore, methodologies to 
reproducibly manufacture uniform microspheres in specified ranges, and others to check 
compliance, are required (Iwata & McGinity, 1992). 
1.3.3 Drug characterization 
Microparticles are differentiated by morphology and architecture, i. e., how the drug is 
deposited. This generally gives two distinct structures, microspheres and microcapsules 
with subdivisions of the latter according to Figure 1.3. With reference to Figure 1.3, 
microcapsule classically defines a microparticle in which a central core is surrounded by a 
rate-limiting membrane (A), whereas microspheres comprise an homogeneous blend of 
both drug, polymer and other ingredients (B). When the microparticle contains several 
distinct drug domains it is a matter of semantics if that particle is to be defined as a 
multinuclear microcapsule (C) or a heterogeneous microsphere (D). What can be stated 
with some certainty is that the physical character of the embedded drug and the polymer 
can have a profound effect on, in particular, drug release kinetics. Two complementary 
techniques have enjoyed most extensive use to elucidate the dispersed state of 
entrapped drug, differential scanning calorimetry (DSC) and X-ray powder 
diffraction 
(XRD). 
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Figure 1.3 Structures of classes of microproducts 
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1.3.3.1 Differential scanning calorimetry 
The final form of an incorporated drug will be affected by factors such as relative drug 
and polymer solubility in the organic medium; rate of solvent evaporation; drug-polymer 
interactivity, e. g., solid solution and initial D: P ratio. Simplistically, where drug loading is 
low, precipitation thereof will occur only after polymer viscosity is so high as to impede 
crystallization. Conversely, at high drug loadings drug precipitation will occur in a more 
fluid polymer phase which permits significant molecular orientation, nucleation and 
subsequent crystallization (Dubernet, 1995). Jalil & Nixon (1990e) identified a monolithic 
distribution of core crystalline phenobarbitone in PDLLA from the appearance of sharp 
endotherms corresponding to drug. Depressions in polymer Tg temperature after 
microsphere preparation signalled a degree of drug-polymer solid solution. In contrast, 
that progesterone could not be detected at 31.7 %w/w in PDLLA was suggestive of solid 
solution. However, annealing studies established a molecular distribution with little mutual 
miscibility (Benoit et al., 1986). Bodmeier & McGinity (1987c) observed a metastable 
distribution of quinidine and quinidine sulphate in PDLLA which yielded recrystallization 
exotherms during the heating cycle. Rapid solvent partitioning during preparation which 
hindered matrix stabilization accounted for these effects. Castelli et al., (1994) used DSC 
to indirectly characterize tolmetin release from PDLLA microspheres by measuring the 
thermal behaviour of a receptor lipid membrane whose response to drug had been 
previously calibrated. 
1.3.3.2 X-ray powder diffraction 
XRD is generally used to confirm the presence of crystalline drug (Cavalier et al., 1986) 
or polymer (Izumikawa et al., 1991; Richey & Harris, 1995) detected by DSC, but XRD 
might be considered more sensitive as evidenced by the fact dehydro-iso-androsterone 
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crystals were detected by this technique to which DSC was oblivious (Ramtoola et al., 
1991). Aso et al. (1992) used XRD to illustrate that the long-term stability of amorphous 
PLLA matrices was compromised by storage above their Tg temperature and under 
conditions of high relative humidity. Recrystallization of matrix polymer was shown to 
generally accelerate drug release, although these changes might have been equally due 
to polymer degradation rather than a redistribution of drug and polymer. 
1.3.4 Spectroscopy 
A plethora of spectroscopic methodologies have been utilized to study drugs and polymer 
prior to (Avgoustakis & Nixon, 1991) and following their fabrication as microspheres. 
Ultraviolet absorption (UV) is generally employed to quantify loading efficiency and drug 
release kinetics due to the rapid and reliable nature of these measurements (Jalil & 
Nixon, 1989; 1990a-e, g, h). Mauduit et al. (1993a) used FTIR to verify polymer acid end- 
group neutralization with basic, gentamycin, during release studies. Conversely, the 
absence of molecular interaction between drug and PLLA was confirmed by FTIR (El- 
Baseir et al., 1997). The chain intimacy of amorphous and crystalline matrices has also 
been compared with FTIR (Izumikawa et al., 1991). Nuclear magnetic resonance (NMR), 
which relies on separate chemical shifts produced by carbons in specific molecular 
environments has been employed to examine sequence distribution or `blockiness' of 
PDLGA copolymers (Avgoustakis & Nixon, 1991; Bendix, 1990). Recently, the utility of 
electron paramagnetic (EPR) and magnetic resonance imaging (MRI) for the assessment 
of PDLGA microviscosity and erosive changes during in vivo implantation have been 
demonstrated. These techniques allow real-time assessment of biodegradation without 
sequential sacrifice of study animals (Wider et al., 1995). 
1.3.5 Surface analysis 
Surface area may affect drug release, biodegradability and product flowability. Gas 
adsorption (BET) gives more reliable measurements of surface area than air permeatry, 
as the former can efficiently measure small and tortuous surface discontinuities which 
can commonly feature on microspherical delivery systems. Hausberger & DeLuca (1995) 
have demonstrated that use of krypton in favour of nitrogen enhanced analytical 
sensitivity allowing accurate determinations on 50 mg of sample, whereas 500 mg is 
generally considered the minimum required when the latter adsorbent is employed. 
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1.3.6 Gel permeation chromatography 
Although relatively crude measurements of MW can be made based on viscometry (Rak 
et al., 1985; Cha & Pitt, 1989), gel permeation chromatography (GPC) based on the size 
exclusion principle allows efficient separation of molecules based on chain length. 
Accordingly, MW distribution and associated statistical indices, number-average (Mn) and 
weight-average MW (Mw) and polydispersity can be readily calculated; the latter being a 
measure of distribution breadth (Hausberger & DeLuca, 1995). GPC has therefore been 
employed to assess the effect of factors considered to alter polymer MW distribution. 
Thus, polymer batch reproducibility (Boehringer Ingelheim, 1992); polymer degradation 
during microencapsulation (Witschi & Doelker, 1998); the effect of 7-sterilization 
(Splenlehauer et al., 1988; Hausberger et al., 1995); in vitro (Wang et al., 1991; Sandrap 
& Möes, 1997) and in vivo degradation (Flandroy et al., 1997; Takada et al., 1997) have 
been examined. The technique has also distinguished between heterogeneous and 
homogeneous polymer degradation mechanisms (Witschi & Doelker, 1998). 
1.3.7 Assessment of in vitro drug release 
The release of entrapped drug from biodegradable microspheres is governed by an 
interplay of many factors, some specific to the formulation, i. e., polymer properties; 
process conditions; matrix morphology; drug physicochemistry, others related to the 
environment and conditions of the in vitro testing, i. e., pH, ionic strength, mechanism of 
agitation. Drug release may be diffusion or degradation controlled. More often, release 
will be a function of both mechanisms, the relative contribution of each being dependent 
on the factors mentioned above. 
Dissolution testing can be considered the definitive in vitro characteristic in determining 
the in vivo potential of a prototype formulation; as a useful determinant of microsphere 
quality; and, as an indicator of batch-to-batch reproducibility (Cowsar et al., 1985). As no 
official recommendations for the examination of drug release from microspherical 
formulations currently exist, a range of methodologies have been described, varying 
considerably in geometry, hydrodynamics and composition of the test environment. 
These variables, in addition to those specific to the formulation, confound comparison of 
the reported literature. The USP paddle dissolution apparatus (Jalil & Nixon, 1990c, d, g; 
Suzuki & Price, 1985), 'shaken-flask' (Wakiyama et al., 1982a), 'rotating bottle' 
(Leelarasamee et al., 1986; Bodmeier & McGinity 1987a; Conti et al., 1991,1994; 
Pavanetto et al., 1992,1994a) have all been described. 
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More recently, in attempts to mimic in vivo drug release conditions (Sansdrap & Moes, 
1997), no difference was found in release of water insoluble nifedipine below and in 
excess of the `sink' threshold. This `sink' convention has implications for the quantity and 
nature of media employed, these factors being primarily dependent on the solubility 
character of the drug. Generally, drug release from microspherical systems has been 
examined using isotonic phosphate buffer at physiological pH (Wakiyama et al., 1982a, b). 
However to solubilize drug, release accelerant, ethanol (Cowsar et al., 1985; Pavanetto, 
1993), has been added to the release medium to obtain `meaningful' results in shorter 
periods of time. Additionally, the proposed use of high (Cowsar et al., 1985) and low 
(Gupta et al., 1993) pH to accelerate polymer hydrolysis, has obvious potential to 
interfere with the release mechanism. Indeed, release of levonorgesterol in proportion to 
media ethanolic content from reservoir fibres suggested a pore-diffusion mechanism was 
operative, which was degradation controlled in the absence of alcohol (Eenink et al., 
1987). Dissolution testing under stressed conditions has advantages in expediting 
formulation development, although interpretation of results is clearly restricted to 
comparison, rather than extrapolation to their potential in vivo performance. 
Surfactants are added to dissolution media principally to deaggregate particles, though 
their potential to reduce microsphere-medium interfacial tension has also contributed to 
enhanced drug liberation (Leelarasamee, 1986,1988a; Wagenaar & Müller, 1994). 
Surfactants, in spite of their positive attributes, are not always without problem. Maulding 
et al. (1986) considered a complex formation between thioridazine and polyethylene 
oxide monostearate was responsible for apparent decrease in drug concentration in the 
dissolution medium at 2 weeks. Elsewhere, use of hypertonic release medium has been 
shown to restrict water penetration, increasing the lag phase before drug release in linear 
relation to ionic strength (Bodmeier & McGinity, 1988a). 
Factors affecting drug release from biodegradable systems are complex and interactive, 
and compound the difficulty in predicting release from these devices. Nonetheless, a 
variety of primary factors have been identified and evaluated in order to achieve a better 
understanding of drug release from these preparations. 
A number of generalized release profiles have been observed, the shape of which can be 
assigned to sequential release phenomena, their duration being dependent largely on 
drug loading and drug and polymer physicochemistry. Biphasic release profiles are 
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typified by water soluble drug release from insoluble matrices (Tsai et al., 1986; Suzuki & 
Price, 1985). The initial release is by dissolution and diffusion of drug from peripheral 
regions of the microsphere, whereas secondary release occurs via drug diffusion through 
the microsphere matrix from less accessible regions. Where the second process is 
complete before degradation of polymer below a critical level where erosion proceeds, 
drug release will be independent of the latter. However, a triphasic release mechanism 
has been repeatedly described (Bodmeier & McGinity, 1988b; Sandrap & Möes, 1993; 
Asano et al., 1989,1990,1991; Hora et al., 1990; Sanders et al., 1985) yielding a 
characteristic sigmoidal release profile. The three distinct phases have been differentiated 
and interpreted in a variety of ways by different authors depending on the properties of 
entrapped drug. Bodmeier & McGinity (1987c) assessed release of quinidine base and 
sulphate salt on the basis of a biphasic diffusional mechanism, comprising an initial lag 
period, a period of rapid drug release and finally, a slow terminal phase. The initial lag 
represented a period of water imbibition, thus plasticizing the polymer. Thereafter, rapid 
drug release corresponded to leaching and diffusion of the drug through pores in the 
hydrated matrix, terminating in matrix diffusion of remaining drug from more inaccessible 
regions. The mechanisms by which triphasic profile arise is highly dependent on drug 
MW. For drug diffusion to occur, a limited solubility in the polymer at least is required. 
Unlike low MW drugs, in the absence of specific chemical interaction, polypeptides will 
either be insoluble in or incompatible with polyesters due to distinct structural 
dissimilarities (Lewis, 1990). Therefore, triphasic release of peptide have been 
interpreted, in contrast to Bodmeier & McGinity (1987b), by a mechanism involving 
significant matrix erosion and degradation. Initial immediate and rapid release was 
attributed to desorption of poorly encapsulated peptide from the periphery of the matrix 
(Hora et at, 1990). The relative contributions of erosion and diffusion were a function of 
protein loading. Little drug release occurred during the lag phase of polymer hydrolysis 
until the oligomers had reached a critical MW, when the implant became sufficiently 
hydrated, and solubilization of oligomers heralded erosion and concomitant peptide 
release. In contrast, biphasic release of the peptide, cyclosporin A, was attributed to a 
typical 'burst' initially and a subsequent linear release in parallel with polymer erosion as 
measured by GPC. Compensatory mechanisms of polymer erosion which 
increased 
matrix porosity, balanced against a thickening diffusion barrier as 
drug was depleted from 
outer regions may account for these differences (Sanchez et al., 
1993). 
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Wakiyama et al. (1981,1982b) studied the release rates of a series of local anaesthetics 
from PDLLA. From SEM studies, after an initial period of diffusion-control, accelerated 
release of butamben corresponding to matrix disintegration was shown to predominate. 
Release rate increased with core loadings, which, in turn, increased disintegration rate 
(Wakiyama et al., 1981). In contrast, drug release independent of drug loading in the 
range 6.5 to 22.8 %w/w has been reported for the hydrophobic drug, nifedipine 
(Sandsrap & Möes, 1993). In a further study (Wakiyama et al., 1982b), release rate 
decreased as anaesthetic solubility in the dissolution medium decreased and as PDLLA 
MW increased in the range 9.1 to 25 kD. The authors considered osmotic pressure 
generated by high loadings of water soluble drugs, accounted for the increased 
disintegration of microspheres at high tetracaine levels. They did not, however, consider 
base-induced hydrolysis of the matrix by the drug as has been observed elsewhere 
(Maulding et al., 1986; Cha & Pitt, 1989). In analogy, thioridazine was shown to 
substantially increase polymer degradation during both microsphere preparation and in 
vitro release studies (Maulding et al., 1986). 
Physicochemistry of the drug determines its solubility in the dissolution medium, but also 
that in the polymer, which, in turn, affects its distribution within the matrix. The 
microstructure of the matrix, i. e., the size of the drug particle in relation to microsphere 
size, porosity etc. has a substantial influence on the release mechanism. Crystalline 
dispersions (Splenlehauer et al., 1986b), molecular dispersions (Le Corre et al., 1996; 
Benoit et al., 1984) and solid solution (Jalil & Nixon, 1990e) are the three primary 
dispersive states of drug within microspheres. Theoretical, where the drug is dispersed at 
the molecular level in the polymer, release should be strictly controlled by the erosion rate 
of the matrix. Benoit et al. (1984) described release according to first-order kinetics for 
progesterone microspheres containing 68 %w/w drug, part of which existed as a discrete 
crystalline phase. In contrast, molecularly dispersed progesterone arose at lower loadings 
of 23 %w/w, release of which followed a square root of time relationship. Le Corre et al. 
(1996) described complex release behaviour inconsistent with the aqueous solubility 
characteristics of four anaesthetic drugs from PDLLA and PDLGA microspheres. Thermal 
analysis explained the significant burst, i. e., 45 % 30 min-' of lipophilic etidocaine from 
PDLLA where it was present as a particulate dispersion. It was also observed that 
lipophilic etidocaine and bupivocaine paradoxically released faster with increasing 
PDLGA MW, whereas hydrophilic mepivocaine and lidocaine followed the opposite trend 
consistent with polymer hydrophilicity. This was attributed to increasing matrix porosity as 
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polymer precipitation rate increased with MW which significantly increased the rate of 
release of lipophilic drugs in particulate dispersion, but had lesser influence on hydrophilic 
drugs in molecular dispersion. A 'channelling threshold' has been coined to describe drug 
loadings, above which the matrix acts more as a scaffold than a barrier (Splenlehauer et 
al., 1986b). In this situation, loadings are at a critical level to form a contiguous network, 
whereby all drug crystals are in intimate contact with neighbouring domains. This results 
in a rapid drug release via dissolution, pore formation and drug diffusion. 
Contrary to the diffusivity and hydrophilicity patterns of crystalline and amorphous 
polymers, morphological factors and the crystalline state of phenobarbitone accounted for 
its more rapid release from semi-crystalline PLLA when compared with PDLLA (Jalil & 
Nixon, 1990c, d, g). For PDLLA, increased polymer MW reduced both dynamic lag-time 
and steady-state release rate, whereas with PLLA the opposite trend was unexpectedly 
observed. This latter effect was ascribed to the earlier precipitation of high, compared to 
low, MW PLLA, resulting in ineffective coating of precipitated drug crystals with the fatter 
polymer. When compared with native drug dissolution, encapsulation of phenobarbitone 
in high MW PLLA paradoxically accelerated drug dissolution due to the small crystallite 
size and high microcapsule porosity. 
In general, drug release rate increases in inverse relation to particle diameter by virtue of 
an increased specific area. Suzuki & Price (1985) reported that the time for 50 % release 
was linearly related to particle diameter. Sansdrap & Wes (1993) found approximately 
zero-order release from nifedipine-bearing particles of 12 µm in diameter, whereas 
sigmoidal profiles reminiscent of Bodmeier & McGinity's (1987b, c) studies were recorded 
at diameters of 83 pm. The lag period (150 h) comprised the time required for deep water 
penetration, microsphere hydration and drug diffusion, all of which occurred 
simultaneously with 12 µm particles. 
Processing parameters of the aqueous solvent evaporation procedure can significantly 
affect drug release via an alteration of drug-matrix deposition kinetics. lzumi'kawa et al. 
(1991) studied the effects of solvent removal rate in the preparation of progesterone 
loaded microspheres. Amorphous drug-matrix microspheres prepared under reduced 
pressure, released progesterone slower than those prepared under ambient conditions, 
irrespective of drug loading. Microspheres prepared at atmospheric pressure, in contrast, 
deposited crystalline drug within a crystalline PLLA matrix accounting for the rapid 
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leaching of drug during in vitro testing. Smith & Hunneyball (1986) demonstrated that 
microspheres of comparable sizes, 1- 10µm, released prednisolone rapidly compared 
with microparticles prepared by grinding a heat-fused mass. In spite of their smooth 
exterior, solvent evaporated particles had a porous microstructure, whereas the dense 
amorphous structure of the microparticles impeded drug release more effectively (Smith 
& Hunneyball, 1986). Use of elevated disperse polymer concentrations has retarded drug 
release by impeding crystal migration to the microsphere periphery. At lower polymer 
concentrations, centrifugal forces within individual droplets supposedly promoted 
movement of dense drug crystals outwards (Splenlehauer et al., 1986b). Post-preparation 
curing by heat (Zhou & Chang, 1988) and solvent (Bodmeier & Chen, 1989) has 
conferred a more efficient sustained release character upon pre-formed particles. 
The inherent properties of the polymer that affect drug release are those that also affect 
the degree of polymer hydrophilicity and crystallinity, namely polymer MW and copolymer 
ratio (Asano et al., 1989). The effect of polymer MW has been repeatedly evaluated 
(Suzuki & Price, 1985; Bodmeier & Chen, 1989; Jalil & Nixon, 1990h). Suzuki & Price 
(1985) reported that an increase in microsphere polymer MW resulted in a significant 
increase in the initial lag during in vitro drug release. The relationship between polymer 
MW and drug release is considered to be dependent on the Tg of the polymer (Jalil & 
Nixon, 1990g). Zhou & Chang (1988) suggested a `critical range' of MW which 
significantly altered drug release rate. Operating in the MW range 12.5 to 16.7 kD, 
superimposable release of prostaglandin was observed up to 14.8 kD, whereas release 
from polymer MW 16.7 kD was considerably reduced. In contrast, Juni et al. (1985) 
reported little dependence of bleomycin release on polymer MW, perhaps as those 
studied lay outwith the `critical range'. 
Drug release from lactic/glycolic acid copolymers has been shown to be dependent on 
comonomer ratio of the polymer (Sanders et al., 1984; 1985; 1986; Heya et al., 1991). 
Sanders et al. (1984; 1986) reported that the copolymer ratio exerted a significant 
influence on the release of narfelin from PDLGA. The total duration of release correlated 
closely with the percent of hydrophobic lactide present in the polymer and the rate of 
polymer hydrolysis. A number of workers have altered the drug release properties of 
PDLLA by blending high with low MW polymers (Bodmeier et al., 1989b; Nozawa et al., 
1991; Asano et al., 1991). Bodmeier et al. (1989b) reported that the rate of caffeine and 
salicylic acid release from PDLLA solvent-cast films increased, as 
the relative proportion 
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of low MW PDLLA in the formulation was increased. The faster drug release from 
polydisperse blends was attributed to a reduction in the Tg temperature of the film and a 
corresponding improvement in polymer hydrophilicity. In contrast, in vitro quinidine 
release decreased as the fraction of low MW PDLLA increased which was attributed to 
ionic interaction of basic and acidic functions on the drug and polymer, respectively. 
1.4 Sustained delivery of antimycobacterials 
In parallel with the AIDS pandemic, the century long decline in the incidence of 
tuberculosis (TB) dramatically reversed in 1985 (Sepkowitz, 1995; Huebner & Castro, 
1995). This epidemiological pattern can be seen world-wide causing serious socio- 
economic stress particularly in developing countries (Chaulet, 1987). In 1993, the World 
Health Organisation (WHO) declared TB a 'global emergency'; the first ever declaration of 
its kind. Nearly three million people died from TB in 1995, surpassing the worst epidemic 
previously recorded in 1900, when an estimated 2.1 million people died (Press report, 
WHO/22). Current prospective estimates of the resurgence consider that the yearly death 
toll will climb to 4 million by the year 2005 (Press report, WHO/23). 
In the presence of drug sensitive organisms, current first line treatments for TB are 
effective in 99 % of cases (Medfile, 1993). However, recommended combinations of 
drugs are complex requiring typically oral administration of two or more drugs for up to 18 
months (Tuberculosis chemotherapy centre, 1970). Compliance is notoriously poor 
(Kilpatrick, 1987), particularly in developing countries where there are logistical difficulties 
in ensuring continuity of supply (Shearer, 1994). Against this background, a more 
alarming trend is the emergence of multi-drug resistant strains of TB (MDR-TB), 
attributable amongst other factors to the failure of patients to adhere to prescribed 
regimes (Huebner and Castro, 1995). Major outbreaks of MDR-TB have resulted in 
clusters of death, particularly in institutional settings such as hospitals, shelters and 
prisons (Waxman et al., 1995). In the developed world it has been estimated that one 
third of all TB cases are resistant to at least one anti-tubercular, and approximately 20% 
have organisms resistant to both of the most efficacious agents, isoniazid (INH) and 
rifampicin (RIF). These statistics are even more pronounced in the developing world 
(Sawert, 1996). The consequences of resistance to both of these agents is severe, 
especially in those co-infected with the HIV virus where fatality rates of up to 89% are 
reported (Shearer, 1994). Furthermore, MDR-TB necessitates the use of less effective, 
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more toxic second-line agents which are several times more expensive than first line 
agents. 
MDR-TB is thought to arise through two main mechanisms: primary drug resistance 
arises through infection with organisms already resistant to antimycobacterial agents; 
and, secondary drug resistance, where infection with an originally sensitive strain 
develops through poorly conceived or complied with therapy (Shimao, 1987). The latter 
has classically been the most common mechanism by which resistant organisms have 
developed. It follows, by reducing the incidence of secondary resistance, by ensuring 
compliance, the latent pool of primary resistant organisms should be reduced. 
The concept of patient non-compliance is not new. As early as 1958, Fox identified the 
necessity of strict adherence to effect a cure, using TB as his model (Fox, 1958). Directly 
observed programs are undoubtedly the most effective way of ensuring patient 
compliance where the administration of each dose is supervised (Fox, 1993a, b; Weis et 
al., 1994). Since daily supervision of chemotherapy is not always practical, attempts have 
been made to determine whether intermittent administration would give satisfactory cure 
rates. Operationally, even twice-weekly intermittent therapy created many problems in 
rural and semi-rural areas, - particularly in developing countries (Tuberculosis 
Chemotherapy Centre, 1970). In the absence of new drugs, procedures or devices which 
afford a reduction in dosage frequency and assure effective plasma drug levels should 
greatly facilitate tuberculosis treatments all over the world. 
1.4.1 Isoniazid 
Over the last decade the group led by Gangadharam and Wise have extensively studied 
the feasibility of ensuring patient compliance by delivery of isoniazid (INH) in 
biodegradable PLLGA matrices (Gangadharam et al., 1989,1991; 1993; 1994; 
Gangadharam & Kailasam, 1993; Hsu et al., 1994,1996; Kailasam et al. 1994a, b). 
Implants were originally manufactured by solvent casting of an INH dispersion in a 
PLLGA (90: 10) matrix as irretrievable films (Gangadharam et al., 1989,1991). The 
extrusion of this same blend has since afforded a retrievable rod device, 2 mm in 
diameter, which can be readily removed by the clinician in the event of toxicity 
(Gangadharam et al., 1993,1994; Hsu et al., 1994). A single dose of INH (25 mg kg-1) 
achieved sustained levels of the drug for 6 weeks in animal lung and liver homogenates, 
comparable to daily oral dosing. The tissue homogenates showed high antimycobacterial 
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activity against Mycobacterium tuberculosis in vitro and in macrophages. Higher doses 
(75 mg kg-1) delivered in the same matrix have shown impressive survival rates of 93 % 
after 30 d when challenged to a virulent M. tuberculosis strain. In the same study, 
mortality rate was equal to that of survival in the saline group at 93 %. 
Gangadharam et al. (1993) examined the morphological changes in INH-PLLGA rods 
under in vitro, simulated in vivo conditions and in animals. Polarization microscopy 
revealed three distinct drug domains of 50 - 200 µm, 5- 50 p. m and <5 µm, the latter 
abundant two of which did not readily leach from the implant and thus accounted largely 
for the approximately zero-order release after the initial `burst' had subsided. The polymer 
recrystallized, swelled 10 fold and became filled with voids after 4 weeks in vivo 
incubation. The folded topography of the implant was not accounted for, but may have 
arisen due to preferential degradation of the amorphous regions of this semi-crystalline 
polymer which created internal stresses during implantation. Hsu et al. have recently 
studied the mathematical treatment of the in vitro release of INH from implants (Hsu et 
al., 1994; 1996) and polymeric foams (Hsu et al., 1996). Confirmation of a pore diffusion 
mechanism was established by the fitting of fractional release data as a function of time 
to the Roseman-Higuchi model. The main processing parameter affecting drug release 
was extrusion pressure, drug loading and rod diameter having a minimal effect. Higher 
extrusion pressures were considered to result in a less porous matrix thus reducing the 
contribution of pore diffusion. Drug receptor foams have been prepared by lyophilizing a 
frozen solution of polymer PLLGA (85: 15) in glacial acetic acid. During incubation of 
these foams in a concentrated solution of INH, successive cycles of evacuation and 
repressurization ensured effective solution penetration to the core of the foam. These 
were again lyophilized, micronized and subsequently extruded. The distribution of drug 
along polymer grain boundaries for dry-mixed implants, compared with the more 
homogeneous distribution throughout the foams, accounted for the lower diffusion 
coefficients of the latter formulations derived from the Roseman-Higuchi model (Hsu et 
al., 1996). 
The same implant has been successfully transferred to other antimycobacterial drugs, 
pyrazinamide (Gangadharam & Kailasam, 1993) and clofazimine (Kailasam et al., 
1994b). The group have ambitiously suggested that an entire tuberculosis chemotherapy 
regimen, consisting of INH, RIF, and pyrazinamide (PYZ) could be conceivably delivered 
in a single or a small number of doses. This laudable aim, if achievable, would contribute 
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significantly to controlling the serious threat of patient non-compliance to the effective 
treatment of tuberculosis. 
1.4.2 Rifampicin 
Micron sized drug delivery systems based on proteinaceous microspheres, liposomes 
and multiple emulsion technology have been recently considered to passively target RIF 
to tuberculosis cavities of the lung. By maximizing RIF concentrations at the affected site, 
it has been reasoned that development of resistance (Pande et al., 1991) and hence 
clinical failure would be reduced, whilst undesirable effects to other organs, particularly 
hepatotoxicity (Mandell & Sande, 1985), would be avoided. Iseri et al. (1989) inferred 
satisfactory localization of RIF loaded albumin microspheres following in vitro 
characterization based on previous scintographic assessment of similarly prepared 
streptomycin bearing systems of the same group (Gürkan et al., 1986). In a sequel 
report, the in vivo distribution of 99mTc-labelled albumin and gelatin microspheres revealed 
significant concentration of these formulations in the lung when injected via a peripheral 
vein (Iseri et al., 1991). Pande et al., (1991) recovered 63 % of administered 
microspherical RIF after 3 h, 30 % persisting at 24 h. Jain & Vyas (1995) similarly found 
65 % localization of liposomal-based drug in the lungs by controlling niosome size. 
Improved therapeutic efficacy and toxicity profile of INH and RIF have been observed for 
INH and RIF encapsulated in lung-specific stealth liposomes challenged to experimental 
M. tuberculosis infection in mice (Deol et al., 1997). Nakhare & Vyas (1995a) successfully 
stabilized RIF containing multiple w/o/w emulsions for prolonged delivery via an 
unspecified route. Furthermore, no reference was made to the effective loading (nor 
chemical stability of entrapped RIF), but that attempted was particularly low at 0.025 
%w/v. Multiple emulsion stabilization of the internal phase was later demonstrated by 
formation of interfacial complex films between macromolecules in the internal aqueous 
phase and non-ionic surfactant in the oil phase (Nakhare & Vyas, 1995b). 
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1.5 Purpose of the present work 
The formulation of antibiotics in lactide/glycolide is hindered by three main factors: large 
daily doses are often required; many antibiotics are relatively unstable; and, most are 
water soluble (Lewis, 1990). Consequently, long-acting antibiotic formulations based on 
poly-a-hydroxy acids have previously been fabricated by anhydrous techniques such as 
phase separation (Vidmar et al., 1984 (oxytetracycline); Owusu-Ababio & Rogers, 1996 
(cephalexin); Yu et al., 1998 (ciprofloxacin)) and o/o1 ESE (Atkins et al., 1998 
(vancomycin)). Although aqueous ESE procedures have been additionally described 
(Martinez et al., 1997 (ciprofloxacin); Esposito et al., 1997 (tetracycline)), recourse to 
more involved techniques such as w/o/w have been required to achieve even modest 
drug loadings (Menegatti et al., 1995; Esposito et al., 1997). 
It was the purpose of this work to investigate the microencapsulation of the 
antimycobacterials, RIF and INH in biodegradable poly-a-hydroxy acids by more 
amenable techniques based on solvent evaporation. These drugs were specifically 
selected due to their high dose, moderate to high water solubility and chemical instability; 
properties which have hampered efficient encapsulation and subsequent characterization 
of long-acting microspherical forms. Furthermore, these formulations were designed with 
the intention of delivery via alternative routes to address some of the short-comings of 
existing oral therapies, e. g., patient non-compliance and systemic side effects. 
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2. Analytical Method Development 
David F. Bain 
2.1 Introduction 
One of the most important tasks for the preformulation scientist is the development of 
analytical procedures which allow the accurate determination of drug in a number of 
different media and contexts. Direct UV absorption measurements - in the absence of 
matrix chromophoric interferents or significant drug instability - are generally favoured 
due to the rapid and reliable nature of these measurements. However, where other UV 
absorbing species are present, or significant drug decomposition is a feature of the 
drug(s) under study with the solvents or procedures used, techniques which specifically 
separate and quantify the species of interest are required. High-performance-liquid- 
chromatography (HPLC) is now generally considered the technique of choice for such 
assays due to its separation selectivity and versatility in terms of analyte detection. 
The inherent instability of RIF and INH necessitates techniques of accurately determining 
not only the parent drugs but also the putative decomposition products, i. e., stability- 
indicating assays. These should allow the accurate determination of drug release from 
biodegradable systems, as well as the assessment of any deleterious effects of the 
processes and solvents used in the preparation of these systems. Associated with the 
development of biodegradable microspheres is the high analytical burden of multiple 
samples which require replicate measurements, demanding assay procedures which are 
not only robust, and, by definition, reproducible, but are also rapid allowing efficient 
throughput of samples without compromising analytical accuracy. Therefore, in the 
absence of suitable established assays, it was necessary to develop methodology which 
satisfied these criteria. Furthermore, the fact that heat denaturation of albumin-bearing 
microspheres and prolonged release studies were anticipated as part of the formulation 
development work in this study, it was also considered necessary to develop suitable 
HPLC methods to quantify the effects of such operations. 
Following development of satisfactory chromatographic separations, it is generally 
accepted that the reliability of analytical procedures can only be assured when 
the 
attributes of the methodology have been scrutinized under the conditions of 
the 
procedures intended use. These data comprise what is known as assay validation, which, 
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for stability-indicating procedures, should describe fairly rigorous testing of the analytical 
accuracy, specificity and reproducibility of the technique. 
As INH and RIF are often administered together, the validity of a technique for their 
simultaneous determination is axiomatic. In addition, combination assays have several 
operational and pragmatic advantages when compared with individual determinations of 
the species of interest. These include time efficiencies, increased sample throughput, 
reduced capital costs in terms of not having dedicated equipment for individual assays, 
notwithstanding the economic and environmental implications of reduced solvent 
consumption. For in vivo assessment of the formulations suggested as future work in this 
thesis, a chromatographic separation of RIF, INH and their principal metabolites was 
additionally developed. 
2.2 Experimental procedures 
2.2.1 Materials 
All materials used in the experimental work contained in this thesis are tabulated in 
Appendix 1. No further reference is made to these hereafter. 
2.2.2 Chromatographic procedures 
The modular liquid chromatograph comprised a Jasco (Tokyo, Japan) PU-980 isocratic 
chromatography pump and a UV-975 variable wavelength UVNIS detector. 
Chromatograms were recorded either on a BBC Servegor chart recorder (Belmont 
Instruments, Glasgow) or a Shimadzu SPD-M6A UV photodiode array (PDA) detector in 
conjunction with its associated software package (Tokyo, Japan). The latter equipment 
allowed the spectral properties of eluted analytes to be additionally examined. 
Quantification of detector response was performed at 240 nm (RIF) or 263 nm (INH) and 
measured as heights or integrated areas using a Hewlett Packard 
(Avondale. PA, USA) 
HP 3395 integrator. A Rheodyne 7125 injection valve (Cotati, CA, USA) fitted with a 20 . tl 
fixed volume loop was used for sample introduction by direct 
injection. The column- 
switching (CS) configuration was utilized in the backflush mode. 
A Shimadzu (Tokyo, 
Japan) LC-5A isocratic pump was used to load a 50 x2 mm precolumn packed with 
10 
µm ODS-Hypersil. CS was facilitated using a 
Rheodyne 7120 switching valve as seen in 
Scheme 2.1. For CS procedures, a 400 µl fixed volume sample loop was used. 
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All columns used were slurry-packed in the laboratory - using propan-2-ol, hexane and 
methanol serially - at a pressure of 55 MPa using a Stanstead (Essex, UK) pneumatic 
pump. The analytical column used for the RIF and INH stability indicating HPLC assays 
were 100 x 4.6 mm i. d and 200 x 4.6 mm respectively, both packed with 3 µm 
octadecylsilyl-modified silica (ODS-Hypersil). A 30 x 4.6 mm i. d. in-line guard column was 
similarly packed. Development of an assay capable of simultaneously separating INH, 
RIF and their principal metabolites involved use of a number of reverse stationary phases 
in a variety of column dimensions. 
r-(-i 
Detector 
Analytical column 
Load phase . 
Valve with 
sample loop 
Scheme 2.1 Schematic of switching valve configuration 
Mobile phase 
Waste 
The column-switching configuration and solvent flow patterns can be seen in Scheme 2.1. 
Chromatographic conditions for CS were as follows: 
1. the precolumn and analytical columns were conditioned with load and analytical 
phases respectively for two minutes (position A); 
2. HPLC water was used to load the samples from the injection loop, at a rate of 1.0 mL 
min-' to the precolumn for 1.5 min (position B). The analytes were retained at the top of 
the precolumn while the sample solvent and poorly retained medium adjuvants were 
eluted to waste, and; 
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3. the valve was then switched, directing the analytical phase (as above) through, and 
eluting the retained analytes from the precolumn for separation on the analytical column 
(position C). 
2.2.3 Assay validation 
2.2.3.1 Linearity 
Linearity of detector response was established by preparing solutions of RIF and related 
products from DMSO standard at eight levels between 0.5 - 50 and 0.05 - 50 pgmL-1 for 
DI and CS, respectively. DMSO was chosen for preparation of standard solutions as it 
has been shown to maintain RIF stability (Karlson & Ulrich, 1969) unlike methanol and 
acetonitrile in which RIF has limited stability (Graham, 1979). These concentrations 
represented the anticipated concentration range of dissolution samples paying regard to 
the need to maintain `sink' conditions. The resultant peak areas of triplicate injections at 
each level were averaged, and linear regression of these values versus concentration 
was performed. In analogy, calibration standards of INH and related degradates were 
prepared in Sorensens buffer modified (SBM) containing 0.1 %w/v Tween®80 (pH = 7.4 ± 
0.1) in the approximate range 1- 150 µgmL-1. The increased concentrations when 
compared with those for RIF, reflected the greater solubility of INH and the reduced 
sensitivity demands with respect to the need to maintain 'sink' conditions. Limited interim 
validation for linearity in aqueous medium of the combination assay of RIF, INH and 
associated analytes was performed. Individual analytes were chromatographed at 5 
levels over the range 200 - 2000 ngmL-1. 
2.2.3.2 Reproducibility 
Within-day precision was established by repeat injections of each analyte at an 
approximate concentration of 1 pgmU1 for RIF and associated analytes, whereas a 
concentration of 5 pgmU1 was used for INH and isonicotinic acid (INA). In contrast, 
between-day precision was demonstrated by the constancy of the calibration statistics for 
each analyte, determined on 5 successive days. 
2.2.3.3 Specificity 
Assay specificity was established based on peak geometry and correspondence of peak 
position with that of reference standards where these were available 
irrespective of the 
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HPLC procedure. In addition, peak purity index was also computed by comparison of the 
absorbance ratio at two wavelengths of the up-slope, apex and down-slope of each peak 
using PDA detection for both RIF and INH stability-indicating procedures. 
2.2.3.4 Accuracy 
Accuracy of the CS configuration was established in the presence of parent drug and 
decomposition products by a standard addition method by spiking dissolution samples at 
concentrations of 1,5 and 20 pgmL-1 for RIF and RSV only. Corresponding standards for 
INH and INA were at levels of 5,20, and 50 pgmL-1. 
2.3 Results and Discussion 
2.3.1 Stability indicating HPLC assay for rifampicin 
Since the decomposition products of RIF have similar absorption spectra as seen in 
Figure 2.1, or are biologically active, their presence interferes in spectrophotometric and 
microbiological assay techniques, necessitating recourse to HPLC for quantitative 
assessment of RIF stability (Graham, 1979). Chemical structures of RIF and its 
degradates are shown in Figure 2.2. Two major antimicrobial decomposition products 
exist, namely, 3-formyl rifamycin SV (RSV) and rifampicin quinone (RQU) (Seydel, 1970). 
Hydrolysis of the 4-methylamino piperazine moeity in acidic medium results in RSV, 
whereas RQU is formed in alkaline medium in the presence of oxygen (Seydel, 1970). 
Conversely, 25-desacetylrifampicin (DAR) is reportedly formed in alkaline medium in the 
absence of oxygen (Gallo & Radaelli, 1976). 25-desacetyl-21-acetylrifampicin (25-21) and 
25-desacetyl-23-acetylrifampicin (25-23) are formed sequentially from DAR, and, unlike 
other identified decomposition products, have negligible antimicrobial activity (Maggi et 
al., 1968). 
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Figure 2.1 Normalised UV spectra with respect to concentration of rifampicin and its 
decomposition products. Legend indicates the abbreviated analyte. 
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Despite the well reported stability problems associated with RIF (Seydel, 1970; Graham, 
1979; Gharbo et al., 1989; Prankerd et al., 1992; Nahata et al., 1994; Jindal et al., 1995; 
Krukenberg et al., 1996; ) few stability-indicating procedures have been described. HPLC 
has been used to analyse the stability of RIF in suspension formulations, although the 
reports lack analytical detail (Nahata et al., 1994; Jindal et al., 1995). Krukenberg et al. 
(1996) described a further stability-indicating HPLC method to examine the stability of 
extemporaneously prepared RIF suspensions. Graham (1979) developed a reverse- 
phase HPLC procedure capable of separating and quantifying RIF and its decomposition 
products in bulk formulations. Both the latter reports described chromatography having a 
relatively high analysis time of 18 min and both used a complex tertiary mobile phase. For 
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routine stability analysis, short analysis times which allow high sample throughput with a 
concurrent reduction in solvent consumption are advantageous. The ability to determine 
inactive degradates of RIF, as well as those with antimicrobial activity, provides additional 
information which has hitherto not been reported. 
2.3.1.1 Method development 
Protracted analysis times are a general feature of published RIF stability-indicating 
methods. Graham (1979) previously reported the need for gradient elution to produce 
efficient separation and to elute RQU in a reasonable time using ODS stationary phase 
packing, presumably due to differences in analyte hydrophobicities when compared with 
parent RIF and other degradation products. The chromatographic separation described 
here was based on a bioassay of RIF and its two main metabolites, DAR and RSV (Ratti 
et al., 1981). This procedure achieved adequate resolution of these three analytes on 
ODS with a mobile phase of acetonitrile - 50 mmol L-1 aqueous phosphate buffer (37 - 63) 
adjusted to pH 4.5. 
In Figure 2.3 the effect of mobile phase pH on analyte column capacity factor is 
presented. With the exception of RQU, marked decreases in capacity factors and thus 
retention as pH increased, were generally observed around pH 4.5 - 5.5. This was 
attributed to changes in the ionization character of the C, and C4 para-hydroxy array seen 
in Figure 2.2, thus explaining the alternative ionization behaviour of RQU, in which this 
feature is absent. 
These data corroborate the existence of a third dissociation constant proposed by 
Prankerd et al. (1992) at pH 5.93 for RIF but contest its assignment to the N- 
methylpiperazine nitrogen, absent from RSV, yet present in RQU. Nonetheless, above pH 
4.5 - 5.5 the charge associated with hydroxyl deprotonation reduced overall analyte 
hydrophobicities and therefore retention. At pH 2.0 the reduced retention of all analytes 
except RSV corroborates the pKa assignment of Prankerd et al. (1992) to the piperazine 
nitrogens common to all other analytes except RSV. Based on this behaviour, the 
selection of a mobile phase pH of 4.5 by Ratti et al. (1981) would be expected to greatly 
reduce assay ruggedness, analyte retention being particularly sensitive to small variation 
in pH around this value. 
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Figure 2.3 Variation of column capacity factor for rifampicin and its degradates as a 
function of mobile phase pH. Chromatographic conditions: mobile phase, acetonitrile - 50 
mmol L-1 aqueous phosphate buffer (36 - 64); flow rate of 1.0 mL min' through a 100 x 
4.6 mm I. d. column packed with 3 µm octadecylsilyl-modified silica. Detection at 240 nm. 
Legend indicates abbreviated analyte. 
The hydrophobicity conferred on RQU by its quinone =0 groups has resulted in the use 
of less hydrophobic stationary phases, octasilyl-modified silica, to reduce analyte 
retention (Graham, 1979). However, increases in pH beyond 7.0 resulted in sufficient 
ionization of the remaining naptholic hydroxy group of RQU to adequately reduce 
retention and achieve acceptable analysis times. The mobile phase flow rate was 
additionally increased to 1.4 mL min"', to further shorten analysis run time without 
affecting analyte resolution. 
Elevated mobile phase pH is known to have a potentially deleterious effect on column 
performance through hydrolysis of the bonded ODS (R. B. Taylor, personal 
communication). Representative chromatograms in Figure 2.4 show that the use of pH 
7.5 and an in-line guard column resulted in adequate resolution whilst maintaining 
acceptable analysis times. Constancy of retention times and integrated areas for all 
analytes throughout the present work demonstrated the in-line guard column ensured 
analytical column longevity. The optimal analytical phase for both direct injection (Dl) and 
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(CS) chromatographic configurations comprised acetonitrile - 50 mmol L-' aqueous 
phosphate buffer (36 - 64) adjusted to pH 7.5 with orthophosphoric acid delivered 
isocratically at 1.4 mL min-'. 
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Figure 2.4 Normalised representative chromatograms of rifampicin and its decomposition 
products for each chromatographic configuration. Chromatographic conditions: mobile 
phase, acetonitrile-50 mmol L-' aqueous phosphate buffer (36-64) adjusted to pH 7.5; 
flow rate of 1.4 mL min-' through a 100 x 4.6 mm W. column packed with 3µm 
octadecylsilyl-modified silica. Detection at 240 nm. 
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Peaks were assigned by correspondence of position when compared with reference 
standard. It is noteworthy that 25-21 and 25-23 could not be resolved, using the 
described analytical phase. Attempts to resolve these by manipulation of pH and solvent 
strength were largely unsuccessful or had an unfavourable effect on the retention of other 
analytes. Nonetheless, no other published method has considered the presence of these 
two decomposition products, which, significantly, are biologically inactive. In addition, an 
equilibrium has been shown to exist between 25-21 and 25-23 with acetyl migration 
occurring readily in solution between positions 21 and 23 (Maggi et al., 1968). Therefore, 
although the described method cannot quantitate these compounds individually, the 
capability of quantifying these collectively would be of significance due to their 
antimicrobial inactivity. 
Two chromatographic configurations were examined using the developed mobile phase; 
DI and a CS procedure. The determination of low dose potent drugs (Bell & Ip, 1993) in 
dissolution samples has utilized CS as a technique to preconcentrate the active 
ingredient on a small precolumn, with backflushing on to the analytical column for 
separation. This technique has particular utility for determination of released drug during 
dissolution testing particularly where demands on analytical sensitivity are high. Such 
situations prevail where the drug is of low aqueous solubility; is of low dose (given that 
dissolution testing is normally performed in 900 mL of aqueous buffer); or, has low 
intrinsic UV-absorbing capacity. In addition, batch sizes for microspherical formulations 
are not uncommonly in milligram amounts. This, coupled to the need for several 
characterization techniques with replicate measurement, e. g., drug content, DSC, particle 
size analysis and microscopy for a single batch of product, favours techniques such as 
CS which allow a reduction in the sample required without compromising the precision 
and accuracy of any measurements made. 
In analytical terms, the loading of hydrophobic analyte with water on to hydrophobic ODS 
phase should ensure its tenacious retention as a plug of analyte at the top of the 
precolumn. Where this analyte behaviour prevails, efficient sample clean-up whilst 
preventing band-broadening effects, which ultimately reduce analytical sensitivity and 
column efficiency, should result. Band-broadening occurs as a result of the analyte being 
introduced to the analytical column during valve switching as a diffuse band rather than a 
concentrated plug. In Figure 2.5, where the effect of precolumn loading time on peak 
height for RIF and RSV is presented, peak depression associated with band-broadening 
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was observed consistent with analyte migration and diffusion in the precolumn with 
elevated loading times. Therefore a compromise between adequate sample clean-up and 
minimal band-broadening must be attained. Absence of interfering peaks from dissolution 
medium adjuvants, and satisfactory peak heights seen in Figure 2.4 showed these 
competing factors were optimally satisfied at loading times of 1.5 min. 
0 ! -- i+ 
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Loading time / min 
Figure 2.5 Effect of precolumn loading time on the peak height response for rifampicin 
and 3-formyl rifamycin SV. Chromatographic conditions: loading phase, water isocratically 
delivered at 1.0 mL min-' through a 50 x 4.6 mm i. d. column packed with 10 µm 
octadecylsilyl-modified silica. Other conditions as per Figure 2.4. Legend indicates 
abbreviated analyte. 
2.3.1.2 Assay validation 
The results in this section are presented as a comparison of the two chromatographic 
configurations studied. As the assay was principally developed with a view to monitoring 
release of RIF from prolonged-release biodegradable polymeric devices, dissolution 
medium was initially used as diluent for validation of both chromatographic configurations. 
However, a broad peak appeared at 25 min using DI which was absent when Tween® 80 
was not included in the diluent. No evidence of this peak was noted when precolumn 
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loading times >_ 1.5 min were employed, thus highlighting the sample clean-up utility of 
CS. As no discernible differences in chromatographic characteristics were detected for 
RIF and its degradates in the presence or absence of Tween® 80, validation data for 
direct injection was obtained without the addition of Tween® 80. 
The slope consistency of the standard graphs was checked on 5 successive days which 
yielded the regression statistics seen in Table 2.1. Whereas, the RSD of the slope for all 
analytes using CS was <1%, the corresponding statistics for DI were more variable. The 
mean intercepts for all calibration lines using CS were not greater than ± 0.95 % of the 
values for detector response at the 100 % analyte level. The corresponding values for 
both DAR and 25-21/25-23 exceeded the recommended limits of ±2% (Braggio et al., 
1996) which were 3.56 % and 4.23 % respectively when DI was employed. This is 
attributed to a protracted solvent front probably arising from the addition of weakly 
retained protectants and medium adjuvants as can be seen in Figure 2.4. With CS the 
loading step allowed washing of these weakly retained additives during preconcentration, 
greatly reducing the amounts passing to the analytical column. This explains their 
absence in chromatograms using this configuration. 
Table 2.1 Regression statistics for calibration of detector response with rifampicin based 
analytes using direct injection and column switching, n=5. 
Analyte Direct injection Column switching 
Mean slope Mean r2 (RSD) Mean slope Mean r2 (RSD) 
(RSD) (RSD) 
DAR 3.008x105 (1.84) 0.997 (0.13) 5.755x106 (0.99) 0.998 (0.13) 
25-21/23 2.195x105 (1.98) 0.998 (0.18) 4.403x106 (0.85) 0.999 (0.10) 
RIF 3.188x105 (1.59) 0.998 (0.15) 5.906x106 (0.98) 0.999 (0.03) 
RSV 3.332x105 (1.51) 0.999 (0.09) 6.404x106 (0.28) 0.999 (0.01) 
RQU 2.628x105 (1.65) 0.992 (1.30) 5.423x106 (0.72) 0.998 (0.12) 
CS yielded superior reproducibility for all analytes, with a RSD of 0.25 - 0.65 % compared 
with 1.75 - 3.56 % for DI. Ordinarily, a2% difference between replicate injections would 
be acceptable for HPLC (Bell & Ip, 1993). Clearly DI was inadequate at lower drug 
concentrations. Large variations for DAR (RSD = 3.56 %) and 25-21/25-23 (RSD = 2.48 
%) were attributed to variable solvent front effects. Day-to-day precision was established 
by the low RSD values for the calibration statistics listed in Table 2.1. 
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Specificity was evident from the accuracy data obtained below and also from the 
chromatogram shown in Figure 2.4. Further to this peak purity was examined for RIF and 
RSV during dissolution runs using PDA detection. Peak homogeneity was established by 
measuring the UV spectra on the up-slope, apex and down-slope of each peak for RIF 
and RSV during release studies. Values of peak purity index were computed to be > 0.99 
for RIF and RSV throughout. 
Using the standard addition method, linear regression of the areas obtained versus 
concentration added yielded straight lines for RIF (r2 = 0.997) and RSV (r2 = 0.998) 
parallel to calibration lines using aqueous standards of the same concentrations. The 
intercepts on the area axis corresponded well to the initially determined RIF and RSV 
areas for pre-spiked dissolution samples (P > 0.01). 
In addition to the above data, limit of quantification for each analyte studied in the RIF 
stability-indicating procedure was determined, the results of which can be seen in Table 
2.2. 
Table 2.2 Limits of quantification for rifampicin and its decomposition products. 
Chromatographic Sample Limit of Quantification / ngmL"' 
configuration volume / µl 
DAR 25- RIF RSV RQU 
21/23 
Direct injection 20 215 275 250 260 400 
Column switching 400 20 36 25 24 39 
CS allowed the application of a large volume of sample to the precolumn, where the 
analytes were preconcentrated before separation and determination. Increases in 
analytical sensitivity were accordingly quantitative with the mass of analyte applied to the 
precolumn, whereby a 20-fold increase in detector response was recorded using CS in 
proportion to the increase in injection volume when compared with direct injection (P > 
0.01). Band-broadening effects associated with prolonged precolumn loading stages with 
column switching were not discernible from comparisons of chromatograms using each 
configuration shown in Figure 2.4. It follows, therefore, the limits of quantification could be 
reduced further by sequential application of injections to the precolumn. However, for the 
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purposes of the current work, single application of a 400 µl loopful resulted in adequate 
sensitivity. 
2.3.2 Stability indicating HPLC assay for isoniazid 
Despite the fact that the instability of INH has been described in a number of contexts: 
including aqueous solution (Lewin & Hirsch, 1954; Pawelczyk et al., 1969); sugar media 
(Hald, 1969; Rao et al., 1971; Jain & Madan, 1974); determination of carcinogenic 
hydrazine residue (Butterfield et al., 1981; Matsui et al., 1978,1983; Lovering et al., 
1982); and, in biological matrices for therapeutic drug monitoring (Hutchings et al., 
1983a, b, 1988); no HPLC stability-indicating procedure has been described in the 
English-speaking literature. Hutchings et al. (1983a, 1988) used HPLC to demonstrate 
the protective action on INH and its principle metabolite, acetylisoniazid, of storage at -70 
°C and 4 °C for plasma and saliva samples, respectively. Instability, prevented by such 
treatment, may have led to erroneous assumptions of non-compliance or over-dosage in 
samples not so treated. Adulterant isoniazid-derived hydrazine has been detected by TLC 
(Matsui et al., 1977), GLC (Matsui et al., 1983) and normal phase HPLC (Butterfield et al., 
1981; Lovering et al., 1983). Several reports have investigated the condensation of 
isoniazid with reducing sugars, glucose and fructose to form the corresponding 
isonicotinoyl hydrazones (Hald, 1969; Rao et al., 1971; Jain & Madan, 1974) using a 
variety of titrimetric and fluorimetric methodologies; specificity of which relied on the free 
amine moeity of the parent drug. Only two early studies of the aqueous stability of INH 
are reported (Lewin & Hirsch, 1954; Pawelczyk et al., 1969). These described insensitive 
colorimetric and non-specific microbiological methodologies in the earlier report, whereas 
the latter exploited an involved separation by TLC followed by polarographic analysis of 
the INH eluate. 
In aqueous solution, INH readily undergoes hydrolysis to yield isonicotinic acid (INA); 
isonicotinamide (IAD), diisonicotinoylhydrazine (DIN) and hydrazine (Lewin & Hirsch, 
1954). Whereas in anaerobic conditions the hydrolysis of INH follows pseudo first-order 
kinetics, the decomposition in 02 is more complicated and the definitive products thereof 
have not been identified (Pawelczyk et al., 1969), although isonicotinamide (IAD) and iso- 
nicotinic acid N-oxide (INN) are potential candidates. Figure 2.6 illustrates the chemical 
structures of these products. 
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Figure 2.6 Structural features of isoniazid and its decomposition products 
David F. Bain 
Degradation has been shown to be sensitive to the presence of free cupric or manganous 
ions, whereby drug destruction has been shown to be prevented by a number of 
substances with the common capacity of binding such ions, e. g., EDTA and certain 
polybasic organic acids, e. g., citrate. Furthermore, addition of dilute hydrogen peroxide 
greatly increased INH deterioration. Thus, oxidation catalysed by certain metal ions 
appears to be a significant degradative route to unprotected INH. Elimination of the 
effects of these insults, however, confers significant stability on the drug (Lewin & Hirsch, 
1954). 
2.3.2.1 Method development 
The chromatographic separation was based on the parent drug, INH and its predominant 
hydrolytic decomposition product INA. Two other potential degradates, IAD and INN were 
additionally examined. The basis of the separation was performed on octadodecyl- 
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modified silica (ODS). Available log Po values for INH, IAD, INA were -0.70, -0.37, -0.57, 
respectively (Hansch et al., 1995). Values for INN and DIN could not be sourced. These 
values indicate the hydrophilic nature of these analytes which were anticipated to have 
low retention on hydrophobic stationary phases such as ODS. Thus, adequate retention 
and resolution were achieved by the use of a long column packed with 3 µm particles to 
maximize column efficiency. In Figure 2.7 the profile of column capacity factor as a 
function of pH can be seen at an organic modifier level of 20 %v/v methanol. 
The retention behaviour of the analytes was consistent with their ionic character between 
pH 2.0 - 4.0 whereby protonation of the basic terminal primary hydrazide NH2 reduced the 
lipophilicity and thus retention of both INH and IAD with reduced pH. Conversely, 
enhanced retention of INA and INN was attributed to protonation of the carboxylic acid 
moeity common to these compounds as pH decreased, rendering them more 
hydrophobic. The anomalous behaviour above this range could not be ascribed to the 
ionization constants and was a consequence of the low and variable to values which 
affected the determination of column capacity factor. 
2 3 4 6 7 8 5 
pH 
Figure 2.7 Variation of column capacity factor as a function of pH for 1) INH; 2) INA; 3) IAD, and, 
4) INN. Chromatographic conditions: mobile phase methanol - 20 mmol L"' aqueous phosphate 
buffer (20 - 80) at a flow rate of 1.4 mL min-' 
through a 200 x 4.6 mm i. d. column packed with 3µm 
ODS-Hypersil. Detection at 263 nm. 
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Figure 2.8 Variation of column capacity factor as a function of organic modifier 
concentration: INH (1); INA (2); lAD (3); and, INN (4). Chromatographic conditions: 
mobile phase methanol - 20 mmol L-' aqueous phosphate buffer pH 6.0 at a flow rate of 
1.4 mL min-' through a 200 x 4.6 mm i. d. column packed with 3 µm ODS-Hypersil. 
In general, retention was poor as indicated by the low capacity factors for all analytes, 
particularly INA and INN. In order to achieve adequate separation of analytes and 
increase their retention a pH of 6.0 was selected whilst the organic modifier concentration 
was reduced, the effect of which on column capacity factor can be seen in Figure 2.8. 
Additionally, selection of a pH at which INA eluted before INH was anticipated to increase 
the overall mass sensitivity for this principal degradation product which would be present 
in most analyses at considerably lower levels than the abundant INH. Based on the 
profiles in Figure 2.8, the chromatographic separation seen in Figure 2.9, which achieved 
adequate resolution of all analytes and a satisfactory distance of the chromatographic 
peaks from the solvent front, utilized a mobile phase comprising methanol - 20 mmol L-' 
aqueous phosphate buffer (5 - 95) at pH 6.0. The assay based on this solvent system 
was thereafter validated according to section 2.3.2.2. At a flow rate of 1.4 mL min-', this 
solvent was pumped through a 200 x 4.6 mm W. column packed as above with 3 p. m 
ODS-Hypersil. 
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Figure 2.9 Normalized representative chromatograms with respect concentration of 
isoniazid and its decomposition products. Chromatographic conditions: mobile phase, 
methanol - 20 mmol L"' aqueous phosphate buffer (5 - 95) adjusted to pH 6.0; flow rate of 
1.4 mL min-' through a 200 x 4.6 mm i. d. column packed with 3 µm octadecylsilyl- 
modified silica. Detection at 263 nm. Labels indicate abbreviated analyte. 
2.3.2.2 Assay validation 
The constancy of regression statistics was assessed on four consecutive days, 
regression statistics of which feature in Table 2.3. Compliance with the recommended 
limit of variation of the slope cited by Braggio et al. (1996) of ± 2.0 % was confirmed 
indicating the absence of solvent front persistence as discussed in section 2.3.1.2. The 
mean intercepts were less than ± 0.95 % relative to the magnitude of the corresponding 
detector response at the 100 % analyte level. 
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Table 2.3 Between day regression statistics for isoniazid derived analytes n=4 
Analyte Mean slope x 10'5 (RSD) Mean r2 (RSD) 
INH 1.031 (1.35) 0.999 (0.103) 
INA 1.173 (1.94) 0.997 (0.125) 
IAD 0.482 (0.78) 0.999 (0.054) 
INN 1.963 (1.89) 0.999 (0.070) 
The variability of repeat injections at an approximate analyte level of 10 pgmL-' are 
presented in Table 2.4. Between day precision was established as per section 2.3.1 
Table 2.4 Normalized precision data for INH and degradates at a concentration of 10 
µgmL-', n=5 
Analyte 
Attribute INH INA lAD INN 
Peak area x 10'6 1.002 1.178 0.479 1.928 
RSD I%0.16 0.45 0.29 0.42 
Linear regression statistics for the standard additions of 5,20 and 50 µgmL-' to 
dissolution samples from albumin based formulations (section 9.3) yielded parallel 
straight lines for both INH (r2 = 0.989) and INA (r2 = 0.970) to that of the corresponding 
regression derived from aqueous standards of the same concentration. The intercepts on 
the area axis equated to INH and INA concentrations in pre-spiked dissolution samples (P 
> 0.05). 
Specificity of the procedure was confirmed as per section 2.2.3.3 based on accuracy 
data, peak purity index and peak position with respect to standard solutions. Peak purity 
indices for INH and INA were > 0.99 and > 0.98 respectively. The interfering peak in the 
RIF assay (section 2.3.1), considered to emanate from Tween®, was not apparent during 
validation. The longer column used for INH compared with RIF would have had greater 
on-column diffusive effects, which apparently eliminated the baseline perturbence 
associated with this peak. 
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2.3.3 Combination HPLC assay for rifampicin and isoniazid 
Determination of biological INH and RIF levels has, historically, been of great interest due 
to the interactions of their metabolism which frequently culminates in hepatotoxicity 
(Lecaillon et al., 1978; Ratti et al., 1981; Guillaumont et al., 1982; Oldfield et at., 1986; 
Woo et al., 1987; Lau et al., 1996). Metabolic variability between patients due to liver 
degradation of INH into inactive AcINH by an acetyltransferase whose activity is 
genetically determined, allied to powerful induction of RIF on liver metabolism, 
complicates dose prediction (Guillaumont et al., 1982). Numerous HPLC assays for the 
determination of INH (Hutchings et al., 1983) and RIF (Lecaillon et al., 1978; Ratti et al., 
1981; Oldfield et al., 1986; Lau et at., 1996) in biological matrices have been reported. 
However, few combination assays for anti-tubercular drugs have been developed, 
presumably due to the chromatographic challenge of efficiently separating INH, PYZ and 
RIF, drugs of dramatically different hydrophobicities. Consequently, those which are 
described invariably involve gradient elution to achieve acceptable analysis times (Woo et 
at., 1987). Guillaumont et al. (1982) developed a method in which RIF and INH, and their 
main metabolites, DAR and AcINH, respectively, could be differentially extracted from a 
single plasma sample. Separation and determination thereafter was performed on the 
same stationary phase, ODS, but using different mobile phases. Separation of INH and 
RIF and some of the latter's degradation products for formulation evaluation (Shah et at., 
1992) and dissolution monitoring (Gharbo et al., 1989; Jindal et at., 1994) are amongst 
few other combination assays described. The assay described below (section 2.3.3.1) 
was developed in a speculative manner, and, although not utilized in the work described 
hereafter, should prove invaluable pending full validation during assessment of in vivo 
performance suggested as part of further work in this thesis. 
2.3.3.1 Method development 
The developed HPLC procedure for simultaneous separation of RIF, INH and their 
predominant metabolites in man, DAR, RSV and AcINH respectively was indirectly based 
on a earlier chromatographic method for INH and PYZ (Gaitonde & Pathak, 1990). The 
oxidation product of RIF, RQU, was also prospectively considered to account for the 
probable deterioration of RIF during extraction procedures of analytes from biological 
matrices. Gaitonde & Pathak (1990) reported a rapid, sensitive and precise method for 
the estimation of INH and PYZ in plasma and urine. However, the authors used RIF as 
internal standard, a particularly illogical choice given that RIF invariably features in 
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treatment regimes for tuberculosis and would therefore be present as an interferent in 
biological samples requiring analysis. Indeed, the recoveries of > 99 % quoted for both 
analytes, INH and PYZ, irrespective of the biological medium, questioned the need for its 
inclusion. Moreover, the authors failed to identify the potential utility of a procedure 
purported to separate the three principle anti-tubercular drugs in clinical use. 
The stationary phase utilized by Gaitonde & Pathak was a mixed-phase ODS-cyano (CN) 
(phase proportions unspecified). Attempts to source in the UK the Excaliber® ODS-cyano 
(CN) column described in that work were unsuccessful. Therefore, the current work 
examined a mixed-phase ODS and CN of arbitrary composition ODS : CN (1: 1). A pH of 
2.0 was chosen to develop the chromatographic separation as all analytes at this pH, 
were either protonated bases, e. g., RIF, DAR, RQU, and INH or uncharged moeties, e. g., 
RSV. AcINH was also considered protonated at this pH due to the available hydrazide 
NH2 moeity on this molecule. Consequently, the separation strategy of Taylor et al. 
(1984) was adopted which involves addition of an hydrophobic ion-pairing agent to the 
mobile phase to manipulate retention of both charged and uncharged analytes. This has 
proved a powerful technique allowing the separation of analytes of widely different 
hydrophobicities and ionic character (Taylor et al., 1984). In Figure 2.10 the effect of 
hydrophobic sodium dodecyl sulphate (SDS) addition to the mobile phase on analyte 
retention can be seen on both mixed phase ODS-CN phase and ODS to elucidate the 
contribution that CN made to the overall separation. 
The chromatographic response of the analytes to SDS can be generally interpreted as 
follows. Initially there is an increased retention for protonated species, e. g., RIF, RQU, 
DAR, INH and AcINH as the adsorbed charged pairing ion, SDS, electrostatically attracts 
these ions to the stationary phase surface, where they subsequently desolvate and are 
retained. The amount of SDS adsorbed on the stationary phase surface increased upon 
further addition of SDS, thus reducing the available surface for analyte desolvation. The 
retention of all charged analytes therefore reaches a maximum, after which point, 
retention decreased. As an uncharged solute, RSV showed a typical profile of reduced 
retention in parallel with the reduced availability of stationary phase surface for 
desolvation as SDS concentration increased. 
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Figure 2.10 Variation of column capacity factor for rifampicin, isoniazid and related 
compounds with various concentrations of sodium dodecyl sulphate (SDS) in the mobile 
phase. Chromatographic conditions: mobile phase, acetonitrile - 10 mmol L-1 aqueous 
phosphate buffer (50 - 50) adjusted to pH 2.0; flow rate of 1.4 mL min-' through: A, a 200 
x 4.6 mm i. d. column packed with 5 µm CN-ODS (50: 50); and, B, a 150 x 4.6 mm i. d. 
column packed with 3 µm ODS. Detection at 240 nm. Legend indicates abbreviated 
analyte. 
Analytical method development 61 
Development and characterization of biodegradable microspheres containing selected antimycobacterials David F. Bain 
Comparison of the_plois_ in Figure 2.10 revealed a number of important observations. At 
the high organic modifier concentrations used, INH and AcINH were poorly retained on 
ODS alone as anticipated from the data in section 2.3.2.1. Therefore, SDS was added to 
improve retention of these weakly-retained species. Nonetheless, the small, but 
measurable parabolic behaviour as a function of SDS concentration revealed that ionic 
interaction was contributing to the retention mechanism of these analytes. Inclusion of 50 
%w/w CN phase further enhanced retention disproportionately to the increase in column 
length, i. e., 200 compared with 150 mm, thus illustrating a contribution of this material 
also to overall retention of INH and its metabolite. Additionally, the use of CN ensured 
adequate separation from the solvent front of the most poorly retained analyte, AcINH. In 
general, all RIF associated analytes were less retained on the mixed-phase column. This 
was attributed to poorer adsorption efficiency of the SDS on the less hydrophobic ODS- 
CN phase, although the adsorption isotherms were not however measured to support this 
postulation. Further evidence for this was the up-shift in peak position of maximum 
retention for such analytes on the mixed-phase column. It was reasoned that the 
approximately two-fold reduction in retention times of RIF derived analytes at a SDS 
concentration of 200 mmol L-1 on ODS-CN compared with exclusively ODS was 
operationally advantageous. Therefore, these data support the use of the mixed-phase 
column which achieved adequate resolution of weakly retained AcINH from the solvent 
front, whilst maintaining acceptable analysis times. An SDS concentration of 200 mmol 
L-1 was chosen for the final mobile phase which represented the optimal separation in 
terms of resolution, sample throughput and finally, assay ruggedness; whereby small 
changes in SDS concentration would have little effect on analyte retention at such high 
levels. A representative chromatogram of the final separation is shown in Figure 2.11. 
The optimal mobile phase comprised acetonitrile - 10 mmol L-1 aqueous phosphate buffer 
(50 - 50), 200 mmol L-' SDS, adjusted to pH 2.5. 
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Figure 2.11 Representative chromatogram of: rifampicin, isoniazid and related 
compounds. Chromatographic conditions: mobile phase, acetonitrile - 10 mmol L-' 
aqueous phosphate buffer (50 - 50), 200 mmol L-' SDS, adjusted to pH 2.5; flow rate of 
1.4 mL min-' through a 200 x 4.6 mm i. d. column packed with 5µm ODS-CN (50: 50). 
Detection at 240 nm. Labels indicate abbreviated analyte. 
2.3.3.2 Assay validation 
Preliminary validation of detector linearity yielded the regression statistics presented in 
Table 2.5. Variation in the gradient of the slope generally complied with the limits 
specified by Braggio et al. (1996), with the exception of INH. Correlation coefficients of 
the concentration-response plots established linearity for all analytes when injected 
individually. Whereas, the mean intercepts fell within ± 0.95 % limit relative to the 
magnitude of the detector response at the 100 % level, corresponding values for both 
INH (-2.15 %) and RSV (-2.36 %) did not comply when a mixed standard containing all 
analytes was analysed. In addition, the slope of the calibration lines fell to 0.795 and 
2.205 for INH and RSV respectively. These data indicate a reduced detector response 
Analytical method development 63 
Development and characterization of biodegradable microspheres containing selected antimycobacterials David F. Bain 
than that anticipated. Furthermore, an additional peak appeared on these chromatograms 
at 3.25 min. 
Table 2.5 Regression statistics for calibration of detector response for rifampicin, 
isoniazid and related analytes, detection at 240 nm, n=3. 
Analyte 
AcINH 
INH 
DAR 
RIF 
RSV 
Mean slope x 105 (RSD) 
0.786 (1.98) 
0.845 (2.15) 
2.885 (1.28) 
2.963 (1.89) 
2.475 (0.94) 
Mean r2 (RSD) 
0.977 (2.35) 
0.985 (1.98) 
0.973 (1.95) 
0.980 (1.23) 
0.972 (2.01) 
Jindal et at. (1994) earlier speculated that complex formation between INH and RSV may 
occur in solution in dynamic equilibrium with the starting analytes. They did not, however, 
elaborate on the potential mechanism of the_ reaction which it is proposed here_ occurs 
according to the scheme in Figure 2.12. Subsequent to hydrolysis of RIF to RSV, 
condensation following nucleophilic attack by the electonegative hydrazide NH2 yields the 
corresponding imine. The reduction in the gradients of the calibration lines for both 
analytes is approximately quantitative at 5- 10 % complete although this reaction 
requires rigorous characterization to assess the error it may confer on quantitative 
measurements of these analytes where they co-exist in biological samples. 
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Figure 2.12 Proposed mechanism of reaction between 3-formyl rifamycin SV and 
isoniazid in aqueous solution 
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2.4 Conclusion 
Stability-indicating assays for both INH and RIF and their predominant degradation 
products have been developed and suitably validated in the context of their predominant 
prospective use, i. e., monitoring drug release and formulation stability assessment. The 
use of these separations to quantify drug release from long-acting biodegradable 
formulations is described in the following chapter. From validation data both stability- 
indicating assays were concluded to be linear, precise and specific, hence conforming to 
the basic requirements for stability-indicating procedures (Taylor et al., 1994). Further 
attributes of the procedure for RIF was the use of a binary analytical phase which 
increases assay robustness and, most significantly, a reduced analysis time compared 
with procedures previously described (Graham, 1979; Krukenberg et al., 1996; Jindal et 
al., 1995). The assay for INH used a mobile phase with a small organic modifier 
concentration which was considered advantageous on economic and environmental 
grounds. 
A rapid isocratic separation for INH and RIF and their main metabolites as well as RQU 
was developed which obviated the use of gradient elution to achieve acceptable analysis 
times. The technique used ion-pairing methodology on a mixed-phase column, which, 
pending suitable validation and the development of extraction procedures, represents a 
significant improvement on previously reported work. This separation would form the 
basis of the quantitative determination of both drugs from in vivo release studies 
proposed in this thesis as part of further work. This method, however, requires further 
rigorous validation in biological media. In particular, the apparent complex formation 
between INH and RSV requires further investigation to elucidate its mechanism of 
formation and the extent of reaction before the assay may be reliably applied to the 
determination of levels of these analytes in biological samples. 
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3. Preformulation 
3.1 Introduction 
Preformulation encompasses techniques and studies to determine those physical and 
chemical properties of the particular drug substance which may affect development and 
performance of an efficacious dosage form. This information is essential for rational and 
efficient dosage form design and largely dictates the formulation strategies employed. 
Moreover, these preliminary data allow the formulator to anticipate problems which may 
preclude certain approaches, whilst exploiting inherent drug properties which favour 
others. Preformulation studies must be performed in the context of the overall therapeutic, 
and thus, formulation objective. These entail selective investigations to assess the 
prospective processability of the drug substance itself, and, its manufacturability when 
mixed and compounded with other ingredients. In short, preformulation should provide the 
investigator with a sound working knowledge of the drug to expedite formulation 
development. 
In spite of having identical therapeutic indications, in Figures 2.3 and 2.7 respectively, it 
was shown that RIF and INH have very different chemical structures, and hence 
physicochemistry. Initial preformulation studies were based on solubility, spectral and 
crystalline properties, considered key properties for the preparation and subsequent 
characterization of biodegradable microspheres. These were supplemented with 
analytical and degradation data in response to formulation development difficulties as 
these were encountered. 
3.2 Experimental procedures 
3.2.1 Ultraviolet spectroscopy 
Ultraviolet (UV) spectra were recorded in the X range 200 - 600 nm. After obtaining UV 
spectra, calibration standards over the approximate concentration range 
0.5 - 50 µgmL-1 
were prepared in a range of aqueous and non-aqueous solvents and absorbance 
measured at their respective wavelengths of maximum absorbance, 
Xmax. From linear 
regression of absorbance on concentration, specific absorbance coefficients, 
A; 'T, 
, were 
computed and the regression statistics recorded. 
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3.2.2 Crystallinity and polymorphism 
3.2.2.1 Preparation of crystals 
Supersaturated solutions of drug were prepared by adding excess drug to various 
solvents of a spectrum of polarity: water (620 °c = 80); acetonitrile (620 °c = 38.8); methanol 
(620 oc = 33); ethanol (620 °c = 25); acetone (620 °c = 21); butanol (620 °c = 17.1); 
dichloromethane (620 °c = 9.08); and, chloroform (620 °c = 4.806); which were incubated at 
37 ± 0.5 °C in sealed vials. Supersaturated solution was clarified from undissolved drug. 
Nucleation was then induced by cooling the solution either slowly (at room temperature) 
or quickly by quenching in ice. The crystals thus formed were stored under vacuum at 24 
± 2.0 °C over silica gel prior to characterization. The habit of recrystallized drug was 
assessed microscopically. 
3.2.2.2 Differential scanning calorimetry 
Melting points and enthalpies of fusion for recrystallized products were assessed by 
differential scanning calorimetry (DSC 7, Perkin-Elmer, Connecticut, USA) as part of 
investigations of crystal polymorphism. Samples (5 -7 mg) were scanned at a heating 
rate of 20 °C min-' in a N2 atmosphere. DSC scans were recorded with the associated 
computer controlled software. Instrument calibration was performed on the melting 
endotherms of indium and zinc standards. 
3.2.2.3 Infrared spectroscopy 
Subsequent to vibrational milling (Model CE95, Retsch, Germany), and drying at 100 ±5 
°C for 24 h, potassium bromide was used to prepare drug embedded discs for infrared 
spectral analysis. Discs containing 5 %w/w drug were pressed at 8 tonnes for 15 min 
under vacuum. Infrared (IR) spectra obtained (Perkin-Elmer model 186, Perkin-Elmer, 
USA) were examined and characteristic peaks assigned. 
3.2.2.4 Intrinsic dissolution rate 
Flat-faced discs of drug as supplied and crystalline products weighing 200 ±5 mg and of 
diameter 11 mm were compressed at 10 tonnes for a dwell time of 5 min using a single 
punch Manesty F3 tablet press (Manesty Machines Ltd., Liverpool, 
England). High 
compaction pressures were used to ensure minimal tablet porosity. 
Single tablets were 
secured centrally to the base of a USP dissolution basket with molten 
hard paraffin wax. 
After complete submersion, excess wax was removed 
from the exposed aspect of the 
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tablet to provide a defined area (0.950 cm2) from which dissolution could occur. The 
basket was attached to the stirring shaft rotating at 100 ± 1.0 rpm and submerged in 1L 
of distilled water maintained at 37 ± 0.1 °C. Dissolved RIF and INH were determined by 
UV absorption at 270 and 263 nm, respectively. The amount of RIF or INH dissolved per 
unit surface area was plotted against time. The slope of the initial portion of each profile 
was expressed as a function of the surface area exposed to compute an intrinsic 
dissolution rate, Co (mg cm-2 min-1). Triplicate determinations of Co were performed on 
each batch of recrystallized product. 
3.2.3 Solubility studies 
3.2.3.1 Saturation solubility 
Saturation solubilities of both RIF and INH were examined by addition of a variety of 
aqueous and non-aqueous solvents to an excess of powdered drug in vials. After an 
equilibration period of 8 h, dissolved drug was determined by HPLC. For aqueous based 
solvent systems, equilibration time was limited to 1h as a result of concomitant hydrolytic 
reactions which interfered with saturation solubility determination. Additionally, a number 
of temperatures were examined for selected solvents. Where decomposition exceeded 10 
% of saturation solubility the result was disregarded and repeat determinations 
performed. 
3.2.3.2 pH-solubility profile 
The solubility of INH at various pH values was determined as follows. Under constant 
stirring, excess drug was added to a dilute acidic medium (0.1 mol L") in a double 
jacketed beaker plumbed to a circulating water bath maintained at 37 ± 0.5 °C. This 
mixture was allowed to equilibrate for 2 h. Thereafter, samples (5 mL) were removed by 
syringe through an attached Acrodisc (Gelman, UK) syringe filter of pore diameter 0.45 
µm. The samples were diluted where appropriate and the concentration of INH in the 
resultant solution was determined by the HPLC procedure detailed in section 2.3.2. Fresh 
INH suspension was prepared after the pH was successively increased by controlled 
addition of 0.01 mol L-1 NaOH. The solubilities of INH were plotted against pH. 
The above procedure for INH was followed with the following modification 
for RIF. Due to 
the significant oxidative and hydrolytic decompositions, equilibration 
times were arbitrarily 
reduced to 1h in sealed vials under agitation at 
1 Hz. This step sought to minimize 
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degradate interference through `salting-in' or '-out' effects. To excess drug, degassed 
`universal' citric-phosphate buffer (0.01 mol L) in the pH range 2.2 - 7.5 was added to fill 
the vials thus minimizing headspace and the available 02. Dissolved drug after dilution 
was determined by HPLC as described in section 2.3.1 and then plotted against pH. The 
arbitrary 10 % decomposition limit was applied throughout. 
3.2.4 Drug-polymer interactions 
Subsequent to gently grinding in a mortar with a pestle and sieving (aperture size 100 
gm), individual physical mixes of INH and RIF with a range of Resomer® polymers (1: 1) 
were prepared in small vials with vigorous shaking. Samples (5 - 15 mg) for RIF 
containing mixes were scanned according to the following programme: 1) from 25 - 210 
°C at 10 °C min-'; 2) cooled to 25 °C at 30 °C min-' and; 3) repeat of 1). Samples 
containing INH were subject to the same program with the exception that the maximum 
scan temperature was 185 °C. Individual polymers as supplied were similarly scanned. 
3.2.5 Stability 
3.2.5.1 Rifampicin 
The time course of RIF instability was studied in isotonic Sorensens buffer (modified) 
(SBM) (Dawson et al., 1962) of pH 7.4 ± 0.1 at 37 ± 0.5 °C. Individual stock solutions of 
RIF, RSV and RQU (1 mgmL-1) were freshly prepared in dimethylsulphoxide (DMSO). At 
time zero, amounts of stock solution of each compound yielded nine individual solutions, 
at three concentrations between 3- 50 pgmL-' for each compound when added to 100 mL 
buffer prewarmed in a Grant SS40-2 (Cambridge, UK) thermostated bath. The protective 
effect of various antioxidants was evaluated. Sampling frequency was determined by 
interim analysis of the degradation kinetics. Samples, withdrawn by syringe, were 
analysed by HPLC as described in section 2.3.1. Undecomposed RIF and RSV were 
plotted against time and the kinetics of degradation examined with the aid of an iterative 
curve-fitting programme (CurveExpert version 1.3, Daniel Hyams, 112B Crossgate St, 
Starkville, MS, 39759). 
3.2.5.2 Isoniazid 
The kinetics of INH decomposition were investigated in Sorensens phosphate buffer 
(modified) (SBM), pH 5.8 (approx. 0.07 mol L'). and pH 7.4 (approx. 0.10 mol L 
); 
Mcllvaines citric-acetate buffer, pH 5.88 (approx. 0.28 mol L) and pH 7.4 (approx. 0.37 
mol L-), and; Walpoles acetate buffer, pH 5.8 (approx. 0.07 mol 
L) (Dawson et al., 
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1962). An aqueous standard solution of INH was freshly prepared for each buffer system, 
which, upon dilution in 100 mL of buffer solution yielded a concentration of 20 ±5 µgmL-1. 
Actual pH ranges were all ± 0.1 pH unit of that cited and remained so throughout the 30 d 
period of the study. Samples were withdrawn from sealed flasks by syringe and analyte 
concentration was determined by HPLC (see section 2.3.2). The kinetics of degradation 
were computed as described above. 
3.3 Results and Discussion 
3.3.1 Ultraviolet spectroscopy 
UV spectra of INH and RIF in aqueous solution are shown in Figure 3.1. The range of 
solvents were chosen to speculatively represent those to be used in subsequent 
microencapsulation procedures and other operations. Of particular interest were the A. max 
values, which represented the optimum X of measurement to achieve maximum 
sensitivity where direct UV quantitative methods were used. Summaries of the absorption 
characteristics of INH and RIF are provided in Tables 3.1 and 3.2 respectively. 
200 250 300 350 400 
Wavelength / nm 
Figure 3.1 Ultraviolet spectra of rifampicin and isoniazid in water at 24 ± 2.0 °C 
For INH, the spectral changes under basic conditions were attributed to rapid hydrolytic 
decomposition of INH to INA as described by Lewin & Hirsch (1954). Thus, after 5h the 
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peak at 272 shifted to 256 nm, whilst that at 325 nm largely disappeared. Consequently, 
to minimize errors in the determination of spectral statistics from alkaline solutions, 
absorbance measurements were recorded immediately after solution preparation. 
Table 3.1 Ultraviolet spectral attributes and statistics of isoniazid in a range of aqueous 
and non-aqueous media at 24 ± 2.0 °C, n=2. 
Solvent Xmax t nm 
water 
I% w/w PVA 
0.01 M HCI 
0.01 M Na OH 
chloroform 
dichloromethane 
acetonitrile 
©ýý 
'ý1 cm 
r, 2 
261 305 0.999 
262 298 0.998 
213,265 417 0.999 
272 
, 
295,325 298 0.999 
259 286 0.979 
258 259 0.985 
260 262 0.987 
* wavelength of measurement for Beer-Lambert regression 
Table 3.2 Ultra-violet spectral attributes and statistics of rifampicin in a range of aqueous 
and non-aqueous media at 24 ± 2.0 °C, n=2. 
Solvent 
water 
I% w/w PVA 
0.1 M HCI 
0.1 M Na OH 
chloroform 
dichloromethane 
acetonitrile 
Xmax / nm d1% ^fcm 
ý 
235,338,470 
235,337,478 
235,335,465 
245,335,458 
ý 245,298,390 
403 0.979 
398 0.983 
410 0.999 
416 0.999 
380 0.995 
245*, 295,390 394 0.999 
244*, 295,390 398 0.998 
* wavelength of measurement for Beer-Lambert regression 
3.3.2 Crystallinity and polymorphism 
The crystalline form of the drug can affect both the production and 
biological behaviour of 
the finished form (Florence and Attwood, 1988), through its influence on 
flow, matrix 
architecture and surface area-dependent dissolution 
(Bodmeier & Chen, 1988). In 
addition, during preformulation investigations it is of vital 
importance that sufficient care is 
taken to determine polymorphic tendencies of, in particular, poorly soluble 
drugs. It is well 
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documented that polymorphic forms of the same drug may exhibit significantly different 
dissolution behaviour resulting in significant variation in therapeutic response when 
administered orally (Florence & Attwood, 1988). It follows these manifestations may also 
alter the release behaviour of the polymorphic candidate when applied to fabrication 
processes involving different solvents and temperatures where these have been shown to 
promote their formation, e. g., microencapsulation (Benoit et al., 1986). Of more 
fundamental interest is the geometry of the crystalline population, referred to as crystal 
habit. Geometrical factors are potentially more influential in micronized systems, 
particularly where drug constitutes an appreciable volume of the overall solid. 
3.3.2.1 Crystal habit 
Irrespective of the solvent from which the drugs were recrystallized, INH yielded needle- 
and RIF plate-shaped crystals, respectively. Qualitatively, corresponding products 
prepared at 0 °C were smaller in mean size compared with those at 24 ± 2.0 °C due to 
greater supersaturation _ and 
more extensive nucleation under quenched conditions. 
Bodmeier & Chen (1988) encountered problems with crystal habit during 
microencapsulation studies of caffeine. The authors assigned the needle morphology of 
encapsulated drug to ingredient incompatibility when spray-dried with PDLLA. Moreover, 
such crystal habit created a crystalline network of drug contiguous with the surface which 
contributed to the rapid release of drug. Accordingly, similar difficulties were anticipated 
during microencapsulation of INH described later in this thesis. 
3.3.2.2 Differential scanning calorimetry 
The quantitative determination of endothermic, e. g., fusion, sublimation and exothermic 
events, e. g., crystallization and degradation have many applications in preformulation 
studies, including determination of purity, solvation, degradation and excipient 
compatibility. In addition, detection of polymorphism is another useful utility for which DSC 
has been specifically applied in these studies. 
Polymorphic species have different molecular arrangements in the solid state, such that 
they behave as different chemical entities exhibiting variable physicochemical properties, 
e. g., solubility, density, crystal habit, optical, melting points and heats of 
fusion (Wells, 
1986); the latter two properties explaining the widespread application of DSC as a 
suitable tool for the investigation of their prevalence under the conditions of 
drug 
formulation, manufacture and use. 
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Typical DSC scans for each substance are shown in Figure 3.2, whereas thermal data are 
summarized in Table 3.3. 
INH - 
RIF - 
110 130 150 170 190 210 230 
Temperature / °C 
Figure 3.2 DSC scans of isoniazid (INH) and rifampicin (RIF) as supplied 
The single sharp endotherm at approximately 175 °C for INH was typical of the melting 
characteristics of a highly ordered crystalline substance. The small variation in the melting 
point and AH values tabulated in Table 3.3 suggested the absence of significant 
polymorphic forms of this drug. In contrast, RIF as supplied showed a more diffuse 
melting endotherm at 197.9 °C (AH = 14.05 Jg-) followed by an exothermic event at 
205.6 °C (AH = -9.44 Jg-) which may be due to either recrystalization or decomposition. 
Subsequent to these events, exothermic baseline noise was considered to indicate 
dramatic decomposition of RIF at - 240 °C. Polymorphism has not been reported for RIF. 
However, DSC scans of precipitated crystals of RIF consistently exhibited a peak position 
5- 15 °C below that of drug supplied. The crystalline structure of a penta-hydrate form of 
RIF has been solved (Gadret et al., 1975), which, by inference, cannot preclude the 
potential for a range of pseudopolymorphs. This might have accounted for the variation in 
peak position observed. The variation in the enthalpy values for RIF precipitates was 
attributed to low enthalpies for these events allied to the difficulty in discerning where the 
switch from melting endo- and recrystallization exotherms occurred. Based on these data, 
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the assessment of polymorphism for RIF was unclear. Nonetheless, it was reasoned that 
the variation in heats of fusion for the recrystallized products would not translate to 
significant variations in dissolution rate. The intrinsic dissolution data presented in section 
3.3.2.4 largely supported this statement. 
Table 3.3 DSC thermal statistics of rifampicin and isoniazid crystals prepared from a 
variety of aqueous and non-aqueous solvents (n=1) 
Drug INH RIF 
Preparative conditions/ °C 
0 25 0 25 
Tm / °C AH / Jg71 Tm / °C OH / Jg'1 Tm / °C OH / Jg'1 Tm / °C OH / Jg'1 
Solvent 
water 173.7 247.8 172.2 246.4 * 
methanol 173.8 285.8 173.5 222.8 *** 
ethanol 174.8 202.7 172.1 264.0 185.1 14.12 182.1 16.13 
butanol 172.9 219.7 173.1 245.4 185.8 14.02 188.2 15.13 
acetonitrile 173.2 238.1 174.3 267.1 183.5 15.46 186.1 14.23 
chloroform 173.4 222.4 172.5 240.1 185.1 12.45 189.4 13.45 
dichloromethane 175.1 236.1 175.1 224.6 184.4 13.67 187.4 14.13 
acetone 172.1 285.6 173.3 241.8 184.4 18.79 184.4 15.25 
* no data available due to insufficient solubility and the prohibitively large quantities of expensive rifampicin required to yield 
sufficient crystalline product for characterization 
3.3.2.3 Infrared spectroscopy 
Characteristic peaks for both INH and RIF are listed in Tables 3.4 and 3.5, respectively. 
Table 3.4 Characteristic infrared vibrations for isoniazid (KBr disc) 
Wave number/ cm" Assignment 
3300 - 3100 
1670 
1560 
1640 
bonded N-H and C-H 
C=0 
amide (NH bend) 
NH2 deformation 
IR data may also be used to tacitly demonstrate the presence of polymorphs, where, 
for 
instance, crystallization of these forms involves significant 
hydrogen bonding between 
adjacent lattice molecules or entrapped solvent 
in the case of pseudopolymorphs. No 
significant difference in the IR spectra were observed 
in these studies irrespective of the 
solvent or crystallization conditions 
for both INH and RIF, casting doubt on the existence 
of pseudopolymorphs, of particularly, 
RIF. 
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Table 3.5 Characteristic infrared vibrations for rifampicin (KBr disc) 
Wave numberl cm' 
3300 -2300 
1715 
1640 
1620 
1570 
1540 and 1520 
1255,1040 and 1020 
Assignment 
broad NH and OH bonded 
CH3CO 
CO 
amide I (carbonyl stretch) 
C=C 
amide 11 (amide NH bend) 
C-O-C acetyl (CO stretch) 
3.3.2.4 Intrinsic dissolution rate 
Intrinsic solubility data (Ca) for prepared RIF and INH crystals are presented in Table 3.6. 
Average values (RSD) were 8.12 (14.7) and 7.83 (9.76) mgcm-2 min-' for INH crystals 
prepared at 0 and 25 °C respectively, whereas corresponding statistics for RIF were 3.94 
x 10-2 (12.5) and 3.51 x 10-2 (14.3) mgcm-2 min"'. Values derived from crystals prepared 
at 0 °C were, on average, greater than those at 25 °C, although there was no significant 
difference between preparative conditions for INH nor for RIF (P > 0.05). Greater Co for 
crystals grown at 0 °C were probably due to the finer granulometry of these products 
compared with those prepared at 24 ± 2.0 °C. 
The subtle differences in intrinsic solubility data for INH shown were attributed to a variety 
of experimental factors, although it is recognized that without accurate X-ray diffraction 
data no firm conclusions can be drawn nor can the absence of polymorphs be 
unequivocally stated. These factors include variation in compression pressure and dwell 
time, particle size and shape (which may effect compression behaviour and powder 
consolidation), and the presence of lattice-bound solvent. The relative non-reproducibility 
of the Co results represented by the relative standard deviation values (RSD), support 
these ideas. Nonetheless, comparison of the Co results for INH and RIF demonstrated an 
approximately 150 - 200 fold difference in solubility of the 
former compared to the latter. 
In general terms, the correspondence of this factor for saturation solubility data presented 
in section 3.3.4.2 validated the Co results. 
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Table 3.6 Intrinsic dissolution statistics for isoniazid and rifampicin crystals prepared in a 
variety of aqueous and non-aqueous solvents (n=3) 
Drug INH RIF 
Preparative conditions I °C 
0 
C ! mg 
cmý min "i 
Solvent 
25 0 25 
RSD / Co / mg RSD / Co / mg RSD / C, / mg RSD / % cm 2 min-1 % cm 2 min -1 % cm 2 min'' % 
(x 102) (x 102) 
water 8.21 5.6 7.44 8.2 
methanol 7.28 15.1 8.35 12.5 ** 
ethanol 6.83 4.5 7.92 7.2 4.56 26.4 2.87 21.5 
butanol 8.35 7.4 7.16 6.3 3.54 8.6 4.13 25.6 
acetonitrile 7.33 8.1 8.26 11.3 3.46 19.2 3.75 11.2 
chloroform 8.52 4.5 9.26 4.7 3.51 16.2 3.15 17.1 
dichloromethane 8.81 6.7 7.12 8.8 4.23 17.9 3.67 8.7 
acetone 6.62 8.6 7.14 3.2 4.35 23.5 2.95 16.5 
* no data available due to insufficient solubility and the prohibitively large quantities of expensive rifampicin required to yield 
sufficient crystalline product for characterization 
For RIF, Co statistics were more variable compared to INH, rendering interpretation 
particularly difficult. The non-reproducibility of the results had arisen due to experimental 
variation rather than true differences between different batches of crystals. In addition to 
the factors listed for INH, this variation was accounted for by the difficulties and 
consequent inaccuracies in determination of low concentrations of RIF by direct UV 
measurement and the inherent elasticity of RIF, which hindered the compression of discs 
of smooth and unbroken morphology which did not `cap'. The data for RIF were therefore 
inconclusive, against a background of IR data suggesting the absence of true polymorphic 
forms, whereas interpretation of DSC results was less clear. Polymorphism, however, has 
not been reported for this drug (Gadret et at., 1975). 
3.3.3 Drug-polymer interactions 
As a rapid screen, thermal analysis can be exploited to investigate and predict 
physicochemical interactions between ingredients which might affect the production of a 
stable and efficacious form with consistent biopharmaceutical performance (Wells, 1986). 
These studies allow ingredient substitution for alternative compatible materials where the 
interaction is likely to be significant during formulation manufacture, administration or use. 
In a chemical sense, under anhydrous conditions, poly-a-hydroxy acids are generally 
stable in the solid state when in intimate contact with a drug substance. 
However, when 
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hydrated, hydrogen-bonding (Bodmeier & Chen, 1989; Mauduit et al., 1993a) and 
polymer degradation catalysis (Ramtoola et al., 1992; Maulding et al., 1986) have been 
observed with selected basic drugs. Of greater concern are physical interactions between 
encapsulate and encapsulant, e. g., solid solution, eutectic formation. Dependent on drug 
loading and their extent, such interactions determine the ultimate physical form of the 
drug in the polymer upon microencapsulation, or, conversely, account for variation in the 
thermomechanical properties of the polymer in the presence of drug (Dubernet, 1995). 
In this study, all samples were double scanned: the first scan indicated the existence of 
chemical or physical interaction upon intimate contact during the heating cycle; the 
second temperature gradient was recorded to provide an indication of the effect of 
quench cooling, which although performed in the absence of solvents, correlated to the 
precipitation kinetics of codissolved materials during microsphere formation using 
techniques where rapid solid deposition occurs, e. g., spray-drying. 
Due to the amorphous nature of the Resomer® materials investigated, they possessed a 
T9 with no melting endotherm. Affected by heating rate and polymer history, Tg represents 
a change in heat capacity of a polymer due to specific changes at this point in polymeric 
molecular motion. Thus, below the Tg the polymer atoms and chains undergo low 
amplitude vibratory motion rendering the material brittle and inelastic. This is referred to 
as the `glassy' state. Above the T9, the so-called `rubbery' state prevails, in which the 
polymer chains undergo translational, rotational and diffusional movement (Ford & 
Timmins, 1989; Kerc & Srcic, 1995) resulting in an increase in polymer free volume 
(Hausberger & DeLuca, 1995). Related to a stress-relaxation phenomenon, an 
endothermic peak may overly the Tg, the magnitude of which is largely related to polymer 
nature, storage time and conditions, and the thermal history of the sample (Serajuddin et 
al., 1986; Dubernet, 1995). 
3.3.3.1 Rifampicin 
For RIF, with the exception of R104, the first scan revealed no significant interaction 
between drug and polymer, whereby both the T9 and melting-recrystallization events of 
polymer and the drug respectively were evident as seen in Figure 3.3. The absence of the 
Tg of R104 was attributed to the fact that the T. for such low MW material was outwith 
the 
studied temperature range (manufacturer quotes a broad range of 
5- 25 °C). 
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Figure 3.3 First heat DSC scans of: 1) RG502 as supplied; 2) physical mix of RG502 : 
RIF (1: 1) and; 3) physical mix of R104 : RIF (1: 1) at 10 °Cmin"'. Key: A, glass transition; 
B, RIF melting endotherm; and, C, RIF recrystallization exotherm. 
Table 3.7 First heat DSC statistics for physical mixtures of rifampicin and Resomer® (1: 1) 
(n=2). Enthalpies expressed per unit weight total sample. 
Resomer® Anomalous endotherm Melting endotherm Recrystallization exotherm 
onset/°C peak / °C area /J g' onset/°C peak/ °C area /J g"' onset / °C peak / °C area /J g"' 
RG502 44.9 47.5 2.76 188.8 193.5 0.92 196.3 198.5 0.66 
RG503 51.5 53.9 2.78 188.3 193.8 1.91 198.0 200.7 1.08 
RG503H 52.2 54.8 2.64 187.8 194.0 1.93 198.0 200.4 1.28 
RG504 52.3 55.1 3.31 187.9 194.1 2.73 197.9 200.4 1.57 
RG506 54.2 57.0 2.44 189.2 194.8 2.08 198.4 200.8 1.62 
RG752 50.9 53.8 2.87 189.2 193.2 0.81 197.1 198.8 0.53 
RG755 55.7 58.3 3.37 187.6 193.9 2.35 197.5 200.5 2.30 
R202H 53.6 56.5 3.65 189.1 189.9 0.27 198.7 201.0 0.18 
no thermal events recorded for R104 
The solubilization of RIF within the rubbery R104 matrix at a temperature corresponding 
to, or below that of the melting point of RIF, accounted for the absence of a melting 
endotherm for the drug. Bodmeier et al. (1989) similarly noted an increased solubility of 
quinidine, a drug of comparable aqueous solubility (1 in 2000; Merck Index, 1976) to that 
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of RIF (1 in 1000), as the proportion of low MW R104 incorporated to high MW PDLLA 
(120 kD) solvent-cast films, increased. 
The magnitude of the enthalpy differential between melting-recrystallization events, 
present with all other mixes, relative to their theoretical values, provided an index of the 
solubility of the drug in the polymer. Caution is recommended with such deductions as 
drug solubility is being determined at elevated temperatures by this method rather than 
ambient, where the solubility is likely to be considerably different (Dubernet, 1995). 
Interpretation of the results in this respect was confounded by variable enthalpy values as 
a consequence of sample demixing. This effect was particularly problematic in the present 
work with high MW RG755, RG504 and RG506. The large particle size of these materials 
allied to their ductile nature which hindered efficient grinding, resulted in drug-polymer 
segregation in the small vial used to prepare these mixes. Consequently, appreciable 
RSD values were associated with enthalpy measurements for these samples. 
Notwithstanding these difficulties, some general trends were derived from the data in 
Table 3.7. Melting enthalpy values increased with MW of polymer irrespective of polymer 
class, i. e., RG50X, RG75X and R series indicative of reduced drug miscibility. 
Additionally, for material of comparable MW, the solubility of RIF increased in parallel with 
the substitution of more hydrophilic glycolic units with D/L-lactic units. Thus, based on 
melting energy requirements, RIF solubility was in descending order: R202H (11 kD); AH 
= 0.27 Jg 1> RG752 (20 kD); AH = 0.81 Jg-' > RG502 (15.5 kD); AH = 0.92 Jg-'. 
The thermal characteristics of the second heat scan were quite different from that of the 
corresponding initial scan, although several common features were present. These 
included the disappearance of the melting-recrystallization for RIF and the reduced peak 
area for the endotherm associated with the polymer T9 in addition to an up-scale shift of 
same. The former effect was attributed to the greater solubility of RIF after solubilization, 
due to its deposition as micronized domains during quenching. These domains provided 
considerably greater exposed surface area which facilitated solubilization of drug in 
polymer during the second heating. Rapid solidification during cooling impeded the 
mobility of drug molecules in the increasingly viscous polymer, leading to extensive 
nucleation and the production of numerous small crystalline domains in the matrix. 
Therefore, unlike the original drug particles in the physical mix, these interposing domains 
were sufficiently small to have an additional effect at the molecular level, whereby 
enhanced chain stiffness was created and maintained in the polymer chains. This so- 
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called `filler-effect' (Dubernet, 1995) is presumably attributable to the low heat transfer 
coefficient of these domains compared with neighbouring polymer chains. This results in 
diminished translational movement of molecules. Consequently, during the second scan a 
resultant elevation of the Tg was observed, most notably for R104 where, contrary to the 
first scan, an on-scale T9 event was observed at 41.5 °C. 
3.3.3.2 Isoniazid 
The first scan thermal statistics of the INH - Resomer® mixes are summarized in Table 
3.8. 
Table 3.8 First heat DSC statistics for physical mixtures of isoniazid and Resomer® (1: 1) 
(n=2) Enthalpies expressed per unit weight total sample. 
Resomer® Anomalous endotherm Melting endotherm 
onset / °C peak / °C enthalpy / Jg 1 onset / °C peak / °C enthalpy / Jg'' 
RG502 45.7 48.2 1.93 166.0 169.9 78.5 
RG503 52.4 54.6 2.41 166.3 170.3 68.0 
RG503H 53.9 55.9 1.62 164.9 169.8 78.6 
RG504 53.6 55.9 1.86 167.5 170.7 90.5 
RG506 54.0 56.6 1.87 165.9 170.0 92.0 
RG752 51.7 54.3 2.28 169.7 173.0 70.2 
RG755 56.2 58.4 1.59 170.1 172.8 74.0 
8104 158.4 168.1 61.9 
R202H 54.0 56.8 3.29 168.4 173.0 68.6 
* 
no thermal events recorded 
The results indicated that no significant interaction was evident based on the fact that all 
peaks were reconciled with those from individual scans. Whereas normalized enthalpy 
values of polymer relaxation corresponded generally well with those from polymer alone, 
enthalpies of fusion for INH were consistently lower than that anticipated, i. e., AH = 123 
Jg"1. Enthalpy depression may have arisen due to the interaction of the drug with its 
polymeric environment. Consequently, the measured value has a component for the 
enthalpy of mixing of the molten INH in the rubbery polymer as well as solubilization of a 
fraction of INH which confounds the comparison of experimental and theoretical heats of 
melting (Theeuwes et at., 1974). This postulation is supported by the fact that irrespective 
of the polymer, Tg depression during the second scan was indicative of partial, if not 
complete, solid solution. The solvency of each polymer followed a similar pattern to that 
for RIF, whereby the % theoretical melting enthalpy values increased as MW increased 
and as glycolic units were introduced, indicative of reduced INH solubility at the melting 
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point of the drug. The corresponding values in ascending order were: R202H (11 kD), AH 
= 55.7 %< RG752 (20 kD), AH = 57.0 %< RG502 (15.5 kD), AH = 63.8 %. 
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Figure 3.4 Second heat DSC scans of physical mixes of, 1) RG755: INH (1: 1); 2) RG752 
: INH (1: 1); 3) RG502: INH (1: 1); 4) R202H: INH (1: 1) and; 5) R104: INH (1: 1) at 10 °C 
min-'. Key: as before, D, melting endotherm of INH, and E, recrystallization exotherm of 
INH. 
The emergence of recrystallization and melting events seen in Figure 3.4 indicated a 
fraction of INH existed as a molecular dispersion in addition to that as solid solution for 
R202H and RG755. Quench cooling (30 °Cmin-l) inhibits nucleation and subsequent 
crystallite growth as the polymer viscosity approaches infinity below the Tg (Dubernet, 
1995). Upon heating, molecular mobility increases and crystal growth occurs accounting 
for the exotherm at 115 °C and the associated melting endotherm at 158 °C for both 
R202H and RG755 as seen in Figure 3.4. 
The down-shift in the melting endotherm for INH is consistent with that observed for both 
RIF and INH during the first run, and that of clonazepam reported elsewhere (Benelli et 
al., 1998). The propensity for recrystallization is a complex function of the interaction of 
the molecules with their polymeric environment, molecular mobility and matrix viscosity. In 
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general, such events correspond to limited solubility of drug in the fluid matrix, supporting 
the conclusions for the first scan. Furthermore, the ratios of melting endotherm: 
recrystallization exotherm were similar for both R202H and RG755 at 3.61 and 3.65 
respectively, suggestive of the same crystalline form. The coincidence of event 
temperatures lent further support to the absence of polymorphism in these matrices in 
contrast to the results for progesterone in PDLLA where both a and ß forms were 
observed (Bodmeier & Chen, 1988) 
In conclusion, thermal data indicated the variation in the behaviour of RIF and INH when 
mixed and fused with a range of Resomer® Polymers. INH appears to exist in partial solid 
solution with all materials, whereas RIF remains predominantly molecularly dispersed 
after quench cooling. These data are however artificial in the sense these events were 
recorded at elevated temperatures. Consequently, their significance is probably limited to 
situations where fabrication technologies are associated with the use of significant heat. 
Nonetheless, the operative procedures used to prepare microspheres from raw polymer 
may significantly alter the arrangement of polymer chains, and, in turn, their thermal and 
ageing behaviour, rendering DSC an excellent technique to check polymer characteristics 
after microsphere formation (Dubernet, 1995) in addition to elucidation of the dispersive 
state of drug within polymeric matrices (Bodmeier & McGinity, 1987c; EI-Baseir et al., 
1997; Benoit et al., 1986). 
3.3.4 Solubility studies 
3.3.4.1 Saturation solubility studies 
Determined saturation solubilities of both RIF and INH in a variety of aqueous and non- 
aqueous solvents are tabulated below in Table 3.9. 
These data highlight the dramatic difference in the solubility of RIF and INH, a primary 
factor which determines the strategies employed to encapsulate drugs in biodegradable 
materials (Whateley, 1992). In general, INH solubility increased with solvent polarity, 
whereas with RIF, the opposite trend was observed. Fong et al. (1986) cited an aqueous 
solubility criterion of < 0.023 gL"1 for efficient encapsulation. On this 
basis, neither drug, 
particularly INH, would be effectively encapsulated by aqueous ESE. 
David F. Bain 
83 
Preformulation 
Development and characterization of biodegradable microspheres containing selected antimycobacterials David F. Bain 
Table 3.9 Saturation solubility characteristics of rifampicin and isoniazid as supplied in 
various aqueous and non-aqueous solvents (n=3). 
Drug 
Solvent 
water 
water 
water 
ethanol 
dichloromethane 
dichloromethane 
chloroform 
chloroform 
1% w/w PVA 
1% w/w PVA 
1% w/w PVA 
methanol 
butanol 
n-hexane 
ethyl acetate 
acetonitrile 
acetonitrile 
halothane 
* not determined 
INH RIF 
Temperature / Solubility/ RSD /% Solubility / RSD /% °C mg mL"' mg mL"' 
25 145 1.2 0.93 9.4 
37 245 0.9 1.72 7.5 
50 316 0.5 2.93 3.1 
25 25.2 1.3 8.91 5.0 
25 1.95 1.3 216 6.5 
37 9.62 6.2 388 9.6 
25 6.53 4.3 349 4.6 
50 12.3 1.2 930 10.2 
25 89.1 3.5 1.41 1.5 
37 190 2.1 2.32 2.6 
50 311 1.3 6.15 4.6 
25 42.8 1.4 
25 3.81 2.6 ** 
25 *2 4.3 ** 
25 3.21 7.2 181 2.3 
25 2.91 9.3 ** 
50 13.4 6.3 ** 
25 ** 76.9 2.2 
2 
practically insoluble (British Pharmacopoeia, 1988) 
3.3.4.2 pH solubility profile 
Encapsulation efficiency is, with few exceptions, an attribute of the microsphere 
production process which is omnipresent in reports which describe microsphere 
characterization (Hausberger & DeLuca, 1995). This is due to the ease by which this 
characteristic can be readily determined; its inter-relationship with other microproduct 
features (morphology, drug release); its implications on dose volume; and, its utility as a 
ready marker of the repeatability of the overall process. The problem suffered by the 
aqueous ESE process of low encapsulation efficiency due to premature partitioning of 
soluble or moderately water soluble drugs prior to deposition of a coherent polymer 
microsphere crust is well documented (Bodmeier & McGinity, 1987a-c). 
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Figure 3.5 pH-solubility profiles for rifampicin and isoniazid at 24 ± 2.0 °C 
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The pH solubility profiles of INH and RIF are presented in Figure 3.5. For amphoteric 
compounds, such as RIF, aqueous solubility increases markedly at pH values below and 
above the pKa values for the drug of 1.7 and 7.9 respectively. These respective 
dissociation constants have been, in the opinion of Prankerd et al. (1992), wrongly 
assigned to the C1, C4 and C8 of the phenolic hydroxy groups (pKa = 1.7), and the 
piperazine nitrogen (pKa = 7.9), respectively. Prankerd et al. (1992) argued that the value 
for the piperazine nitrogen accounted for the acidic group, consistent with other 
azomethines, e. g., diazepam, whilst the value at 7.9 was accordingly associated with the 
aforementioned hydroxy array. This group also hypothesized a third dissociation constant 
for the N-methylpiperazine, N-CH3, at 5.93, to which the potentiometric titration method 
previously used would have been oblivious (Maggi et al, 1966). However, in contrast to 
the chromatographic behaviour in section 2.3.1, the pH - solubility profile studies did not 
corroborate the existence of a third dissociation constant. During saturation solubility 
studies, the pH of prospective continuous phase for aqueous ESE, 1 %w/v solution of 
PVA, was 5.3. It has been proposed (Zhifang et al, 1993) and demonstrated (Bodmeier & 
McGinity, 1987a-c) that buffering of the aqueous continuum to a pH of low drug solubility 
can minimize drug partitioning and thus maximize encapsulation efficiency. Therefore, 
whereas buffered PVA solutions at pH < 1.5, or, > 8.0 were anticipated to greatly 
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decrease RIF encapsulation efficiency, unbuffered PVA provided a medium which 
minimized extraction of RIF during encapsulation. 
Protonation constants for INH of 2.0 and 3.6 for the hydrazide N and pyridine N 
respectively have been cited (Rekker & Nauta, 1964). A further dissociation constant of 
10.8 for the terminal primary amine has also been measured. In analogy to RIF, this 
pattern of ionization is consistent with the pH-solubility data for this drug. 
3.3.5 Stability studies 
3.3.5.1 Rifampicin 
Decomposition studies were performed to examine whether the oxidation of RIF could be 
avoided, and, if so, would quantification of identified degradates allow accurate 
determination of RIF released over prolonged periods. Preliminary investigations showed 
iso-ascorbic acid (IAA) had the greatest activity in preventing oxidation of RIF to RQU.; t, 2 
i, A = 69.3 h compared with tY, control = 2.45 h. Sodium metabisuiphite showed intermediary 
activity; t% = 4.85 h. Addition of RQU stock solutions to SBM containing IAA caused a 
rapid reduction of the quinone to RIF. At an IAA concentration of 0.01 %w/v, after initial 
reduction of RQU to RIF, a peak corresponding to RQU appeared after 4 d, indicating 
lack of antioxidant protection with the introduction of air during each sampling operation. 
No such peak was evident when 0.1 %w/v IAA was used. Therefore, having stabilized RIF 
to oxidation, decomposition studies focused on the hydrolysis of RIF to RSV at an IAA 
level of 0.1 %w/v. The consecutive transformation of RSV to other unidentified products 
was also examined. 
Reversible addition of water across the azomethine bond of RIF to form a transient 
carbinolamine, which then rearranges, is the proposed mechanism of hydrolysis 
(Prankerd et al., 1992) yielding RSV and UV transparent 1-amino-4-methyl-piperazine 
(AMP) as shown in Scheme 3.1 
RIF + H2 0 RSV + AMP 
Scheme 3.1 Hydrolysis of RIF to RSV 
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Table 3.10 Initial (a) and terminal (ß) rate constants for hydrolysis as a function of RIF 
and RSV concentration in Sorensens modified buffer, pH = 7.4 ± 0.2 and 37 ± 0.5 °C, n=3 
Analyte Initial Conc /ax 103 / RSD /%ßx 104 / RSD /% r2 
µ9mL-' h-, h" 
35 6.535 2.789 2.860 2.015 0.999 
RI F 14 5.702 2.025 2.885 4.522 0.997 
3.5 4.181 1.985 2.551 5.582 0.999 
35 --3.092* 4.068 0.993 
RSV 14 --2.777* 1.714 0.995 
3.5 --2.649* 4.068 0.997 
. kinetic constants arising from secondary decompositions 
Using a feathering technique, the rate constants for the initial, a, and terminal, ß, phases 
of RIF decomposition seen in Figure 3.6 are reported in Table 3.10 according to the 
biexponential expression 3.1 shown below: 
[RIF] = Ae-«t + Be-O' (Equation 3.1) 
where A and B are constants, a and ß are the pseudo first-order rate constants 
associated with the initial and terminal phases of RIF decomposition. First-order kinetic 
constants for RSV decomposition, when studied alone, are in Table 3.11. 
Table 3.11 Kinetic constants for deterioration of RSV in Sorensens modified buffer, pH 
7.4 ± 0.2 and 37 ± 0.5 °C (n=3) 
Analyte Initial Conc Ißx 904 1h-' RSD I% 
µgmL"' 
f2 
50 2.739 2.310 0.999 
RSV 20 2.611 3.832 0.998 
5 2.689 5.132 0.987 
Examination of the kinetics of other azomethine containing compounds has yielded similar 
biexponential patterns, indicative of an equilibrium decomposition process (Prankerd & 
Stella, 1989). The biexponential pattern can be explained by a rapid pseudo first-order 
hydrolysis of RIF to RSV until equilibrium is attained, followed by a slow parallel 
deterioration in concentration of both RIF and RSV as shown in Figure 3.6. 
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Figure 3.6 Semi-logarithmic plots of the time-dependent decrease in rifampicin and 
increase in 3-formy1rifamycin SV as a function of initial rifampicin concentration in 
Sorensens modified buffer at pH 7.4 ± 0.2 and 37 ± 0.5 °C, (concentration in key in units 
of µgmr') (n=3) 
The terminal phase is a consequence of serial decomposition of RIF, RSV or both. These 
secondary reactions are assumed to be first-order based on the linearity of the terminal 
phase with semi-logarithmic treatment. This pattern was reported previously by Prankerd 
et al. (1992) for RIF decomposition at acidic pH which these authors attributed to parallel 
secondary reactions of both RIF and RSV. Chromatograms for starting solutions after 
equilibrium was attained showed a coincidence of peaks corresponding to these 
unidentified secondary products. Interestingly, all peaks appeared in both chromatograms 
suggesting (assuming the absence of a highly retained species associated with the 
secondary decomposition of RIF) all secondary decomposition products emanated from 
RSV. Further support for this was the absence of peaks corresponding to DAR and 25- 
21/23, the putative products of RIF decomposition under the conditions of the study. The 
nature of the secondary degradates is unknown, although the desacetylated equivalent of 
RSV would seem a plausible product (Seydel, 1970). Finally, in Table 3.11, the 
concurrence of the rate constants for RSV deterioration, when studied alone, and those 
for the terminal phase of RIF decomposition listed in Table 3.10, further corroborates this 
hypothesis. 
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3.3.5.2 isoniazid 
A variety of reports have described both oxidative and hydrolytic sensitivities for INH, 
although the products thereof, are, in general, poorly defined. However, where anaerobic 
conditions prevail, isonicotinic acid (INA) is the predominant degradate of INH in aqueous 
solution, its rate of formation is reported to be sensitive to both the nature and the 
concentration of the buffer salt used (Pawelczyk et al., 1969). Thus, the stability of INH 
under anaerobic conditions in hermetically sealed vessels filled with various degassed 
buffer solutions was examined, the kinetic statistics of which are presented in Table 3.12. 
Table 3.12 Pseudo first order kinetic statistics of isoniazid decomposition in a variety of 
buffer solutions at 37 ± 0.5 °C (n=4) 
pH ± rate constant RSD / rz RSD / half-life x RSD / 
Buffer 0.2 x 104 / (h"1) %% 10-31 h% 
Walpoles acetate 5.8 3.481 6.70 0.981 1.75 1.996 7.00 
Mcllvaines 5.8 4.873 3.72 0.989 0.83 1.424 3.65 
7.4 3.136 6.65 0.985 0.96 0.231 6.64 
Sorensens 5.8 5.326 6.48 0.991 0.83 1.308 6.29 
7.4 4.111 6.12 0.989 0.41 0.169 6.14 
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Figure 3.7 Semi-logarithmic plots of the hydrolytic decomposition of 
isoniazid in various 
buffer system at 37 ± 0.5 °C, n=4. Legend 
indicates buffer system and pH ± 0.2. 
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Hydrolytic decomposition arises through cleavage of the hydrazine side-chain to yield 
isonicotinic acid and hydrazine. During the decomposition study, the chromatographic 
peak area decrease for INH showed semi-logarithmic dependence on time as seen in 
Figure 3.7, corroborating the pseudo first-order kinetics observed by other workers 
(Pawelczyk et al., 1969). Meantime, a peak with capacity factor corresponding to that of 
INA appeared on the chromatograms. The identity of this substance was tentatively 
confirmed by PDA detection as INA. In general terms, these data are consistent with the 
observations of Lewin & Hirsch (1954) and Pawelczyk et at. (1969) where INH was shown 
to be maximally stable around pH 5.0 - 6.0, instability increasing above and below this 
value, i. e, pH 7.4. The effect of buffer salt however is only in partial corroboration of the 
work of Pawelczyk et al. (1969), whereby INH stability was found to be maximal in 
Walpoles buffer, but of reduced stability at pH 5.0 when compared with pH 7.0, contrary 
to the results in the present study at pH 5.8 and pH 7.4. However, both the variation in pH 
and the higher ionic strength at pH 7.4 in the current work probably accounts for the 
apparent disparity upon comparison of the results with previous work. Indeed, Pawelczyk 
et at. (1969) found INH instability increased with ionic strength. In contrast to the effect of 
buffer type observed in Figure 3.7, Lewin & Hirsch (1954) demonstrated that citrate had a 
protective effect, whereas acetate salts hastened INH deterioration. This effect was 
attributed to the ability of the former anion, unlike acetate, to chelate metal ions, which 
themselves were implicated as potential catalysts, in particular divalent manganese and 
cupric cations. 
3.3.6 Dissolution methodology development 
The release pattern of drug from carrier matrix will largely determine the efficacy of any 
given formulation. Correlations of in vitro and in vivo drug release are uncommon. 
Nonetheless, in vitro drug release studies, when used as a comparative tool, are an 
essential component of any formulation development programme. With long-acting 
biodegradable delivery devices in vitro release studies might be prolonged; typically 
upwards of several weeks. Moreover, the instabilities of INH and 
RIF necessitates 
techniques of accurately determining not only the parent drug, but also the putative 
decomposition products, i. e., stability-indicating assays. This should allow accurate 
determination of drug release from biodegradable systems, as well as the assessment of 
any deleterious effects of the processes and solvents used 
in the preparation of these 
systems. 
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When monitoring drug release from biodegradable formulations, a number of approaches 
can be adopted. Either the amount of drug released into the dissolution medium can be 
measured, or, alternatively, the amount remaining in the formulation. The former may 
involve recovery by clarification and replacing the total volume under study to ensure the 
`sink' status of the medium. The latter procedure, utilized by Bissery et al. (1984) to 
indirectly determine the release of CCNU (1-(2-chloroethyl)-3-cyclohexyl-nitrosourea) 
from PLLA microspheres, requires tedious preparation of multiple vessels corresponding 
to each sampling interval. Ordinarily, therefore, aliquots are taken and the volume 
sampled replaced with fresh medium which is - from a throughput, accuracy and 
repeatability point of view - preferred. 
3.3.6.1 Rifampicin 
The instability of RIF has resulted in errors in determining release rate from conventional 
tablet and capsule formulations (Gharbo et al., 1989; Shah et al., 1992; Jindal et al., 
1994). Preliminary release studies of RIF from biodegradable microspheres using direct 
UV spectrophotometry showed a rapid `burst'; a characteristic of these systems. Initially, 
released RIF was observed to transform rapidly from an orange RIF solution to its purple 
quinone, RQU. This decomposition was accounted for by exploiting the approximate 
`isobestic' point seen in Figure 2.1 for RIF and its decomposition products at 270 nm. 
However, subsequent absorbance measurements showed an exponential decay in 
magnitude with decomposition of RQU to a poorly absorbing or UV transparent product. 
Therefore, stability of RIF was investigated to identify the decomposition products and 
their kinetics of formation. From preliminary investigations, the rate of formation of RQU 
was found to be a function of the headspace and thus the amount of available 02 in the 
vessels used. Therefore, a controlled investigation of the kinetics of RIF decomposition in 
sealed vessels was performed, the results of which are presented in section 3.3.5.1. 
These vessels were fitted with rubber bungs which allowed the withdrawal of samples 
with minimal introduction of air throughout the study. 
The terminal decomposition phase shown in Figure 3.6 precluded the simple cumulative 
quantification of RIF and RSV as a technique to monitor overall RIF release from long- 
acting biodegradable systems. In this situation the apparent amount released may 
decrease where the rate of secondary deterioration exceeds the rate of RIF appearance 
in the dissolution medium. Hence, a mathematical correction for the amounts lost to 
secondary reactions was required to accurately monitor RIF release. Using the calculated 
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values of the terminal phase rate constants, equation 3.2 was applied to account for the 
secondary decomposition of RIF and RSV occurring between each sampling interval: 
(X t, +X 
2 
t2 
2ett 
(Equation 3.2) 
where L is the amount of RIF-derived analyte lost between each time interval t. Xt, and 
Xt2 are the total amounts of RIF released calculated from peak areas of RIF and RSV at 
time tj and t2 respectively, whereas (3term is the terminal rate constant describing the 
parallel loss of RIF and RSV. The validity of this approach was based on the parallelism 
of the terminal phases for RIF and RSV secondary decomposition and the respective rate 
constants independence of concentration. 
Dissolution profiles for rifampicin release from PLLA microspheres are presented in 
Figure 3.8. The accuracy of this approach is a function of the time interval between 
samples; accuracy theoretically improving with more frequent sampling. However, given 
the slow rate of the secondary decomposition phase, daily intervals. were considered 
adequate. 
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Figure 3.8 Release profiles of rifampicin from Resomer®L204 poly(L-lactide) (MW= 78 
kD) microspheres prepared by aqueous emulsion solvent evaporation at drug: polymer 
ratios of: 1) 0.2: 1.0; 2) 0.5: 1.0, and; 3) 1.0: 1.0 at 37°C in Sorensens buffer modified at 
37 
± 0.5 °C and pH =7.4 ± 0.1 (n=3). 
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The method was further validated by the measurement, at different time periods during 
dissolution, of the amount of RIF remaining in recovered microspheres. This calculation 
accounted for the mass of sample initially added; original microsphere drug loading; and 
the cumulative amount released at the corresponding time point. Validation data are 
presented in Table 3.13. 
Table 3.13 Validation statistics of the rifampicin dissolution methodology based on 
reconciliation of total loaded rifampicin from microspheres prepared with ResomefOL204 
by emulsion-solvent-evaporation at various drug: polymer (D: P) ratios at 37 ± 0.5 °C in 
SOrensens buffer modified pH =7.4 ± 0.2 (n=3). 
D: P ratio Loading / Differential between residual microsphere loading and amount 
(% w/w) released/ % (RSD) after time /h 
1 10 30 
0.2: 1.0 9.81 1.62 (5.62) -1.51 (6.71) -2.51(7.52) 
0.5: 1.0 18.8 1.53 (2.35) -2.56 (6.85) -2.54 (6.52) 
1.0: 1.0 23.1 1.41 (2.65) -1.15 (7.81) -3.51(4.52) 
The differential between that released and the residual RIF in the microspheres was 
positive after one day, but became negative at five days. This trend was consistent with 
the inherent inaccuracies of the methodology to determine overall RIF release whereby 
corrections for that lost are an overestimate based on the arithmetic mid-point of a first 
order decomposition process. The RSD in Table 3.13 are consistent with the 
reproducibility data for the validated column-switching procedure (section 2.3.1) 
3.3.6.2 Isoniazid 
In contrast to RIF, the cumulative concentrations of INH and INA corresponded with the 
initial INH concentration throughout the study regardless of the study medium (P > 0.05). 
These data indicate that the instability of INH terminated with the formation of INA, serial 
decompositions if these arose occurring at an immeasurable rate within the time-frame of 
the stability study (32 d). Moreover, this feature allowed the accurate determination of 
INH release from long-acting devices. 
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Figure 3.9 Normalised UV spectra with respect to concentration of isoniazid (INH) and its 
potential degradates: isonicotonic acid (INA); isonicotinamide (INACT) and; isonicotonic 
acid N-oxide (INN) in distilled water at 24 ± 2.0 °C at a theoretical concentration of 0.004 
%w/v. Legend indicates abbreviated analyte. 
Reports of long-acting PDLGA preparations describe a variety of analytical methodologies 
to monitor the release of INH. These include spectrophotometry following condensation 
derivitization with vanillin (Pattisapu et al., 1993; Gangadharam at al., 1994) to form an 
amide (Fieser & Fieser, 1957); direct spectrophotometry (Hsu et al., 1994; 1996); and, 
HPLC for bioanalysis of serum and urine INH and AcINH levels (Gangadharam at al., 
1991; Kailasam et al., 1994). Significantly, none of these reports made mention of the 
instability of INH at physiological pH. Instability may have introduced errors, invalidating 
the mathematical analysis of INH release described in the report of Hsu et al. (1994) 
where direct UV spectrophotometry at 262 nm was the detection method. The potential 
for errors of ultimately 10 % in magnitude during the 50 d study is apparent from Figure 
3.9 where comparison is made of the UV spectra for INH and INA at 262 nm. 
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Figure 3.10 Absorbance ratios for isoniazid and albumin (I: A) at an isoniazid: albumin 
concentration ratios of, 1) 1: 10; 2) 1: 2 and, 3) 1: 1 in water at 24 ± 2.0 °C 
An alternative approach would be to exploit the isobestic point for INH and INA at 228 or 
253 nm as seen in Figure 3.9. Formulations described later in this work which contained 
interferents, such as weakly UV absorbing or refractive excipients, e. g., albumin limited 
this direct approach. The data in Figure 3.10 indicates the presence of albumin would 
introduce spectophotometric inaccuracies into calculations of drug release based on 
these measurements. Based on these ratios at 228 nm, the errors introduced from direct 
UV measurement were 20 % and 181 % at I: A ratios of 1: 1 and 1: 10 respectively, 
whereas at the alternative isobestic point of 253 nm, these errors were reduced to 
approximately 1.5 and 10 % for the corresponding ratios. However, such errors were 
considered unacceptable necessitating recourse to HPLC for the determination of drug 
released. 
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3.4 Conclusion 
Preformulation studies of INH and RIF highlighted the physicochemical differences of 
these two therapeutically similar drugs. In the context of the microencapsulation studies in 
proceeding chapters, their contrasting solubility profiles were of utmost significance. This 
overriding factor precluded a single encapsulation procedure by which the drugs could be 
coformulated and has been the principle property influencing the techniques and 
approaches examined during formulation development. Ultraviolet spectroscopic studies 
revealed isobestic points for both INH and RIF, although only those for the latter drug 
were of particular utility. In contrast to RIF, where the absence of polymorphism requires 
confirmatory X-ray study, there was little evidence for the existence of polymorphism for 
INH. Drug-excipient interaction studies revealed little interaction between physical 
mixtures of both RIF and INH with Resomer®. Repeat scans after quench-cooling allowed 
the assessment of interactivity at the molecular level. Overall, INH appeared to be more 
soluble in Resomer®, as evidenced by polymer plasticization, whereas general Tg 
elevation with RIF indicated little polymer-drug solid solution. Finally, stability studies 
allowed strategies for monitoring the release of both drugs from long-acting formulations 
to be devised. The method developed for INH relied on the cumulative quantification of 
parent and the predominant hydrolytic degradate, INA, whereas that for RIF took account 
of the biexponential decomposition of RIF to RSV, exploiting the terminal pseudo 
equilibrium under the prospective conditions of the release studies in so doing. 
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4. Characterization of biodegradable poly-a-hydroxy acid-rifampicin microspheres 
prepared by the aqueous emulsification-solvent-evaporation technique 
4.1 Introduction 
In parallel with the AIDS pandemic, tuberculosis is re-emerging as a global health 
problem (Huebner & Castro, 1995). Current oral treatments are prolonged and complex 
requiring strict adherence to effect a cure (British National Formulary, 1995). Compliance 
is notoriously poor, particularly in developing countries where there are logistical 
difficulties in ensuring continuity of supply, leading to treatment failure, or worse still, the 
development of resistant strains of M. tuberculosis (Fox, 1958). Therefore, operational 
arrangements or devices which facilitate compliance should significantly aid tuberculosis 
control programmes world-wide. 
Few reports of RIF micronized systems exist in the literature (Pande et al., 1991; Nakhare 
et al., 1995). Neither of these papers reported the effective loading of RIF. Prodigious 
research effort to achieve high drug loadings in the biodegradable poly-a-hydroxy acid- 
based microspheres has been made (Bodmeier & McGinity, 1987a-c). When 
administered orally, relatively high doses of RIF are required to maintain effective blood 
levels (Shearer, 1994). In the context of injectable devices, and in particular for low 
potency drugs such as antibiotics (Martinez et al., 1997), high loadings should allow a 
reduction in dosage volume. This, in turn, aids administration, alleviates discomfort 
associated with injection, and/or, allows a larger dose to be administered thus reducing 
dose frequency. 
The work in this chapter sought to investigate the utility of poly-a-hydroxy acids as a 
sustained release material for RIF microspheres prepared by aqueous emulsification- 
solvent-evaporation (ESE). To this end, the effects of: varying drug: polymer (D: P) ratio; 
continuous and disperse phase volumes; and, presaturation of the continuum prior to 
dispersion of a RIF-polymer cosolution have been examined. The effect of process 
parameter modification with respect to microsphere loading, morphology, size and RIF 
release was examined. 
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4.2 Experimental procedures 
4.2.1 Microsphere preparation 
Table 4.1 Experimental conditions for the granulometric optimization of rifampicin-bearing 
microspheres prepared by aqueous emulsification-solvent-evaporation (n >_ 2) 
Batch Process variables 
PLLA PDLGA Stirring / rpm PVA / %w/v 
12 600 1 
34 700 1 
56 850 1 
78 1000 1 
9 10 1100 1 
11 12 1000 0.1 
13 14 1000 0.5 
15 16 1000 2 
Other process parameters were maintained constant at: disperse volume, 20 mL; continuum volume, 150 mL; and, D: P 
ratio (0.2: 1.0). 
Table 4.2 Experimental conditions for the drug loading optimization of rifampicin-bearing 
microspheres prepared by aqueous emulsification-solvent-evaporation (n >_ 2) 
Batch Dispersed RIF/ g Phase volumes / mL RIF saturated 
continuum 
PLLA PDLGA Disperse Continuum 
780.2 20 150 no 
17 18 0.2 20 150 yes 
19 20 0.5 20 150 no 
21 22 0.5 20 150 yes 
23 24 1 20 150 no 
25 26 1 20 150 yes 
27 28 0.5 10 150 no 
29 30 0.5 15 150 no 
31 32 0.5 30 150 no 
33 34 0.5 20 75 no 
35 36 0.5 20 100 no 
37 38 0.5 20 125 no 
*Whereas PLLA microspheres were prepared with chloroform as the disperse solvent, dichioromethane was employed for 
PDLGA microspheres 
Cosolutions of PDLGA (RG506) or PLLA (L204) and RIF were prepared in DCM or CFM 
respectively. Volumes equivalent to 1g of polymer were dispersed in a continuum of 1 
%w/v PVA in a tall-form beaker (equilibrated just below the boiling point of the respective 
organic solvent: 37 ± 2.0 °C for DCM; and, 53 ± 2.0 °C for CFM). Immediately prior to 
addition of the disperse phase, the magnetic stirrer was calibrated in a darkened room 
with a transistor stroboflash model 12090 stroboscopic lamp (Dawe Instruments, 
UK). 
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Stirring was maintained (1000 t 50 rpm) for 4h to allow adequate hardening of the 
microspheres. Subsequent to recovery by filtration (Wattman, UK), microspheres were 
washed in situ with deionized water (500 mL) and dried in a desiccator under vacuum for 
>_ 168 h prior to characterization. Process parameters for particle size and drug loading 
optimization are detailed in Tables 4.1 and 4.2, respectively. All batches were prepared 
at least in duplicate. 
4.2.2 Drug loading 
Microspheres (10 ± 2.0 mg) were dissolved in 10 mL of acetonitrile. The solution thus 
formed was diluted to 50 mL with double distilled water and the precipitated polymer 
removed from a2 mL aliquot by centrifugation at 13 500 rpm for 4 min (Micro Centaur, 
MSE, UK). The resulting supernatant was analysed by HPLC as described in section 
2.3.1. Each batch was analysed in triplicate. The weight contribution of RIF to the overall 
microsphere mass was expressed in units of %w/w total material. In addition, the 
percentage of dispersed drug encapsulated was computed from the ratio of actual to 
theoretical drug loading, i. e., encapsulation efficiency . 
4.2.3 Microsphere yield 
After washing and drying, the recovered product was weighed and expressed as a 
percentage of the total solid material dispersed in the continuum. 
4.2.4 Particle size analysis 
Microspheres, 30 ±6 mg, were incorporated to a paste with a few drops of dispersant 
(Coulter Electronics Ltd., Luton, UK), and deaggregated in 50 mL distilled water with aid 
of 3 min ultrasonification (Decon, UK). The mean volume diameters (µm) of the different 
batches were determined by Coulter Multisizer (Coulter Electronics Ltd., Luton, UK) 
equipped with either a 140 p. m or 200 gm aperture diameter tube. Each batch was 
examined at least in duplicate, the result for each replicate being the average of three 
withdrawals. 
4.2.5 Scanning electron microscopy 
Photomicrographs were captured for morphological examination of the microspheres. 
Samples were mounted on copper stubs and sputter-coated with gold-palladium (Polaron 
model SC7640) and scanned using a Cambridge Stereoscan model S90B electron 
microscope (Cambridge instruments, UK). 
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4.2.6 In vitro drug release 
Microspheres, 10 ± 2.0 mg, to which was added 100 mL SOrensens buffer containing 0.1 
%w/v IAA preheated to 37 ± 0.5 °C, were shaken horizontally at 1.5 Hz in hermetically 
sealed bottles. Samples were withdrawn via hypodermic syringe. An identical volume was 
replaced through the attached syringe filter to return entrapped microspheres and to 
maintain dissolution volume. Drug released was determined by an HPLC method which 
accounted for released drug lost to secondary decompositions during release studies 
described in section 3.3.6.1. Dissolution profiles of percentage cumulative RIF release 
versus time were then plotted. Each batch was studied in triplicate. This methodology is 
hereafter described as method A. 
4.3. Results and Discussion 
That countless reports of the preparation and characterization of biodegradable drug- 
loaded microspheres by ESE have appeared in the literature, is testament to the 
conceptual simplicity of the technique and its amenability to most laboratories. Despite its 
simplicity, the characteristics of the product are affected by many, often interacting 
variables such as: drug solubility; type and concentration of emulsifier; polymer 
composition; viscosity; phase ratios of the emulsion system; rates of solvent transfer; 
and, component interactions (Bodmeier & McGinity, 1988b; Li et al., 1995). Models of 
microsphere formation based on phase separation were devised by Bodmeier & McGinity 
(1986; 1987a, b). Four major diffusional processes were considered important, namely, 
drug, organic solvent and oligomer out, and non-solvent in. The direction and magnitude 
of solvent - non-solvent transfer dictates the rate at which the microglobule surface 
concentration reaches a critical concentration when phase separation and simultaneous 
microsphere formation occur, which, in turn, determines drug loading and other 
microsphere properties. Given the complexity of the encapsulation process, it was 
therefore considered necessary to examine selected parameters in an effort to maximize 
previously unexamined RIF loading in the polymers selected. 
4.3.1 Influence of emulsifier and stirring rate 
Particle size and distribution were considered useful indices of the reproducibility of the 
ESE process. Moreover, for preparations intended for injection subcutaneously a 
target 
range of 10 - 90 µm for comfort of administration 
has been suggested (Beck et al., 1985; 
Jalil & Nixon, 1990a). Both dispersing agent and stirring rate are of primary importance in 
the emulsification step, the latter providing the energy, whilst the surfactant 
decreases the 
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interfacial tension between phases thus stabilizing dispersed droplets (Arshady, 1991). 
Under otherwise standard conditions, the effect of these two parameters was initially 
examined, the granulometric results of which are shown in Table 4.3. 
Table 4.3 Granulometric statistics (volume) of microspheres prepared by emulsification- 
solvent-evaporation at various stirring rates and emulsifier concentration, n>6. 
Preparative conditions according to Table 4.1. 
PLLA PDLGA 
Batch mean diameter! µm RSD !% Batch mean diameter! µm RSDI% 
1 93.2 30.2 2 46.0 25.6 
3 72.2 24.6 4 30.5 20.5 
5 60.3 10.2 6 26.7 3.21 
7 38.5 16.5 8 21.7 20.5 
9 34.5 10.2 10 19.8 5.28 
11 123 11.5 12 45.1 2.25 
13 42.5 8.9 14 21.8 8.95 
15 34.2 11.1 16 18.9 10.0 
Mean particle diameter decreased with stirrer speed which is consistent with the results of 
others using comparable preparative conditions (Benita et al., 1984; Jalil & Nixon, 1990b; 
Zhifang et al., 1993; Sansdrap & Moes, 1993; Sanchez et al., 1993; Nakhare & Vyas, 
1995). Linear regression of mean diameter on stirring rate yielded correlation coefficients 
of r2= 0.973 and 0.8218 for PLLA and PDLGA, respectively. Deviations from linearity 
were attributed to aggregation of dispersed globules at low shear rates, with a resultant 
positive skew in the particle size distribution as observed by others (Conti et al., 1995a). 
For PLLA, at 600 rpm (#1), broad particle size distributions resulted (10 - 150 µm), 
whereas at faster agitation rates of 1000 rpm (#7), microspheres with narrower size 
distributions (19 - 60 µm) were obtained. Therefore, stirring speed 
has an effect on both 
microsphere size and also their distribution, whereby as the stirring rate 
is increased, the 
microspheres become smaller and the size distribution narrower. 
Accordingly, an optimal 
stirring rate of 1000 rpm was selected, as above this value, excess 
bubbles and foaming 
were generated in the emulsion. The consistently larger mean 
diameters for PLLA were 
accountable to the greater MW and the chain stiffening action of stereospecific and -tactic 
CH3 side-chain. These effects were partially offset by the viscosity-reducing action 
of 
processing at higher temperatures with PLLA compared with 
PDLGA. 
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PVA is the most commonly employed emulsifier in ESE procedures for biodegradable 
polymers (Wada et al., 1988a, b; Zhifang et al., 1993 Conti et al., 1995; Boisdron-Celle et 
al., 1995). Granulometric data in Table 4.3 shows that beyond 0.5 %w/v PVA, higher 
concentrations of PVA had little bearing on the mean microsphere size. However, it was 
observed that for very low concentrations of emulsifier, spherical microspheres were 
obtained, but with a notably larger mean diameter than for higher concentrations. 
Moreover, a considerable number of aggregates were formed during manufacture, which 
necessitated their removal (via sieving, mesh # 100) prior to particle size analysis. In 
order to eliminate these aggregates, the minimum PVA concentration used was set at 1 
%w/v, which also corresponded to the concentration which gave the narrowest particle 
size distribution. For example, particle size for PDLGA-prepared microspheres varied 
between 5- 45 p. m at 1 %w/v (#8), which widened to 10 - 125 µm at 0.1 %w/v (#12), and 
to 8- 57 p. m at 2 %w/v (#16). Therefore, in the interest of product reproducibility, 1 %w/v 
was the preferred concentration. 
Overall, particle size distributions complied with the recommended range for 
subcutaneous administration. However, although within-batch variation in mean diameter 
was small (typically 1-3% RSD), between batch RSDs for identical conditions were 
often in excess of 15 %. These data highlight the importance of the initial emulsification 
step to the final microsphere characteristics. The temperature of the continuum was 
considered of particular importance. Small variations around the boiling point of the 
disperse solvent can dramatically alter the diffusion rate of solvent, and hence the rate of 
ongoing viscosity changes of the microdroplets. Measures adopted in chapter 5 to restrict 
such variation included more stringent control of the disperse addition rate and adoption 
of an in-water drying modification (Bodmeier & McGinity, 1987a, b, c) whereby evaporation 
proceeds at ambient temperature without the application of heat. Indeed, because the 
solubility of DCM in water is reduced at elevated temperatures (2.5 %v/v at 15 °C 
compared with 0.88 %v/v at 45 °C (Horvath, 1982)), whilst potentially improving drug 
loading due to accelerated solvent diffusion initially, such modification might have 
exacerbated the between batch non-reproducibility. However, data in chapter 5 illustrate 
that modifications improved granulometry overall. The inclusion of baffles in the emulsion 
vessel, shown to improve particle size reproducibility (Bodmeier & McGinity, 1987a), and 
reduce particle size and polydispersity (Crossan & Whateley, 1994) was not, however, 
investigated. 
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4.3.2 Production attributes 
Mean microsphere yield was consistently greater than 70 %, yield generally increasing 
with encapsulation efficiency as a smaller fraction of dispersed RIF was lost to the 
continuum. Accordingly, yields were generally greater for microspheres prepared from 
PDLGA compared with those from PLLA commensurate with their enhanced drug 
loading. The encapsulation efficiency demonstrated a similar trend. Batch #18 prepared 
from PDLGA showed a paradoxical encapsulation efficiency of 120 %. This was attributed 
to the partitioning of dissolved drug from the continuum to the disperse prior to 
microsphere hardening which significantly retarded drug diffusion thereafter. By 
comparison, the maintenance of microglobule fluidity for longer periods when CFM was 
used as the solvent with the corresponding PLLA product (#17), accounted for the net 
outward diffusion of drug with this batch. 
4.3.3 Loading 
In a therapeutic context, notwithstanding patient acceptability, there exists a theoretical 
physiological limit to the quantity of microspheres which can be effectively administered in 
a single dose. Furthermore, high solid concentrations of microsphere suspensions might 
affect the syringeability of such forms. Hence, the practical utility of long-acting injectable 
formulations containing high dose drugs, such as RIF, necessitates that the drug should 
constitute a significant proportion of the overall formulation volume. Modification of phase 
volume (Sansdrap & Moes, 1993; Bodmeier & McGinity, 1986,1987a, b; Le Corre et al., 
1994), D: P ratio (Wakiyama et at., 1981,1982b; Jalil & Nixon, 1989; Ramtoola et at., 
1991); continuum pH (Bodmeier & McGinity, 1986a; 1987a, b; Le Corre et al., 1994; 
Polard et al., 1996) and presaturation of the continuum (Splenlehauer et al., 1988; Jalil & 
Nixon, 1989a; Zhifang et at., 1993) represent the principle strategies which have been 
previously adopted to attain high core loading of microspheres prepared by various 
techniques based on the ESE principle. Accordingly, selected parameters were varied to 
assess their influence on principally drug loading and other related microsp'here 
characteristics. The pH of a1 %w/v PVA solution was 5.3 which itself represented a value 
of minimum RIF solubility according to Figure 3.8. Therefore, unbuffered continuum was 
employed throughout these investigations. 
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4.3.3.1 Disperse volume 
Table 4.4 shows the effect of change of disperse volume on drug loading. Drug loading 
was inversely related to initial disperse volume, irrespective of the polymer used. This can 
be explained by considering the viscosity of the initial polymer solution. As the disperse 
volume decreases, there is a concomitant increase in disperse volume viscosity. 
Consequently, solutions become more difficult to disperse explaining the corresponding 
increase in mean particle size from 44 ± 2.5 p. m to 80 ± 5.4 gm and from 28 ± 2.3 µm to 
58 ± 3.8 µm for PLLA and PDLGA respectively as disperse volume decreased from 30 to 
10 mL. It is noteworthy that PLLA solutions were noticeably more viscous than PDLGA 
solutions of identical concentration at 24 ± 2.0 °C. Associated with the increase in mean 
microsphere size, is a reduction in the specific surface area of the product. Therefore, 
because of the low mass transfer surface area and high mass transfer resistance 
associated with an increase in viscosity, the amount of drug lost to the continuum 
decreased. This resulted in higher loading as disperse volume decreased. 
Table 4.4 Production attributes of microspheres prepared by emulsification-solvent- 
evaporation under various experimental conditions (n >_ 2). Preparative conditions 
according to Table 4.1 and 4.2. 
PLLA PDLGA 
Batch Yield/ Loading EE /% Batch Yield Loading l EE /% 
%a /%W/W /%b %wlw" 
7 88.1 7.59 51.5 8 95.2 13.89 95.3 
17 90.2 12.99 83.9 18 96.3 18.12 120.7 
19 89.2 13.89 50.7 20 94.2 25.89 86.7 
21 92.1 14.30 51.9 22 96.5 26.12 87.4 
23 78.3 21.00 42.0 24 87.5 34.11 68.2 
25 74.3 19.92 39.8 26 88.2 35.12 70.2 
27 74.2 20.48 61.4 28 89.2 31.60 94.8 
29 88.1 17.60 52.8 30 94.5 28.39 85.2 
31 86.2 12.80 38.4 32 92.5 22.82 68.5 
33 85.2 16.13 48.8 34 93.2 27.59 82.8 
35 90.1 15.05 45.2 36 94.2 25.89 77.7 
37 87.6 14.65 44.0 38 92.1 25.79 77.4 
a RSD <_ 12.3, b RSD < 10.2, ° RSD <_ 8.9, d RSD <_ 10.1 
The loading differences noted between PLLA and PDLGA, whereby loading was 
consistently higher for PDLGA batches, are contrary to the ideas proposed above based 
on differences in microsphere size, whereby a reduction in particle size should reduce 
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drug loading. These differences can be attributed to the nature of the organic solvent in 
which the drug and polymer were dissolved. DCM was chosen for PDLGA because of the 
solubility problems of this polymer in CFM (Bendix, 1991). CFM was initially chosen as 
the organic solvent for PLLA instead of DCM because of the increased solubility of RIF in 
CFM of 930 ± 25 mgmL-1 (50 °C) compared with 388 ± 15 mgmL 1 for DCM (37 °C). By 
maximizing RIF solubility in the disperse phase, this was considered to minimize 
partitioning, and therefore loss of RIF from the formed microspheres to the continuum. 
The results, however, do not support this rationale for reasons outlined below. 
Preformulation studies gave solubilities of 2.4 ± 0.11 %v/v (25 °C) and 0.75 ± 0.18 %v/v 
(25 °C) for DCM and CFM in 1 %w/v PVA, respectively. With the ESE procedure, the 
organic solvent must first partition into the continuum, from where it then evaporates at 
the surface of the emulsion. The rate at which solvent partitions into the continuum will be 
a function of organic solvent solubility in the continuum; environmental temperature; and, 
the viscosities of the disperse and continuum phases. This, in turn, will determine the 
resistance to mass transfer of the drug out of the disperse phase and ultimately the final 
drug loading. During solvent evaporation, DCM diffuses more rapidly than CFM into the 
continuum leaving more drug in the polymer matrix. As the volume of disperse phase 
reduced, then the period before polymer phase separation occurs decreased and hence a 
smaller proportion of dispersed drug is lost to the continuum and drug loading accordingly 
increased. 
4.3.3.2 Temperature of evaporation 
The complex effect of evaporation temperature differences on overall loading could not 
be adequately assessed. The greater viscosity of PLLA solutions noted at 24 ± 2.0 °C 
would be, in part, offset at higher processing temperatures when compared with PDLGA. 
Moreover, solubility of RIF in 1 %w/v PVA is known to increase approximately two-fold at 
55 °C, compared with 39 °C, to 6.00 ± 0.18 mgmL1. This would undoubtedly favour loss 
of dispersed RIF to the continuum, although overall, partition coefficients should have 
remained constant as similar changes were observed regards drug solubility in the 
disperse media. 
4.3.3.3 Continuum volume 
The effect of change of continuum volume on drug loading is shown in 
Table 4.4. 
Partitioning of drug from the disperse phase into the continuum, with a consequent 
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reduction in drug loading, is a common problem associated with the ESE procedure. By 
reduction of the continuum volume it was presumed that less drug would partition out of 
the central disperse phase as less drug would be accommodated by a reduced volume of 
liquid, and hence result in an increase in drug loading. From Table 4.4 it can be seen that 
only modest increases in drug loading were achieved with a two-fold reduction in 
continuous volume. These differences were paralleled by a modest increase in particle 
size, which, for reasons outlined above, could equally explain the results. Furthermore, a 
reduction in continuum volume might well impede organic solvent evaporation, thus 
negating any favourable effect. 
4.3.3.4 Drug: Polymer (D: P) ratio 
Table 4.4 shows that absolute loading actually increased with an increase in D: P ratio. In 
contrast, however, the loading efficiency decreased. This was expected as at higher D: P 
ratios, on one hand, more drug is available for entrapment, while on the other, higher 
drug concentrations initially set up greater concentration gradients across the liquid 
interphase so a larger proportion of the drug is lost to the continuum. 
By saturating the continuum with RIF, the concentration gradient is minimized, or even 
reversed. However as the D: P ratio increased, the amount of undissolved drug filtered 
with the microspheres accordingly increased. Associated with this undissolved drug was a 
reduction in product yield from 95.3 ± 5.4 % to 87.5 ± 6.5 % at D: P ratios of 0.2: 1.0 and 
1.0: 1.0 for PDLGA respectively. These values were approximately 5 to 10 % lower for the 
corresponding batches prepared with PLLA. At even higher D: P ratios loading 
paradoxically decreased (data not shown). As loading increases, it follows that drug 
constitutes a larger proportion of the overall microsphere volume. The probability of drug 
existing at the surface therefore increases. Unlike PDLGA, no obvious differences were 
observed with PLLA microspheres at different D: P ratios. However, Figure 4.1 shows 
electron micrographs of PDLGA-based microspheres at different D: P ratios and those 
prepared from saturated and non-saturated continuum. At low D: P ratios (A), PDLGA 
microspheres with a continuous surface were prepared. However, at higher D: P ratios 
surface roughness and large pores were evident (B), the morphology worsening in the 
presence of a presaturated continuum (C). Other workers have reported that 
presaturation had the effect of promoting crystal growth (Jalil & Nixon, 1989a) not 
dissimilar to the `pockets' of RIF evident here. In comparison, in Figure 4.3 (D), PLLA 
microspheres showed a continuous surface, albeit `dimpled', even at high 
D: P ratios. 
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These differences can be attributed to the higher processing temperature used with PLLA 
which facilitated the film-forming character of the polymer, whereby the softening 
temperature of PLLA was exceeded but not for PDLGA. Higher loadings for PDLGA 
would also increase the probability of surface defects in accordance with the concept 
proposed above. 
4.3.4 In vitro drug release 
The rate and profile of drug release are the definitive parameters which determines the 
overall efficacy of a DDS. From Figure 4.2, the principle factors affecting release are the 
nature of the polymer and the D: P ratio. Drug release was characterized by a biphasic 
profile constituting an initial `burst' of release followed by a very slow terminal phase over 
the time-scale of the release study. Rapid release of surface bound or loosely associated 
drug in the superficial areas of the microspheres, subsequent to very slow release by 
diffusion through a dehydrated polymer network typically results in the essentially 
asymptotic profiles of release observed. The magnitude of the asymptote is a function of 
the proportion of drug at the surface and the depth of microporosity. On the basis of an 
homogeneous dispersion of drug throughout the matrix, these values were found to be 
directly related to drug loading. Release from PDLGA during the terminal phase was 
found to be slightly faster than from the corresponding PLLA microspheres, in accordance 
with the increased degradation rate of this family of polymers as the co-monomer ratio 
approaches unity. The degree of crystallinity conferred on PLLA by the stereotactic CH3 
sidechain renders the polymer hydrophobic when compared with the amorphous nature 
of PDLGA. However, the high MW of the examined PDLGA renders this material 
essentially hydrophobic. 
Surface observation can be useful in assigning reasons to a particular pattern of release 
of a drug from biodegradable polymers. Initial release behaviour is a function of the 
nature of the microsphere surface, such as smoothness, porosity and continuity. In Figure 
4.1 (B) & (C) the increased number, depth and diameter of pores observed, aggravated 
the `burst' of release, however in (A), the absence of such defects and the 
correspondingly lower `burst' substantiates this reasoning. 
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Figure 4.1 Photomicrographs of PDLGA microspheres prepared at a drug: polymer ratio 
of: A, 0.2: 1.0 (#8) (Mag", 2.5 k); B, 1.0: 1.0 (unsaturated continuum) (#24) (Mag", 1.49 k); 
C, 1.0: 1.0 (saturated continuum) (#26) (Mag", 1.29 k). 
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Figure 4.2 In vitro release profiles of rifampicin from microspheres prepared by 
emulsification-solvent-evaporation at various drug: polymer (D: P) ratios from: A, PDLGA 
(68 kD); and, B, PLLA (78 kD) using method A at 37 ± 0.5 °C. Legend indicates the D: P 
ratio of the disperse phase. (n > 3, RSD <_ 6.6) 
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Figure 4.3 Photomicrographs of PLLA microspheres prepared at a drug: polymer ratio of 
1.0: 1.0 (#23) : A, before washing (Mag" 1.5 k); B, after 0.5 L distilled water (Mag" 1.5 k); 
C, after 1.0 L distilled water (Mag" 1.5 k); and, D, after 1.5 L distilled water (Mag" 2.0 k). 
No distinct differences in drug release during the terminal phase were seen for 
microspheres prepared with PLLA, despite the large variation in drug loading. The 
differences in initial release with increasing D: P ratio can be explained by considering the 
washing phase of microsphere preparation. Drug adhering to the surface cannot 
be 
considered encapsulated. However, from Figure 4.3, it can be seen that 
insufficient 
washing can lead to drug persisting on the microsphere surface. The 
dimpled surface on 
PLLA microspheres was considered to facilitate the harbouring of drug 
in these loci. Each 
batch prepared was washed with 500 mL of water. However it can 
be seen from Figure 
4.3 more than 1L is required to adequately remove all drug residue. 
At higher D: P, 
increasing amounts of undissolved drug were noted in the continuum 
during microsphere 
filtration. It follows that increasing amounts would be harboured in the dimples on the 
surface of the microsphere. These observations would explain 
the differences in 'burst' 
release in the absence of any surface differences, and 
the subsequent parallelism of the 
dissolution profiles by the very slow degradation rate of the studied 
PLLA. Moreover, the 
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determined loadings may therefore be inaccurate, as an increasing proportion of 
measured drug as D: P increases may be adsorbed or otherwise physically attached, not 
encapsulated. 
Finally, the differences in release profile for microspheres prepared from unsaturated and 
saturated continuum can be seen in Figure 4.4. Few differences are of note, with the 
exception of the initial 'burst' which was generally higher in those preparations prepared 
with a saturated continuum. Interestingly, at a D: P ratio of 1.0: 1.0 with PLLA, 
microspheres prepared from a saturated continuum (#25) had a lower drug loading when 
compared with those prepared without continuum presaturation (#23) as shown in Table 
4.4. At lower D: P ratios, increased loading with saturation of the continuum followed the 
general trends of greater `burst' and overall release rate. 
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Figure 4.4 In vitro release profiles of rifampicin from microspheres prepared by 
emulsification-solvent-evaporation at a drug: polymer (D: P) ratio of 1.0: 1.0 using method 
A 
at 37 ± 0.5 °C. Legend indicates the polymer used, and whether rifampicin was 
(saturated) or not (unsaturated) added to the continuum prior to emulsification of 
the 
disperse phase. (n >_ 3, RSD <_ 3.4) 
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4.4 Conclusion 
The results show that the successful encapsulation of RIF into biodegradable PLLA and 
PDLGA microspheres is favoured by low disperse volumes, with continuum volume 
having a lesser influence. Loading has also been shown to be a function of D: P ratio and 
the organic solvent used, DCM being favoured. Further work would include studies of the 
encapsulation of the degradation product of RIF, RSV, which itself is not orally 
bioavailable, but has been shown to be pharmacologically equieffective to RIF during in 
vitro microbiological testing (Gallo & Radaelli, 1968). The rationale would be to take 
advantage of its significantly lower water solubility, i. e., 0.005 mgmL-1 (Seydel, 1970) in 
an effort to further enhance drug loading. The asymptotic profiles of drug release 
irrespective of polymer represented unfavourable profiles for the intended application. 
Accordingly, the fabrication of microspheres based on more hydrophilic combinations of 
poly-a-hydroxy acids to modulate RIF release described in chapters 6,7 and 8 requires 
investigation. Preliminary studies have been undertaken using albumin as emulsifier, 
where satisfactory microspheres were prepared of approximately 20 %w/w drug loading. 
Albumin was selected as emulsifier owing to its biocompatibility (Bazile et al., 1992). 
Furthermore, it is postulated that post-preparation recovery of the microspheres by spray- 
drying should lay down an effective coat of albumin upon the existing layer of protein 
molecules which adsorb (Verrecchia et al., 1993) and denature at the microsphere- 
continuum interface during preparation (Landry et al., 1997). The examination of various 
techniques to denature this coating, e. g., heat and chemical, and the separation of the RIF 
microcapsules from spray-dried coating should also constitute further work. Microsieving 
should provide a suitable technique for the latter stage. However, to allow effective 
separation of the two populations, particle size would require to be optimized to ensure 
the microspheres were sufficiently small to allow effective coating, whilst being sufficiently 
large enough to allow population differentiation. Preliminary studies with image analysis 
have indicated its utility in the expedient determination of the agitation requirements to 
achieve a particular prospective granulometry based on measurements made during the 
emulsification stage. This technique also offers excellent potential for real-time 
investigations of the microsphere formation mechanism under different experimental 
conditions, and should be additionally considered as further work. 
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5. Characterization of biodegradable rifampicin microspheres prepared by spray- 
drying 
5.1 Introduction 
In chapter 4, modification of phase volumes allied to continuum presaturation using an 
emulsification-solvent-evaporation (ESE) technique, achieved 30 %w/w drug loading for 
RIF-bearing PDLGA microspheres. Despite high loadings, these formulations generally 
showed a characteristic (Smith & Hunneyball, 1986; Ike et al., 1992; Polard et al., 1996) 
and intolerable `burst' of drug release during the early stages, followed by a very slow 
release of residual entrapped RIF. In recent years, as an alternative to ESE as a 
preparative technique, spray-drying has emerged as a convenient method for the 
production of large quantities of biodegradable microspheres as a one-step process from 
a polymeric solution in which drug has been suspended - as solid particles (Bodmeier & 
Chen, 1988; Mathiowitz et al., 1992; Benelli et al., 1998) or emulsified droplets (Bitz & 
Doelker, 1995; Bittner et al., 1998) - or codissolved (Conte et al., 1994a; Wagenaar & 
Müller, 1994; Pavanetto et al., 1993). Consequently, in contrast to ESE prepared 
microspheres, respective production and characteristics of which are time-consuming and 
dependent on many variables, comparatively fast throughput of a product with high and 
predictable drug loading and reproducible product character can be readily attained 
(Giunchedi & Conte, 1995). The ease of scale-up and the techniques potential as a 
continuous process are further evidence of its industrial applicability. Indeed, Parlodel® 
LAR (Sandoz, Switzerland), which is one of only a few commercialized injectable 
microsphere formulations currently available (Benita, 1996), originates from spray-drying 
technology. 
A number of workers have compared the attributes of spray-dried biodegradable 
microspheres with other preparative techniques including: aqueous ESE (Pavanetto et 
al., 1994a; Conti et at., 1994; Benelli et at., 1998); glycerin ESE (Conti et al., 1991; 
Pavanetto et at., 1992; Benelli et at., 1998); solvent extraction (Conti et al., 1991; 
Pavanetto et al., 1992); o/o' ESE (Benelli et al., 1998); w/o/w ESE (Giunchedi et at., 
1998); and, ASES (Bitz & Doelker, 1995; 1996). Pavanetto et at. (1991,1992) prepared 
spray-dried particles of superior sphericity, narrower size distribution, 
higher 
encapsulation efficiency - from which vitamin D3 was released in a more controlled 
manner - than equivalent products prepared by 
ESE. Spray-dried hydrocortisone 
acetate-PDLLA microspheres demonstrated a two-fold increase 
in encapsulation 
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efficiency allied to a more controlled release when compared with those of equivalent 
diameter from ESE (Giunchedi et al., 1998). During a further comparison of ESE with 
spray-drying, Conti et al. (1994) observed approximately equivalent yields and particle 
granulometry for both techniques. The absence of surface-attached tolmetin with the 
latter technique, compared with the former, yielded a reduced `burst', despite drug loading 
being higher with spray-dried products. Comparison of theoretical and actual specific 
surface areas for ESE and spray-dried diazepam-PDLLA microspheres highlighted the 
porous nature of those prepared by ESE with otherwise equivalent characteristics in 
terms of drug loading and release (Pavanetto et al., 1994a). Benelli et al. (1998) recently 
reported that extensive partitioning and subsequent recrystallization of suspended 
clonazepam particles resulted in ESE-prepared microspheres with substantial adsorbed, 
but little entrapped, drug (despite modification of both the volumes and natures of the 
individual phases). In contrast, spray-drying achieved efficient encapsulation of similarly 
dispersed particles due to the rapid rate of microsphere formation. Significantly, this 
appears to be the only report of the use of the Resomero-H series for microencapsulation 
by spray-drying. 
In view of these encouraging results, the purpose of the work described in this chapter 
was to compare the characteristics of microspheres prepared by the ESE technique 
optimized with respect to RIF loading in chapter 4, with highly loaded RIF products 
prepared by spray-drying. These investigations allowed the selection of a preparative 
procedure for further investigation based on the overall features of the products from, and 
the attributes of, each technique. A range of amorphous biodegradable Resomer® 
polymers was examined to identify individual materials providing satisfactory release 
profiles which warranted further investigation. 
5.2 Experimental procedures 
5.2.1 Microsphere preparation 
5.2.1.1 Emulsification-solvent-evaporation 
Microspheres were prepared by the procedure described in section 
4.2.1 with the 
exception that evaporation was performed at ambient 
(24 ± 2.0 °C), not elevated (37 ± 
1.0 °C), temperature. Processing parameters were maintained constant at: continuum, 
150 mL of 1 %w/w PVA; disperse phase, 20 mL; 
D: P (0.5: 1.0) (3 g total solid). The 
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disperse was added to the continuum at a rate of 0.66 mLs-1 under constant stirring at 
1000 ± 50 rpm. Each batch was prepared in either duplicate or triplicate. 
5.2.1.2 Spray-drying 
A cosolution similar to that of the disperse phase above was diluted appropriately to 100 
mL to yield a3 %w/w solution (20 %w/w RIF) in a CFM: DCM (50: 50) cosolvent. Process 
parameters were: inlet = 50 °C; outlet = 43 °C; feed = 3.5 mLmin'1; flow 600 NLh-1; and, 
aspiration = 100 %. Spray-dried microspheres based on RG502, R202H and R104 were 
additionally examined at RIF loading of 11.1 %w/w (D: P = 0.125: 1.0,2.25 %w/v) 20 
%w/w (D: P = 0.250: 1.0,2.50 %w/v) and 27.3 %w/w (D: P = 0.375: 1.0,2.75 %w/v). The 
effects of altering aspiration, inlet temperature and feed solvent were examined in an 
effort to improve microsphere yield for those based on RG502H. Microspheres were 
stored at 24 ± 2.0 °C in vacuo for >_ 168 h prior to characterization. Each batch was 
prepared in either duplicate or triplicate. 
5.2.2 Cloud-point titration 
Polymer solubilities in DCM and DCM: CFM (50: 50) cosolvent were indirectly determined 
by methanol (MeOH) cloud-point titration as described by Hausberger & DeLuca (1995). 
Polymer, 125 ±5 mg, was dissolved and titrated against MeOH. The cloud-point was 
determined as the minimum volume of MeOH that resulted in a sustained turbidity. 
5.2.3 Microsphere characterization 
5.2.3.1 Yield 
Whereas microsphere yield from aqueous ESE was determined by the procedure in 
section 4.2.3, the following procedure was followed to determine the proportion of 
material retrieved after spray-drying. With reference to Figure 1.2, powder was recovered 
by meticulously scraping all material from the collector (1) and the down-facing aspect of 
the cyclone (G) - collector interface. These materials were pooled and stored under 
vacuum at 24 ± 2.0 °C for >_ 168 h before characterization. 
5.2.3.2 Drug loading 
Drug loading and encapsulation efficiency were determined by the method 
detailed in 
section 4.2.2. 
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5.2.3.3 Particle size analysis 
Microspheres prepared by ESE were sized according to section 4.2.4, whereas the 
following modifications were made to that procedure for the corresponding spray-dried 
products. Microspheres (20 ± 5.0 mg) were prepared into a paste with two drops of 
dispersant (Coulter Electronics, Luton, UK) to which was added 50 mL of filtered saline. 
Deaggregation was facilitated by ultrasonification using an Sonicator XL ultrasonic probe 
(Heat Systems, N. Y., USA). Following validation of the deaggregation method, analyses 
were performed by Coulter Multisizer (Coulter Electronics Ltd., Luton, UK) fitted with a 70 
gm orifice tube under constant stirring. Mean diameter and other granulometric statistics 
were thereafter determined on a population and volume basis by analysis of the % 
undersize particle size distribution using an iterative curve-fitting programme 
(CurveExpert version 1.3, Daniel Hyams, 112B Crossgate St, Starkville, MS, 39759). 
Selected samples were also examined by Laser diffraction for comparison purposes 
(Helos, Sympatec, Germany). Statistics, d25, d50 , d75, were selected as indices of 
distribution dispersity. 
5.2.3.4 In vitro drug release 
Drug release was examined by method A described in section 4.2.6. Additionally, initial 
RIF release was examined by the USP paddle (type II) apparatus (Sotax AT7, Basel, 
Switzerland); which is hereafter referred to as method B. Thus, microspheres, 50 ± 5.0 
mg, were immersed in 500 mL of medium maintained at 37 ± 0.1 °C and agitated at 100 
±1 rpm. Samples were withdrawn automatically over 3h and assayed 
spectrophotometrically at 330 nm, i. e., the isobestic point of RIF and its major quinone 
degradation product at the analytical pH. 
5.2.3.5 Scanning electron microscopy 
Images were captured according to section 4.2.5. 
5.2.3.6 Differential scanning calorimetry 
A computer-associated Perkin Elmer Pyris 1 differential scanning calorimeter 
(Connecticut, USA) was used to characterize the thermal behaviour of microspheres and 
establish the dispersed state of entrapped RIF. Microspheres, 3-6 mg, were analysed 
under a stream of N2. instrument calibration was established by using 
the melting 
endotherms of indium and zinc standards. The heating programme was as 
follows: 1) 25 
to 200 °C at 10 °Cmin_l (first run); 2) 200 to 25 at 30 °Cmin-l; 3) isothermal 
for 4 min at 25 
°C, and; 4) repeat of 1 (second run). 
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5.3 Results and Discussion 
The industrializability of any DDS preparative process is based on factors such as 
'process efficiency', i. e., the ratio of product output to time and financial input, and 
process sophistication, which, in turn, determines the extent to which the process can be 
repeated and scaled-up without affecting the properties so carefully designed into the 
system at the development stage. One further determinant is the proportion of overall 
material processed that results in product with the intended characteristics The-relative 
expense of commercially available poly-a-'hydroxy acids gives added significance to this 
latter factor, i. e., product yield. 
5.3.1 Yield 
The factors which determine product yield are the solubility of the polymer and drug in the 
organic solvent (and aqueous phase with ESE), whereas the mechanisms by which 
material is lost from the microspheres is a function of the microsphere formation principle 
for each technique. The yield with ESE is determined by the ability of the process to 
prevent aggregation of the microspheres and on the solubility of the polymer in the 
extraction and washing media. The characteristics of aerosol drying, which, in turn, 
determines the aerodynamic and impaction behaviour of the particles within the 
glassware, are known to affect yield with spray-drying (Masters, 1992). 
Production attributes are presented in Table 5.1. With the exception of RG752, yields 
were consistently higher for ESE compared with spray-drying due to the factors 
discussed below. With ESE, yield decreased with RIF loading as drug was lost to 
partitioning, although that lost could not be quantitatively reconciled with the overall yield 
due to inherent material losses during recovery and washing procedures. This was 
particularly true of RG752 (#17), where an average yield of 54.7 % indicated significant 
loss of polymer in addition to drug during microsphere formation. By comparison, 
RG502H (#7) had a comparable yield to other batches -- and a similar RIF payload to 
#17 - in spite of the fact that RG502H has a lower MW (8 compared with 20 kD) which 
would be presumably more liable to chain leaching during emulsification than RG752 
(Bodmeier et al., 1989; Le Corre et al., 1994b). Alternatively, this apparent anomaly may 
be attributable to greater loss of material during microsphere recovery as the particle size 
decreases. However, on this basis, R104 (#3) was expected to show the poorest yield. 
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Table 5.1 Production attributes of microspheres prepared by emulsification-solvent- 
evaporation (ESE) and spray-drying from a range of Resomero materials (RSD in 
parenthesis) (n >_ 2) 
ESE Spray-drying 
Batch Yield /% Loading / EE a Batch Yield! % Loading / EE a 
%w/w l% %w/w /% 
R202H 1 86: 0 (3.2) 27.0 (5.4) 81.8 
R104 3 80.7 (5.8) 29.4 (6.2) 89.1 
RG502 5 76.3 (6.3) 12.5 (3.2) 30.6 
RG502H 7 81.0 (4.6) 16.1 (5.2) 33.9 
RG503 9 78.0 (1.2) 21.3 (7.1) 64.5 
RG503H 11 78.0 (0.1) 23.7 (8.5) 71.8 
RG504 13 84.3 (11.7) 20.8 (5.2) 63.0 
RG506 15 --- 
RG752 17 54.7 (8.6) 10.1 (3.7) 30.6 
RG755 19 72.3 (3.2) 16.8 (7.8) 50.9 
encapsulation efficiency 
2 52.0 (5.4) 32.4 (0.6) 98.2 
4 48.8 (1.4) 32.2 (1.0) 97.6 
6 56.2 (22.2) 32.2 (1.2) 97.6 
8 44.2 (2.6) 32.8 (1.3) 99.4 
10 69.6 (4.0) 32.7 (1.4) 99.0 
12 58.8 (18.8) 33.9(l. 2) 102.7 
14 63.3 (4.7) 33.2 (0.8) 100.6 
16 71.3 (1.9) 34.1 (0.8) 103.3 
18 65.8 (7.5) 33.1 (1.0) 100.3 
20 68.3 (0.6) 32.9 (0.0) 99.7 
For spray-dried microspheres, adherence of partially dried micropartic'les to the glassware 
walls (see Figure 1.2) and/or their discharge through the cyclone (G) exhaust will result in 
a reduction in product yield. Thus, a spray-heat-air pattern should be established which 
minimizes these effects and ensures maximal deposition of the dried material in the 
product collection chamber (1). The optimum conditions are a function of factors such as: 
residual solvent, and thermal behaviour of the product, which themselves are interrelated 
to the parameters of processing: drying temperature; aspiration and feed rate; choice of 
solvent; and, volumetric air flow. Given the multitude of interacting factors which might 
affect yield, optimal parameters for individual feeds are difficult to predict. However, from 
observations made in this work, a number of general rules have been established. Inlet 
air flow and temperature should have sufficient drying capacity to ensure efficient 
desiccation of the sprayed microdroplets. Conversely, the drying temperature should be 
below that of Tg of the polymer, or, more correctly, that of the drug-polymer composite, so 
as to prevent sticking of tacky material to the glassware. 
Under otherwise identical conditions, variation in production yield shown in Table 5.1 was 
ultimately attributable to differences in polymer physicochemistry. 
Important factors are 
the Tg and the solubility character of the polymer, the latter of which 
influences the 
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residual solvent content of the polymer, which itself alters the former through a 
plasticizing action. Absolute solubility determinations of poly-a-hydroxy acids are 
inherently difficult due to gel formation at high polymer (40 - 60 %w/w) concentration. 
Indirect measurements of the solvation power of organic solvents can be made based on 
cloud-point titration (Hausberger & DeLuca, 1995; Mehta et at., 1996) and viscosity 
determinations (Stevens, 1990). Methanolic cloud-point volumes for individual polymers 
are shown in Table 5.2. - 
Table 5.2 Methanolic cloud-point for selected Resomer° polymers, n =2. 
Methanol / mL 
Polymer R202H R104 RG502 RG502H RG503 RG503H RG504 RG752 RG755 
Solvent 
DCM 18.84 > 30 4.05 3.95 3.20 3.17 2.95 6.20 4.68 
DCM: CFM 17.39 > 30 1.88 1.75 1.43 1.24 0.80 5.98 4.35 
In general terms, for the same class of polymer, as the Tg reduced and the solubility of 
the polymer in the feed medium increased with a reduction in MW as shown in Table 5.2, 
the yield fell. Reduced yield was also attributable to increased levels of solvent residue, 
which plasticized the polymer and further reduced its Tg. Upon impact with the hot 
glassware walls, the resultant surface tackiness promoted microsphere adherence and 
consequently a lower proportion of material reached the product collector. The reduced 
yields observed with PDLLA compared with PDLGA were therefore accountable to the 
considerably greater solubility of PDLLA in the coso'lvent used. Solubility of PDLGA 
copolymers were considerably greater in DCM compared with DCM: CFM, but likewise 
decreased as both MW and glycolide content increased. Furthermore, dependent on the 
molar ratio of monomeric units, materials of comparable MW possessing terminal 
free 
carboxylic end-groups were of lower solubility than their end-capped equivalents. 
Thus, 
from indirect measurements of polymer solubility based also on methanolic `cloud-point', 
Mehta et al. (1996) found the solubility of PDLGA (50: 50) was essentially 
independent of 
MW, whereas PDLGA (75: 25) demonstrated a significant inverse 
dependence below 15 
kD. The results in Table 5.2 show this trend extends beyond the narrow range studied 
by 
these workers. 
Product porosity should also influence yield through 
its dependency on polymer 
deposition rate during drying as discussed in detail in chapter 
7. Briefly, rapid solvent 
119 
Spray-dried biodegradable ri, fampicin microspheres 
The preparation and characterization of biodegradable microspheres containing anti-mycobacterial drugs David F. Bain 
evaporation rates associated with spray-drying typically result in a product of high 
porosity (Wagenaar & Müller, 1994; Rafler & Jobmann, 1994). Scanning electron 
microscopy revealed dimpled but otherwise smooth surfaces for all products, absent of 
'blow-holes' and overt surface porosity. More controlled rates of polymer deposition that 
prevail as polymer solubility increases with a reduction in MW, allow greater microglobule 
contraction and polymer consolidation. This should conceivably result in a product of 
reduced porosity. Associated with an increase in product density is a commensurate 
increase in product yield as fewer particles are exhausted from the apparatus. The results 
however contradict this pattern, whereby increased polymer solubility reduced product 
yield, e. g., R202H and R104. These data suggest that the effect of residual solvent is 
more influential than that of product porosity in the context of the drying parameters used. 
Alternatively, increases in MW, which result in higher precipitation rates should more 
rapidly form a dried crust at the surface of the particle during drying. This crust then acts 
to impede further solvent transfer which results in high levels of solvent residue. However, 
during the short sojourn involved in the transformation of spray microglobules to solid 
microparticles, this residual DCM (1.325 qcm-3) and CFM (1.48 gcm"3), which is 
predominantly concentrated deep in the particle, will maintain the density of the product 
diffusing hours to days later, after which time the product has been harvested. 
Furthermore, the surface of the products would be essentially `dry' and would not, 
therefore, readily adhere to the glassware. Conversely, with lower MW materials, 
particularly PDLLA, more controlled deposition and consolidation result in retention of 
greater loads of plasticizing organic solvent for longer periods in the surface layer. The 
probability that upon collision with walls of the drying chamber the polymeric matrix would 
be sufficiently tacky to remain attached is greatly increased. These theoretical 
considerations of polymer-dependent plasticizing organic load were not 
however 
confirmed (the DSC investigations were performed after loss of solvent during extensive 
storage). Residual solvent appears to have a far from simple effect 
depending on its 
position of entrapment: surface residue can reduce yield 
by promoting glassware 
adherence; or, conversely, solvent located in the microsphere core might minimize 
density-dependent loss through the exhaust. 
5.3.2 Drug loading 
As a result of enhanced polymer solubility and consequently 
delayed microsphere 
solidification with ESE, drug loading generally 
decreased with MW decrease within a 
polymer class. Additionally, as shown in 
Table 5.3, the associated increase in specific 
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surface area and decrease in diffusional pathlength as mean particle diameter decreased 
with polymer MW, facilitated the diffusion of RIF during preparation from premature 
microspheres. Differential behaviour between polymers of approximately equal MW, i. e., 
RG752 (10 kD); RG502 (15.5 kD); and, R202H (11 kD), illustrated that MW did not 
exclusively dictate drug loading. In terms of monomer composition, drug loading was 
minimal with 75: 25 (D, L: G), increasing at ratios of unity and further still with PDLLA. 
Indeed, the lowest MW polymer studied, R104, which should have theoretically showed 
the lowest drug loading by virtue of its superior solvent solubility and smallest mean 
diameter, demonstrated the highest loading of all the materials examined. 
Theoretically, drug loading of microspheres prepared by spray-drying should be identical 
to the weight percentage of drug in the homogeneous component solution sprayed 
providing drying parameters, solvents or additives used do not promote drug 
decomposition as air is the theoretical continuous phase to which drug cannot be lost. In 
spite of this, a continuum of encapsulation efficiencies have been reported from 99 % for 
tolmetin (Wagenaar & Müller, 1994), through 60 - 80 % for diazepam (Pavanetto et al., 
1993b) to as low as 14 % for vitamin D3 (Pavanetto et al., 1991; 1992). RIF is an unstable 
compound, degrading in air to its quinone derivative (Maggi, 1966). Instability in some 
organic solvents has also been reported (Graham, 1979). Under the mild conditions used 
to spray-dry the feed and the short contact time with CFM: DCM, no detectable 
decomposition occurred. Therefore, encapsulation efficiencies determined were 
quantitative (P > 0.05), corresponding to 97.6 - 103.3 % of that initially added regardless 
of the polymer used. This variation coincided with the precision and recovery data of the 
chromatographic technique employed. Moreover, this feature allowed the preparation of 
microspheres of predictable and reproducible drug loading. The poor encapsulation 
efficiency in reported work (Wagenaar & Müller, 1994; Pavanetto et al., 1991; 1992) 
remains unexplained, but may have arisen due to decomposition of encapsulant or 
inaccuracies in the analytical methodology. 
5.3.3 Particle size analysis 
Owing to the small particle size of spray-dried microspheres and their associated high 
surface energy, samples for analysis required fairly aggressive dispersion 
to ensure 
effective deaggregation and hence reliability of results. Accordingly, the effects of: various 
concentrations of dispersant, Tween® 80; sonification time; and, sonification 
intensity 
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were investigated, the granulometric statistics for batch #4 subjected to such treatment 
are shown in Table 5.3. 
Table 5.3 Effect of dispersion treatment on the granulometric (volumetric) characteristics 
of batch #4 determined by Coulter Multisizer 
Sonification / min 
13 
Power Tween® 80 
/ %w/v 
David F. Bain 
5 
diameter Jµm d25 dso d75 d2s dso d75 d25 d5o d75 
208.40 10.4 12.3 6.42 9.48 11.1 6.05 8.75 9.9 
0.01 4.89 6.75 9.56 4.39 5.45 8.15 4.08 5.15 7.80 
0.1 3.72 4.68 7.50 3.38 4.40 7.60 2.89 3.92 6.50 
308.50 10.1 12.2 5.81 7.02 9.85 4.62 5.26 5.99 
0.01 2.75 3.45 6.08 2.69 3.89 5.95 2.75 3.51 5.81 
0.1 2.70 4.45 7.40 2.64 3.59 6.06 2.70 3.51 5.65 
403.95 5.70 7.75 3.15 5.40 6.27 2.95 5.15 5.80 
0.01 2.63 3.90 5.50 2.60 3.58 5.40 2.41 3.71 5.48 
0.1 2.40 3.68 5.50 2.40 3.59 5.35 2.38 3.61 5.45 
d25 d25 d25, represent the 25,50 and 75 % undersize quartiles 
Particle size was found to decrease as: the wetting action of Tween® 80 increased with 
increased surfactant concentration; and, the energy delivered increased with time and 
power of ultrasonification. Intense forces delivered by the ultrasonic probe, conventionally 
used to homogenize biological media, have obvious potential to rupture the 
microspheres. It was therefore prudent to utilize the minimum intensity and duration of 
dispersion to obviate negative skew of the size distribution. Accordingly, power 4 
delivered for 1 min in a medium containing 0.1 %w/w Tween® 80 was selected as the 
optimal conditions for thorough dispersion without particle break-up. The constancy of 
diameter indices with treatment time seen in Table 5.3 validated this selection. 
Furthermore, dispersion medium was surrounded by an ice jacket to minimize drug 
dissolution and microsphere distortion by the heat generated during operation. Using this 
protocol, granulometric statistics for each preparation are shown in Table 5.4. 
Corresponding statistics determined by laser diffraction are shown in Table 5.5. The 
higher mean diameters with the Coulter electrical zone technique compared with laser 
diffraction reflected the differences in the two diameters presented and the counting 
principles of each technique. 
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Table 5.4 Ganulometric statistics (volume) of microspheres prepared by emulsification- 
solvent-evaporation (ESE) (RSD <_ 18.03) and spray-drying (RSD s 10.8) from a range of 
Resorner® materials determined by Coulter Multisizero 
Mean particle diameter! µm 
ESE 
Batch d25 d50 d75 
R202H 1 18.2 33.8 40.2 
R104 3 12.1 18.6 28.5 
RG502 5 19.2 28.2 38.2 
RG502H 7 17.9 27.8 38.4 
RG503 9 35.1 44.4 49.8 
RG503H 11 33.2 45.2 50.2 
RG504 13 37.4 48.3 53.5 
RG506 15 --- 
RG752 17 13.9 16.4 23.4 
RG755 19 38.1 50.2 61.. 3 
Spray-drying 
Batch d25 d50 d75 
2 4.46 4.37 6.14 
4 2.99 3.37 5.68 
6 4.18 5.64 8.60 
8 4.21 5.82 8.62 
10 3.49 4.38 5.92 
12 4.24 6.18 9.32 
14 3.57 4.46 5.85 
16 3.82 4.75 6.39 
18 4.18 5.68 8.45 
20 3.89 5.11 7.79 
Table 5.5 Ganulometric statistics (population) of microspheres prepared by 
emulsification-solvent-evaporation (ESE) (RSD < 15.12) and spray-drying (RSD <_ 9.2) 
from a range of Resomer® materials determined by laser diffraction 
Mean particle diameter/ µm 
ESE Spray-drying 
Batch d25 d50 d75 Batch d25 d50 d75 
R202H 1 26.7 33.9 43.5 2 2.02 4.13 7.22 
R104 3 14.9 21.1 30.4 4 2.04 4.04 7.03 
RG502 5 18.5 38.7 48.0 6 2.03 3.94 6.63 
RG502H 7 19.5 29.6 40.3 8 1.66 3.19 5.66 
RG503 9 28.0 41.7 53.5 10 2.11 3.99 6.65 
RG503H 11 36.0 44.4 54.5 12 2.10 4.10 6.85 
RG504 13 47.5 60.1 66.5 14 2.36 4.62 7.77 
RG506 15 --- 16 2.39 4.44 7.39 
RG752 17 17.6 26.7 35.5 18 1.78 3.40 5.56 
RG755 19 42.5 51.3 65 20 2.39 4.71 7.98 
In general terms, the mean diameter, d50, was several fold larger for microspheres 
prepared by ESE when compared with those derived from spray-drying. The exponential 
dependence of solution viscosity with %w/v polymer demonstrated by Armstrong et al. 
(1994), accentuated MW dependent viscosity changes. Accordingly, under constant 
agitation (1000 ± 50 rpm), mean diameter increased with MW for each class of polymer, 
as disperse viscosity, and hence resistance to shear, increased. Previous comparisons of 
the techniques yielded similarly distributed ESE-prepared tolmetin-PDLLA (Conti et al., 
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1994), diazepam-PDLLA (Pavanetto et al., 1994a), vitamin D3-PDLLA microspheres 
(Pavanetto et al., 1992) when compared with spray-drying. These results were 
attributable simply to the more energetic emulsification of the disperse afforded by the 
Ultraturrax equipment used in published reports when compared with the limited 
dispersion capacity of the magnetic bar used here. 
Particle size distributions of spray-dried microspheres are characteristically 
monodisperse, polymer concentration and MW being primary determinants of mean 
particle size (Pavanetto et al., 1993; 1994a). Where polymer concentration in the starting 
solution is maintained constant, the spray globule size increases with polymer MW 
(Pavanetto et al., 1992) due to enhanced intermolecular forces between polymer chains 
(Bodmeier & Chen, 1988), until a limiting MW is reached, where threads, not 
microspheres result due to insufficient force to break up the stream of feed solution. 
Discrete microspheres were observed by SEM confirming that this critical MW was not 
exceeded in the present work. Owing to the use of relatively dilute solutions (2 %w/w 
polymer), granulometric statistics for spray-dried microspheres demonstrated only a 
general qualitative dependence on polymer MW (size increasing as solution viscosity, 
microdroplet volume and final porosity increased with polymer MW). This feature, 
however, had the advantage that particles of comparable granulometry could be readily 
prepared from materials of contrasting chemistry and MW. Conversely, these data 
equally illustrate the relative inflexibility of the Minispray® 191 apparatus in terms of 
preparation of particles of widely different size distribution, in comparison to ESE where 
process changes can achieve several decade shifts in mean diameter. 
5.3.4 Scanning electron microscopy 
The morphology of microspheres prepared by ESE were consistently inferior than 
respective batches prepared by spray-drying as illustrated by selected photomicrographs 
shown in Figures 5.1. The only exception was for R104, where monodisperse smooth 
spheres were prepared by ESE, largely free of associated particulate debris. Surface 
flaws included crenulation, surface pockets and pitting, whereas ill-formed spheroidal, 
disc-shaped and broken microspheres were apparent on a population basis. These 
features became more prevalent as MW increased within a class of polymers, with the 
exception of microsphere breakage which became more frequent as MW decreased. The 
solidification point, at which polymer precipitation commences, occurs later as the MW of 
the polymer decreased. Furthermore, the associated persistence of matrix plasticity 
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Developing crust 
permitted more extensive and controlled contraction of the microdroplets as MW reduced 
prior to surface hardening which thereafter resisted further consolidation. In analogy to 
spray-dried microspheres, the diffusion of residual solvent occurred with a partial collapse 
of the hardened surface to produce the crenulated morphology. The within batch 
spectrum of surface features seen in Figure 5.1 (C) was attributed to the controlled 
addition of disperse to initially solvent free continuum. This created a range of DCM 
transfer rates amongst microglobules as the continuum rapidly saturated and equilibrium 
was achieved. 
Droplet of co- 
dissolved or - 
suspended 
solid 
A. Porous 
B. Concave 
C. Shrivelled 
Figure 5.2 Schematic of particle formation during spray-drying 
Figure 5.2 shows a generalized particle formation mechanism proposed by Kawashima et 
al. (1972), based on the physicochemistry of spray-dried salicylate-binder microgranules 
and observations of the morphological changes of the droplets as a result of the drying 
process. During drying, rapid evaporation of solvent from the droplet surface results in 
crust formation once the surface concentration reaches saturation point. Where the crust 
is sufficiently permeable (A) to allow passage of core solvent no change in appearance 
occurs during subsequent drying. On the contrary, low porosity films impede mass 
transfer, resulting in the formation of craters or holes as vapour expands and inflates 
and/or fractures the particles (B). Alternatively, more pliable, albeit impermeable crusts 
may yield a dimpled / shrivelled surface (C). Particle architecture is therefore a function of 
the vaporization characteristics of the solvent and its interaction with polymeric and other 
dissolved components, e. g., solubility of the microdroplet. 
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Figure 5.1 Photomicrographs of microspheres prepared by emulsification-solvent-evaporation from: A, R104 (#3); B, 
RG502H (#7); C, RG503H (#11); and D, RG503 (#9) (all Mag" x0.5 k);. and by spray-drying from: E, R202H (#2); F, R104 
(#4); G, RG502 (#6); and H, RG504 (#14). (all Mag" x10 k). 
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The variable morphology of the spray-dried particles was ascribed to MW and associated 
solubility differences between the polymers studied, which, in turn, affected the kinetics of 
microdroplet drying and consolidation. The poor solubility of PDLGA (monomer ratio 
50: 50) has been attributed to the existence of blocks of consecutive glycolide units which 
confer a degree of crystallinity on the material (Bendix, 1990) with consequently very poor 
solubility in common solvents (Deasy et al. 1989), particularly CFM. Therefore, during 
drying a crust rapidly forms at the surface of microspheres prepared from PDLGA. 
Subsequent loss of deep-seated solvent causes core contraction and surface collapse, 
leading to a partial destruction of sphericity as deep folds are formed at the microsphere 
surface. These features generally became increasingly apparent as polymer solubility 
decreased with MW and glycolide ratio increase as seen in Figure 5.1. On the contrary, 
PDLLA, for which CFM is considered a good solvent, yielded microspheres of smooth 
spherical morphology for both low (R104, #4) and moderate MW (R202H, #2) polymer as 
shown in Figure 5.1 (E, F); due to more controlled consolidation associated with its 
enhanced solubility. Pavanetto et al. (1993) examined a range of MW PDLLA, PDLGA 
and PLLA materials spray-dried from CFM, CFM: DCM (50: 50) and dichloroethane. 
Despite similar surface distortion with PDLGA prepared microspheres, the authors 
concluded that CFM: DCM cosolvent was the most convenient in terms of yield of 
production (35 - 45 %) and microsphere morphology as detected by optical microscopy. 
On the basis of this, and subsequent reports using this system (Pavanetto et al., 1993, 
Conti et al., 1994), this cosolvent was accordingly selected for preliminary spray-drying 
work in this thesis. The work of Pavanetto et al. (1993) did not, however, examine DCM 
alone which has been subsequently identified as a universally superior solvent for spray- 
dried poly-a-hydroxy acids during the work in this chapter. 
5.3.5 Differential scanning calorimetry 
The dispersed character of entrapped RIF and its effect on the thermal properties of each 
individual polymer were examined by DSC. The thermal indices for the first run and that 
after quench cooling to remove any thermal history are shown in Tables 5.6 and 5.7, 
respectively. The first DSC scans were typified by an endotherm which overlaid the Tg 
prior to broad and shallow endo- and exotherms between 140 - 190 °C. These latter 
events, shown in Figure 5.3 (A), were assigned to the melting and recrystallization of 
largely molecularly dispersed RIF; their diffuse character being a function of the finely 
divided state of these domains. In the absence of confounding variables such as drug 
loading, polymer deposition rates, residual solvent load and drug-polymer interaction, the 
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T. should exhibit a MW dependence. However, the position and magnitude of the 
anomalous endotherm is a function of the degree of disorder conferred on the matrix 
during fabrication; the dispersed nature of entrapped drug; and, the extent of relaxation 
recovery that occurs on storage. The extent of the latter ageing process is also a function 
of the residual solvent load as discussed in chapters 6 and 7 of this thesis. Accordingly, 
faster deposition rates associated with spray-drying generated greater matrix disorder 
and hence higher temperatures were required to free restricted chain motion. The greater 
`filler' effect with higher drug loadings made an additional contribution to this up-scale shift 
with spray-drying. By comparison of respective batches with comparable drug loads 
prepared by ESE and spray-drying (#1 & #2; #3 & #4), the influence of the former factor 
cannot be underestimated. 
Table 5.6 First heat DSC statistics for rifampicin-loaded microspheres prepared with a 
range of Resomei materials by emulsion-solvent-evaporation and spray-drying 
ESE Spray-drying 
Resomer® Batch Onset l Peak / °C Area / Jg" Batch Onset l Peak / °C Area I Jg'' 
# °C # °C 
R202H 1 56.0 57.9 11.5 2 65.2 67.7 3.28 
R104 3 47.8 49.8 7.37 4 63.8 66.5 7.76 
RG502 5 47.8 49.8 7.32 6 50.5 53.1 6.40 
RG502H 7 53.2 55.8 4.77 8 58.1 61.4 5.71 
RG503 9 57.4 59.0 10.6 10 55.9 57.7 7.02 
RG503H 11 56.0 57.8 7.82 12 56.8 59.2 5.51 
RG504 13 55.8 57.7 7.88 14 57.0 58.7 6.00 
RG506 15 --- 16 56.2 58.0 6.33 
RG752 17 56.7 58.0 10.0 18 58.3 59.6 6.11 
RG755 19 59.8 61.2 7.62 20 61.1 62.7 5.96 
The area of the endotherm associated with the T9 was shown to increase as the MW of 
the polymer decreased due to the enhanced mobility of shorter chains and, as drug 
loading decreased due to a reduced chain stiffening effect of fewer interposing drug 
molecules. The actual position of the Tg showed a pattern consistent with drug loading 
and the factors detailed above. Apparently anomalous behaviour with low MW material, 
R104 (2 kD), which registered a Tg at 49.8 °C, when compared with higher MW RG502 
(15 kD) was adequately explained on the basis of drug loading and polymer structure. 
Analogous patterns were exhibited by lower MW RG503H and RG502H and higher MW 
RG503 and RG502, although it is acknowledged their lower MW may have facilitated 
stress-relaxation associated elevations of Tg. 
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Figure 5.3 First (A) and second (B) DSC scans of selected batches of microspheres 
prepared by emulsification-solvent-evaporation (ESE) and spray-drying (SD). Legend 
indicates polymer used, abbreviated preparative technique. 
Subsequent to quench cooling, the statistics for the second run, whilst being independent 
of the fabrication process, are, however, influenced by the melt-quench process in so far 
as it appears to alter the balance of RIF which exists molecularly dispersed and that 
which is in solid solution. In Figure 5.3 (B), the absence of an on-scale T. with ESE 
prepared RG502H compared with RG502 microspheres was considered due to an 
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enhanced polymer interaction with RIF due to an increased density of free COOH end- 
groups. This interaction may have rendered a greater fraction of loaded RIF in plasticizing 
solid solution. By comparison, due to a greater drug payload, the respective spray-dried 
particles had an overwhelming fraction of molecularly dispersed RIF which negated the 
plasticizing effect of the fraction of RIF in solid solution such that an on-scale Tg persisted 
within the scan range. 
Table 5.7 Second heat DSC statistics for rifampicin-loaded microspheres prepared from a 
range of Resome? materials by emulsion-solvent-evaporation and spray-drying 
ESE Spray-drying 
Resomer® Batch Tg(o) / °C %Cp / °C ACp / Batch Tg(o) / %Cp / °C ACp / 
# Jg''*C # °C Jg-l*°C 
R202H 1 41.15 43.17 0.26 2 48.81 51.55 0.35 
R104 3 39.43 40.76 0.26 4 42.02 44.78 0.20 
RG502 5 40.00 40.76 0.37 6 37.05 39.26 0.30 
RG502H 7y`8 33.78 34.44 0.12 
RG503 9 43.90 45.33 0.47 10 40.23 41.22 0.21 
RG503H 11 42.04 43.62 0.22 12 39.18 40.86 0.26 
RG504 13 44.68 45.98 0.30 14 42.27 42.70 0.23 
RG506 15 --- 16 42.84 44.05 
0.27 
RG752 17 44.67 46.00 0.38 18 43.78 44.98 0.24 
RG755 19 48.52 50.30 0.38 20 49.52 50.27 0.25 
'no on-scale T. 
5.3.6 In vitro drug release 
Irrespective of the nature of the polymer or the microsphere fabrication process, RIF 
release was characterized by a biphasic profile comprising a 'burst' of drug release, 
followed by a protracted phase during which time residual RIF was liberated as shown in 
Figure 5.4. However, the nature of the polymer dictated the extent and rate of these 
phases. A number of general trends were identified consistent with polymer 
MW, drug 
loading and particle granulometry. Microspheres prepared from relatively hydrophilic 
RG502 (#5 & #6), RG502H (#7 & #8) and R104 (#3 & #4) demonstrated a substantial 
`burst' (50 - 100 %) within 24 h, prior to a relatively slow release 
thereafter. With the 
exception of RG752_ (#1.7) and RG502 (#6) prepared 
by ESE and spray-drying 
respectively, all other products seldom achieved greater than 
30 % drug release during 
the 14 d study period of examination using method A. Whereas the magnitude of 
the 
'burst' from comparably loaded spray-dried products showed greater correspondence 
with polymer MW and hydrophilicity, deviations 
from this pattern for ESE were attributed 
to variation in drug loading, whereby `burst' increased with 
drug loading. Consistent with 
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their greater mean diameter and diffusional pathlength, respective microspheres prepared 
by ESE demonstrated a generally slower release and reduced 'burst' when compared 
with the corresponding product prepared by spray-drying. The porous matrix of #17 with 
RG752 accounted for deviation from this trend. 
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Figure 5.4 Effect of fabricating polymer on rifampicin release from microspheres using 
method A prepared by., A, emulsification-solvent-evaporation; and B, spray-drying, n=3 
(RSD_3.5) 
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Figure 5.5 Effect of fabricating polymer on rifampicin release from microspheres using 
method 8 at 37 ± 0.5 °C and 100 ±1 rpm prepared by., A, emulsification-solvent- 
evaporation; and B, spray-drying, n=3 (RSD <_ 3.5) 
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Method B, when used to more closely examine the `burst' of release, only served to 
magnify this feature due to the greater microsphere surface area exposed to the medium 
using this technique as seen in Figure 5.5. These data typify the release of molecularly 
dispersed drug within hydrophobic poly-a-hydroxy acid microspheres, corroborating 
previous reports of drug release from spray-dried microspheres loaded with 
hydrocortisone (Giunchedi et al., 1995), theophylline (Bodmeier & Chen, 1988) and 
naftidrofurylhydrogenoxalat (Bruhn & Müller, 1991) where drug loading dependent `burst' 
followed by insignificant release was consistently observed. 
5.3.7 Further spray-drying studies on selected polymers 
5.3.7.1 Effect of drug loading 
Three polymers, R104, R202H and RG502H were selected to study the effect of drug 
loading on microsphere characteristics, and, in particular, drug release kinetics. These 
materials were chosen on the basis of their relative hydrophilicity in the case of R104 and 
RG502H which permitted substantial drug release within the 14 d study period. The 
selection of R202H was based on its excellent sprayability as evidenced by SEM, a 
feature also apparent with R104 and RG502H. In order to reduce the 'burst', the 
proportion of drug was sequentially reduced whilst polymer concentration in the feed was 
fixed at 2 %w/w. Consequently, it was anticipated because relatively more polymer was 
available to encapsulate the RIF codissolved in the feed solution, the accessibility of the 
release medium to entrapped drug, and hence release, would be reduced. Irrespective of 
the nature of the polymer, drug loading itself was again found to correspond to the 
nominal loadings (P > 0.05). Microsphere yield, however, was shown to be particularly 
sensitive to both drug loading and polymer type as seen in Table 5.8. 
Table 5.8 Effect of rifampicin loading on the yield of microspheres prepared by spray- 
drying with selected Resomer° materials. 
R202H R104 RG502H 
Loading / %w/w Batch Yield /% Batch Yield /% Batch Yield /% 
11.1 
20 
27.3 
33 
21 58.6 24 21.7 27 4.4 
22 84.0 25 70.0 28 7.2 
23 68.4 26 42.2 29 42.5 
2 52.0 4 48.8 8 44.2 
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Two general drying effects were considered to account for the parabolic dependence of 
microsphere yield on drug loading. On the one hand, T. temperature increased with drug 
loading due to the `filler effect of interposing drug domains, the magnitude of which 
increased as the volume contribution of RIF increased. Accordingly, the probability that 
microspheres adhere to the hot glassware elements in the event of collision was inversely 
proportional to drug loading. On the other, the aerodynamic balance which promotes 
particle deposition in the product collector was progressively disrupted as the solid 
content of the feed increased. Theoretically, there exists a critical mass and density at 
each instrument flow rate and aspiration which allows efficient product-air separation in 
the cyclone and the onward descent of particles into the collector. Interpretation is 
therefore further complicated by changes in solid content and solubility differences of the 
feed which alter the mass and density of the microspheres prepared. Nonetheless, by 
comparison with R104 and R202H, the former effect appeared to predominate with 
microspheres prepared with RG502H over the studied loading range. These data 
highlight some of the potential scale-up issues of spray-drying despite its otherwise 
excellent industrial potential as a preparative technique. 
Drug release profiles of these products are presented in Figure 5.6. Contrary to that 
anticipated, release rate actually decreased as drug loading increased. This was 
attributed to T9 elevation and increased matrix hydrophobicity as drug payload increased, 
both of which retarded water penetration and subsequent RIF release by diffusion 
from 
these relatively hydrophilic matrices. The influence of drug loading became more 
apparent as the hydrophilicities of the materials decreased in rank order 
R104 > RG502H 
> R202H. The influence of Tg on drug release from similar systems 
is discussed in detail 
in chapter 6. 
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Figure 5.6 Effect of drug loading on the release of rifampicin using method B (at 37 ± 0.1 °C and 
100 ±1 rpm) from spray-dried microspheres prepared with: A, R202H; B, R104; and C, RG502H. 
Legend indicates the drug loading in units of % wlw, n=3 (RSD <_ 3.2) 
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5.3.7.2 Effect of processing parameters 
Particularly low yields when spray-drying low MW materials has been attributed to heating 
effects in the collector (Witschi & Doelker, 1998). These authors concluded that the 
spray-drying of such materials was generally problematic. In an effort to improve the yield 
of spray-dried samples prepared from RG502H, variation in inlet temperature, feed 
(co)solvent and aspiration were examined at an otherwise fixed feed composition 
corresponding to batch #28. Microsphere yields from these studies are presented in 
Table 5.7. 
Table 5.7 Effect of selected spray-drying parameters on the yield of microspheres 
prepared from RG502H (2.5 %w/v total solid, 20% w/w rifampicin) 
CFM: DCM (1: 1) DCM 
Inlet/ °C 60 50 50 
David F. Bain 
40 
Aspiration /% Batch Yield/ % Batch Yield /% Batch Yield /% Batch Yield /% 
100 28 7.2 32 8.0 35 62.8 38 74.8 
75 30 16.0 33 7.2 36 40.0 39 42.4 
50 31 17.6 34 16.8 37 6.4 40 33.2 
The results in Table 5.7 show that yield increased with decreased aspiration for the mixed 
solvent, whereas the opposite trend was observed when DCM was used alone. 
Furthermore, reductions in inlet temperature resulted in generally a reduced yield with 
CFM: DCM, in contrast to consistently higher yields with DCM. Under identical processing 
conditions (inlet = 50 °C), with the exception of aspiration at 50 %, yield was improved 
several fold. This is in contrast to the results in section 7.3.2 where comparable yields (40 
- 60 %w/w) of PDLLA microspheres were obtained with: DCM (inlet = 40 °C); CFM: DCM 
(inlet = 50 °C); and, CFM: DCM (inlet = 40 °C). This anomaly was attributed to the 
solubility differences found with cloud-point investigations of PDLGA and PDLLA in the 
studied solvents which can result in architectural, solvent residue and thermal differences 
between products prepared by identical processing, which, in turn, alter both the 
aerodynamic behaviour through and the impaction behaviour of the material to the 
glassware. Given the interactivity of various processing parameters and a lack of 
knowledge of the exact solubility behaviour of RG502H in the studied solvents, it proved 
difficult to assign concrete reasons for the pattern of yield observed. That said, the 
following possible explanations are advanced. 
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Assuming ideal behaviour, the heat requirements to evaporate DCM and CFM: DCM are 
approximately equal. Therefore, the rate of solvent evaporation increases with drying 
temperature resulting in a more porous microsphere matrix. As aspiration is then 
increased, a higher proportion of material of low specific weight is exhausted from the 
apparatus. The differential behaviour between solvents at inlet = 50 °C could be assigned 
to solubility differences between the feed solvents. The poor solubility of PDLGA 
(monomer ratio 50: 50) compared with PDLLA was discussed above. Therefore, the 
inclusion of CFM in the feed solvent created greater matrix porosity due to faster polymer 
deposition during drying. Accordingly, the fraction lost via the exhaust again increased 
with an increase in the vacuum applied. Additionally, regulation of aspirator performance 
also serves to alter the volume of heated drying air within the apparatus and in turn the 
energy available for evaporation. It follows, as aspiration is reduced, evaporation occurs 
in a more controlled fashion to yield a more coherent product which is less readily 
exhausted. Moreover, the theoretical value of critical specific density required to 
overcome the aspirating vacuum and ensure deposition in the collector is reduced, and 
so the proportion of material deposited increased. Conversely, due to the comparatively 
greater solubility of PDLGA in DCM alone, during drying a more coherent matrix is 
deposited. In contrast to those prepared from a proportion of CFM, an increased vacuum 
is therefore required to draw this material of higher specific weight through the apparatus, 
thus accounting for the increased yield as the vacuum increased. Additionally, further 
reductions in inlet temperature resulted in enhanced microsphere densification and 
conceivably higher solvent residual which itself increased microsphere apparent density 
and further promoted product yield. Furthermore, that the solubility of PDLLA is 
approximately equal in DCM and CFM accounts for the differential behaviour between 
PDLGA here and the yield data for PDLLA based microspheres in chapter 7. 
Collected product (and that exhausted from the apparatus) require further fundamental 
investigation, i. e., pycnometric, granulometric and thermal to establish the architectural 
changes associated with varying drying parameters to establish their effect on particle 
impaction and aerodynamic properties. Preliminary investigations of this type for PDLLA 
are accordingly described in chapter 7. In view of the interactivity of process and material- 
related factors, such tedious empirical investigations appear necessary to define the 
drying conditions providing optimum yield. Preliminary studies of polymer solubility based 
on cloud-point titration and a knowledge of the vaporization characteristics of the solvent 
used, however, provide a considered starting point for such investigations. In general, use 
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of good polymer solvents and a compromise drying temperature in terms of solvent 
residue and particle coherence appear to promote the formation of relatively dense 
particles with acceptable yields. 
0 20 40 60 80 100 
Time /h 
80 T B 
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120 140 160 180 
Figure 5.7 Effect of selected spray-drying parameters on the release of rifampicin using method B 
at 37 ± 0.1 °C and 100 ±I rpm from microspheres prepared from batches, #28,30-40 
(RSD s 7.25, 
n=3). Legend indicates batch #. 
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The effect of spray-drying parameters on drug release profiles is shown in Figure 5.7. In 
contrast to microsphere yield, the release of RIF was generally insensitive to variation in 
drying parameters with the exception of batch #31 and #34 prepared at inlet = 60 and 50 
°C respectively from coso'ivent at an aspiration of 50 %. Contrary to the considerations of 
microsphere formation rate, these highly porous products paradoxically showed the 
slowest drug release. However, reasons for poor yield considered why material was lost 
from the apparatus, not why the proportion which constituted the yield was deposited in 
the collector. On this basis, it is considered that due to the theoretically high porosity of 
#31 and #34, the cyclone selectively deposited large particles which possessed sufficient 
critical mass to overcome the aspirating vacuum. The much reduced specific surface area 
associated with such large particles might have accounted for this apparent anomaly. It is 
acknowledged that these ideas require verification by granulometric and pycnometric 
investigation. Overall, the relative insensitivity of drug release from these products was 
attributable to their relatively high hydrophilicity which overshadowed otherwise subtle 
variation in microsphere architecture. 
5.4 Conclusion 
In contrast to ESE, microspheres with high and predictable loadings, reproducible 
granulometry, acceptable morphology and of high production yields could be readily 
produced using spray-drying regardless of the physicochemistry of the poly-a-hydroxy 
acid used. Furthermore, comparable quantities of product can be prepared by spray- 
drying in a fraction of the time required with ESE. Other workers have reported that 
microsphere formation was not possible using ESE when high proportions of low MW 
PDLLA were to be incorporated, presumably due to leaching of the polymer into the 
aqueous continuum during the emulsification and evaporation stages (Bodmeier et al., 
1989). By avoiding the use of water, spray-drying allows the preparation of microspheres 
containing relatively hydrophilic R104, RG502H and RG502. Limited examination of 
processing conditions identified DCM as a superior solvent to the CFM: DCM cosolvent 
conventionally used due to the superior solvent power of the single solvent as identified 
from cloud-point measurements of polymer solubility. Use of low inlet temperatures and 
high aspiration - to offset reductions in drier performance - attained high yields with 
low 
MW RG502H, despite its high affinity for organic solvent and its low T9, features which 
generally limit the proportion of recovered material. 
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In analogy to ESE, spray-dried biodegradable microspheres exhibited considerable 'burst' 
release particularly at high drug loadings (Conti et al., 1994), due to their small particle 
size. Contrary to diffusion theory, increased drug loading paradoxically decreased drug 
release rate from selected spray-dried hydrophilic systems due to a 'water-proofing' 
effect. Use of slowly degrading polymers resulted in a reduced 'burst' but with a 
protracted terminal release phase. Accordingly, in the following chapter, the utility of 
blending hydrophilic low MW with moderate MW PDLLA is examined to modulate both 
the 'burst' and protracted phases of RIF release. 
Overall, based on the favourable attributes of the technique, spray-drying has been 
selected for the remaining work in this thesis. Moreover, a limited but systematic study of 
selected parameters has established both conditions and materials, i. e., polymers and 
solvents suitable for further investigation of RIF encapsulation within the context of the 
current work. 
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6. Modulation of rifampicin release from spray-dried microspheres: combinations 
of low and moderate molecular weight poly(DL-lactide) 
6.1 Introduction 
In chapter 5, as an alternative to ESE as a preparative technique, spray-drying was 
demonstrated to be a convenient method for the production of large quantities of 
biodegradable microspheres as a one-step process from a polymeric solution in which 
RIF was co-dissolved. Additionally, comparatively fast throughput of a product with high 
and predictable drug loading and reproducible product character could be achieved. In 
analogy to ESE, spray-dried biodegradable PDLLA microspheres exhibited a 
considerable `burst' release (Bruhn & Müller, 1991) particularly at high drug loadings 
(Conti et al., 1994) due to the small particle size, large surface area and short diffusional 
pathlength of these systems as shown in chapter 5. Use of slowly degrading polymers 
resulted in a reduced `burst', e. g., RG504 and RG755 but with a protracted terminal 
release phase. 
The permeability of these polymers has been increased by incorporating channelling 
agents, such as polyethylene glycol (PEG) and polyvinyl pyrrolidone (Lalla and Sapna, 
1993). Wichert & Rohdewald (1990) improved the processability of high MW PDLLA by 
addition of plasticizing PEG to facilitate emulsification of solvent-free disperse phases. 
Juni et al. (1985b) accelerated the release of bleomycin by inclusion of fatty acid esters to 
the microsphere matrix. Pluronic". surfactants have also been investigated as a means to 
control the initial `burst' of protein and to modify its long-term release profile (Park et al., 
1991). Alternatively, incorporation of protein, bovine serum albumin (BSA), to hydrophobic 
PLLA has modulated theophylline release by leaching from hydrophilic channels thus 
formed from directly compressed pellets (Kader & Jalil, 1998a). Release of propranolol 
HCI and quinidine 804 from similarly prepared PLLA composites has been accelerated 
by 
addition of PDLLA oligomers and salt (NaCI), whereas reduced release rate was 
observed from pellets subjected to a post-preparation DCM dipping 
treatment (Bodmeier 
& Chen, 1989). Deasy et al. (1993) attained suitable drug release rates from an implant 
formed from a series of compressed mini-matrices, whereby faster 
degrading PDLGA 
adjacent spacers increased the surface area and therefore release rate 
from active 
compacts threaded along a single filament. Differential 
degradation, dependent upon 
spacer composition, allowed considerable flexibility and a progressive 
increase in delivery 
rate of anabolic steroid in response to the increased pharmacological need 
of the thriving 
L-lactide) 
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steers. The use of a terpolymer, poly(D, L-lactide-co-glycolide-D-glucose) has accelerated 
the release of bromocriptine from spray-dried microspheres by offering preformed break 
points in the polymer backbone (Kissel et al, 1991). 
An alternative approach, whereby the release of RIF, as a model drug, could be 
modulated, is by varying the proportions of low and moderate MW PDLLA. This 
technique, which avoids the use of potentially toxic release-controlling excipients, has 
previously been applied to the release of relatively small organic molecules from films 
(Bodmeier et al., 1989), o/w solvent-evaporated microspheres (Bodmeier et al., 1989; Le 
Corre et al., 1994b) and microparticles (Mauduit et al., 1993b). Elkheshen (1996) 
examined the ternary effects of mixing low and high MW PDLLA and moderate MW 
PDLGA on microsphere properties prepared by o/ol ESE using a simplex lattice design 
and surface response methodology based on triangular diagrams. Surface responses 
illustrated a range of antagonistic and synergistic interactions for microsphere 
characteristics (e. g., yield, loading, particle size, `burst' effect) illustrating the interaction 
between material and process factors. Nonetheless, within the parameters of the study, 
good correlation of experimental responses and those predicted from model equations 
was demonstrated. Incorporation of fractions of PDLLA significantly sustained the release 
of ciprofloxacin from phase separated microcapsules due to the amorphous film-forming 
character conferred upon the otherwise crystalline PLLA coacervate (Yu et al., 1998). 
Other reports describe the manipulation of release of therapeutic peptide from 
implantable polydisperse PDLLA rods prepared by `melt-pressing' blends of PDLLA of Mn, 
1.4 and 11.5 kD (Asano et al, 1991). In vivo degradation of rods, MW depletion and 
pharmacological response all decelerated or decreased in intensity as the proportion of 
component higher MW PDLLA increased. These trends were paralleled by a progressive 
shift in the degradation profile from parabolic to sigmoidal. Flandroy et al. 
(1997) 
moderated the chemoembolic duration of microspheres prepared with 
Resomer® R206 
(Grandfils et al., 1992) by accelerating the degradation of modified microspheres 
by 
incorporation of R104. 
Despite the technological advantages of the technique, the approach of blending 
hydrophobic moderate MW biodegradable material with hydrophilic 
low MW material to 
modulate drug release has hitherto not been examined using spray-drying 
as an 
alternative to conventional biodegradable DDS preparative methods. 
The work described 
in this chapter sought to exploit the favourable features of spray-drying as 
a preparation 
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technique, whilst assessing the utility of blending % weight ratios of rapidly and 
moderately degrading PDLLA on modulation of in vitro drug release from these systems. 
6.2 Experimental procedures 
6.2.1 Microsphere preparation 
Microspheres containing 20 %w/w RIF were prepared by spray-drying a solution of drug 
and polymer in DCM (3 %w/v total solid) through a 0.7 mm nozzle of a Mini Büchi model 
191 spray-drier (Flawil, Switzerland): inlet temp., 40 °C; outlet temp., 35 °C; flow rate, 600 
NLh-1 ; aspiration, 100 %; and, feed rate, 3.5 mLmin-1. Microspheres were prepared with 
blends of R104 and R202H in the weight proportions 0: 100,10: 90,20: 80,40: 60,44: 56, 
48: 52,52: 48,56: 44.60: 40,80: 20,90: 10,100: 0 respectively. Under identical conditions, 
spray-dried RIF and blank microspheres at weight proportions 48: 52,44: 56 and 40: 60 
were also examined. Further studies with new batches of polymer required that optimal 
proportions of polymer were re-established using weight proportions 40: 60,36: 64,32: 68, 
31: 69,30: 70,29: 71,28: 72,24: 76,20: 80 (R104: R202H). Additionally, the effect of drug 
loading was examined at 1,3,5,10,20 and 50 %w/w total weight at polymer weight 
proportions, R104: R202H, 44: 56 and 40: 60. All prepared materials were vacuum 
desiccated at ambient temperature for at least 168 h before examination, unless 
otherwise stated. 
6.2.2 Microsphere characterization 
Microsphere characterization was performed as previously described in sections 4.2 and 
5.2. with the following modifications. SEM was used for morphological examination of the 
microspheres after, in addition to before, release studies. Particle size distributions for 
selected batches were alternatively determined by manual measurement of the diameter 
of >_ 100 individual particles from SEM photomicrographs. 
The thermal behaviour of microspheres during, and after release studies, was additionally 
examined. Release studies were performed using method B at 33,35,39 °C in addition to 
37 ± 0.1 °C. First and zero order and power law kinetic models were fitted to 10 -< 80 % 
cumulative release using an iterative curve-fitting programme (CurveExpert version 1.3). 
Activation energies of drug release were thereafter determined by plotting the logarithm of 
the first order rate constants against the reciprocal of temperature (K) assuming classical 
Arrhenius kinetics. 
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Hydration investigations were performed during concurrent release studies. Samples of 
microspheres from method B were recovered at predetermined intervals for further 
thermal and gravimetric investigation. Dissolution medium was passed through a 0.2 µ. 'm 
filter under vacuum (Edwards, Crawley, UK) to recover suspended microsphere residue, 
then washed with 200 mL of distilled water. Filtration was continued for 20 s after medium 
had been clarified to remove extra-microspherical surface and interstitial medium. The 
sample was immediately scraped off the preweighed filter, transferred to a tared glass 
slide and uniformly spread across the surface of same. Samples were reweighed after 48 
h storage in vacuo at 24 ± 2.0 °C to determine dried weight and hence the moisture 
content. Thermal analyses were also performed on hydrated samples. In addition the 
effect of annealing conditions on thermal behaviour of selected samples at 37 °C was 
examined. 
6.3 Results and Discussion 
6.3.1 Microsphere characterization 
6.3.1.1 Microsphere morphology and granulometry 
Microsphere characteristics are summarized in Table 6.1. Discrete spherical particles with 
ostensibly smooth morphology as seen in Figure 6.1 were observed from 
photomicrographs of products irrespective of the polymer used. Particle size distributions 
were typical of the technique (Pavanetto et al., 1992), being narrow and monodisperse 
regardless of the polymer blend used. A general increase in mean microsphere diameter 
within the narrow range from 2.11 to 2.98 µm was observed as the proportion of more 
viscous PDLLA, R202H, increased from 10 to 90 %w/w total polymer (Table 6.1). The 
unimodality of particle size distribution was further illustrated by the fact that at all weight 
proportions studied, more than 95 % of particles were < 10µm. These results were 
consistent with the factors discussed in section 5.3.3which affect particle size distribution 
of products prepared by spray-drying. 
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Figure 6.1 Scanning electron micrographs of spray-dried microspheres containing 20 
%w1w rifampicin prepared at weight proportions of Resomer® R 104: R202H of A) 90: 10 
and B) 10: 90 (3 % w/v total solid) (mag" x 104). 
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An additional factor affecting microsphere size is the deposition kinetics of the polymer 
blend. Low MW polymers have a greater solubility in DCM and hence during microsphere 
preparation a greater fraction of the solvent must be removed before solidification and 
microsphere formation occurs. Consequently, the greater the fraction of low MW PDLLA 
used, the higher the polymer concentration in the microdroplet at the point of polymer 
precipitation and the greater the density (and lower the porosity) of the matrix. Assuming 
identical microdroplet volume at the point of generation, particle size should accordingly 
decrease in parallel with overall polymer composite MW. 
Table 6.1 Summary of microsphere characteristics, n=3 
Polymer composition 
Batch Yield /% (RSD) dso/ µm (RSD) 
R104 R202H 
1 100 0 55.8 (6.4) 
2 90 10 63.3 (2.2) 
3 80 20 63.4 (0.1) 
4 60 40 69.9 (9.5) 
5 56 44 65.0 (6.5) 
6 52 48 67.1 (6.5) 
7 48 52 67.2 (1.5) 
8 44 56 65.1 (2.1) 
9 40 60 73.3 (3.2) 
10 20 80 73.8 (4.2) 
11 10 90 80.7 (2.3) 
12 0 100 75.5 (9.3) 
13 48,52.51.2 (3.9) 
14 48 56 46.2 (5.3) 
15 40* 6050.3 (5.4) 
blank microspheres 
2.01 (3.4) 
2.11 (5.5) 
2.39 (1.3) 
3.14 (3.9) 
2.45 (5.1) 
2.65 (2.6) 
2.61 (4.2) 
2.73 (0.8) 
2.77 (4.7) 
2.69 (1.4) 
2.98 (0.7) 
3.23 (2.3) 
3.01 (2.3) 
3.12 (6.3) 
3.42 (3.5) 
Endothermic peak 
/ °C 
54.1 
55.3 
55.3 
57.2 
57.9 
58.1 
58.2 
58.0 
58.0 
58.2 
58.7 
59.3 
42.5 
39.4 
34.9 
6.3.1.2 Microsphere yield 
Yields of production progressively increased overall within the range 55.8 - 80.7 % of the 
total dissolved solid (1.5g) as the fraction of R202H increased as can be seen in Table 
6.1. These data correlated semi-quantitatively with the slight and progressive increase in 
softening onset from 54.1 to 59.3 °C as the fraction of R202H increased. Under identical 
process conditions, yield of production decreases as a function of physicochemical 
factors of the drug - polymer composite, such as softening onset and the affinity of the 
polymer for the feed solvent increase. Consequently, these two factors culminate in a 
reduced product yield as the fraction of low MW PDLLA increases attributable to a greater 
fraction of the total product adhering to the hot glassware walls. Nonetheless, use of a 
reduced inlet temperature and low boiling point solvents, such as DCM, resulted in 
comparatively high product yields compared with previous reports where higher boiling 
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point solvents, such as CFM (Bodmeier & Chen, 1988), or cosolvents of this with DCM 
(Pavanetto et al., 1992; 1993) were employed. Finally, thread production due to 
insufficient force at the spray nozzle can further contribute to poor product yield. 
However, air flow rates of, or above, 600 NLh-1 overcame the intermolecular polymer 
interactions responsible for this phenomenon (Bodmeier & Chen, 1988) resulting in 
efficient spray and subsequent microsphere formation at a polymer concentration of 2.4 
%w/w irrespective of polymer composition. 
6.3.1.3 Drug loading 
As in chapter 5 where individual polymers were used, drug loading was found to be 
quantitative with the proportion of RIF initially dissolved in the feed (P > 0.05). 
6.3.1.4 In vitro drug release 
Studies of a range of poly-a-hydroxy acids in chapter 5 identified two racemic PDLLA 
materials, R104 and R202H, which upon combination might modulate the release of drug 
from each when used alone, i. e., addition of low MW R104 would accelerate the release 
of RIF from moderate MW R202H and vice versa. In comparison to PDLLA of similar MW, 
the Resomer® H series are more hydrophilic, possessing free carboxylic acid end-groups 
which are not end-capped via esterification with alcohols. Consequently, water uptake, 
associated deesterification, erosion and drug release are all more rapid when compared 
with their end-capped equivalents (Mehta et at., 1996; Rothen-Weinhold et at., 1997). 
Preliminary examination of release kinetics of RIF from microspheres prepared with 
relatively large compositional changes showed a dramatic shift in release profile between 
40 and 60 %w/w R104 as seen in Figure 6.2. The gradual effect of increased release rate 
with increased low MW polymer as anticipated and reported elsewhere for films (Mauduit 
et at., 1993c) and solvent-evaporated microspheres (Bodmeier & Chen, 1989), was not 
however realized. Clearly, properties of the polymers and their interaction with their 
environment were contributing to the release profile at a finite polymer composition. Zhou 
& Chang (1988) proposed a critical MW existed, around which the release pattern of drug 
varied significantly. They did not, however, elaborate on the physicochemical 
factor(s) 
affecting this value. 
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Figure 6.2 In vitro release profiles from microspheres containing 20 % w/w rifampicin at 
wide matrix compositional intervals using method A at 37 ± 0.5 °C, n=3. (legend 
indicates the matrix composition expressed as % w/w Resomer® R104) (standard 
deviation <_ 5.0) 
Figure 6.3 represents the release profiles of RIF between the range of polymer 
composition of 40 60 %w/w R104. The general trend of increased release rate was 
observed, consistent with polymer composition. However, disproportionate differences 
were evident between 44 and 48 %w/w R104. In general terms, PDLLA polymers release 
entrapped drugs by a mechanism initially dependent upon diffusion of drug bound to, or 
near, the superficial areas of the microsphere surface. Subsequent to this initial phase, 
dissolution and erosion of oligomeric fractions generated by hydrolytic chain scission is 
the predominant mechanism which facilitates drug release. During this phase, an 
increase in pore volume within the matrix leads to the formation of aqueous channels. 
The inclusion of low MW R104 might serve to propogate pore genesis via leaching of low 
MW material to the release medium (Bodmeier et al., 1989; Fukuzaki et al., 1989; Le 
Corre et al., 1994a). The relative extent of these phases are determined by the nature of 
the entrapped drug (solubility, MW, drug loading and physical form) and the coating 
polymer (polymer MW and MW distribution, copolymer ratio, sequential distribution of 
comonomers and crystallinity). Where drug loading and microsphere characteristics, e. g., 
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morphology, granulometry are identical, as in this study, changes in release rate arise 
solely from differences in the encapsulating polymer. 
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Figure 6.3 In vitro release profiles from microspheres containing 20 % w/w rifampicin at 
narrow matrix compositional intervals using method A at 37 ± 0.5 °C, n=3. (legend 
indicates the matrix composition expressed as %w/w Resomer° R104) (standard 
deviation <_ 5.9). 
The marked difference in dissolution rate which are apparent in Figure 6.4 when method 
B (USP II paddle) was used was attributed to the considerably greater and three 
dimensional agitation afforded by the paddle method when compared to method A 
(shaking bath). In method A, the microspheres aggregated at the base of the vessel as 
opposed to remaining suspended and individualized in method B. Under the aggregated 
conditions which prevail in method A, the available surface area from which drug can be 
liberated via diffusion is markedly reduced, whereas the stationary diffusion boundary 
associated with the diffusion surface is greatly enhanced. These factors culminate 
in a 
multi-fold reduction in drug release rate. 
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Figure 6.4 In vitro release profiles from microspheres containing 20 %w/w rifampicin at 
narrow matrix compositional intervals using method B at 37 ± 0.1 °C and 100 ±1 rpm 
(legend indicates the matrix composition expressed as % w/w R104) (standard deviation _< 
2.0). 
Studies of the release at different stirring rates shown in Figure 6.5 supported this, 
whereby insufficient agitation at reduced stirring rates resulted in a plug of aggregated 
microspheres, which, after settling to the base of the dissolution vessel, showed a very 
slow release of residual drug. The dependence of drug release profile on dissolution 
methodology has been reported elsewhere, albeit not as pronounced (Conti et al., 
1995b). A further contribution to the dramatic differences in release rate for the two 
methods may have arisen due to slight variability in temperature control. The more 
stringent control with method B, i. e., ± 0.1 °C compared with method A, i. e., ± 0.5 °C, 
may have considerably influenced the release profile due to the temperature dependent 
release observed in Figure 6.6. Overall, these data highlight the need for careful 
consideration of experimental variables when studying the in vitro release of drugs from 
long acting DDS. Moreover, wide variation in these data invalidates extrapolation of such 
results to their prospective in vivo performance. 
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Figure 6.5 In vitro release profiles from microspheres containing 60% (A) and 48% (B) 
R104 illustrating the effect of stirring rate on drug release using method B at 37 ± 0.1 °C, 
n=3 (legend indicates the stirring rate expressed as rpm) (standard deviation < 3.4). 
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Figure 6.6 In vitro release profiles from microspheres containing: A, 48 % w/w: and, B, 44 
%w/w R104 illustrating the temperature dependent release observed using method B at 
100 ±1 rpm, n=3 (legend indicates the temperature of release medium ± 0.1 °C) 
(standard deviation <_ 2.0) 
A number of competing factors are influential to the release of drug by diffusion from 
matrices prepared with a fraction of PDLLA oligomers (Bodmeier et al., 1989; Le Corre et 
al., 1994b). On one hand, faster drug release may be attributed to: 1) the reduction of Tg; 
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2) pore formation and associated leaching of oligomers from the matrix, and; 3) polymer 
degradation which itself promotes 1 and 2 above. On the other, drug-polymer interactions, 
such as enhanced drug-polymer solubility, and, more significantly, charge interaction 
between ionized terminal carboxyl and tertiary amine groups, and consequent complex 
precipitation, have been shown to significantly impede the release of drugs with such 
basic moieties, e. g., quinidine from films and microspheres (Bodmeier et al., 1989). This 
latter effect is particularly significant where PDLLA oligomers comprise a substantial 
proportion of the matrix volume due to the high charge density of COOH groups, which 
are ionized at the pH of the release studies (7.4). The effective end-capping of such 
groups by counter drug ions complicates the anticipated pattern of increased release rate 
associated with a more hydrophilic, and hence hydrated matrix of greater diffusivity. 
Associated with an increased matrix density of ionizable carboxyl endgroups is a greater 
free volume within the matrix (Bodmeier et al., 1989) which would further improve drug 
diffusivity by increasing polymer permeability as the proportion of low MW R104 
increased. In the absence of confounding factors, a continuum of release profile would be 
anticipated with a gradual acceleration of drug release with an increased matrix fraction of 
low MW R104, rather than the pronounced differences noted with small changes in matrix 
composition. Clearly other factor(s) which governed the interaction of the matrix with its 
environment were influential. That the mechanism and the drug release rate showed a 
significant dependence on polymer composition as shown in Figure 6.4, and also a 
remarkable dependence on temperature as illustrated by the profiles in Figure 6.6, were 
considered to implicate the T9 as a pivotal parameter in determination of drug release 
kinetics owing to its influence on matrix diffusivity. At the Tg, intrinsic matrix energy is 
sufficient to move large segments of polymer chains (20 - 50 consecutive carbon atoms) 
(Omelczuk & McGinity, 1992). Such motion requires increased free volume and is thus 
associated with a change in the polymer's expansion coefficient. These molecular 
changes greatly facilitate mass transfer by diffusion. Correlation of drug release and the 
matrix Tg per se was not, however, established. The results were attributable to principally 
a reduction in the Tg of the microspheres upon incubation, the magnitude of which was 
inextricably linked to the inherent hydrophilicity of the polymer blend, which increased as 
the proportion of R104 increased. 
In general terms, as water ingresses, matrix plasticization occurs, and the thermal 
character of the polymer changes as the matrix softens. Once the softening 
temperature 
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of the matrix bulk decreases below the temperature of the release medium, water uptake 
accelerates, thus promoting drug release. Accordingly, at a critical polymer composition, 
the inherent hydrophilicity of the matrix is such that the water uptake, and thus matrix 
plasticization, reduces the Tg to a value which approximates to the temperature of the 
dissolution medium. Where medium and Tg temperatures equate, water uptake increases, 
matrix softening propagates and drug release occurs at a controlled rate as the diffusive 
properties of the matrix slowly change under the influence of ingressing water. Outwith 
this range, release is either uncontrollably fast -- where inherent hydrophilicity 
overshadows the influence of Tg -or unacceptably slow -- where insufficient depression 
of Tg arises due to matrix hydrophobicity. In the latter case, the critical MW or 
polydispersity at which matrix hydrophilicity represents correspondence of the Tg and 
medium temperatures, occurs subsequent to ongoing matrix deesterification. The 
sigmoidal patterns of release comprising induction and acceleratory phases observed by 
Bodmeier & McGinity (1987a-c; 1988a) and Ramtoola et at. (1992) with quinidine and 
fluphenazine respectively, were consistent with the mechanism of release described 
herein and the central importance of an evolving polymer Tg. The autocatalytic 
degradation mechanism (whereby propagation of active sites by COOH generation and 
catalysis), described in particular by Ramtoola et at. (1992), did not consider the role of 
matrix Tg, but that increased diffusivity was associated with enhanced microsphere 
permeability, not enhanced molecular mobility of the polymer chains. That said, it is 
recognized that the degradation rate should be substantially accelerated as the matrix 
enters the rubbery hydrated state where chain motion is freed and hydrolytic accessibility 
is enhanced by the concomitant increase in free volume. 
In the context of the proposed role of matrix Tg, as dissolution medium temperature is 
elevated, the smaller the differential between the Tg of the plasticized matrix and the 
medium temperature. Therefore, for each matrix composition there exists a narrow range 
of temperatures at which drug release rate shows a significant rise. 
At 37 °C, matrices 
comprised of >_ 48 %w/w R104 represented a composition above the critical value, 
leading 
to single rapid release phase. In Figure 6.6 by elevating the temperature at which release 
was studied, approximately superimposable profiles of drug release are 
observed for 
matrices with higher R202H content. This further highlights the 
interplay of dissolution 
medium temperature and polymer composition on drug release. 
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6.3.1.5 Thermal analysis 
DSC thermograms in Figure 6.7 represented a monodisperse matrix characterized by a 
single Tg temperature indicative of an homogeneous dispersion of drug and polymeric 
fractions throughout the matrix. Spray-drying of RIF resulted in an apparent destruction of 
the crystallinity evident with unprocessed drug. This was corroborated by the fact no 
crystalline melting endotherm or recrystallization exotherm for RIF were noted with drug- 
loaded microspheres. The endothermic peak which overlaid the Tg of the polymeric matrix 
was attributed to internal stresses created during the rapid evaporation of the solvent 
during micro-droplet drying. This pattern is comparable to that observed with 
biodegradable microspheres prepared using an aqueous ESE technique. In contrast, 
however, Bodmeier et al. (1989) observed a greater reduction of the T9 temperature with 
solvent cast films compared to microspheres thus prepared which they attributed to 
leaching of low MW polymeric fractions to the aqueous continuum with the latter 
technique. It appeared that the Tg position is influenced by the microsphere formation 
mechanism, which Bodmeier et al. (1989) cited as being rapid, a feature which according 
to these workers accounted for the high drug loading and minimum partitioning of the 
drug outwith the disperse phase. However, under these microsphere formation conditions 
it would seem unlikely that low MW polymer would be leached in preference to drug. The 
results of Bodmeier et al. (1989) were more likely attributable to higher residual organic 
solvent burdens in films when compared to microspheres of identical composition. A 
further endothermic event persisted beyond the main endotherm, which can be seen as a 
tail on this main peak. Limited thermal gravimetric analysis excluded residual solvent as 
the cause. Hot stage microscopy showed a dramatic colour change from the 
characteristic orange of RIF to yellow suggesting solubilization of the drug within the 
rubbery matrix. 
Figure 6.7 shows the thermograms of microspheres before and during release studies 
(method A, 7 d) for microspheres composed of 44 and 48 %wlw R104. Distinct changes 
in matrix microstructure were evident after 7d incubation characterized by a broadening 
of the endothermic peak and its downshift to transitions of lower temperature. Initially, this 
reduced onset, particularly at 48 %w/w R104, was considered attributable to oligomeric 
fractions generated by the hydrolysis of the component polymers. However, the degree of 
hydration, which plays a key role in drug release from these systems, results in a diverse 
population of microsphere residue and thus accounts for the broad endotherm observed. 
Significantly, although this broad endotherm persisted with combinations containing 
44 
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%w/w R104, superimposed upon this was the original endothermic peak indicating partial 
preservation of matrix integrity thus further accounting for the slower release from this 
combination. 
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Figure 6.7 DSC thermograms of microspheres containing: 1) 44 %w/w and 2) 48 %w/w 
R104 before dissolution; after dissolution (7 days; method A); 3) 48 %w/w and 4) 44 
%w/w R104; blank microspheres 5) 48 %w/w; 6) 44 °%w/w R104 respectively; 7) 
rifampicin as supplied, and, 8) spray-dried rifampicin. 
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Furthermore, the position of the endotherm is shifted up-scale by increased residue of 
interposing drug molecules at higher drug loadings which are thought to maintain polymer 
chain stiffness within the matrix. This was confirmed by the thermograms of the 
corresponding blank microspheres which exhibited a markedly reduced T9 temperature. 
Therefore, the downshift of this endotherm supports the fractional loss of RIF by diffusion 
through a partially hydrated matrix. However, the Tg temperature of the samples 
assessed did not correspond with the temperature of the dissolution medium. During 
desiccation, the Tg partially recovered upon removal of aqueous plasticizer. Indeed, 
Siemann (1985) recorded reductions of 18 °C in the Tg temperature of hydrated PDLLA 
when compared with anhydrous polymer, i. e., conditions conducive to significantly 
enhanced drug diffusion. In order to establish the interplay of matrix hydrophilicity and T. 
of hydrated matrices in the context of the proposed autohydration mechanism, DSC 
studies of recovered microsphere residue from release studies are described later in this 
chapter. 
6.3.1.6 Scanning electron microscopy 
Scanning electron micrographs presented in Figure 6.8 partially support these arguments. 
No significant differences in microsphere morphology were evident around the critical 
polymer composition whereas, only at high levels of R104, > 80 %w/w, were overt 
microsphere softening and fusion observed, whilst the original microsphere outline could 
still be discerned. 
Figure 6.8 [contd. overleaf] 
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Figure 6.8 Scanning electron micrographs of spray-dried microspheres remaining after 
dissolution for 7d using method A at 37 ± 0.1 °C prepared at weight proportions of 
8104: R202H of A) 90: 10 and B) 44: 56 (magnification x 10). 4 
6.3.2 Further studies of PDLLA blends 
In order to confirm criticality of composite Tg and, assess the relative importance of 
erosion and diffusion to overall drug release, complementary gravimetric, hydration and 
erosion studies, in parallel with thermal and drug release investigations were performed. 
In addition, due to the apparent sensitivity of drug release to matrix composition, separate 
batches of R104 and R202H were re-examined to: 1) to investigate the robustness of this 
approach to the regulation of drug release; and, 2) to ensure an adequate mass of 
microspheres for comprehensive characterization. The effect of drug loading on 
microsphere characteristics of reprepared blends was also examined. Production 
attributes of these microspheres are listed in Table 6.2. 
6.3.2.1 Effect of drug loading on microsphere characteristics 
Thermograms in Figure 6.9 illustrate the progressive elevation of Tg as drug loading 
increased (as tabulated in Appendix 2), consistent with the deposition of insoluble drug 
throughout the matrix. Owing to an increase in microsphere Tg temperature and a 
reduced affinity of the matrix for DCM, yield of production generally increased with drug 
loading. Drug particles uniformly dispersed throughout the matrix served to enhance 
chain stiffness; molecular rigidity increasing with volume and number of interposing 
particles. Prior to thermal comparison, peak area normalization with respect sample size 
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and also polymer proportion was performed. Irrespective of this treatment, the energy of 
the anomalous endotherm decreased with increased drug loading, indicative of reduced 
stress-relaxation due to restricted chain motion imposed by elevated levels of drug. 
Batches of matrix composition 44: 56 (R104: 'R202H) (#16 - 21) behaved similarly. 
Attempts to linearly (r2 = 0.894) and logarithmically (r2 = 0.921) equate drug loading for 
#22 - 27 with Tg displacement (and the endothermic area, r2 < 0.900) were, however, 
unsuccessful. The lack of linearity was partially attributable to the fact that a fraction of 
RIF was considered to exist in solid solution. 
Table 6.2 Microsphere composition and yields of production 
Matrix composition 
Polymer/ %w/w total polymer Yield /% total solid 
Batch 
R104 R202H RIF / %w/w Collector Cyclone Total 
16 44 56 1 42.7 22.0 64.7 
17 44 56 3 41.3 22.0 63.3 
18 44 56 5 46.7 21.3 68.0 
19 44 56 10 32.7 28.0 60.7 
20 44 56 20 40.0 29.3 69.3 
21 44 56 50 47.3 31.3 78.7 
22 40 60 1 45.0 18.0 63.0 
23 40 60 3 42.0 21.7 63.7 
24 40 60 5 32.7 37.7 70.3 
25 40 60 10 21.3 41.3 62.7 
26 40 60 20 25.3 42.7 68.0 
27 40 60 50 42.0 31.7 73.7 
28 40 a 60 20 16.7 56.7 73.3 
29 40 60 20 16.7 60.7 77.3 
30 36 64 20 38.7 42.0 80.7 
31 32 68 20 27.0 37.0 64.0 
32 31 69 20 35.7 40.7 76.3 
33 30 70 20 42.3 46.0 88.3 
34 29 71 20 21.7 60.7 82.3 
35 28 72 20 40.5 31.0 71.5 
36 24 76 20 33.5 39.5 73 
37 20 80 20 37.0 30.5 67.5 
a prepared with original batch of polymer 
The effect of annealing samples at 37 °C for various times was 
investigated to examine 
the microspheres response when subjected to the simulated 
heat of the release study, 
the data for which are shown in Appendix 3. Generally, as 
duration of annealing 
increased, all thermal indices moved up-scale due to the loss of plasticizing residual 
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solvent. It was therefore concluded that the influence of heat alone did not significantly 
alter the character of the matrix, nor did it account for the pattern of release observed. 
The results did, however, indirectly confirm the mutual interaction of microsphere 
hydration and thermal behaviour. 
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Figure 6.9 Normalized DSC thermograms of microspheres with a matrix polymer 
composition of 40: 60 (R104: R202H). Labels indicate rifampicin loading in units of %w/w. 
The corresponding release profiles of batches prepared from 44 %w/w (#16 - 21) and 40 
%w/w R104 (#22 - 27) are shown in Figure 6.10. Release rate was faster, as anticipated 
from microspheres of equivalent drug loading, as the level of R104 increased. Release 
rate also increased as the drug loading increased, commensurate with a relative 
reduction in the amount of available encapsulating polymer and the propensity of the 
matrix to a pore leaching, rather than a matrix diffusion release mechanism. Moreover, 
release rates as defined by first order rate constants were faster - #21,1.804 h-1 (r2 = 
0.978); #28,1.974 h-1 (r2 = 0.982) - when compared with that obtained from the original 
batch of polymers - #8,0.699 h-1 (r2 = 0.937); #9,0.198 
h"1 (12 = 0.912) - at nominally 
identical composition. These data highlight the necessity for extremely stringent polymer 
specification, e. g., MW, polydispersity and comonomer distribution to ensure 
between 
batch reproducibility of product performance of microspheres prepared 
in this manner. 
Apparent sensitivity of release character to change in polymer batch was attributed 
to 
Spray-dried blends of poly(D, L-lactide) 
160 
Development and characterization of biodegradable microspheres containing selected antimycobacterials David F. Bain 
either an actual difference in polymer character, lack of standard pre-characterization 
storage conditions, i. e., time, temperature and vacuum which affected residual solvent; or 
a combination of both (see section 7.3.7). 
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Figure 6.10 Effect of drug loading on release profiles using method B of rifampicin at a 
stirring rate of 100 ±1 rpm and 37 ± 0.1 °C from microspheres with a matrix polymer 
composition of: A, 44: 56 (R104: R202H); and, B, 40: 60 (R104: R202H). 
Labels indicate the 
rifampicin loading in units of %w/w. (n=3, standard deviation <_ 2.5) 
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6.3.2.2 Effect of polymer batch on microsphere characteristics 
Microspheres were reprepared with blends of two batches of R104 with the second batch 
of R202H. Combinations of the original batch of R202H were not examined due to the 
non-availability of this material. With the re-examined batches of microspheres, the critical 
polymer weight proportion for drug release at 37 °C was between 28 and 32 %w/w R104, 
by comparison to 44 to 48 %w/w for the original batches of R104 and R202H as shown in 
Figure 6.11. Release kinetics generally corresponded to that originally observed, rate 
being accelerated by elevated temperature and by the proportion of R104 incorporated. 
Thermographic analysis of the recovered microsphere residue is shown in Figure 6.12 
(data for which features in Appendix 4). 
The deterioration of the pre-dissolution endotherm increased as the temperature of the 
medium increased, commensurate with more extensive hydration and hence drug release 
as seen in Figure 6.11. Nonetheless, a sizeable endotherm persisted at 28 %w/w R104 
(#34) -even at elevated medium temperatures -- which was always greater in area than 
the corresponding sample from 32 %w/w (#29). 
6.3.2.3 Effect of storage time on microsphere characteristics 
Figure 6.11 shows some disparity in the release data for batches prepared with a1 %w/w 
differential around the critical range, when compared with products originally prepared at 
4 %w/w variations. Contrary to that expected, microspheres prepared with 31 (#32) and 
28 %w/w (#35) R104 released drug more rapidly than those prepared at 32 (#32) and 29 
%w/w (#34) respectively. Products prepared within 12 h of one another, i. e., 32 and 24 
%w/w, 31,30 and 29 %w/w, did indeed comply with the expected kinetic pattern of drug 
release. (NB, 28 %w/w was reprepared within 24 h of characterization and not subject to 
the standard >_ 168 h in vacuo storage). As all samples were stored under otherwise 
standardized conditions, it was apparent that the duration of storage affected the release 
character. This was attributed to an ongoing ageing process associated with residual 
solvent load. Batches containing 31 (#32), 30 (#33) and 29 (#34) %w/w R104 were 
therefore freshly prepared and examined at intervals thereafter on the basis of solvent 
residue, thermal and drug release behaviour The latter thermal and drug release data 
feature in Appendices 5 and 6, respectively. Comparable solvent loads of 56.45,55.23 
and 62.23 x 103 ppm were recorded after in vacuo drying to constant weight (for 100 d) 
for batches #32, #33 and #34 respectively. Thermal analyses shown in Figure 6.13 traced 
the rapid development of a significant endotherm associated with the Tg, representing the 
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attainment of a more stable microsphere matrix as demonstrated by the progressive 
retardation of RIF release shown in Figure 6.14. 
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Figure 6.11 Effect of matrix composition on release profiles from microspheres containing 
20 %w/w rifampicin at a stirring rate of 100 ±1 rpm and medium temperatures ± 0.1 °C 
of., A, 33 °C; B, 35 °C; C, 37 °C; and, D, 39 T. Labels indicate the proportion of 
Resomer® R104 as %w/w total polymer, n=3 (standard deviation < 2.3) 
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Figure 6.12 DSC thermograms of recovered and desiccated residue of batch #29 (32 
%w/w R104) and of batch #34 (28 %w/w R104) during dissolution using method B. Labels 
indicate the proportion of R104, and the temperature of the medium, respectively. 
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Figure 6.13 DSC thermograms of batch #33 (30 % w/w R104) after various storage times 
in vacuo at 24 ± 2.0 °C. Labels indicate the storage period in hours, or location of 
collection at t=0. Annotated table indicates the evolution of peak position. 
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Figure 6.14 Effect of storage on the release profiles of RIF at a stirring rate of 100 ±I 
rpm and 37 ± 0.1 °C from microspheres prepared from: A, 31 %w/w R104 (#32); B, 30 
%w/w R104 (#33); and, C, 29 %w/w R104 (#34), n=3. Tabulated data represents the 
first order release rate constants (10 < 80 % release, r2 > 0.980) (standard deviation 
4.8) 
The initial increase in release rate at 3d compared with 1d was attributed to the 
exceptionally high solvent residue at t=0, which: 1) promoted particle aggregation hence 
reducing available surface area; 2) preferentially retained RIF within the microsphere 
matrix retarding partition thereof into the dissolution medium; and, 3) resulted in 
enhanced polymer chain stiffness which transiently increased matrix stability. After 
extensive desiccation, the expected pattern of release with respect R104 content was 
observed. As a consequence of the influence of solvent residue on drug release and 
thermographic characteristics, further characterization was performed only after a period 
of 100 d storage post preparation. Standardization of characterization conditions ensured 
measured differences arose from variation in matrix composition, largely independent of 
the influence of any remaining solvent residue. 
The first order release constants of microspheres after exhaustive storage in vacuo 
prepared from polymer blends R104: R202H (40: 60) original: original (#9), original: new 
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(#28), and new: new (#27) were 0.304,1.469 and 1.843 h-1, respectively. That the 
substitution of R104 had no significant effect on drug release rate (P > 0.05), whereas the 
use of new batch R202H resulted in a significant 5-6 fold increase in release rate (P < 
0.05), identified this latter material as being responsible for the wide variability in release 
rate. It is postulated that slight reductions in MW of the new batch of R202H conferred 
sufficient hydrophilicity on the microspheres such that much less modulating R104 was 
required to attain controlled hydration as the temperatures of the Tg and the dissolution 
medium converged. These data highlight the need for comprehensive polymer 
characterization before device fabrication to ensure predictable performance. 
Furthermore, variations in polymer physicochemistry are consequently accentuated by 
the use of relatively low MW polymers. Whereas Deasy et al. (1989) drew attention to the 
batch-to-batch variability of poly-a-hydroxy acids prepared in-house, commercially 
available polymers have however received scant attention. Therefore, although residual 
solvent has an overlying affect on drug release from the hydrophilic particles, the inherent 
difficulties in the consistent preparation of relatively low MW PDLLA (Dr Liedtke, 1997, 
personal communication) -- prepared by ring-opening polymerization - accounted for 
the variability in polymer performance. 
6.3.3 Studies of release mechanism 
6.3.3.1 Hydration 
In Figure 6.15, the time-dependent destruction of the ordered microsphere structure, as 
evidenced from the progressive decrease in endotherm height and increase in endotherm 
breadth (see Appendix 7), was indicative of progressive hydration during release studies. 
Partial preservation of matrix integrity was again evident at slight increases in R202H 
level beyond the critical composition under the conditions of these investigations. These 
data are corroborated by the hydration data shown in Figure 6.16. The lack of 
direct 
correlation between drug release and hydration profiles was attributed to entrapped 
interstitial water between the microspheres during gravimetric determination which 
resulted in erroneously high levels of calculated water content, particularly 
in the earlier 
stages when the relative error is magnified. 
169 
Spray-dried blends ofpoly(D, L-lactide) 
Development and characterization of biodegradable microspheres containing selected antimycobacterials 
30 
5 
60 
120 
240 
ý= 
480 
#34,480 min 
30 40 50 60 70 
iiiii 
Temperature / °C 
80 
ý 
90 
David F. Bain 
Figure 6.15 DSC thermograms of recovered and desiccated residue of batch #29 (32 
%w/w R104) during dissolution using method B. Labels indicate the dissolution period in 
minutes. Batch #34 (28 %w/w R104) is included for comparison purposes. 
6.3.3.2 Erosion 
Preferential diffusion and loss of oligomers have been cited as a contributing factor to the 
release of drugs from matrices to which a proportion of low MW polymer has been 
incorporated (Bodmeier et at., 1989; Le Corre et al., 1994b). Corroborating evidence has 
included reductions in release medium pH - due to release of oligomers terminating in 
deprotonated COOH groups - and the emergence of oligomeric peaks during the initial 
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`burst' phase during degradation investigations (Witschi & Doelker, 1998) using aqueous 
SEC (Mehta et al., 1996; Park, 1994). Poly-a-hydroxy acids hydrolyse by geometry- 
dependent bulk (homogeneous) or heterogeneous degradation. Microspheres prepared 
from individual polymers are generally considered to degrade homogeneously, although 
drug dependent autocatalytic effects, ordinarily associated with larger devices, have been 
observed with microspheres containing basic drugs (Maulding et al., 1986; Cha & Pitt, 
1989; Ramtoola et al., 1992). In the absence of drug induced catalysis, the intensity of 
autocatalysis is a function of the relative rates of polymer hydrolysis and associated 
oligomer generation, and that of oligomeric leaching. Interpretation is confounded by 
oligomeric extraction during initial polymer degradation which can result in a transient 
increase in Tg and MW (Park, 1994). Nonetheless, where low MW material has been 
purposely incorporated in the design of a delivery system, leaching of oligomeric fractions 
accelerates as the proportion of low MW ingredient increases (Shah et al., 1992, Mehta et 
al., 1996; Mauduit et al., 1996; Witschi & Doelker, 1998); due to reduced Tg, enhanced 
hydrophilicity, free volume, and ultimately, matrix diffusivity. Furthermore, elevated 
temperatures should serve only to accelerate these processes. 
0 1 2 345 
Dissolution time Ih 
6 7 8 
Figure 6.16 Hydration profiles during release studies at 37 ± 0.1 °C and 
100 ±1 rpm 
using method B. Labels indicate the weight proportion of 
R104 (%w/w), n=3. (standard 
deviation <_ 15.8) 
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Table 6.3 Gravimetric determination of erosion of microspheres at various temperatures 
using method B 
Polymer weight differential /% (original) 
Medium / °C 
Batch R1041 %wlw 33 35 
31 32 +10.04 
32 31 +14.52 
33 30 +16.56 
34 29 +16.91 
35 28 +17.01 
36 24 +14.31 
37 39 
+7.13 +2.02 +0.32 
+0.43 +10.99 +5.47 
+7.33 +21.52 +2.33 
+18.03 +9.10 +8.29 
+8.31 +21.51 +1.79 
+10.16 +16.83 -12.54 
The gravimetric determination of microsphere erosion - taking account of released drug 
-- yielded the results in Table 6.3. These data are at odds with the anticipated pattern of 
erosion, whereby, with the exception of #36, at 39 °C, all other matrices showed a net 
weight gain. 
The number of carboxylic end-groups (acid number) is inversely proportional to MW of the 
chains of the fabricating matrix. Thus for low MW species the COOH group density is 
relatively high. Notwithstanding ongoing polymer deesterification which increases COOH 
group density, this situation is further supplemented by the use of H-series PDLLA as the 
complementary polymer, the end-groups of which have free COOH moieties. The 
deprotonation of these groups in contact with aqueous phosphate buffer, pH 7.4, renders 
the loci around the end-chain hydrophilic, which, in turn, facilitates the advance of the 
penetrating solvent front. However, di-sodium salts which interact to restore 
environmental pH, were considered to persist despite washing steps. These imbibed salts 
subsequently precipitate during desiccation. As the proportion of R104 increased, Figure 
6.16 illustrates that the level of hydration increased. Additionally, that the anhydrous and 
hydrated Tg' converge as the medium temperature increases, further enhances hydration, 
matrix protonation, and hence sorption of salt from the medium. However, the magnitude 
of the gain in weight appeared to decrease as the factors promoting matrix hydration 
increased. These data are suggestive of erosion of accessible oligomers from the rubbery 
superficial areas of the matrix. Therefore, two competing processes confound 
interpretation of the gravimetric results. On the one hand, hydration promotes sorption of 
salts which increases matrix mass; on the other, oligomer depletion causes a 
direct 
reduction in weight and a concomitant reduction in the ionic density, with a consequent 
reduction in the binding capacity of the matrix for salt ions. As an aside, neutralization of 
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deprotonated COOH by specific cation-induced salting out effects have been shown to 
inhibit polymer degradation (Reich & Bernickel, 1998). However, the influence of this 
process is considered minimal in the context of the diffusion mechanism which is 
considered to predominate here. In order to elucidate the significance of matrix erosion, 
morphological observation of microsphere residue and size analyses were performed on 
SEM photomicrographs. The population and volume granulometric statistics are shown in 
Table 6.4 and 6.5 respectively. The large variation between population and volume 
statistics was attributed to the existence of a few very large particles which resulted in a 
substantial positive skew for the latter statistic. 
Table 6.4 Effect of polymer composition and medium temperature on the population 
granulometric statistics of microsphere residue recovered after release studies using 
method B 
Medium / °C 
Batch R104 / 
(%wlw) 
33 35 37 39 
Diameter/µm d25 d50 d75 d25 d50 d75 d25 d50 d75 d25 d50 d75 
31 32 
32 31 
33 30 
34 29 
35 28 
36 24 
0.91 1.32 1.96 0.66 0.99 1.48 0.86 1.24 1.83 0.82 1.24 1.91 
0.89 1.28 1.90 0.69 0.95 1.36 0.78 1.17 1.81 0.94 1.36 2.03 
0.99 1.38 1.98 0.89 1.28 1.90 0.73 1.09 1.68 0.91 1.38 2.14 
0.89 1.28 1.90 0.96 1.46 2.28 0.76 1.07 1.56 0.76 1.07 1.56 
0.87 1.25 1.86 0.75 1.11 1.17 0.83 1.26 1.94 1.03 1.58 2.48 
0.85 1.22 1.80 0.68 1.01 1.54 0.82 1.17 1.73 1.06 1.56 2.36 
Table 6.5 Effect of polymer composition and medium temperature on the volume 
granulometric statistics of microsphere residue recovered after release studies using 
method B 
Medium / °C 
Batch R104 / 
(%w/w) 
33 35 
d50 d75 
Diameter/ µm d25 d50 d75 d25 
31 32 
32 31 
33 30 
34 29 
35 28 
36 24 
2.77 3.40 4.87 2.16 3.16 
2.08 3.75 5.41 1.65 3.02 
2.11 3.12 4.69 2.58 3.89 
3.21 4.74 5.60 3.17 4.94 
2.30 3.30 4.59 2.13 3.24 
3.07 4.18 5.03 2.17 3.36 
d25 
37 39 
dw d75 d25 dso d75 
4.05 2.53 3.39 
3.87 5.02 5.88 
5.08 2.35 3.53 
6.67 2.60 3.48 
5.29 2.13 3.24 
4.33 2.61 3.50 
4.33 2.59 3.88 5.54 
6.27 3.57 5.29 6.08 
4.70 3.00 4.49 6.06 
4.11 2.69 3.63 4.26 
5.29 2.40 4.08 6.32 
4.37 4.12 5.88 6.95 
1 
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That no obvious temperature or composition dependent trends were apparent, except 
perhaps for a slight general increase in volume statistics at 39 °C, was accepted as 
evidence that neither erosion, nor swelling made a significant contribution to the 
controlled release of RIF by predominantly diffusion. The porous nature of the particles 
was considered to accommodate the plasticizing water, which also accounted for 
maintenance of sphericity after residue recovery and drying (micrographs not shown). 
Attempts to perform these analyses by laser diffractometry were hindered by partial 
fusion of hydrated samples which resulted in misleading positive skew of the size 
distribution. 
6.3.3.3 Models of release 
Drug release data were fitted to three models of release, namely, first order, zero order 
and the generalized power law, the statistics of which feature in Appendices 8 a-c. The 
latter model demonstrated best correlation overall. However, that both the coefficient and 
exponent varied as the mechanism and kinetics thereof varied with change in release 
conditions and matrix composition, made batch-to-batch comparison difficult. Whereas 
the coefficient increased with temperature irrespective of polymer composition indicative 
of generally a more rapid diffusive mechanism, the exponent decreased at relatively high 
R104 levels, although this trend was reversed at/around the critical composition. These 
variations were considered to reflect the change in the diffusion character of the polymer 
as the hydration and thermal character of the matrix varied under the conditions of the 
release studies. That the data seldom fitted to the Higuchian t0.5 relationship was 
attributed to the lack of matrix inertness whereby matrix hydration and softening provided 
mechanistic control (see Appendix 8a). Linear regression demonstrated the anticipated 
pattern of increased release rate and `burst' as temperature and %w/w R104 increased as 
evidenced by the coefficients denoted by b (gradient) and a (intercept), respectively 
(Appendix 8b). Similarly, first order profiles provided a single index of release rate, 
denoted by the fractional rate constant, b. The fraction of drug released per unit time 
again increased with proportion of R104 and temperature as seen in Appendix 
8c. 
Notional activation energies of drug release were computed by plotting the 
logarithm of 
the first order release rate constant on the reciprocal of release medium temperature 
(K) 
(Jalil, 1989). These data and associated regression statistics are presented in Table 
6.6. 
The activation analogue for the release process was considered 
to represent the 
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resistance to mass transfer of drug through the matrices. Thus, as %w/w of R104 
increases, matrix free volume increases and the energy barrier to drug diffusion 
decreases; resulting in a continuum of release rate. However, the overshadowing 
influence of matrix hydrophilicity and the associated role of matrix Tg account for the 
substantial variation in Arrhenius derived statistics around the critical matrix composition. 
Indeed, Schellhorn & Buchholz (1996) concluded prediction of degradation rate of PDLGA 
and PDLLA was not possible based on Ea values due to extensive hydration, and hence 
change in the degradation mechanism of the matrix in the rubbery state. The poor 
correlation observed at 52 %w/w is attributable to the large variations in first order rate 
constants as the level of hydration, and hence drug diffusivity / release mechanism 
change under the influence of ingressing water. Above this weight composition, hydration 
is ostensibly instantaneous, regardless of temperature (within the studied range). On the 
other hand, controlled temperature-dependent hydration is responsible for constancy of 
Ea below this critical composition range. Comparable statistics were calculated for the 
second batches of studied polymer. Additionally, based on the correspondence of Ea 
values, neither residual solvent nor polymer batch affected the mechanism of drug 
diffusion, although the rates did increase under its influence as shown in Figure 6.14. It 
was therefore concluded that 320 and 630 J mol-1 represented the activation energies for 
RIF diffusion through PDLLA of a rubbery hydrated and glassy anhydrous character, 
respectively. 
Table 6.6 Arrhenius computed activation energies of rifampicin release for selected 
batches before and after exhaustive in vacuo drying at 24 ± 2.0 °C 
Before in vacuo storage After in vacuo storage 
Batch R104 l %wlw E8 /kJ mot' In A f2 Eg ! kJ mo! '' In A l, 
2 
4 60 324.1 55.21 
5 56 324.2 55.27 
6 52 520.3 88.03 
7 48 590.4 99.40 
8 44 631.2 106.0 
9 40 630.7 105.9 
30 36 373.2 61.09 
31 32 626.2 105.0 
32 31 656.5 110.0 
33 30 702.2 117.6 
34 29 619.1 103.5 
35 28 605.7 101.3 
36 24 581.5 1 00.0 
0.963 
0.987 
0.886 
0.957 
0.997 
0.964 
0.952 349.6 59.23 0.957 
0.998 643.4 107.8 0.999 
0.997 636.0 106.6 0.997 
0.994 667.0 111.8 0.993 
0.984 666.9 111.7 0.945 
0.997 618.0 103.3 0.988 
0.983 523.8 87.12 0.972 
data in italics represents the batches prepared from the original PDLLA batches 
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6.3.3.4 Thermal analysis 
In order to confirm the mutual interaction of plasticizing water, matrix thermal character 
and hydrophilicity with that of the dissolution medium temperature, DSC analyses were 
performed on hydrated samples during release studies, the results of which are presented 
in Table 6.7. The transitions reported are those after 15 min air drying, after which time a 
proportion of the total original plasticizing water had been lost; shifting the Tg temperature 
slightly up-scale. 
Table 6.7 DSC analyses of hydrated residue 15 min after recovery during release studies 
at 37 °C using method B 
Tg (%CP% I °C 
Batch #, R104 / (1 w/w total polymer) 
Time / min #29,40 #31,32 #33,30 #37,20 
0 52.39 55.42 55.50 56.18 
5 42.14 39.23 42.31 46.23 
15 39.84 
30 37.02 38.58 40.66 40.38 
45 37.00 
60 38.42 39.15 39.32 44.62 
120 36.11 39.52 42.75 40.02 
240 37.02 38.79 40.23 
480 35.86 37.74 41.23 
DSC of samples immediately after filtration yielded only a broad endotherm, which 
overwhelmed the observed T9 as shown in Figure 6.17. This broad endotherm was 
considered due to interstitial water and the high heat capacity of same. Owing to these 
operational difficulties, 15 min air drying was considered an acceptable compromise in 
terms of data accuracy and event detection. Overall, the different blends showed a rapid 
initial reduction in the Tg as water was absorbed, behaviour typified by amorphous and 
partially amorphous pharmaceutical solids (Hancock & Zografi, 1994). 
Thereafter, a 
general and progressive reduction in Tg occurred as the degree of plasticization 
increased 
with more extensive hydration. Moreover, in accordance with the proposed mechanism of 
release, the Tg and medium temperatures showed remarkable correspondence. 
Generally, as %w/w R104 increased, associated inaccuracies in sample 
handling and 
preparation did not allow the subtle thermal differences - thought 
to be so instrumental 
in the control of drug release - to be discerned around the critical composition 
at which 
drug release showed marked changes in release rate. 
Nonetheless, batch #29, (40 %w/w 
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R104) from which RIF was rapidly released, attained a Tg of _< 
37 °C within 30 min, 
whereas Tg suppression of #37 (20 %w/w R104) was insufficient to achieve medium 
temperature correspondence; consistent with matrix resistance to hydration and the 
consequent low and slow release from the latter blend. 
40 50 60 
Temperature / °C 
70 
Figure 6.17 DSC thermograms of hydrated microsphere residue during dissolution at 37 
± 0.1 °C using method B of. - A, batch #30,60 min dissolution time, immediately after 
filtration; B, as per A, but after 15 min air drying; and, C, batch #33,480 min dissolution 
time, 15 min air drying. 
30 
Multiple Tg represented the formation of several polymer domains in the microsphere 
population. Park (1994) assigned the existence of two Tg' to heterogeneous 
degradation, 
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whereby entrapped oligomers exerted an autocatalytic influence in the PDLLA 
microsphere core, whereas slower degradation in the microsphere shell represented a 
second polymer domain. This postulation fails to account for the three apparent Tg' 
observed with batch #30 (36 %w/w R104) at 60 min annotated on Figure 6.17. The 
presence of a range of particle sizes with different diffusional paths dictates that 
volumetric proportion of the microsphere which exists in the hydrated rubbery state will 
increase as diameter decreases. Therefore, thermal heterogeneity is considered to arise 
due to particle size differences which determine the overall hydrated state of individual 
populations within a range, and not via differential degradation mechanisms (Park, 1994). 
It follows that the diversity of population granulometry contributes significantly to the 
control of drug release from Iow: moderate MW PDLLA blends, where drug release occurs 
by the described autohydration-diffusion mechanism, i. e., as solvent penetrates the 
microsphere core at different rates, hydration and drug liberation by diffusion occur at 
different rates, yielding a controlled profile of drug release (see section 7.3.7). 
6.3.4 Conclusion 
In general terms, drug release accelerated when an increased proportion of low MW 
polymer was employed. Dramatic variation in both release rate and mechanism were 
attributed to hydrodynamic differences between the two release methods studied. 
Hydration, and thus release characteristics, appear to be inextricably linked to the thermal 
character of the polymer blend. There would appear to be a critical polymer composition 
at which hydration and drug release proceed in a controlled fashion, below and above 
which, release shows a pattern reminiscent of either polymer used alone. The high batch- 
dependency of this critical polymer composition was attributed to batch-to-batch 
differences in MW and polydispersity of the moderate MW PDLLA, which, in the absence 
of definitive polymer specification and microsphere pre-fabrication polymer 
characterization may limit the robustness, if not the utility of this approach to 
drug release 
modulation. 
Whereas low molecular impurities and oligomers are putatively inflammatory 
triggers 
(Vert et al., 1992; Bittner et al., 1998), it has been counter suggested 
that increased 
particle hydrophilicity might improve microparticle tolerability 
(Wang, 1990) and that the 
extent and severity of immunogenic reactions are accentuated 
by polymers of low 
degradation rates (Bittner et al., 1998). Accordingly, it is postulated 
that the hydrophilic 
1-8 
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character of these particles may afford greater biocompatibility, particularly to 
immunologically sensitive epithelia, such as those in the lung. Indeed, when administered 
intra-pulmonary, microspheres prepared from moderately high MW PDLLA, 16 kD, have 
been demonstrated to illicit a significant and limiting immune response (Armstrong et al., 
1992; 1994). That 90% of particles were < 10 p. m, and a substantial volumetric proportion 
coincided with the target range of 0.5 3.0 p. m for alveolar deposition, highlights the 
prepared particles potential for drug delivery via this route. Furthermore, the auto- 
hydration mechanism linked to the Tg of the hydrophilic microspheres should facilitate and 
provide controlled drug release in the low volume of liquid which prevails in the lung. 
Finally, temperature dependent release may have application in the delivery of drugs from 
biodegradable systems where elevated local biochemical activity promotes release of 
drug in response to an increased pharmacological need, e. g., delivery of steroids to 
arthritic joints, post-operative antibiotic prophylaxis to joint prostheses. Indeed, recent 
reports specifically indicate RIF-containing regimens to treat staphylococcal infections 
associated with orthopaedic implants (Editorial, Pharmaceutical Journal 1998). 
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7. Investigations of solvent influence on the characteristics of spray-dried 
microspheres 
7.1 Introduction 
Preparative techniques for biodegradable poly-a-hydroxy acid microspheres, with few 
exceptions, employ potentially toxic, halogenated solvents to prepare polymeric solutions 
as a prerequisite for most procedures. However, reports of residual solvent content are 
few in number and have considered only the bio- or ecotoxicological consequences 
thereof, frequently making use of USP limits as markers of acceptability: 50 ppm for CFM; 
and, 500 ppm for DCM (Benoit et al., 1986; Splenlehauer et al., 1986,1989; Gangrade & 
Price., 1992; Ruchatz et al., 1995,1996; Thoma & Schlütermann, 1992; Bitz & Doelker, 
1995). Microparticle architecture and granulometry are principal determinants of the 
magnitude of entrapped solvent; which themselves are a complex interplay between the 
solvent(s) employed, the process and its parameters and the polymer and drug used. 
Additionally, external factors such as drying conditions, i. e., temperature and pressure 
(Mabuchi et al., 1995; Bitz & Doelker, 1995) and duration (Mabuchi et al., 1995) have 
been shown to dramatically alter residual solvent content. Based on the multitude of 
factors which affect residual solvent content, it is little surprise a wide variety of 
determined loads have been reported. 
Splenlehauer et at. (1989) reported a3 %w/w DCM residue in cisplatin-loaded 
microspheres prepared by an aqueous-ESE procedure. Previously, these workers 
identified particle size, drug loading and the addition of non-solvent as being influential 
factors on residual solvent load (Splenlehauer et al., 1988). Benoit et al. (1986) found 1.8 
- 4.7 %w/w DCM residue in progesterone-bearing microspheres, whereas dramatically 
lower values of 0.036 - 0.68 %w/w were determined for preparatively and compositionally 
similar particles after drying in vacuo (Courteille et at., 1994). Norethisterone-loaded 
microspheres prepared by Lewis et al. (1988) harboured 0.25 %w/w organic residue. In 
contrast, prodigiously low values of < 59 ppm have also been recorded for microparticles 
prepared by solvent evaporation (Gangrade & Price, 1992). 
As a result of regulatory restrictions and apparent bioincompatibilities, the substitution of 
DCM and CFM with less toxic acetone (ACT) (Rafler & Jobmann, 1994) and 
halothane 
(HAL) (Guiziou et al., 1996) has been proposed for the preparation of biodegradable 
microspheres by spray-drying and ESE respectively. Other workers 
have examined the 
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potential of alternative microparticle preparative techniques in reducing toxic residue. 
These latter studies have however yielded conflicting results. Thoma & Schlütermann 
(1992) reported a reduced organic residue in cinchocain-bearing microspheres prepared 
by spray-drying (0.3 %w/w) when compared with those from a solvent-evaporation 
procedure (2.1 %w/w). On the contrary, Bitz & Doelker (1995) observed considerably 
greater organo-burdens in tetracosactide-loaded particles prepared by spray-drying than 
the corresponding product of a w/o/w process. Differential CFM and DCM loads of 934 - 
5998 ppm and 281 - 705 ppm respectively were presumably a result of the use of a 
reduced inlet temperature during spray-drying with less volatile CFM. Storage in vacuo for 
72 h effectively reduced the DCM load within USP limits, whereas CFM failed to conform 
after such treatment. More recently, aerosol solvent extraction system (ASES) (Ruchatz 
et al., 1995,1996), a technique which relies on the extraction properties of supercritical 
C02, has emerged as a process yielding microparticles with consistently low organic 
residue in the range 87 - 450 ppm. Bitz & Doelker (1996) demonstrated during a 
comparison of three preparative methods, including w/o/w, methanolic residue complied 
with an arbitrary limit of 1000 ppm immediately after preparation, whereas ASES 
prepared material required storage under vacuum to conform regards DCM. In spite of a 
higher inlet temperature, non-compliant CFM residue persisted in particles spray-dried 
from CFM: DCM, whereas DCM was satisfactorily removed after 72 h storage. To 
eliminate toxicological considerations, microparticles have been prepared without the use 
of organics. Wichert & Rohdewald (1990) developed a novel preparative technique which 
obviated the use of organic solvent, whereby solid microspheres were formed by quench 
cooling subsequent to emulsification of a molten mixture of drug and polymer. Others 
have described the grinding of cooled mixtures in which drug was incorporated to molten 
PDLLA (Smith & Hunneyball, 1986). 
Despite the growing number of publications concerned with the toxicological implications, 
no specific reports on the influence of residual solvent on the physicochemical 
characteristics of PDLLA microspheres exist. Indeed, some workers have discounted the 
influence of residues as high as 1.8 - 4.7 %w/w as being insignificant (Benoit et al., 1986). 
This chapter demonstrates the influence of solvent choice on microsphere characteristics 
prepared by spray-drying from CFM, DCM, ACT, halothane (HAL) and mixtures thereof. A 
single fixed matrix composition was selected from Chapter 6 to allow detailed evaluation 
of the effects of solvent and correlation of microsphere properties in relation to solvent 
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physicochemistry and the interaction of polymer with solvent in the context of the spray- 
drying process. 
7.2 Experimental procedures 
7.2.1 Microsphere preparation 
Microspheres of fixed composition were prepared from (co)solutions (3 %w/w total solid) 
containing poly(D, L-lactide) Resomer® R104 (24 %w/w), R202H (56 %w/w) and RIF (20 
%w/w). Solutions were spray-dried at a constant air flow and feed rates of 600 NIh-1 and 
3.5 mLmin-1 respectively, according to the parameters in Table 7.1. Microspheres were 
harvested and characterized at predetermined intervals during storage under vacuum 
desiccation. Selected physicochemical data of the organic solvents used are presented in 
Table 7.2 
Table 7.1 Preparative conditions for microspheres prepared with various organic 
solvents, n=1 
Batch Solvent (s) Spray parameters 
Nature Ratio Inlet/ °C Outlet/ °C Aspiration /% 
1 DCM 100% 40 35 100 
2 DCM: ACT 2: 1 40 35 100 
3 DCM: ACT 2: 1 40 35 50 
4 ACT 100% 40 35 100 
5 DCM: CFM 1: 1 40 35 100 
6 DCM: CFM 1: 1 50 39 100 
7 CFM: ACT 2: 1 40 35 100 
*8 DCM 100% 40 35 100 
9 HAL 100% 50 40 100 
10 HAL 100 % 40 40 100 
Key: DCM, dichloromethane; ACT, acetone; CFM, chloroform; HAL, halothane 
blank microspheres 
Table 7.2 Physicochemical properties of solvents used to prepare microspheres 
Property 
MoL formula 
Mol. weight / RMU 
Boiling point / °C 
/ (g cm 3) d25 25 
Heat capacity25 *c / (J K-' MOO 
OHap / (kJ mof') 
Molar volume / cm3 mo(' 
Aqueous sol. / (% v/v) -c 
Solvent DCM CFM ACT HAL 
CH2CI2 CHCI3 C3H60 C2HBrCIF3 
84.94 119.39 58.08 197.39 
39.9 61.7 56.5 50.2 
1.325 1.480 0.788 1.825 
100.88 116.90 
27.98 29.37 
64.11 80.67 
2.500 
25 'C 
0.79225 
°C 
0.880 
45 °C 
0.71241 °C 
74.52 100.01 
29.08 29.07 
73.52 105.44 
miscible25 0C 0.34525 °c 
miscible25 oc 0.800 37 oc 
data obtained from the Handbook of Chemistry and Physics (1967-68), Rathburn 
Chemicals and Zeneca pharmaceuticals 
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7.2.2 Solubility studies 
David F. Bain 
7.2.2.1 Viscosity 
Viscosities of the polymer blend-RIF cosolution (3 %w/w total solid) in each individual 
solvent were determined in triplicate with a U-tube viscometer (size A) at 25 ± 0.1 °C in a 
thermostated bath. Prepared solutions were allowed to stand for 24 h prior to 
measurement to ensure complete polymer solution. Flow times were measured again 
after 168 h to ensure the solvents studied did not promote solvolysis of the polymer 
chains during this equilibration time. Flow times exceeded 150 s for all measurements. 
Water (1.000 Cp25 oc) , ACT (0.316 Cp25 oc) and CFM (0.542 Cp25 °c) were used as flow 
time-viscosity calibrants (Handbook of Chemistry and Physics, 1966-67). Viscosities in 
centipoise were determined by substitution of the experimental values in Equation 7.1: 
fl2PItl 
III - (Equation 7.1) P2t 2 
where ill and 112 are the respective viscosities of the unknown and standard liquid, pi 
and p2 are the corresponding densities, and, tj and t2 are the flow times, respectively. 
Densities for dilute polymer solutions were assumed to be equal to the density of the pure 
solvent used to prepare these solutions, thus eliminating density terms from equation 7.1. 
Relative viscosities were determined according to equation 7.2: 
11 
11 rel - (Equation 7,2) 110 
where q and r10 are the viscosities of the polymer solution and solvent, respectively. 
Kinematic viscosity was additionally calculated by equation 7.3: 
ý 
ý kin = (Equation 7.3) 
where p was assumed to be equal to the density of the solvent. 
7.2.2.2 Cloud-point titration 
The cloud-point of R202H was determined as described in section 
5.2.2 in the individual 
solvents used to prepare microspheres. Triplicate measurements were made. 
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7.2.3 Product attributes 
Drug loading and yield were determined as described previously. Where yields were 
extremely low, additional material was retrieved from the cyclone wall to allow 
comprehensive characterization. Morphological examination and particle size analyses 
were performed as described in section 6.2.2. 
7.2.4 Residual solvent 
7.2.4.1 Gravimetric analysis 
The loss of solvent residue from microspheres stored in vacuo at 24 ± 2.0 °C was 
followed gravimetrically from a sample of each batch (>_ 300 mg) until the samples 
attained constant weight. Constant weight was considered attained where three 
successive weekly measurements varied by less than ± 0.05 mg total sample. 
7.2.4.2 Head-space analysis 
A Perkin-Elmer Autosystem gas chromatograph (Connecticut, USA) fitted with a flame 
ionization detector was employed, to which was interfaced a Perkin-Elmer HS 40 
headspace injector. The data was processed using Turbochrom® version 4.1 software. 
Standard solutions of DCM, CFM, ACT and HAL were prepared in phenoxyethanol at five 
levels in the concentration range 0.01- 0.20 p. LmL-1. Approximately 25 mg samples were 
accurately weighed into individual headspace vials, to which 1 mL of phenoxyethanol was 
added to disperse samples. The standards and samples were loaded into the headspace 
injector and after a predefined time in a heated compartment a constant volume of the 
headspace was admitted to the gas chromatograph. Calibration graphs for each solvent 
studied were constructed by linear regression of the peak areas obtained from standards 
on concentration prepared. The residual solvents present in the samples were then 
determined after correction for solvent densities from peak areas obtained by reading off 
the calibration graphs. 
7.2.5 Particle architecture 
The surface areas of selected samples were analysed by BET adsorption using a 
Micromeritics® 2360 Gemini (Micromeritics, Dunstable, UK). Analyses were performed 
with N2 as adsorbate. Free space of sample was measured using 
He gas. True densities 
of drug-bearing and drug-free microspheres, batch #1 and 
#8 respectively, were 
determined by He gas as 1.311 and 1.276 gcm-3 
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7.2.6 Thermal analysis 
The effect of in vacuo storage at 24 ± 2.0 °C on the thermal characteristics of 
microspheres prepared with different solvents was examined by DSC as described in 
section 5.2.3.6. Onset, mid-point, heat capacity change, ACp, and corresponding indices 
of the anomalous endotherm associated with the Tg were determined. In addition, the 
thermal behaviour of microsphere residue after dissolution was examined as described in 
section 6.2.2. The activation energies of the Tg for each batch at constant weight were 
calculated by linear regression of the logarithm of the scanning rate, 0, on the reciprocal 
of Tg (K-') according to Equation 7.4 (Fukuoka et al., 1986): 
lný =C' -- 
Ea 
RT (Equation 7.4) 
where C' is a constant for a given polymer, and T is the apparent T9 corresponding to the 
linear heating rate, 4. Equation 7.4 therefore represents a heating rate analogue of the 
Arrhenius activation energy equation for the Tg. 
7.2.7 In vitro release studies 
Drug release was investigated by the USP paddle (method II) described as method B in 
section 5.2.3.6 at a stirring speed of 100 ±1 rpm and temperature of 37 ± 0.5 °C 
immediately after microsphere preparation and at 5,10 and 100 d storage under vacuum 
at 24 ± 2.0 °C. The first order release rate constant at each time interval was determined 
based on the data for 10 -< 80 % cumulative drug release using CurveExpert 1.3. 
7.3 Results and Discussion 
In technological terms, the criteria for solvent selection for the preparation of 
biodegradable poly-a-hydroxy acids by ESE is based on factors such as the solubility 
constraints of polymer and solvent mass transfer considerations, e. g., partial water 
miscibility of DCM allowed controlled phase separation whereas use of water miscible 
ACT produced distorted agglomerates due to rapid solvent exchange (Bodmeier & 
McGinity, 1988b). The same selection criterion for solvent use for spray-drying have been 
arbitrarily applied, with little justification for their selection on technological grounds. Thus, 
DCM (Bodmeier & Chen, 1988; Mathiowitz et al., 1992; Gupta et al., 1993; Wagenaar & 
Müller, 1994), CFM, and mixtures thereof (Pavenetto et al., 1993; Conti et al., 1994; 
Conte et al., 1994a; Giunchedi et al., 1998) are invariably used; the work of 
Rafler & 
Jobmann (1994) who utilized acetonic systems on toxicological grounds excepted. 
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Under the conditions of rapid microdroplet desolvation which prevail during spray-drying, 
the more rapid the polymer deposition rate the greater the overall porosity of the particles 
formed. Thus, the use of solvents in which the polymer has low solubility, or those which 
require low absolute quantities of thermal energy to effect vapourization, should provide 
more rapid polymer phase separation -- and hence greater void volume - by 
comparison to solvents of high solvency and heats of vapourization. The total heat 
requirements - taking account of specific heat capacities, boiling points, latent heats of 
vaporization and molar volumes -- to vaporize 100 mL of each individual solvent were in 
ascending order: HAL, 29.96 kJ; CFM, 41.73 kJ; ACT, 42.76 kJ; and, DCM, 46.17 kJ. 
Therefore, microsphere porosity should be inversely related to these values, HAL-based 
products being of greatest porosity whereas other solvents should generate particles of 
approximately equal porosity. This postulation assumes no differences in the solubility of 
the polymer between solvents, which, on the contrary, was found to increase in 
approximately the opposite order to that given above. 
7.3.1 Solubility studies 
Theoretically, both the heat required to vaporize that solvent and polymer solubility 
therein should determine microdroplet solidification point. Variation in drug release 
described later, considered as a reliable indirect indicator of matrix structure, was 
apparently more influenced by differences in the magnitude of the polymer-solvent 
interaction as discussed below, than the heat requirements. 
7.3.1.1 Cloud-point titration 
End-point volumes for R202H were in ascending order 12.50,13.85,14.94 and 17.09 mL 
for HAL, ACT, CFM and DCM, respectively. Microsphere porosity and hence drug release 
was considered to decrease in the same trend, contrary to the results observed. It was 
reasoned that cloud-point is useful for comparison of the relative solubilities of 
different 
polymers in the same solvent system, However, due to potential cosolvency effects, 
cloud-point provides a relatively unreliable index where the quality of 
different solvents for 
identical polymer systems is being considered. Consequently, viscosity 
determinations 
were performed, which are believed to provide a more accurate 
indication of the intensity 
of association between polymer and solvent. 
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7.3.1.2 Viscosity studies 
Polymer chains conform differently depending on the quality of the solvent in which they 
are dissolved (Bodmeier & McGinity, 1988b). Thus, in dilute solutions greater solvency is 
marked by an increased viscosity due to enhanced chain stiffness as a result of the 
chains existing in a more expanded state - with a commensurate increase in 
hydrodynamic volume (Stevens, 1990) - than in a poor solvent. Bodmeier & McGinity 
(1988b) observed relative viscosities in ascending order: ACT < benzene < DCM < CFM. 
Armstrong et al. (1994) found an exponential increase in viscosity with polymer 
concentration for DCM and HAL over the range 1-8 %w/v, whereby the exponent for 
HAL was notably greater than that for DCM. Based on these data, which substantiate the 
results in Table 7.3 for relative viscosity, the solvation power - and thus polymer 
solubility therein - of the four studied solvents in ascending order was concluded to be 
ACT < DCM < CFM < HAL. 
Table 7.3 Viscosity data for rifampicin-polymer solutions in selected organic solvents at 
25 ± 0.1 °C, n=3 
Solvent 
Viscosity DCM CFM ACT HAL 
Absolute / cp 0.778 1.080 0.414 1.252 
Kinematic / cs 0.584 0.730 0.524 0.668 
Relative 1.495 1.636 1.310 1.616 
7.2.1.3 Theoretical considerations 
An alternative approach to the quantification of solvation power of a solvent is that of 
solubility parameters (Barton, 1975). The basic premise of the solubility parameter 
concept is a correlation between cohesive energy density (potential energy per unit 
volume) and mutual solubility. The one-component solubility parameter of Hildebrand, 
which approximates to equation 7.5 is considered useful for regular solutions, i. e. those 
without specific interaction or molecular polarity: 
/N0.5 
t s_ _ V V 
(Equation 7.5) 
where E is the molar cohesive energy and V is the molar volume. 
Generally, a good 
solvent for a certain (nonelectrolyte) solute such as a polymer has a solubility parameter 
value close to that of the solute. 
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Shively et al. (1995) measured the solubility of PDLLA in solvents having total solubility 
parameters ranging from 8.9 - 14.8 cal1/2 cm-3'2 to empirically determine a Hildebrand 
total solubility parameter for PDLLA of 9.8 call/2 cm-3'2. A second slightly smaller solubility 
maxima at 13.0 call/2 cm-3'2 was also observed with a distinct trough between these two 
values. Assuming a true density for the PDLLA composite studied of 1.276 gcm"3, a total 
theoretical solubility parameter can be calculated based on molar attraction constants by 
equation 7.6 (Martin, 1993): 
6= /C^rim. %fiýý 7 CI 
M is_yuaIIUII 1. uj 
where M and p are the MW of the repeat unit and polymer density respectively. Such a 
calculation yields a value in accord with that determined by Shively et at. (1995) of 9.68 
cal1'2 cm-3! 2. 
Table 7.4 Solubility parameters of (co)solvent(s) used to prepare spray-dried 
microspheres calculated by Equation 7.9 
Solubility parameter/(cal'12 cm 
Solvent(s) Ratio Sd Fd 5p FP bh Fh So 
ACT 100 % 7.6 47.2 5.1 27.9 31.7 21.1 9.8 
DCM 100 % 10.0 45.5 8.9 34.6 40.5 14.1 13.7 
CFM 100% 8.7 66.9 1.5 11.0 11.5 21.5 9.3 
DCM: CFM 1: 1 9.35 53.4 5.2 26.5 29.7 16.9 11.5 
CFM: ACT 2: 1 8.33' 59.4 2.69* 17.9 19.2 21.4 9.3 
DCM: ACT 2: 1 9.2 46 7.6 32.8 38 16 12.4 
TCTF reference 7.2 0.8 7.2 
TCE reference 9.2 2.5 10.6 
HAL 100% 15.9 
TCTF (1,1,2-trichlorotrifluorethane) and TCE (1,1,2, -trichloroethane) as reference solvents from Barton (1975). 
Based on the data in Table 7.4 and theoretical determination of solubility parameter, both 
DCM and CFM were predicted to be excellent solvents for PDLLA. However, the 
correspondence of parameters for ACT and PDLLA (Shively et al., 1995) should render it 
a superior solvent. This is in contrast to viscosity determinations where it was concluded 
the poorest of those studied. In the absence of literature vales, the total solubility 
parameter of HAL, 80, was theoretically determined from AHvap as 
15.9 ca'l1/2 cm-3/2 from 
Equation 7.7: 
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r Hvap 
- RT) 
0.5 
ýV) 
David F. Bain 
(Equation 7.7) 
where R is the gas constant, and T is the absolute temperature. For a liquid to dissolve a 
polymer, the differential between their 8o should be less than 2 (Martin, 1993). Contrary 
therefore to viscosity determinations, HAL would be expected to behave as a polymer 
non-solvent. Indeed, the calculated value for HAL appears too large when compared with 
related molecules TCTF and TCE. Additionally, the intermolecular forces of attraction of 
fluorinated hydrocarbons are relatively small: they are non-polar liquids with low solubility 
parameters (Horvath, 1982); and, whilst miscible with aliphatic hydrocarbons (80 = 7.0), 
partial miscibility prevails with solvents of 80 >_ 8.5. These data highlight the limitations of 
the single solubility parameter to predict solvent performance. The Hildebrand hypothesis 
has been largely superseded by the multicomponent solubility parameter approach of 
(Hansen, 1967). The total solubility parameter, 8, is the square root of the sum of the 
contributions from dispersive forces , 8d , polar interactions, bP , and hydrogen bonding, 
sh , according to Equation 7.8. 
b2=6d+bP+bh (Equation 7.8) 
Where cosolvents are used the individual parameters contributions are additive, defined 
by Equation 7.9: 
6 x, c ý1Sx, 1 +ý 26 x, 2 (Equation 7.9) 
where x= d, p, h and o is the corresponding volume fraction of each component. The 
partial solubility parameters of the (co)solvent(s) studied here are presented in Table 7.4. 
Bodmeier & McGinity (1988b) used a ternary diagram with fractional partial Hansen 
parameters - calculated according to Equation 7.10 - constituting the axes to define the 
solubility envelope of PDLLA. 
F= (Equation 7.10) F,, (öd 
+6 +8h) 
Where F. is the fractional contribution from dispersive, polar and hydrogen bonding 
forces. Overall, from the position of the phase boundary, relatively high fractional 
dispersive forces appeared to be the most significant factor for polymer solubility. Polar 
forces were of secondary importance, whereas solvents with relatively strong 
hydrogen 
bonding components had poor solvent power. Therefore, from these collective 
observations, good solvency for PDLLA should prevail for solvents which possess a So 
100. bx 
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value of 9.8 ± 2.0 ca 11/2 cm-3/2, a considerable contribution to which is from dispersive 
forces. These considerations place DCM, ACT and CFM in order of solvent power 
ascendancy. The mixture of DCM: ACT was anticipated to be the poorest cosolvent with 
the lowest dispersive contribution and a total solubility parameter corresponding to the 
solubility trough determined by Shively et at. (1995). Similarly, DCM: CFM was also 
anticipated to occupy this trough, whereas CFM: ACT better matched the criteria of a good 
solvent. Few of these data however correlated with the factors considered to be critical to 
microsphere deposition kinetics, and, in turn, release kinetics. Viscosity was therefore 
considered a more reliable marker of solvent power; solubility parameters, whilst being a 
useful predictive tool of gross polymer solubility, could not differentiate between the subtle 
differences apparently so critical to matrix structure under the aggressive desolvation 
conditions of microsphere preparation. 
7.3.2 Product attributes 
The chemical inertness of the studied solvents was established by the fact that drug 
loading corresponded to the nominal 20 %w/w (P > 0.05) for all batches. The low levels of 
RQU detected during analyses were consistent with limited oxidative degradation inherent 
to the associated extraction procedure. Polymer stability was indirectly confirmed by the 
constancy of viscosity determinations after 168 h storage. 
Microsphere yields and site of product deposition are listed in Table 7.5. The polymer and 
processing factors which affect yield of production were discussed in sections 5.3.1 and 
6.3.1.2. Variation in microsphere yield is ultimately attributable to variable solvent-polymer 
interactions between the solvents used, which, in turn, affects: microsphere architecture 
through its influence on the deposition kinetics of the microsphere matrix; solvent residue; 
and, the Tg of the microsphere matrix, as does drying temperature. Indirect studies of 
polymer solubility in the four solvents based on viscosity measurements (section 7.3.1.2) 
indicated solvency power increased in the following order: ACT < DCM < CFM < HAL. The 
concentration at which the polymer blend achieved saturation should therefore show an 
identical trend. Additionally, in the absence of confounding factors, the propensity of the 
polymer to retain solvent as unwanted residue should increase in parallel with medium 
solvency power. Thus, rapid solvent evaporation of volatile ACT yielded a 
low density 
porous product with low solvent load which was readily exhausted from the apparatus. 
In 
an effort to increase product yield, the aspiration was reduced to 
50 % for batch #3 
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compared with batch #2. The reduced vacuum in the area of the cyclone at this setting 
was expected to assist the deposition of particles of low specific weight in the collector. 
On the contrary, a 10 fold reduction in product yield was observed, whereby a 
considerable proportion of material deposited on the cyclone walls and in the region of the 
vacuum connector at the top of the cyclone. Furthermore, little material impacted with the 
drying chamber suggesting desiccation occurred in this area although the air flow pattern 
was significantly disrupted to promote material impaction on the cyclone walls and 
ultimately reduce product yield. Process generalizations do exist (Büchi, 1993). However, 
these data highlight the complex interplay of drying parameters which operates during 
spray-drying, each of which require specific optimization for individual products. 
Table 7.5 Yields of production of microspheres prepared from various organic 
(co)solutions. (n = 1) 
Solvent Yield /% total solid 
Batch Nature Ratio Cyclone Collector Total 
1 DCM 100% 19.3 42.7 62.0 
2 DCM: ACT 2: 1 17.3 4.0 21.3 
. 3 DCM: ACT 2: 1 0.33 0.01 2.0 
4 ACT 100% 0.33 0.66 2.0 
5 DCM: CFM 1: 1 46.0 10.0 56.0 
6 DCM: CFM 1: 1 28.6 12.7 41.3 
7 CFM: ACT 2: 1 31.0 5.0 36.0 
8 DCM 100% 16.0 39.3 55.3 
9 HAL 100 % 4.0 2.7 6.7 
10 HAL 100% 28.0 8.0 36.0 
Aspiration = 50% 
High solvent residue lowers the Tg. This promotes adherence of product to pre-collector 
glassware elements where the Tg temperature is below that of the drying air, thus 
reducing product yield. Scanning electron micrographs in section 7.3.3 did not reveal any 
discernible differences between batches, even at high magnification. These features were 
typical of the formation of a porous pliable crust during microsphere formation which 
permitted the transfer of solvent, without distortion, according to the model of Kawashima 
et al. (1972). In contrast to this overall pattern with ACT based solvents, reduced 
microsphere formation rate associated with the use of DCM, CFM and 
HAL, particularly at 
lower temperatures, resulted in a more coherent matrix. High solvent residue reported 
in 
section 7.3.5 is associated with the formation of a more coherent matrix with a greater 
density which reduces the proportion of particles exhausted 
from the apparatus, whilst 
promoting particle deposition in the apparatus collector. Considerable residue of relatively 
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dense solvents presented in Table 7.5 such as DCM, CFM and HAL contributes to 
individual particle density and further promotes high microsphere yields. 
7.3.3 Scanning electron microscopy 
Irrespective of the solvent system used to prepare these products, photomicrographs 
revealed discrete microspheres with seemingly smooth morphology absent of blow-holes 
and other surface discontinuities, morphological flaws associated with spray-drying of 
volatile solvents (Masters, 1992). Particle granulometry was typically characterized by a 
unimodal, narrow size distribution. The high halothanic residue in batch #9 accounted for 
the apparent partial fusion of microspheres shown in Figure 7.1 (B) which was considered 
to occur after formation in the collection vessel. 
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Figure 7.1 Photomicrographs of. - A, batch #1 (magn, 10 k); B, batch #9 (magn, 10 k); 
C, 
batch #4 (mag", 10 k); and, D, batch #4, (magn , 
50 k). Batch # according to Table 7.1. 
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Histographic variation in mean diameter shown in Figure 7.2 was explained in the context 
of the generalized pattern of particle formation based on solvent power. Under otherwise 
constant processing parameters, variation in microdroplet size is a function of the 
intermolecular forces between chains, or, more simply, solution viscosity. Therefore, 
microdroplet diameter at the point of generation would be expected to increase in the 
order: ACT < DCM < CFM < HAL. That the particles had no surface distortion, e. g., 
collapsed / shrivelled surface, it follows that microsphere mean diameter should exhibit a 
similar trend. However, with the exception of DCM, with which the volume distribution was 
positively skewed by a few particularly large particles, microsphere diameter increased as 
solvent strength decreased, supportive evidence of more rapid polymer deposition and 
the generation of a more open porous matrix. In contrast, solvents of greater solvent 
power and heat requirements preserved particle fluidity for longer periods during drying, 
e. g., HAL and CFM: DCM respectively. This allowed for more controlled polymer deposition 
and solvent transfer to the surface from where evaporation occurred, with a resultant 
increase in matrix density and a reduced mean diameter. 
7.3.4 Residual solvent 
Polymer-solvent affinity and drying conditions were influential factors on microsphere 
architecture, which, in turn, affected the level of residual organic adulterant. Despite the 
interplay of these factors, two generalizations based on the data could be made: 1) 
retention of solvent was in parallel to solvency power of individual solvents; and, 2) high 
matrix porosity promoted solvent loss. 
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Figure 7 .2 Histograms of population 
(A) and volume (B) granulometric statistics for 
compositionally identical microspheres. Legend represents 25% (d25), 50% (d50) and 
75% (d75) undersize quartiles. Processing parameters according to Table 7.1. 
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7.3.4.1 Gravimetric determination 
The profiles of solvent loss from selected batches can be seen in Figure 7.3, whereas the 
absolute values of solvent residue are presented in Table 7.6. 
Table 7.6 Gravimetric determination of solvent residue in compositionally identical spray- 
dried microspheres (#8 excepted) prepared from different solvents as a function of in 
vacuo storage time at 24 ± 2.4 °C, n=1. Batch # according to Table 7.1. 
Residual solvent x 103 / ppm 
Batch 123456789 10 
Time/d 
0 60.69 40.52 42.30 24.73 93.52 68.06 106.3 86.23 90.56 125.5 
5 29.26 8.16 9.12 6.09 62.56 48.25 70.25 40.31 40.23 75.23 
10 17.53 1.41 2.15 1.59 18.25 10.26 22.12 26.01 23.22 45.21 
15 9.03 0.28 0.32 0.45 4.56 1.85 7.27 11.06 12.36 15.1 
Substantial loads of residual solvent were recorded irrespective of the solvent system and 
drying parameters: ACT, 2.48 %w/w; DCM, 6.07 %w/4v; and, HAL, 12.6 %w/w. On a 
volume basis the corresponding values were 3.14 %l 4.56 % and 6.85 %. The residues 
might be alternatively expressed in units of mols0, kgmat 1 as 0.043,0.072 and 0.064 
respectively. Regardless of the units used to describe the residue and, irrespective of 
normalization for density and MW differences of the solvents determined, residual load 
increased with solvency power and hence polymer affinity for each individual solvent. The 
only exception to this was DCM when expressed on a molar basis. Viscosity 
measurements, used as an indirect measure of solvency power, showed a remarkable 
linearity when plotted against residual solvent of the microspheres prepared from the 
three individual solvents as seen in Figure 7.4. 
The effect of encapsulated drug on residue level, in analogy to polymer blend, 
did not 
correlate with the solubilities determined during preformulation at 24 ± 
2.0 °C: ACT ( 41.7 
mgmL-) < HAL ( 76.9 mgmL-1) < DCM ( 216 mgmL") < CFM ( 
349 mgmL-1). Thus, it was 
concluded that the polymer had the overriding influence on residual solvent as 
it 
comprised the predominant component of the matrix. 
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Figure 7.3 Semi-logarithmic profiles of solvent loss from compositionally identical spray- 
dried microspheres prepared from different solvents during in vacuo storage at 24 ± 2.0 
°C. Legend indicates batch according to Table 7.1. 
In processing terms, an increased inlet temperature, i. e., 50 compared with 40 °C 
resulted in a reduced solvent load for DCM: CFM (#6 and #5) and HAL (#9 and #10) as a 
result of greater drying efficiency at elevated temperatures. Elevated inlet temperatures 
were anticipated to produce greater matrix porosity associated with more rapid polymer 
deposition and hence more rapid residue depletion. On the contrary, decreased kinetic 
constants for solvent loss in Table 7.7 for comparable batches prepared at 50 °C when 
compared with those at 40 °C were at apparent odds with this hypothesis. The initial rates 
of solvent loss were consistent with the anticipated pattern however, loss of linearity with 
the onset of a secondary slower phase of solvent loss accounted for this disparity. 
Table 7.7 First order regression statistics for gravimetrically determined solvent loss from 
compositionally identical spray-dried microspheres prepared from different solvents during 
in vacuo storage at 24 ± 2.0 °C, n=1. Batch # according to Table 7.1. 
Batch 
123456789 10 
Statistics 
k/ d-' 0.088 0.126 0.126 0.130 0.081 0.068 0.089 0.087 0.052 0.073 
to 5/d7.875 5.500 5.500 5.331 8.556 
10.19 7.787 7.966 13.33 9.493 
0.985 0.824 0.831 0.909 0.809 0.839 0.876 0.977 0.739 0.919 
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As presented in Figure 7.3, log-linear dependence of solvent load on drying time was 
observed for microspheres prepared from single solvents. This allowed the theoretical 
prediction of total drying time to achieve essentially equilibrium organic residue after 
seven half-lives of: DCM, 55.1 d; ACT, 37.3 d; and, HAL, 66.5 d. Seven half-lives was 
selected as this period corresponded to compliance of batch #1 with USP limits for DCM. 
Different diffusion and vaporization characteristics of the individual solvent components 
were considered to account for the deviations from linearity for mixed solvents and the 
resultant poor coefficients of correlation seen Table 7.7. Thus, the faster evaporation 
kinetics of the residual fraction of poorer solvent, e. g., ACT when compared with solvents 
of greater affinity, e. g., CFM and DCM resulted in an apparent biexponential drying plot. In 
general all plots showed an 'elbow' at around 15 d storage. During the early stages of 
solvent loss, ongoing `stress-relaxation' processes result in matrix structural changes at 
the molecular level. This feature, coupled to the reduced concentration gradient and 
increased diffusional pathlength might account for the approximate first-order drying 
kinetics. 
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Figure 7.4 Plot showing the apparent relationship between absolute viscosity 
(3 %wlv) of 
rifampicin-polymer blend in individual solvents versus 
the residual solvent content of 
microspheres prepared with same 
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7.3.4.2 Head-space analysis 
Headspace gas chromatographic analysis has largely superseded both thermogravimetric 
and chlorine analysis (Benoit et al., 1986) for organic residue determinations due to the 
high mass sensitivity and selectivity afforded by the technique (Gangrade & Price, 1992). 
Owing to these attributes, headspace analysis was therefore employed to confirm the 
preferential loss of solvents during storage. Linearity of detector was established for each 
individual solvent as seen in Table 7.8. Absence of interference was established as the 
mean intercepts for all calibration lines were not greater than ± 0.95 % of the values for 
detector response at the 100 % analyte level. 
Table 7.8 Regression statistics for detector response on concentration of individual 
solvents for head-space analysis, n=5. 
Regression statistic 
slope x 10 intercept x 10 
Solvent 
ý 
ACT 5.634 1.749 1.000 
DCM 4.382 2.092 0.999 
CFM 2.606 0.899 1.000 
HAL 6.964 2.200 0.999 
The results of the GC headspace analysis are presented in Table 7.9. No ACT was 
detected in these analysis and the results did not correlate with the residues determined 
by gravimetric means, although general trends were still evident in relation to solvent 
power. The absence of ACT and largely DCM was attributed to solvent loss and the delay 
in analysing samples sent to a remote site for investigation. Notwithstanding these 
practical difficulties, omnipresence of CFM in samples prepared with a fraction of this 
solvent, allied to the absence of cosolvent, confirmed the preferential loss described 
above and observed in Figure 7.3. Likewise, considerable halothanic residue confirmed 
the high solvent powers of these two solvents and the intransigent retention of same. 
Indeed, the affinity of both drug and polymer for CFM was strikingly apparent by its 
detection in batch #1 where it was not used. This apparent anomaly was perhaps 
attributable to the use of CFM to prime and clean the feed tubing and the 
drier nozzle 
prior to spraying the feed solution. 
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Table 7.9 Head-space gas chromatographic determination of solvent residue in 
compositionally identical spray-dried microspheres prepared from different solvents as a 
function of in vacuo storage time at 24 ± 2.0 °C, n= 1. Batch # according to Table 7.1. 
Residual solvent x 104 / ppm 
Batch Solvent(s) Storage time /d05 10 
1 
2 
5 
6 
7 
9 
10 
CFM 0.122 0.0210 0.00968 
DCM 0.0126 -- 
CFM 17.55 3.559 2.112 
CFM 13.31 2.006 2.232 
CFM 34.57 0.735 0.804 
HAL 41.96 40.35 44.29 
HAL 53.16 43.74 37.24 
7.3.5 Particle architecture 
Density determination of drug-bearing and drug-free microspheres, batch #1 and #8 
respectively, were 1.311 and 1.276 gcm-3. Using the volume size distributions described 
above and assuming zero porosity, these values were used as a reference for the 
determination of theoretical surface areas for selected batches. The experimental results 
are compared with theoretical values in Table 7.10. 
Table 7.10 Theoretical and determined specific surface areas for selected batches of 
compositionally identical spray-dried microspheres (batch #8 excepted), n=1. Process 
parameters as per Table 7.2. 
Specific surface area / (m2 g 1) 
Batch Theoretical Experimental Factor of Deviation (E_li) 
(T) (E) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0.186 
0.270 
0.154 
0.208 
0.242 
0.292 
0.265 
0.132 
0.300 
0.290 
1.43 
2.28 
2.30 
2.99 
3.05 
2.78 
7.68 
8.44 
11.06 
12.36 
23.12 
9.59 
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The considerable deviation between theoretical and determined surface areas was 
attributed to the use of true density, whereas apparent density would provide a more 
accurate index of the actual number of particles which constituted one gram of 
microspheres. Notwithstanding the limitations of these determinations and, despite the 
apparent pore-free nature of all batches from SEM, substantial N2 accessible pores were 
evident from these measurements; typically a feature of spray-dried PDLLA particles 
(Conti et at., 1991; Pavanetto et at. 1992). These workers calculated a three-fold increase 
in specific surface area for spray-dried particles when compared with non-porous particles 
of equivalent diameter. Correlation between porosity and anticipated polymer deposition 
kinetics based on solvency power was generally poor, although batch 1,2 and 4 did follow 
the expected pattern. 
The absence of drug in the formulation had the most remarkable effect on overall 
porosity. During drying it is postulated that drug precipitates before the polymer thus 
behaving as nuclei around which polymer can deposit. Shively et al. (1995) determined an 
approximate solubility of PDLLA in `good' solvents of 750 - 1000 mg. It is postulated that 
the greater the differential between drug and polymer solubility then the greater the phase 
separation between the components. Thus, in ACT (RIF solubility = 41.7 mgmL), drug 
precipitates before the polymer concentration, and therefore viscosity, can reach a critical 
value which impedes further crystal growth around formed nuclei. This feature should 
result in larger precipitates embedded within the matrix when compared with solutions 
sprayed from CFM (RIF solubility = 349 mgmL-) where drug dispersion within the matrix 
should approximate to the molecular state. Relative drug and polymer deposition kinetics 
also might have implications for the thermal character of the matrix. Drug might otherwise 
have a `salting-in' effect as was apparent with progesterone (Benoit et al., 1986). Delayed 
polymer precipitation under these circumstances would be considered to produce a less 
porous matrix. There are particular limitations to the reliability of these results, however 
they do act to illustrate the considerable influence of solvent choice on matrix 
architecture, which, in turn, is a principal determinant of drug release 
kinetics as 
discussed in section 7.3.7. 
7.3.6 Thermal analysis 
It is well established that the thermal history of the polymer can greatly affect 
the 
observed Tg. Influential factors include, preparation temperature, cooling rates 
and 
subsequent annealing conditions (Ford & Timmins, 1989). 
The area and position of the 
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anomalous peak associated with the Tg have been found to increase with decreasing 
cooling rate of melt during glass formation (Serajuddin et al., 1986; Fukuoka et al., 1986). 
These observations reflected the dynamics of freezing of molecular motion and the 
quantity of glass relaxation occurring during same. Consequently, matrices thus formed 
can be considered to possess an excess of enthalpy when compared to their equilibrium 
state which is released slowly under ambient conditions, whereupon the polymer 
molecules attain a more favourable thermodynamic arrangement. This latter process is 
referred to as enthalpy relaxation (Kerc & Srcic, 1995). 
The endotherm for spray-dried products is, by analogy, also a function of the rate at which 
large scale molecular motion is frozen during polymer deposition. Therefore, deposition 
rate dictates both matrix coherence and the amount of strain or excess enthalpy in the 
system. Increased matrix density restricts polymer chain motion due to reduced free 
volume both at a macroscopic and microscopic level. This factor was considered to 
account for the suppression of Tg with ACT derived products, whereas increased density, 
molecular association and bonding of those prepared from DCM or HAL elevated the 
ultimate Tg for compositionally identical products. Thus, T. was accepted as a useful 
index of matrix compactness. The extent of division of RIF should also affect the position 
of the Tg. At low states of division, e. g., exclusively embedded crystals, polymer and drug 
behave as two phases and the position of the Tg should correlate to that in the absence of 
drug. As the state of division increases there is a parallel elevation of T. with the 
introduction of interposing drug particles between polymer chains, the effect of which is 
maximal when the drug is molecularly dispersed. In this latter state however, the Tg may 
fall dramatically with the onset of solid solution where the polymer and drug interact 
significantly. Thus, as described in section 7.3.5, larger drug crystallites f precipitates 
formed with ACT, compared with CFM, would result in a reduced `filler-effect' and a lesser 
elevation of Tg. This postulation is largely consistent with the position of the determined 
Tg in relation to drug solubility in the various solvents. 
This simplification when comparing melt quenching and spray-drying 
is however 
complicated by the facilitative action of solvent residue on isothermal enthalpy relaxation, 
although from Table 7.11 peak position, if not area, followed this trend. 
The comparative 
data for quench cooling rates was however based on the measurement of 
Tg temperature 
immediately after preparation rather than upon storage. Therefore, 
the endothermic areas 
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at 100 d were a reflection of the total strain conferred during drying, which was 
accordingly inversely related to solvency power. Furthermore, the final endothermic area 
(which represents the residual strain in the system), whilst being inversely related to 
overall matrix stability, showed a remarkable correlation with drug release rate. 
Table 7.11 Thermal analysis of the ageing effects of compositionally identical spray-dried 
microspheres upon storage at 24 ± 2.0 °C in vacuo. Process parameters as per Table 7,1 
Transition 
Peak / °C '/2Cp / °C Endotherm / (Jg") 
Time fd05 10 100 05 10 100 05 10 100 
Batch 
1 53.6 
2 47.1 
3 45.1 
4 40.4 
5 
6 
7 
8 43.2 
9* 
10 
56.8 57.1 61.5 52.6 54.5 53.9 56.2 2.45 2.62 4.15 
51.4 52.3 56.3 43.3 45.7 47.0 49.1 * 4.23 4.21 5.40 
50.9 51.6 54.6 41.3 44.9 45.3 45.9 4.35 4.66 6.21 
44.7 45.9 48.6 38.9 37.6 37.7 40.3 * 2.79 3.65 5.69 
57.5 57.0 59.0 39.8 50.6 51.6 55.0 * 2.60 3.40 5.60 
58.0 59.3 62.9 46.4 52.2 53.3 55.6 * 2.68 3.25 5.20 
52.9 53.0 58.2 39.0 46.3 46.8 48.0 * 4.07 4.12 6.74 
48.6 48.5 51.3 39.4 42.1 42.0 42.1 * 5.64 6.51 8.12 
48.9 51.1 59.0 42.9 47.0 47.3 50.7 2.06 4.17 4.79 
48.1 52.1 59.8 37.3 43.2 43.8 49.5 **6.86 5.57 
* large diffuse peak between 30 - 70 °C 
data based on 2nd scan 
In relation to solvent residue, thermograms revealed diffuse, in some cases indiscernible 
thermal events for freshly prepared products, whereupon desiccation an endotherm (heat 
capacity maximum) rapidly developed, the magnitude of which was time- and solvent- 
dependent as seen in Figure 7.5. Moreover, the position of the endotherm and the 
underlying Tg shifted up-scale as the plasticizing action of the residual solvent diminished 
with increased storage time. Residual solvent load determined the magnitude of this shift, 
which increased as the solvency of the solvent system increased and, in contrast, the 
drying temperature decreased. This ageing process, traced by the up-scale shift of the Tg 
and the development of an endotherm, represented loss of `stored' energy generated by 
rapid microsphere formation during spray-drying as discussed above. Whereas with ACT 
prepared products, high matrix porosity allows rapid residue evaporation, reduced 
microsphere formation rate with other solvents studied, particularly at 
lower inlet 
temperatures, results in a more coherent matrix. High matrix tortuosity associated with 
the use of good solvents contributed to the tenacious retention of organic solvent. 
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Additionally, high and persistent solvent residue permitted significant polymer relaxation 
upon storage due to its plasticizing action. 
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Figure 7,5 DSC thermograms of microspheres after various storage times in vacuo at 24 
± 2.0 °C. Key: a) immediately after preparation; b) 5 d; c) 10 d; and, d) 100 d. Number 
indicates batch according to Table 7.1. 
After exhaustive in vacuo drying, apparent activation energies in Table 7.12 of T9 were 
determined. The effect of heating rate on the position of Tg temperature is shown in 
Figure 7.6. Three indices of glass transition were considered in these calculations: onset 
temperature, If ; maximum temperature of the anomalous endotherm, Tm ; and, post- 
transition baseline-endotherm intersept, T; . 
The regression statistics demonstrated 
excellent correlation for Tf and Tm whereas comparatively poor linearity using the Ti. 
Nonetheless, the computed statistics associated with the latter index, the general 
convention for such calculations (Ford & Timmins, 1989), were used for assessment. 
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Figure 7.6 DSC thermograms at various scanning rates of batch #1 at constant weight 
(plot labels indicate scanning rates in °Cmin') 
Apparent activation energies in Table 7.12 for the T9 were inversely related to the 
enthalpy of the endotherm for the associated recovery process. The latter parameter was 
however directly related to the level of solvent residue which facilitates molecular 
movement associated with relaxation. Structural relaxation is associated with the 
formation of a more stable microsphere matrix and has been described in terms of the 
`Hole Theory' of bulk viscosity. In simple terms, during relaxation, hole disappearance and 
genesis occur concurrently, however, an equilibrium is thought to exist between the 
`liquid' lattice and the number and volume of holes during relaxation. Consequently, the 
volume and the energy of holes decrease through an activated state, the potential barrier 
to which can be considered proportional to the apparent Ea. Thus, based on this factor, 
microspheres prepared from DCM: ACT (#2 & 3) and HAL (#9 & #10) were expected to 
result in slowest drug release (section 7.3.7). However, these indices are relative and give 
no indication of the initial or final energy state of the matrices. Additionally, related to 
relaxation, the T9 of the matrices formed proved a more reliable indicator of microsphere 
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stability, release rate decreasing as the Tg increased. Clearly, other factors influenced by 
the drying process, such as matrix density, have a role in determining the magnitude of 
the Tg and the rate and extent of relaxation recovery, which, in turn, modulate drug 
release as described in section 7.3.7. 
Table 7.12 DSC derived activation energies of glass transition for microspheres at 
constant weight. Process parameters according to Table 7.1. 
Tg Transition 
Onset, Tf Extrapolated baseline, Tj Endothermic peak, Tm 
Batch Ea / intercept r, 2 Ea / intercept ? Ea / intercept r2 
kJmor' kJmor' kJmor' 
1 58.5 178.1 0.95 54.7 167.1 0.99 39.5 120.4 1.00 
2 43.2 134.7 0.95 37.1 128.3 0.92 38.4 119.1 0.98 
3 38.9 121.8 0.99 36.1 113.8 0.91 37.2 115.7 0.98 
4 70.8 225.4 0.97 75.9 241.9 0.91 50.0 158.2 1.00 
5 45.7 139.2 0.98 46.0 140.6 0.92 43.1 130.8 1.00 
6 45.3 138.0 0.98 46.2 140.9 0.90 43.6 132.0 1.00 
7 42.8 132.7 0.98 38.4 119.6 0.90 37.8 116.5 0.99 
8 48.7 153.1 0.97 40.1 126.8 0.99 44.1 138.0 0.99 
9 38.1 155.3 0.97 32.0 107.2 0.94 34.9 107.1 0.99 
10 39.7 159.7 0.98 35.0 108.8 0.95 35.3 108.2 1.00 
7.3.7. Drug release studies 
In the previous chapter the thermal behaviour of blends of low and moderate MW PDLLA 
was identified as a critical determinant of RIF release. Other important factors include 
matrix hydrophilicity and structure. For compositionally identical microspheres, intrinsic 
hydrophilicity should remain ostensibly constant. Thus, the remarkable differences in 
release of RIF with change in process conditions as seen in Figure 7.7 can be attributed 
to a resultant variation in matrix architecture and thermal character as discussed 
throughout this chapter. 
Upon incubation, microspheres slowly hydrate. Water ingresses slowly causing matrix 
softening until the matrix Tg temperature corresponds to that of the dissolution medium, 
when water uptake accelerates promoting drug release by predominantly diffusion. This 
mechanism accounts for the sigmoidal pattern seen in Figure 7.7 for microspheres 
prepared from DCM and DCM: CFM blends. These comprised induction, accelerated and 
slow terminal phases. For drug release in Figure 7.7, however, from microspheres 
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immediately after preparation with high residual solvent, the Tg was close, if not below 
that of the dissolution medium, resulting in a rapid 'burst' with a short induction period. As 
residual solvent is lost under vacuum, the 'burst' reduces and the induction period 
lengthens as polymer chain stress-relaxation occurs, elevating the Tg, which retards RIF 
release. 
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Figure 7.7 Effect of storage in vacuo at 24 ± 2.0 °C on release profiles for microspheres 
prepared from different (co)solvent(s): A, batch 1 (DCM); B, batch 4 (ACT); C, batch 5 
(DCM: CFM, 1: 1); and, D, batch 9 (HAL) Process parameters according to Table 7.1. Inset 
Table details first order release constant (10 - <_ 80 %) (Key indicates the storage time in 
days). 
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At high matrix porosity, thermal behaviour is largely inconsequential, release being 
characterized by a single rapid phase, the rate of which increases as a function of matrix 
free volume. Thus, release from microspheres prepared from ACT was largely 
independent of storage time, release accelerating as the proportion of ACT used in 
microsphere preparation increased in line with the production of a more porous matrix as 
illustrated by the first order release rate constants of drug release annotated on Figure 
7.7. Furthermore, the substitution in acetonic mixtures of CFM for DCM had little effect on 
drug release. 
Reports of the use of HAL for microsphere preparation are limited to the preparation of 
microsphere by aqueous ESE (Armstrong et al. 1994,1995; Guiziou et al., 1996). HAL 
was proposed on the grounds of its comparable physicochemistry to DCM and its inferred 
biocompatibility - assigned to the stability of the C-F bond (Horvath, 1982) -- in its use 
as an inhalational anaesthetic. Comparisons with DCM demonstrated a manifest 
difference in matrix stability, the magnitude of the burst and, the overall rate of drug 
release being greater for HAL-based products. This was ascribed to T9 depression, as a 
result of solvent residue in corroboration of the results presented here. 
Table 7.13 Effect of processing parameters on first order release rate constants for 
rifampicin release (10 - _< 
80 %) from spray-dried microspheres prepared from different 
(co)solvent(s) after exhaustive in vacuo drying at 24 ± 2.0 °C. Process parameters 
according to Table 7.1. (n = 3) 
Regression statistics 
Batch 
1 
2 
3 
4 
5 
6 
7 
9 
10 
k/ h"' (RSD) 
0.13 (3.19) 
1.41 (5.38) 
2.69 (16.8) 
4.56 (1.70) 
0.53 (18.41) 
0.96 (5.46) 
1.85 (5.00) 
0.54 (0.26) 
0.54 (0.91) 
intercept (RSD) 
106.7 (1.34) 
88.4 (0.13) 
107.7 (3.49) 
57.5 (5.20) 
167.5 (17.5) 
273.0 (12.9) 
117.4 (5.12) 
125.9 (0.39) 
99.5 (0.95) 
i2 (RSD) knorm / h-' 
0.993 (0.28) 0.21 
0.975 (0.44) 1.51 
0.999 (0.07) - 
0.954 (0.59) 6.36 
0995 (0.14) 0.64 -'---%---i 
0.995 (0.21) 
0.992 (0.07) 
0.9$7 (0.29) 
0.999 (0.05) 0.54 
Jalil & Nixon (1990d, e, g, h) normalized fractional rate constants for phenobarbitone 
release in respect of specific surface area. Such corrections 
do not, however, take 
account of the distribution skew and, more importantly, the effect of 
diffusional pathlength 
as a consequence of such deviations from distribution normality. 
Particle size 
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distributions were comparable in the current work with the exception of batch #1 (#2 & 
#3). Nonetheless, rate constants after normalization against batch #10 with respect 
surface area (according to data in Table 7.10) are included in Table 7.13. Irrespective of 
such treatment, release from batch #1 remained the most sustained despite the fact that 
the Tg for batch #5, at 62.8 °C, was anticipated to confer the slowest release of drug. This 
disparity was attributed to the existence of a limited number of relatively large particles 
which comprised approximately 33 % of the total volume of the sample. Therefore, 
regardless of the correction for surface area, a meaningful proportion of drug had to 
diffuse through a significantly greater pathlength to be liberated from batch #1 when 
compared with batch #5. Overall, these observations account for the greater induction 
period with batch #5, consistent with T9, but the more rapid release thereafter due to 
reduced diffusion pathlength from these particles, when compared with batch #1. In 
general, however, due to the otherwise similar granulometric characteristics of other 
batches, the corrected rate constants showed good correlation with T9 as shown in Figure 
7.8. 
T9/°C 
62 
60 
58 + 
56 
54 -ý 
52 
50 
48 ý 
0 1 2 4 5 
6 3 
rate constant / h-1 
Figure 7.8 Apparent correlation of glass transition temperature of spray-dried 
microspheres and first order release rate constant 
(0 - <_ 80 % release). 
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Figure 7.9 DSC thermograms of recovered residue from in vitro release studies at 37 ± 
0.1 °C and 100 ±I rpm. Legend indicates batch #. 
That the endothermic peak of thermograms for recovered sample residue after dissolution 
became more erratic and broader as particle size distribution increased in breadth is 
supportive evidence for differential hydration, and thus diffusion characteristics, from 
particles of variable mean diameter between batches. In Figure 7.9, thermal 
characteristics of batch #1 represent a disperse population, whereas batch #5 and #9 
were consistent with the monodisperse character of these products. Batch #4, 
accordingly, showed intermediate thermal behaviour. 
7.4 Conclusion 
Under the conditions of these studies, solvent choice has a profound influence on the 
characteristics of biodegradable microspheres prepared by spray-drying. The influence of 
solvent power on microdroplet drying kinetics, within extremely narrow 
limits, accounts for 
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this remarkable sensitivity of microsphere properties to solvent choice. Viscosity studies 
provided a seemingly useful index of solvent power. Drug release was determined by 
exclusively macroscopic features, e. g., architecture for relatively poor solvents, ACT, 
whereas microscopic changes, which altered thermal character were also influential with 
good solvents, DCM and HAL. Moderate evaporation rates associated with good solvents 
appear to promote the formation of coherent microspheres whilst providing high product 
yield. This latter feature accounts for the ultimately slower release from microspheres and 
the high original residual solvent of products thus prepared. On the one hand, high 
solvent residue accelerates release initially through a matrix plasticizing action, on the 
other, it facilitates molecular mobility, associated stress-relaxation, which manifests as a 
progressive elevation of the softening temperature which was paralleled by an increase in 
the induction period and a general retardation of drug release. 
Of the solvents studied, microspheres prepared from DCM were considered superior. 
Indeed, a recent report has hailed DCM an ideal choice of solvent, rejecting its 
carcinogenicity and ecotoxicity (Jones, 1996). The rapid drug release from acetonic 
products precluded use of this solvent. Microspheres properties from HAL were 
considered intermediate; however, protracted storage times were required to ensure 
satisfactory solvent removal. Architectural improvements might be achieved by the use of 
reduced drying temperatures with both ACT and HAL. 
On a precautionary note, the effect of high solvent residue on microsphere release 
character might result in erroneous conclusions being drawn where adequate 
desiccation 
has not been performed. Overall, solvent choice for spray-drying 
has a considerable 
influence on the final microsphere characteristics and should accordingly 
be carefully 
considered from both a technological in addition to a traditional 
toxicological viewpoint. 
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8. Modulation of rifampicin release from spray-dried microspheres: combinations 
of poly(DL-Iactide) and poly(DL-Iactide-co-glycolide) 
8.1 Introduction 
Biodegradable poly-a-hydroxy acids drug-loaded microspheres have recently been 
investigated to target chemotherapeutics to the lung whilst providing a sustained release 
and thus therapeutic action (Armstrong et al., 1994,1995; Giunchedi et al., 1995,1998; 
Guiziou et at., 1996; El-Baseir et at., 1997). Pathologically, asthma has hitherto been the 
focus of these studies. Microencapsulated hydrocortisone (Giunchedi et al., 1995,1998), 
beclomethasone and nedocromil sodium (El-Baseir et al., 1997), and, more speculatively, 
NSAIDs (Armstrong et al., 1994,1995; Guiziou et at., 1996) have been suggested as 
having potential in the control of chronic inflammatory conditions when delivered directly 
to the lung. 
Despite inherent disadvantages when compared with spray-drying, preparation of 
inhalational microspheres has largely relied upon various modifications of the ESE 
principle. El-Baseir et at. (1997) reported adjustment of stirring rate and emulsifier 
concentration was required to achieve a suitable size for aerolization. Preparation times 
of 5 and 7.5 h were required for batches of nedocromil sodium and beclomethasone 
prepared by w/o/w and o/w ESE, respectively. Guiziou et al. (1996) included a 24 h post- 
preparation in situ incubation step, prior to microsphere recovery, to presumably extract 
residual solvent. Further modifications involved substitution with the anaesthetic, 
halothane (HAL), as an alternative solvent in response to the suspicion that DCM residual 
was the cause of the pro-inflammatory activity of PDLLA microspheres delivered to the 
lung (Armstrong et al., 1992; 1994). Both solvents resulted in a significant respirable 
fraction of the overall microsphere population, the authors quoting a range of 2.0 - 6.0 µm 
(Guiziou et al., 1996). In contrast, Giunchedi et al. (1995; 1998) concluded advantageous 
loading and the overall convenience of spray-drying outweighed the lower yields when 
compared with granulometrically similar particles prepared by single and double emulsion 
methodologies. Notwithstanding these advantages, the rapidity with which equivalent 
quantities of microspheres can be produced by spray-drying further underlines 
its 
outstanding utility for the preparation of microspheres with inhalational application. 
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As TB affects an extensive area of the lung tissue (not only the area adjacent to the 
bronchial wall), inhalation therapy alone might not be able to penetrate deeply enough to 
achieve effective concentrations. However, certain medical opinion believe that inhaled 
sustained release microspheres may have application as an adjunct to oral therapy to 
deliver high concentrations of antimycobacterials to the luminal aspect of tuberculosis 
cavities (P Chapman, 1998, personal communication). Conventional therapy does not 
penetrate well into this area from the pulmonary capillaries. Such an approach, may, 
therefore, have a particular role in retractable infection or to effect an earlier cure than 
conventional oral regimes alone. Furthermore, resultingly shorter treatment schedules 
might alleviate the drug resistance problems associated with patient non-compliance 
which complicates protracted therapy. Finally, targeting of a fraction of the overall therapy 
may reduce the incidence of dose-limiting hepatotoxicity associated with systemically 
administered RIF (Mandell & Sande, 1985). 
In chapters 6 and 7, microspheres of high and predictable loading and the required 
granulometry for deep alveolar penetration, 0.3 - 3.0 µm, were readily prepared by spray- 
drying. Moreover, the incorporation to ostensibly hydrophobic materials of a fraction of 
PDLLA oligomers should provide more sustained release of drug when compared to the 
typically asymptotic behaviour of piroxicam and hydrocortisone in PDLLA of 16 - 330 kD 
(Armstrong et al., 1994,1995; Guiziou et al., 1996) and 28 kD (Giunchedi et al., 1995), 
respectively. It is anticipated that the low volume of liquid which lines the pulmonary 
epithelium would serve only to accentuate this latter pattern of release. 
The purpose of the work in this chapter was therefore to investigate the comparative 
utility of blending low MW PDLLA (Resomer® R104) with a MW and compositional range 
of lactide-glycolide copolymers of greater MW than the complementary 
PDLLA examined 
in chapters 6 and 7. Higher MW materials were selected to obviate 
the batch-to-batch 
variation in polymer behaviour considered attributable to small changes 
in MW 
demonstrated in chapter 6. Additionally, given the critical balance of matrix 
hydrophilicity 
and the associated role of Tg to the provision of controlled 
drug release, use of more 
hydrophilic copolymers was intended to offset MW dependent 
hydrophobicity as chain 
length of the copolymer increased. 
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8.2.1 Microsphere preparation 
Microspheres were prepared from Resomer® R104 combined with each of RG502 (15.5 
kD); RG503 (39 kD); RG503H (33.5 kD); RG504 (56.5 kD); RG752 (20 kD) and RG755 
(63 kD) at polymer weight proportions: 44: 56; 40: 60; 36.6: 63.3; 33.3: 66.6; (30: 70, RG752 
and RG755 only); 25: 75; 20: 80; 10: 90, (RG502; RG503; RG503H; and, RG504 only). 
Solutions (3 %w/v) of RIF (20 %w/w total solid) and polymer blends were prepared in 
DCM. Processing parameters were: inlet = 40 °C; outlet = 35 °C; flow rate, 600 NLh-' ; 
aspiration, 100 %; and feed, 3.5 ml-min-1. Batch # was assigned according to Table 8.1. 
Table 8.1 Polymeric composition and batch index of spray-dried microspheres prepared 
from blends of Resomer® R104 and various Resomer® lactide-glycolide copolymers 
containing 20 %w/w rifampicin (n = 1) 
Complementary Batch 
polymer R104 / (1o w1w) 44 40 36.6 33.3 30 25 20 10 
RG502 17 13 19 31 37 25 
RG503 28 14 20 32 38 26 
RG503H 39 15 21 33 39 27 
RG504 4 10 16 22 34 40 28 
RG752 5 11 17 23 29 35 41 
RG755 6 12 18 24 30 36 42 
8.2.2 Microsphere characterization 
Microsphere yield was calculated as described in section 5.2.3.1, whereas solvent 
residue was determined as described in section 7.2.4.1 for microspheres prepared from 
each polymer blended with 25 %w/w R104 (Batch #31 - 36). Drug release was monitored 
by method B as described in sections 5.2.3.4. Drug release profiles were assessed by the 
fitting of these data to the reciprocal biexponential function shown below as 
Equation 8.1: 
% released = 100 - (A*expý`t + g*exp 
ßt) (Equation 8.1) 
where A and B are coefficients for the two concurrent first order processes, 
the rates of 
which are defined by the rate constants, exponents a and 
ß, respectively. The rates of 
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release were examined again at 33,35,37 and 39 ± 0.1 °C to examine the temperature 
dependence of drug release. Activation energies of the initial phase of drug release were 
calculated as per section 6.2.2. 
8.3 Results and Discussion 
8.3.1 Microsphere yield 
Corresponding microsphere yields for products of the compositions detailed in Table 8.1 
feature below in Table 8.2. Using the optimized conditions described in section 5.3.7, with 
few exceptions, yields were greater than 50 %, which compares favourably with previous 
reports (Pavanetto et al., 1992; 1994a). Yields were generally 10 % lower than those for 
PDLLA combinations of comparable R104 content. These data approximate to the 
differential behaviour observed for PDLLA and PDLGA spray-dried by Wagenaar & Müller 
(1994) and are assigned to the influence of deposition kinetics and subsequent density- 
dependent yields discussed for individual polymers and combinations of PDLLA in 
sections 5.3.1 and 6.3.1.2, respectively. Summation of the yields for each composition of 
R104 and, for each group of batches based on polymer type, revealed no apparent 
trends with regard to these variables. Accordingly, variation was attributed to small, yet 
apparently significant between-batch differences in spray-drier performance. 
Table 8.2 Total yields of spray-dried microspheres prepared from blends of Resomer® 
R104 and various Resomer® lactide-glycolide copolymers containing 20 %w/w rifampicin 
(total solid) 
Complementary Yield /% 
polymer R104 / (%w/w) 44 40 36.6 33.3 30 25 20 
10 
RG502 68.0 66.0 54.6 57.3 65.3 64.0 67.3 
RG503 61.3 66.0 56.3 59.3 62.6 66.6 66.6 
RG503H 62.0 55.3 53.3 58.0 78.6 64.0 55.3 
RG504 64.0 74.6 60.6 60.6 78.0 64.6 47.3 
RG752 68.6 72.6 59.3 59.3 49.3 65.3 64.0 
RG755 64.6 65.3 57.0 54.6 58.6 67.3 60.6 
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8.3.2 Effect of polymer type 
Inherent polymer properties, i. e., polymer hydrophobicity and Tg temperature, and 
resultant matrix architecture were identified in chapters 6 and 7, respectively, as the two 
principle factors which affected drug release from spray-dried microspheres prepared 
from combinations of low and moderate MW PDLLA (of equivalent drug loading and 
granulometry). According to the data in chapter 7, under standard processing conditions, 
the microporosity of the resultant microspheres (and hence drug release rate) is inversely 
related to polymer solubility in the feed solvent. 
Of the other factors, hydrophilicity increases as: lactide: glycolide ratio decreases, being 
maximal at 15: 85 (Gilding & Reed, 1979); as MW decreases; and, as the density of free 
terminal carboxylic acid groups increases. Moreover, polymer Tg is reduced as the 
glycolide contribution increases whereby fewer CH3 sidechains permits greater axial 
chain rotation. Accordingly, these factors culminate in PDLGA being substantially more 
hydrophilic and diffusive than PDLLA racemate of equivalent chain length. 
8.3.2.1 In vitro drug release 
The profiles of drug release were governed by matrix architecture and polymer 
hydrophobicity. These influenced the relative magnitude of both the extent (denoted by A 
and B) and the rates (denoted by a and ß) of the two concurrent first order processes as 
defined by equation 8.1. The overall excellent fit of the experimental data as shown in 
Appendix 9 a-f to the reciprocal biexponential function provided reliable indices for the 
comparison of the effect of material, and the variables of processing and characterization 
on drug release of the combination matrices prepared. 
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Figure 8.1 Effect of matrix composition on release profiles of rifampicin from 
microspheres prepared from a range of Resomer®materials blended with R104, weight 
proportion : A, 44; B, 33.3; C, 25; and, D, 20 % w/w (total polymer) at a stirring rate of 100 
±1 rpm and 37 ± 0.1 °C. Labels indicate the material used. (n = 3, standard deviation 
5.7) 
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In Figure 8.1, the effect of polymer type on the release profile of RIF is shown at selected 
levels of oligomeric adjuvant, R104. Release profiles were almost invariably characterized 
by a `burst' of release followed by a slow diffusion of inaccessible RIF. At 44 %w/w R104, 
the profiles comprised essentially a single rapid phase whereby the inherent hydrophilicity 
conferred on the matrix by R104 overwhelmed the sustaining action of complementary 
PDLGA Resomer®. With the exception of RG755, this was also true of matrices prepared 
with 33.3 %w/w R104. However, at 25 %w/w, differential behaviour was observed as 
overall matrix hydrophilicity and thermal properties became more influential. Further 
reduction in the oligomeric contribution, resulted in release profiles which approximated to 
those shown in Figure 5.5. On the contrary, the intrinsic hydrophilicity of RG502 resulted 
in essentially a single rapid release phase, irrespective of the blend studied. The potential 
for ionic interaction between deprotonated COOH and basic moieties of RIF was 
considered to account for the unexpectedly slower release from microspheres prepared 
with RG503H (33.5 kD) when compared with that of more hydrophobic, higher MW, end- 
capped RG503 (39 kD). 
The magnitude of the `burst' effect is dependent on the proportion of overall drug which is 
immediately accessible to the release medium. Therefore, the specific surface area of the 
microspheres, matrix hydrophobicity, and, microporosity, are all influential. The latter 
factor describes the volume, and hence the depth of, porous interconnection, which was 
anticipated to increase with polymer MW in accordance with the general rules of polymer 
deposition. However, the contact angle will simultaneously increase with matrix 
hydrophobicity, therefore restricting the ability of the medium to wet the surface and 
penetrate the core by capillary action. Thus, faster deposition of RG504 from DCM and 
greater associated microsporosity during microdroplet drying was considered to account 
for the enhanced `burst' when compared with that from RG503. Despite the higher MW of 
RG755 (63 kD), its overall greater solubility in DCM and resultingly greater matrix 
densification - allied to its greater hydrophobicity - accounted 
for the reduced `burst' 
with this material when compared with PDLGA of equivalent MW, RG504 (56.5 
kD). By 
analogy, more sustained release from RG752 (20 kD) containing microspheres, when 
compared with RG502 (15.5 kD) at identical levels of R104 was also observed. 
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8.3.2.2 Thermal analysis 
The thermal behaviour of the matrix was instrumental in the modulation of drug release 
from microspheres prepared from blends of low and moderate MW PDLLA. In Table 8.3 
the peak position of the anomalous endotherm for each batch is presented. Other 
associated thermal indices feature in Appendix 10. In chapter 7, the position of the 
anomalous peak was considered a useful index of microsphere stability for matrices of 
identical composition. In contrast, the position of the endotherm for different materials is 
affected by more fundamental factors such as MW and monomeric composition (Kerc & 
Srcic, 1995). Furthermore, these factors affect the degree of stress conferred on the 
matrix during drying and also its ability to undergo relaxation which is itself influenced by 
the level of solvent residue within the matrix. The complex interplay of these factors 
dictates the final peak position of the anomalous endotherm and therefore confounds 
comparison based solely on this index. Nevertheless, a generalized pattern of Tg 
elevation was observed as the R104 level decreased, the complementary polymer MW 
increased, and, the density of chain stiffening CH3 sidechains increased. These data are 
presented in Table 8.3 and shown in Figure 8.2. 
Table 8.3 Peak position of the anomalous endotherm of microspheres prepared from 
blends of Resomer® R104 and various Resomer® lactide-glycolide copolymers containing 
20 %w/w rifampicin (total solid) 
Complementary 
polymer R104 / (%w/w) 
RG502 
RG503 
RG503H 
RG504 
RG752 
RG755 
Anomalous endotherm / °C 
44 40 36.6 
48.2 48.2 47.3 
52.3 55.8 51.5 
57.0 56.4 53.1 
56.7 55.6 54.3 
56.4 58.1 57.1 
53.6 59.3 59.3 
33.3 25 20 
49.3 52.1 49.7 
54.3 56.3 55.3 
57.4 57.0 54.5 
57.1 56.7 56.5 
56.8 57.0 55.8 
60.2 59.2 60.1 
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Figure 8.2 First heat DSC thermograms of microspheres containing 20 % w/w rifampicin 
prepared with 25 %w/w 8104 in a range of Resomer® lactide-glycolide copolymers (batch 
#31 - 36 as per Table 8.1). Labels indicate the complementary material used. 
8.3.3 Effect of oligomer proportion 
8.3.3.1 In vitro drug release 
The effect of R104 content on the coefficients and exponents of release data fitted to 
equation 8.1 is shown in Figure 8.3. The data presented were considered in general 
terms, deviations from these generalities are selectively discussed. Theoretically, the A 
and B coefficient terms of equation 8.1 represent the percentage contributions of the 
initial rapid and the slow terminal phases of drug release. Accordingly, as shown in 
Figures 8.5 (1) and (2) respectively, as the `burst' of drug release increases there is an 
approximate reciprocal decrease in the magnitude of B, the latter representing the 
percentage of inaccessible drug. Mechanistically, A and B represent the fractions of drug 
released by diffusion through a hydrated network and anhydrous glassy matrix, 
respectively. The initial process is the product of diffusion through either aqueous filled 
channels or through a hydrated matrix, both of which afford minimal resistance to 
drug 
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liberation. It follows that, the constants, a and ß, define the rates of these respective 
diffusive processes during the time course of the release studies. 
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Figure 8.3 Profiles of the effect of oligomeric contribution, R104, on the coefficients (1, A; 
2, B) and exponents (3, alpha; 4, beta) of rifampicin (20 %w/w) release data fitted to 
equation 8.1 using method B at 37 ± 0.1 °C and 100 ±1 rpm from spray-dried 
microspheres prepared from a range of lactide-glycolide copolymers. Legend indicates 
the complementary material used. 
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That A predominated over B for RG502, irrespective of the blend, is consistent with the 
inherent hydrophilicity of this material and the rapid diffusion of the large majority of drug 
through a hydrated matrix. The 'burst' progressively increased with the proportion of 
R104. It is postulated that R104 level dependent leaching at the surface of the 
microsp'heres increased the fraction of accessible RIF; the number, depth and dimension 
of the pores conceivably all increasing with levels of oligomer. However, gravimetrically 
derived data failed to convincingly substantiate this erosive contribution and was 
accordingly disregarded for reasons outlined in section 6.3.3.2. Nonetheless, it was 
reasoned that approximately linear increases in the magnitude of A with %w/w R104, was 
supportive evidence for the propagation of drug release by pore diffusion. Considerable 
parallelism and correspondence of values of A and B were observed for PDLGA (50: 50) 
blends below 33.3 %w/w. Within this range, hydrophobic effects overwhelm thermal and 
hydrophilic characteristics, whereby variation in the 'burst' were attributable to the 
influence of R104 leaching and other structural effects. Above this level, matrix hydration, 
over and above architectural differences was influential, confounding differential 
interpretation. This linearity extended over a broader range with blends of PDLGA (75: 25) 
when compared with PDLGA (50: 50) in keeping with the greater hydrophobicity of these 
materials. 
The relative magnitude of the two first order processes are additionally influenced by the 
extents of same, e. g., a small `burst' may yield an exceptionally high value for a, whereas 
a more extensive, and hence significant rapid phase, might give lower values of the same 
index as the depth of inward water penetration determines the extent of the initial phase, 
which, in turn, dictates the thickness of the diffusion barrier through which mass transfer 
occurs. It follows, that the extent of the initial phase has obvious implications for the rate 
of this `burst' - the mechanistic origin of the initial phase dictating 
the observed parabolic 
trend as discussed later in this chapter. The influence of polymer physicochemistry is 
none so more evident than with RG755, whereby a increased with RG755 contribution, 
contrary to the trend observed with PDLGA (50: 50). Lower MW RG752 generally showed 
comparable behaviour. Accordingly, the relative significance of the two release phases 
cannot be equated with their corresponding rate constants, with the exception perhaps 
where the initial phase comprises the predominant release mechanism. 
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On the basis of the autohydration mechanism discussed in Chapters 6 and 7, these data 
suggest that the criticality of matrix composition is accentuated by the use of less 
hydrophobic materials. The inherent hydrophilicity of complementary PDLGA (50: 50) 
polymers results in poorly controlled hydration at the critical level which proved 
exceptionally sensitive to polymer composition. The acuteness of this sensitivity is evident 
from the considerable acceleration - in the presence of comparable A values - of the 
initial phase between 36.6 and 40 %w/w R104, where a values increased from 10 to 40 h- 
1 with PDLGA (50: 50) based products. In contrast, the use of more hydrophobic PDLLA 
described in Chapter 6, R202H, behaved to regulate the autohydration process thereby 
conferring a greater degree of control on the release of RIF by diffusion. The greater the 
correspondence of a and ß, the greater the overall acceptability of the release profile in 
terms of providing constant release. In this respect, few blends afforded satisfactory 
release profiles. Exceptions included batches prepared with 60 % (#11) and 70 %w/w 
RG752 (#29). It is postulated that use of this material of intermediate hydrophobicity had 
a partially analogous effect to that of PDLLA R202H. 
Overall, empirical studies suggest PDLLA represents a more valuable material to explore 
its modulating capacity when combined with oligomers of the same nature. The between 
batch non-reproducibility alludes to the ability to modify release kinetics by modulating the 
MW and hence the hydrophobicity of the complementary material. Hydrophilic plasticizing 
oligomeric fractions behave as `initiator' for the hydration process, itself triggered by the 
correspondence of the medium and Tg temperatures. On the other hand, complementary 
PDLLA served to modify release rate and is referred to as `modulator'. Furthermore, the 
more coherent matrices formed with PDLLA by virtue of their enhanced solubility in DCM 
further supports their use in preference to PDLGA. However, in the event that a suitable 
solvent with greater solvency for PDLGA can be identified, improvements in matrix 
coherence are conceivably possible with copolymer. 
8.3.3.2 Thermal analysis 
During thermal analysis, a second peak shown in Figure 8.4 was recorded after the 
anomalous T. - associated endotherm in PDLGA 
(50: 50) blends of >_ 25 %w/w R104 
during the first scan, the relative magnitude of which was a direct function of the 
proportion of oligomer incorporated as shown in Figure 8.5. At 
20 %w/w the second 
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endotherm became poorly discerned and was largely absent at 10 %w/w. Solubilization of 
undissolved RIF was the putative origin of this second peak as evidenced from cursory 
hot stage microscopy observations described in section 6.3.1.5. Summation of the total 
area for both peaks revealed an approximately constant energy requirement for both 
processes of 5.0 Jg-1. Therefore, as the proportion of R104 decreases, a greater fraction 
of the dispersed RIF simultaneously dissolves as molecular motion is freed at the T9. The 
relative magnitude of the secondary peak is hence a marker of overall RIF solubility within 
the matrix blend, higher temperatures and additional energy being required to solubilize 
the undissolved remainder. 
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Figure 8.4 Effect of the proportion of R104 on the first heat DSG 
thermograms of 
microspheres containing 20 %w/w rifampicin prepared with 
56 %w/w RG752, (#5), and 
#1, #7, #13, #19, #37 with 56,60,63.3,66.6, and 80 %wlw RG502, respectively. 
Labels 
indicate the batch # according to Table 8.1. 
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Figure 8.5 Effect of the proportion of R104 incorporated on the relative magnitude of the 
second peak during the first DSC scan of microspheres containing 20 % w/w rifampicin 
prepared with a range of Resomer® lactide-glycolide copolymers. Labels indicate the 
copolymer used. Inset Table indicates the linear regression statistics of each plot. 
Linear regression data for these plots has been inset to Figure 8.5. The approximate 
parallelism of the plots indicated the solubility dependence of RIF on %w/w R104 was 
essentially equal irrespective of the PDLGA (50: 50) studied. However, the displacement 
of the plots up the ordinate indicated RIF solubility decreased as complementary polymer 
MW decreased. Plot extrapolation to the intercept on the abscissa gave solubility limits of 
18.2,19.6,23.4 and 24.5 %w/w R104 for RG502, RG503, RG503H and RG504, 
respectively. In contrast, regardless of the oligomer concentration, no secondary peak 
was observed with RG752, nor with RG755. Increased lactide content appeared to 
improve the solubility of RIF at the Tg as was corroborated by the data in chapter 6 where 
racemate PDLLA demonstrated similar behaviour. However, the MW dependence of RIF 
solubility is also evident with racemate PDLLA from the `salting-out' influence of R104 
combined with RG50X materials. The significance of these data is not known; however, 
diffusion is considered to accelerate as mutual drug-polymer solubility improves. On the 
contrary, these subtle solubility differences are probably overshadowed by the reduced 
free volume within the matrix and increased hydrophobic effects as MW increases, which 
serve to impede diffusion. 
Spray-dried combinations of PDLLA and PDLGA 
227 
Development and characterization of biodegradable microspheres containing selected antimycobacterials 
4 
35 60 
27 
39 
33 
21 
65 
David F. Bain 
70 
Temperature / °C 
Figure 8.6 Effect of the proportion of R104 on the first heat DSC thermograms of 
microsphere residue from release studies using method B at 37 ± 0.1 °C and 100 ±1 rpm 
containing 20 % w/w rifampicin prepared with RG503H. Labels indicate the batch # 
according to Table 8.1. 
The effect of oligomer content on the thermograms of microsphere residue from selected 
batches prepared with RG503H after 8h drug release study is shown in Figure 8.6, 
whereas data for all other batches appear in Appendix 11 a-g. Enhanced hydration and 
more extensive drug release resulted in a progressive decrease in the amplitude of the 
endotherm as %w/w R104 increased. However, microspheres with relatively high levels 
of RG503H largely retained their pre-dissolution thermographic features. The minimal 
endothermic fronting observed was attributed to modest surface hydration. Furthermore, 
as RIF was released and the overall residual loading fell within the solubility limits of the 
blend at the T9, the second endotherm disappeared. 
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8.3.4 Effect of medium temperature 
Figures 8.7 and 8.8 show the effect of medium temperature on the release profiles at 25 
%w/w R104 and profiles of the initial release phase on R104 %w/w for selected blends, 
respectively. In contrast to matrices derived from blends of PDLLA, temperature generally 
had a minimal effect on the profile of RIF release at 25 %w/w for PDLGA (50: 50) based 
microspheres as shown in Figure 8.7 (A). Correspondence of release profiles was 
attributed to hydrophobic effects which impeded hydration and consequent plasticization 
with RG503, RG503H and RG504. This was also true of microspheres derived from 
RG755. Instantaneous hydration of RG502 based blends yielded profiles comprising a 
single rapid phase. In contrast, the differential behaviour with RG752 shown in Figure 8.7 
(B) indicated this composition approximated to the critical level. 
The profiles of the initial phase were generally parabolic where the critical composition fell 
within the studied range. Parabolic behaviour was attributed to the evolution of the initial 
`burst' from one dependent exclusively on matrix microporosity, whereas the rate and 
extent of microsphere hydration augmented this phase beyond the critical level of %w/w 
R104. Thus, on the one hand, a increases as the %w/w R104 at the surface and 
therefore rate of hydration increases, while on the other, limited solvent penetration at 
lower levels of oligomer result in an extremely rapid short-lived `burst' phase. Examination 
of Figure 8.5 showed that exceptions included RG502 and RG755, where increases in 
the rate of hydration (RG502) or extent (RG755) resulted in a progressive increase and 
decrease respectively in the values of a as %w/w R104. 
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Figure 8.7 Effect of temperature on the release of rifampicin from microspheres prepared 
from 25 %w/w Resomer® R104 and: A, RG503; and, B, RG752 using method B at 100 ± 
1 rpm. Labels indicate the temperature ± 0.1 °C of the release medium. (n =3, RSD <_ 3.8) 
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Figure 8.8 Profiles of the effect of oligomeric contribution on the rate of the initial release 
phase of rifampicin as defined by equation 8.1 from microspheres prepared from blends 
of Resomer® R104 and. A, RG502; B, RG503H; and, C, RG755 using method B at 37 ± 
0.1 °C and 100 ±1 rpm. 
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Generally, the respective a values converge at the parabolic trough, indicative of release 
by largely pore diffusion due to the low temperature dependent solubilization of surface 
and weakly associated RIF. Modest increases in release rate with temperature at this 
point were attributed to the endothermic nature of RIF dissolution in aqueous medium as 
demonstrated in Chapter 3. Attempts to define the temperature dependence of 
dissolution of spray-dried RIF were hampered by its rapidity due to the high surface 
energy conferred -on the drug in its amorphous form (Corrigan, 1995). Studies at a 
reduced temperature range (23-29 °C) with intended extrapolation to that of the release 
studies failed to improve this situation. The rapidity of RIF dissolution also contributed to 
the variability of values for a, where initial release was often complete after a few 
sampling intervals. Above the critical composition, temperature dependent hydration of 
the matrix resulted in an enhanced contribution of the initial phase to overall release as 
previously inaccessible domains not contiguous with the porous surface are freed by 
water imbibition. The profiles in Figure 8.7 (B) illustrate an enhanced `burst' with medium 
temperature, whereas the A indices in Appendix 9 a-f would suggest an opposite trend 
above the critical composition. This is due to a concomitant and interfering increase in the 
secondary phase of release with temperature which results in a compensatory 
suppression of the computed extent of the `burst'. Nonetheless, the constancy of the A 
values below the critical composition indicates a set fraction of drug was released 
irrespective of medium temperature; further supportive evidence for release by 
exclusively pore diffusion. 
Quantitative evaluation of the temperature dependence of R'1F release for the initial phase 
was performed according to the Arrhenius equation as described in section 6.3.4. The 
computed statistics are presented in Appendix 12. The activation energies of diffusion 
through hydrated and anhydrous PDLLA were determined in chapter 6 as 320 and 630 J 
mol-1, respectively. The erratic nature of the determined a values generally resulted in 
poor correlation of the data when fitted to the Arrhenius function. Therefore, only data 
which yielded a r2 > 0.85 were considered. Significantly, matrix microporosity and 
enhanced free volume with the use of copolymers resulted in markedly lower values 
for 
Ea compared with PDLLA. Values of 110 ± 30 J mol-' at 33.3,25,25,40 
for RG502, 
RG503, RG503H and RG755, respectively, were considered to represent the 
temperature 
dependent dissolution of accessible RIF domains due to their general correspondence 
to 
the respective minima in Figure 8.8. Despite their greater porosity, moderately 
higher 
values for RG504 based microspheres, 170 ± 40 J moll 
(33.3 - 36.6 glow/w) were 
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attributed to the more extensive initial phase which necessitated diffusion of RIF through 
an overall more tortuous matrix. Corresponding values for RG752 of > 200 J mol-' above 
33.3 %w/w were considered due to enhanced matrix coherence by virtue of its greater 
solubility in the organic solvent used for microsphere preparation. It is acknowledged the 
relatively low values of Ea for the initial phase were due to the significant contribution of 
pore diffusion, which occurs more readily than that through a hydrated matrix as was the 
case with PDLLA. 
8.3.5 Effect of residual solvent on microsphere characteristics 
Comparable residual solvent loads of 2.03 %w/w (RG502), 2.47 %w/w (RG503), 2.36 
%w/w (RG503H), 2.04 %w/w (RG504), 2.61 %w/w (RG752), and 1.83 %w/w (RG755) 
were gravimetrically determined from microspheres prepared with 25 %w/w R104. In 
analogy to PDLLA blends examined in chapters 6 and 7, thermal indices detailed in 
Appendix 13 progressively increased with an approximate logarithmic dependence of 
time. Therefore, these stress-relaxation data mirrored the first order kinetics of residual 
solvent loss determined for PDLLA blends in section 7.3.4. The statistics of release data 
determined after 14,40 and 120 d storage fitted to Equation 8.1 are presented in 
Appendix 13. General, albeit small, reductions in A, a, and ß and simultaneous increases 
in B were observed as stress-relaxation stabilization of the matrix proceeded under the 
influence of residual solvent load. The minor variation in these indices was consistent with 
the predominant influence of matrix architecture on release data of the matrices at 25 
%w/w R104, in contrast to their thermal behaviour as was the case with PDLLA blends. 
Indeed, relatively high microporosity of copolymer derived microspheres aided rapid 
solvent loss. It follows, molecular rearrangement was restricted, yielding release profiles 
reminiscent of those seen with acetonic based microspheres in chapter 7. 
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8.4 Conclusion 
Owing to high matrix porosity associated with the use of DCM as solvent for the spray- 
drying of PDLGA, release profiles of RIF from microspheres based on blends of R104 
and PDLGA were typically characterized by a substantial `burst', matrix hydrophobicity 
accounting for the slow terminal diffusion of residual RIF thereafter. These data contrast 
with that in chapter 6, where coherent microspheres prepared from comparable blends of 
PDLLA released RIF by a controlled hydration mechanism based on microsphere 
hydrophilicity and thermal behaviour. Overall, the sensitivity of RIF release to small 
changes in matrix composition was accentuated with the use of PDLGA as 
complementary polymer. The data for RG502H blends for instance, suggested that bulk 
hydration, once triggered, occurs in an uncontrolled fashion with PDLGA, whereas the 
inclusion of hydrophobic lactic acid units served to moderate this process with PDLLA. 
Thus, in the absence of suitable, superior solvents for PDLGA, it is PDLLA that remains 
the most promising excipient for the preparation of inhalational microspheres which will 
adequately release their payload in a controlled fashion once impacted in the surrounding 
small volume of liquid in the lung. 
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9. Preparation and characterization of biodegradable microspheres containing 
isoniazid 
9.1 Introduction 
Despite substantial in vitro and in vivo assessment of biodegradable INH implantable 
systems (Gangadharam et al., 1989,1991; 1993; 1994; Gangadharam & Kailasam, 1993; 
Hsu et al., 1994,1996; Kailasam et at. 1994a, b), no reports of the drug's delivery by 
biodegradable microspheres have been described. This is undoubtedly attributable to the 
unfavourable physicochemistry of INH, particularly its hydrophilicity, which has 
discouraged investigation when formulated as biodegradable microspheres. 
As an alternative to poly-a-hydroxy acids, more hydrophilic polymers have been spray- 
dried: chitosan (Genta et at., 1994), polycaprolactone (Giunchedi et al., 1994b) 
hydroxypropyl cellulose (HPC) (Lee at al., 1997) casein (CAS) (Foster & Leatherman, 
1995) and albumin (ALB) (Conte et al., 1994b; Giunchedi et al., 1994a). The latter 
material has been used to both accelerate (Giunchedi et at., 1994a) and sustain drug 
release (Pavanetto et at., 1994b) when spray-dried. Carbamazepine showed a 
remarkable acceleration in dissolution rate when encapsulated in ALB (Giunchedi et at., 
1994b). In contrast, thermal denaturation of ALB conferred sustained release on 
dexamethasone by exposure to dry-heat for 6- 24 h at both 100 and 150 °C. 
Additionally, ALB has itself been encapsulated in PDLLA (Gander et al., 1996) and 
PDLGA (Bittner et al., 1998) by spray-drying. Double-walled microparticles have also 
been prepared by a 2-step spray-drying procedure (Lee et at., 1997). To minimize the 
deleterious effects of organic solvent on activity, antibody HBsAg was first embedded in a 
spray-dried hydroxypropylcellulose (HPC) matrix. The cores thus formed were 
subsequently suspended in an ethylacetate solution of PDLGA which, when spray-dried, 
produced antibody microcapsules. HBsAg retained 92 % of its original activity and gave 
comparable antibody titres to conventional two shot alum formulation. Elsewhere, 
dispersions of preformed spray-dried acid orange and somatostatin have been coated 
with polyanhydride by spray-drying (Mathiowitz et al., 1992). 
Transmission of M. tuberculosis is primarily via the pulmonary route. 
Thus, droplets 
expelled during coughing, sneezing or talking represent a significant risk 
to those sharing 
air-space with the infected individual. Even with treatment of 
INH to sensitive organisms, 
individuals generally remain sputum-positive for 14 d during which 
time they can infect 
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many others (Lemke, 1995). In terms of disease control and public health, much is 
therefore to be gained by expedient attainment of sputum negativity, for which intra- 
pulmonary delivery of bactericidal INH directly to the lesions might have great potential 
(Crofton, personal communication, 1996). 
Therefore, the potential of effective encapsulation of INH at high drug loadings for 
localized delivery of high concentrations of INH to tuberculosis lesions was investigated. 
In this respect, the formidable potential of spray-drying as a preparative technique has 
been investigated as part of recently popularized two-stage techniques, whereby 
preformed cores are coated with a rate limiting element in the form of a biodegradable 
polymer (Mathiowitz et al., 1992; Lee et al., 1997). 
9.2 Experimental procedures 
9.2.1 Microsphere preparation 
9.2.1.1 Production of small cores 
Aqueous isoniazid 12.5 %w/v solution (100 mL) was spray-dried in the preparation of 
drug cores for subsequent coating with poly-a-hydroxy acid according to Table 9.1. 
9.2.1.2 Microencapulation of small cores 
Selected drug cores were coated with RG755 at core: polymer ratios 0.5: 1.0; 0.5: 2.0 and 
0.5: 3.0. Solvent, DCM, was used to separately prepare a dispersion (50 mL) and solution 
(50 mL) of INH (500 mg) and polymer, respectively. Cores were dispersed with 
ultrasonification (Sonicator XL, Heat Systems, N. Y., USA) and polymer solution added 
under constant stirring. This suspension was then spray-dried at inlet = 40 °C; flow = 600 
NLh-1; aspiration = 100 %; and feed =4 mLmin-1. 
9.2.1.3 Microencapulation with proteinaceous polymers 
Solutions of INH and protein, albumin (ALB) and casein (CAS), were prepared in HPLC 
water (3 %w/v total solid) at D: P ratios of 0.1: 0.9,0.2: 0.8,0.3: 0.7,0.4: 0.6 and 0.5: 0.5 
according to Table 9.2. Processing parameters were: inlet = 110 °C; outlet = 75 - 77 °C; 
flow = 800 NLh-1; aspiration = 100 %; and feed =4 mLmin"1. Each batch was prepared in 
duplicate. Heat denatured (125 ±5 °C, 24 h) microspheres (500 mg) with D: P ratio 
0.1: 0.9 (#27) 0.3: 0.7 (#29) and 0.5: 0.5 (#31) were dispersed and spray-coated with 
RG755 (2.5 %w/v, 100 mL) in DCM as described in section 9.2.1.2. 
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Table 9.1 Spray-drying conditions for the preparation of isoniazid spheres for 
microencapsulation 
Batch Inlet / °C Outlet / °C Flow / NLh"' Pump /% Yield/ % 
1 155 116 800 5 25 
2 145 111 800 5 22 
3 135 107 800 5 19 
4 125 100 800 5 15 
5 165 123 800 5 25 
6 165 120 600 5 <1 
7 155 116 600 5 <1 
8 145 114 600 57 
9 135 98 600 55 
10 125 96 600 5 18 
11 165 132 400 5 <1 
12 155 125 400 5 <1 
13 145 115 400 5 <1 
14 135 103 400 5 <1 
15 125 95 400 5 <1 
16 145 117 800 10 25 
17 145 99 800 15 22 
18 145 89 800 20 23.5 
19 145 86 800 25 21 
20 165 115 800 10 20 
21 165 113 800 15 10 
22 165 111 800 20 22 
23 165 100 800 25 27 
24 155 110 800 10 30 
25 155 105 800 15 17 
26 155 99 800 20 18 
Aspiration = 100 % 
Table 9.2 Spray-drying parameters and production attributes of isoniazid-protein 
microspheres (n = 2) 
Batch Dissolved solid / 200 mL 
albumin casein 
27 32 
28 33 
29 34 
30 35 
31 36 
Yield /% 
INH /g protein /g albumin casein 
0.6 
1.2 
1.8 
2.4 
3.0 
5.4 
4.8 
4.2 
3.6 
3.0 
52.9 51.4 
52.7 48.8 
55.5 47.2 
53.7 32.7 
45.1 31.0 
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9.2.2 Microsphere characterization 
Drug loading was assessed by extraction of INH from microspheres (10 mg) in a mixture 
of HCI (0.01 mol L-1,20 mL) and DCM (20 mL). Each layer was separated and drug 
extracted quantified by HPLC as described in section 2.3.2. Morphological assessment of 
spray-dried microparticles was performed by SEM. Particle size analysis were performed 
on Mastersizer S (Malvern Instruments Ltd., Malvern). Image analysis to further assess 
the aggregative state of selected batches was also performed (Coulter Electronics Ltd., 
Luton). Drug release studies were performed according to method A with quantification of 
released drug by HPLC (section 2.3.2). Spray-dried INH and encapsulated products 
thereof were examined by DSC as described in section 5.2.3.6. To quantify the degree of 
disorder conferred on crystalline INH by spray-drying, the entropy analogue was 
determined for each batch based on thermal indices according to equation 9.1. 
Asf = 
°Hf (Equation 9.1) T 
M 
Residual moisture for selected batches was also determined (CA-20, Mitsubishi Kasei 
Corporation, Japan). XRD was also performed on selected batches of ALB microspheres 
before and after heat denaturation in dried air at 125 ± 5.0 °C for 3,6,10 and 24 h. 
9.3 Results and Discussion 
9.3.1. Characterization of INH cores 
Although the effect of flow rate, pump speed and aspiration were all systematically 
examined, it was apparent that spray conditions below 600 NLh_1 and 100 % aspiration 
gave inadequate yields, i. e., <5%. This was considered due to the dense character of 
the ostensibly crystalline particles produced. The high specific weight of these products 
required a considerable vacuum to effectively draw the particles through the apparatus. In 
addition, high flow rates were required to sufficiently divide the stream of solution, 
producing particles below the critical mass which thus remained airborne 
in the 
glassware. Due to the rapidity of the process, spray-drying is known to generate 
disorder 
in the crystal lattice (Corrigan, 1995), not uncommonly destroying crystallinity completely 
(Broadhead et al., 1992; Masters, 1992); as was shown in chapter 
6 for RIF. On the 
contrary, the crystalline character of the cores produced was verified 
by DSC as shown in 
Figure 9.1 and by the calculation of the entropy analogues 
for each product. 
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Characteristic melting endotherms were present in all spray-dried products with only 
small reductions in both heat of melting, i. e., 206 ± 5.60 Jg-' and entropy analogue 0.451 
± 0.03 Jg-1 K-1 when compared with stock reference for which corresponding values were 
211 Jg-' and 0.473 Jg-1 K-', respectively. Furthermore, SEM revealed geometrical 
regularity, some products appearing distinctly cuboidal as shown in Figure 9.2 (B). The 
small particle size and associated high surface energy accounted for considerable 
aggregation evident both in optical and SEM micrographs in Figure 9.2 (A) and (D) 
respectively. Particle fusion was further facilitated by residual moisture, which ranged 
between 0.55 - 3.25 %w/w, with no clear dependence on drying parameters. Collision of 
partially dried microdroplets in the area of the drying chamber further contributed to 
particle fusion seen in Figure 9.2 (C & D). 
105 123 170 186 200 
as supplied 
spray-dried 
138 153 
Temperature / °C 
Figure 9.1 Representative DSC scans of spray-dried and crystalline isoniazid. 
Owusu-Ababio & Rogers (1996) prepared cephalexin PLLA microparticles, precipitating 
polymer around preformed spray-dried particles. By suspending spray-dried 
cores in a 
polymer solution, spray-dried polyanhydride microcapsules 
thus obtained had diameters 
approximating to those of the drug particles. 
The authors concluded that a single drug 
particle was contained within each microparticle 
(Mathiowitz et al., 1992). On this basis, it 
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was reasoned that a suitable product for subsequent coating should possess a mean 
diameter smaller than that normally generated by spray-drying of the coating, be 
deaggregated and of uniform diameter. No product actually satisfied these criteria. 
Morphologically, #11 appeared to yield the highest proportion of small uniform and 
individualized particles, however, yields were particularly low; the drying parameters 
appeared to fraction suitable particles. Accordingly, #5 was selected in terms of particle 
appearance, shape and fusion of those batches yielding > 15 % of that attempted. 
Figure 9.2 Micrographs of INH cores captured by optical microscopy (A), and scanning 
electron microscopy: B, #6 (Mag" = 5.01 k); C, #8 (Mag" = 2.10 k); and, D, #24 (Mag" _ 
2.00 k). 
Irrespective of the D: P ratio, release profiles were characterized by a rapid release of 
drug, i. e., 100 % in <5 min. This was attributed to the poor coating efficiency of 
the slowly 
degrading polymer RG755 and the partial solubility of 
INH in the suspending solvent, 
DCM (1.95 mgmL-1). The former effect was exacerbated 
by the aggregative nature of the 
suspended cores which required probe sonification 
to facilitate dispersion, which, in turn, 
aided solubilization of approximately 30-50 
% of added INH. The inclusion of surfactant to 
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aid particle wetting, and judicious choice of dispersion solvent in which INH and poly-a- 
hydroxy acid have minimal and maximal solubility, respectively, should conceivably 
improve the sustained release character of such particles. The substitution for other 
polymers, e. g., polyanhydrides with which the coating utility of spray-drying has been 
demonstrated (Mathiowitz et al., 1992), represents another parameter which requires 
further investigation. 
9.3.2 Characterization of isoniazid-protein microspheres 
In order to prepare deaggregated particles of uniform diameter and of improved 
sphericity, highly loaded INH spheres were prepared with proteins, ALB and CAS (Magee 
et al., 1993). These materials were selected on the basis of their sprayability (Foster & 
Leatherman, 1995) and putative biocompatible (Magee et al., 1993). In addition, these 
proteins can be denatured by heat and/or chemical modification (Chen et al., 1987; Gupta 
et al., 1989) during (Przyborowski et al., 1982) or subsequent to spray-drying (Pavanetto 
et al., 1994b) to confer an additional level of sustained release on entrapped drug. 
9.3.2.1 Morphology and granulometry 
Yields of production in Table 9.2 showed a remarkable dependence on particle size 
distribution presented in Figure 9.3 (A). The relative invariability of granulometry for ALB 
microspheres corresponded well with their yield, whereas yield decreased in direct 
relation to particle diameter with CAS. These data support the fact that a critical range of 
microsphere mass exists, below and above which, product is either exhausted or impacts 
before the region of the cyclone. Both phenomena result in dramatic reductions in yield. 
Scanning electron micrographs revealed typical surface disparities (Pavanetto et al., 
1994b; Foster & Leatherman, 1995), including blow-holes, surface folds, shrivelling and 
sphere fracture. These arise due to the non-equilibrium drying conditions which prevail 
during drying of multi-phase microspheres which creates internal pressurization and 
regional stresses at the evaporating surface (Masters, 1992). Accordingly, the surface 
characteristics deteriorated as the phase ratio approached unity, i. e., as drug loading 
increased as shown in Figure 9.4. This deterioration was traced by an increased 
tendency to aggregate and by deviation from microparticle sphericity; reminiscent of drug 
cores shown in Figure 9.2. For comparable compositions, 
ALB based spheres 
demonstrated greater individualization and sphericity. The faster drying of 
ALB compared 
with CAS was reflected in the preponderance of the 
former to `blow-holes' (internal 
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pressure) and the latter to folding. These morphologies reflect the position of the product 
in the drier as surface precipitation occurred. Folding is suggestive of the surface 
solidification arising at a point below the boiling point of the solvent, whereas blow-holes 
indicate precipitation at a region closer to the nozzle where the air is hotter (Masters, 
1992). 
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Morphological results observed with ALB microspheres are in contrast to those previously 
observed with nicardipine-bearing spray-dried particles (Conte et al., 1994b). Upon 
introduction of nicardipine to the spray solution, smooth microspheres resulted in 
comparison to the shrivelled appearance of the corresponding blank ALB product. This 
was presumably due to amorphous nature of the drug under the conditions of preparation 
(Conte et al., 1994b). However, crumpled surfaces have also been observed with 
carbamazepine (Giunchedi et al., 1994) and dexamethasone (Pavanetto et al., 1994b). 
Figure 9.4 Scanning electron micrographs showing the effect of isoniazid: protein ratio at 
0.1: 0.9,0.3: 0.7 and 0.5: 0.5 on the morphology of spray-dried albumin (A, B, C) and casein 
(D, E, F) microspheres respectively. 
9.3.2.2 Thermal analysis 
DSC scans presented in Figure 9.5 showed a characteristic event around 100 °C as 
aqueous residue was driven off under the heating cycle. The origin of this event was 
confirmed by its absence in DSC scans of heat denatured microspheres. The propensity 
for INH to recrystallize even under the rapid drying conditions was evident from the 
presence of sharp endotherms at all INH: ALB ratios although their position did not always 
correspond to that expected for INH. In contrast, only at the highest studied D: P ratio did 
a melting event for INH appear in CAS based systems. The origin of the 
broad endotherm 
at 125 - 135 °C and 140 - 170 
°C for ALB and CAS microspheres respectively was 
considered due to the interaction of INH with protein as 
its area increased as the D: P ratio 
approached unity. 
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Figure 9.5 Differential scanning calorimetric analysis of isoniazid loaded microspheres 
prepared with: A, albumin; and, B, casein. Labels indicate batch according to Table 9.2. 
During denaturation, endotherms corresponding to crystalline drug reduced in area in a 
time dependent fashion such that no peak was evident for #27 after 6h and the peak for 
#31 was reduced to half its original area in 24 h. This was considered due to solubilization 
of hydrophilic INH in the hydrophilic ALB matrix. Considerable solubilization of INH in 
CAS was evident from the fact no melting endotherm corresponding to INH was apparent 
after 24 h heat treatment. In addition, the broad ill-defined endotherm between 150 - 175 
°C also disappeared irrespective of the encapsulant. Recoveries of drug were 95 - 100 % 
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during HPLC assessment of denatured samples which ruled-out drug degradation as the 
cause. 
9.3.2.3 XRD analysis 
The crystalline nature of spray-dried INH was confirmed by XRD. Comparison of spray- 
dried INH was made with crystalline drug and a theoretical output based on a previous 
structural solution (Bhat et al., 1974) as shown in Figure 9.6. Despite the presence of a 
thermographic peak corresponding to crystalline INH at D: P ratios of 0.1: 0.9, low signal- 
noise ratios for diffraction intensities as a result of the presence of protein obscured the 
characteristic peaks for the drug. Examination of diffraction patterns of denatured 
microspheres at D: P (0.5: 0.5) verified the persistence of crystalline drug after heat 
treatment. 
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Figure 9.6 X-ray powder diffractograms of A, theoretical 
isoniazid pattern (Bhat et al., 
1974); B, spray-dried isoniazid; C, native albumin; 
D, spray-dried isoniazid-albumin 
microsphere (D: P), 0.1; 0.9; and, 0.5: 0.5 before 
(E) and after (F) heat denaturation at 125 
±5°Cfor24 h. 
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9.3.2.4 In vitro drug release 
Due to the biphasic pattern of drug release, in vitro profiles of denatured ALB 
microspheres were fitted to equation 8.1 to yield the data shown in Table 9.3. 
Table 9.3 Statistics of drug release data fitted to equation 8.1 of heat denatured spray- 
dried isoniazid microspheres using method A at 37 ± 0.1 °C. Batch according to Table 
9.2. (r2 =>0.997, n=3, SD _< 
10.2). 
Biexponential coefficients Quartile release / min 
Batch Denaturation /hA/%a/ B1% P/ 25 50 75 
min" min" 
27 3 99.6 0.235 -0.04 0.001 1.01 2.01 4.23 
6 100.6 0.153 -0.07 0.01 1.91 4.55 9.06 
10 90.3 0.091 9.62 < 0.001 3.55 8.84 19.42 
24 99.36 0.081 0.92 < 0.001 3.61 8.67 17.43 
coated 93.19 0.033 7.84 < 0.001 10.0 24.2 51.3 
29 3 85.8 0.305 14.18 0.002 1.12 2.85 6.71 
6 87.2 0.225 12.77 < 0.001 1.50 3.77 8.68 
10 84.5 0.185 15.45 0.001 1.79 5.21 12.23 
24 84.1 0.089 15.95 < 0.001 4.60 12.57 17.12 
coated 88.25 0.037 11.75 0.002 7.91 19.17 38.92 
31 3 89.6 0.518 10.39 0.005 0.63 1.57 3.48 
6 90.2 0.517 9.82 0.003 0.63 1.56 3.43 
10 88.2 0.360 12.03 0.001 0.98 2.45 4.63 
24 88.3 0.321 11.36 0.004 1.34 2.78 5.98 
coated 89.59 0.058 10.07 0.002 5.44 13.61 29.7 
Release profiles were again all characterized by a predominant `burst' of release followed 
by a very slow release of the small fraction of INH residue. The latter effect was 
considered due to gelation of the protein matrix and subsequent microsphere aggregation 
which greatly increased the diffusional pathlength. Microspheres loaded with 10 %w/w 
(#27) released their total INH payload in the `burst' phase. The extent of the `burst' 
paradoxically decreased for 30 %w/w (#29) and 50 %w/w (#31) microspheres to 90 %. 
This was attributed to more rapid and enhanced aggregation of the microspheres as their 
hydrophilicity increased with greater drug loading. On the one hand, the partial 
solubilization of drug within the matrix during denaturation observed with thermal analysis 
might also account for the apparent increased affinity of the drug for the protein matrix. 
On the other hand, plasticization of the matrix by INH as observed in section 3.3.3.2 
would be expected to accelerate release as drug loading increased. 
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Coating of dispersed denatured microspheres with RG755 resulted in a 2.6,2.1 and 5.5 
fold reduction in the rate of initial release for batch #27, #29 and #31 respectively. 
However, despite the apparent improvement in coating efficiency, effective drug loading 
fell more than six-fold to 1.55,4.61 and 7.92 %w/w due to the presence of spray-dried 
coating / microspheres which were not separated from microcapsules. Calculated 
loadings were approximately 90 - 95 % of that anticipated due to adherence of some 
dispersed microspheres, to the vessel in which they were suspended. Indeed, 
approximate correspondence of batch #27 after 24 h denaturation (10 %w/w loading) with 
the release rate statistics of #31 (7.92 %w/w effective loading) would indicate that little 
was to be gained in terms of sustaining drug release by the additional coating step. 
However, by increasing the size of the microsphere cores to be coated, this might allow 
individual populations of microspheres and microcapsules to be separated and hence a 
partial restoration of drug loading. In addition, as suggested above, judicious choice of 
solvent which dissolves the polymer but has little capacity to dissolve entrapped drug 
might allow further improvements to be made to the preliminary data presented from the 
two-stage encapsulation process. 
9.4 Conclusion 
The highly water soluble and crystalline structure of INH precluded the effective 
encapsulation of spray-dried cores under the spray-drying conditions examined. 
However, encapsulation within spray-dried ALB matrices conferred measurable sustained 
release despite the persistence of crystalline drug. Drug release was further sustained by 
spray-coating of an additional rate-limiting membrane of biodegradable Resomer® but at 
the expense of a several fold reduction in effective loading. It is postulated that 
establishment of an organic solvent in which Resomer® (or other suitable 
biodegradable 
polymer) is soluble but INH is not, would allow improved coating efficiency and 
hence a 
further retardation of drug release. Furthermore, work is required to examine 
the potential 
separation of unwanted microspherical coating from coated microcapsules 
by a suitable 
technique, e. g., microsieving. If improvements in these 
two attributes can be made, it is 
believed- that the early intra-pulmonary delivery of such a product might significantly 
reduce the potential infectivity of the growing population of 
TB victims. 
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General Conclusions 
These studies have affirmed spray-drying as an excellent technique to rapidly and reproducibly 
obtain large quantities of biodegradable microspheres of high loading and predictable 
character. Its industrial applicability is further underlined by its capacity to be a continuous 
process in which microspheres can be prepared aseptically. Moreover, with judicious choice of 
process conditions, spray-drying can efficiently incorporate drugs of different hydrophilicities. In 
addition, although seldom reported, the technique offers attractive opportunities for the 
coformulation of drugs in poly-a-hydroxy acids and other biodegradable polymers. 
In previous reports of spray-dried poly-a-hydroxy acids, scant consideration has been paid to 
solvent selection, whereby strategies to modulate microparticle properties being based solely 
on incipient and excipient physicochemistry. DCM has often being arbitrarily selected based 
presumably on its historical use in other microencapsulation techniques. These investigations 
have provided sound justification for its previous, serendipitous selection with PDLLA, whereas 
optimal solvents for PDLGA are still to be identified. 
Empirical studies suggest PDLLA represents a more valuable material to explore its modulating 
capacity when combined with oligomers of the same nature. The between batch non- 
reproducibility alludes to the ability to modify release kinetics by modulating the MW and hence 
the hydrophobicity of the complementary material. On the one hand, hydrophilic plasticizing 
oligomeric fractions behave as `initiator' for the hydration process, itself triggered by the 
correspondence of the medium and T9 temperatures. On the other hand, complementary 
PDLLA served to modify release rate and is referred to as `modulator'. Furthermore, the more 
coherent matrices formed with PDLLA by virtue of their enhanced solubility in DCM further 
supports their use in preference to PDLGA. However, in the event that a suitable solvent with 
greater solvency for PDLGA can be identified, improvements in matrix coherence are 
conceivably possible with copolymer. Overall, this strategy offers a generic approach by which 
the release of a variety of drugs of comparable solubility character might be modulated. It 
is 
recognized, however, that the critical weight proportions of each polymer providing controlled 
release will vary depending on the influence of each individual drug on the thermal and 
hydrophilic character of the encapsulating composite. 
Where convenient administration devices can be developed, or existing ones utilized, e. g., 
MDIs, intra-pulmonary delivery of spray-dried biodegradable microspheres might alleviate 
some of the problems currently associated with protracted 
therapy of tuberculosis and other 
chronic diseases of the broncho-pulmonary system. 
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Appendix 1. Details of materials used in experimental procedures 
Material 
rifampicin (RIF) 
3-formyl rifamycin SV 
(RSV) 
rifampicin quinone 
(RQU) 
25- 
desacetylrifampicin 
(DAR) 
25-desacetyl-23- 
acetyl rifampicin (25- 
23) 
25-desacety-21 - 
acetyl Irifampicin (25- 
21) 
isoniazid (INH) 
iso-nicotinic acid N- 
oxide (INN) 
iso-nicotinic acid 
(I NA) 
iso-nicotinamide (lAD) 
sodium dihydrogen 
orthophosphate 
disodiurn hydrogen 
phosphate 
sodium acetate 
sodium chloride 
citric acid 
potassium chloride 
acetic acid 
sodium 
metabisulphite 
sodium sulphite 
iso-ascorbic acid 
(IAA) 
Supplier 
Lepetit, Milan, Italy 
Ciba-Geigy, Basel, 
Switzerland 
Merrel Dow, Middlesex, 
UK 
Sigma, St Louis, USA 
Fisher Scientific UK Ltd., 
Loughborough, UK 
Sigma 
Fisher Scientific 
Sigma 
FSA Laboratory Supplies, 
Loughborough, UK 
Sigma 
Sigma 
Grade 
ethical 
analytical 
analytical 
analytical 
analytical 
analytical 
> 99 % 
>99% 
>99% 
>99% 
S. L. R. 
S. L. R. 
S. L. R. 
S. L. R. 
S. L. R. 
Analar 
S. L. R. 
S. L. R 
S. L. R. 
S. L. R 
Comment 
David F Bain 
syn. 3-(4-methylpiperazin- l- 
ylimino-methyl)rifamycin 
degradate of rifampicin 
degradate of rifampicin 
degradate of rifampicin 
degradate of rifampicin 
degradate of rifampicin 
syn. isonicotinic acid hydrazide 
degradate of isoniazid 
degradate of isoniazid 
degradate of isoniazid 
buffer salt 
buffer salt 
buffer salt 
tonicity modifier 
buffer salt 
buffer salt 
antioxidant 
antioxidant 
methanol 
dichloromethane 
acetonitrile 
chloroform 
orthophosphoric acid 
double distilled water 
Rathburn, Walkerburn, 
Scotland 
Sigma 
in-house 
HPLC 
HPLC 
HPLC 
HPLC 
S. L. R 
HPLC 
antioxidant 
buffering acid 
further purified by a Millipore Milli- 
Q system (Milford, MA, USA) 
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Material Supplier Grade 
halothane Sigma 
methanol 
ethanol 
butanol 
acetone 
n-hexane 
ethyl acetate 
Fisher Scientific 
Polyvinylalcohol Sigma 
albumin 
casein sodium 
Resomer® 
L204 Boehringer Ingelheim, 
Ingelheim, Germany 
R104 
R202H 
RG502 
RG502H 
RG503 
RG503H 
RG504 
RG506 
RG752 
RG755 
Comment 
David F. Bain 
stabilized by 0.01% thymol (syn. 2- 
bromo-2-chloro-1,1,1- 
trifluorethane) 
cold-water soluble, 30 - 70 kD 
minimum 98 % (fraction V) 
water-soluble 
poly-L-lactide, 78 kD 
poly-D, L-lactic acid, 2 kD 
poly-D, L-lactide, 11 kD 
poly-D, L-lactide-co-glycolide 
(50: 50) , 
15.5 kD 
poly- D, L-lactide-co-glycolide 
(50: 50), 8 kD 
poly-D, L-lactide-co-glycolide 
(50-50), 39 kD 
poly-D, L-lactide-co-glycolide 
(50: 50), 33.5 kD 
poly- D, L-lactide-co-glycolide 
(50: 50), 56.5 kD 
poly-D, L-lactide-co-glycolide 
(50: 50), 68 kD 
poly-D, L-lactide-co-glycolide 
(75: 25) , 
20 kD 
poly-D, L-lactide-co-glycolide 
(75: 25), 63 kD 
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Appendix 2. DSC data of selected samples prepared with R104: R202H, 44: 66* (#16-21) 
and 40: 60 (#22-27) at various drug loadings 
Transition 
Batch RIF / Tg(on) '/2 Cp ACp Onset Peak AH / Jg" 
%%W/W l °C l °C / Jg-1 * °C / °C / °C 
16 1 35.17 37.78 0.28 39.56 43.17 7.23 
17* 3 37.69 41.07 0.41 42.77 45.56 7.24 
18* 5 37.45 42.05 0.52 43.68 46.23 7.08 
19* 10 38.10 42.82 0.42 43.76 47.50 3.47 
20* 20 42.28 45.25 0.32 47.98 50.59 3.93 
21 * 50 47.28 49.32 0.16 50.09 53.38 0.68 
22 1 36.92 39.78 0.39 40.78 43.95 6.42 
23 3 39.46 41.08 0.18 43.46 46.32 6.30 
24 5 40.10 42.30 0.26 45.25 47.94 6.06 
25 10 42.22 44.76 0.35 47.89 50.34 4.91 
26 20 43.72 47.97 0.43 50.14 52.94 3.56 
27 50 46.08 50.38 0.23 49.80 53.29 0.44 
onset, peak and area refer to the anomalous endotherrn recorded 
during the first run 
Tg(on) - glass transition temperature onset 
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Appendix 3. DSC data of microsphere annealed at 37 °C for various times 
Transition 
David F Bain 
Batch RIF / R104 / Tg(the) Tg(on) 112 Cp ACp / Onset Peak AH / Jg'' 
%w/w lw/w /°C /°C /°C Jg1 '°C /°C /°C 
total 
16 11 37.25 37.63 38.26 0.16 35.88 
2 36.32 
4 26.59 
17 31 37.60 
2 37.72 
4 39.22 
18 51 39.47 
2 40.18 
4 40.08 
19 10 1 42.74 42.11 44.54 0.32 46.47 
2 42.92 41.99 44.42 0.28 46.06 
4 42.37 41.46 43.37 0.32 45.23 
20 20 1 44.53 43.08 46.83 0.41 50.57 
2 44.49 48.42 46.65 0.36 50.56 
4 44.61 42.80 46.93 0.39 50.48 
21 50 1 47.51 44.24 49.25 0.16 52.05 
2 47.52 44.32 50.89 0.18 52.59 
4 47.99 44.83 51.28 0.17 55.89 
22 11 36.25 
2 36.19 
4 37.02 
23 31 39.01 
2 37.90 
4 38.91 
24 51 40.29 39.99 41.95 0.24 41.30 
2 40.48 40.18 41.92 0.21 40.41 
4 40.71 40.21 42.22 0.23 41.46 
25 10 1 43.11 41.43 44.70 0.36 
47.11 
2 43.77 42.34 45.07 0.35 47.01 
4 43.63 42.57 45.29 0.33 47.08 
26 20 1 45.94 43.50 48.34 
0.43 51.36 
2 46.46 45.03 48.73 0.38 
51.63 
4 46.43 44.14 48.53 0.41 
51.87 
27 50 1 48.94 45.68 51.20 
0.19 53.23 
2 48.98 44.34 50.59 0.19 
53.73 
4 49.49 46.07 51.35 0.17 
55.23 
40.38 1.63 
40.57 1.59 
40.82 1.67 
42.13 1.82 
42.45 1.80 
43.65 2.23 
44.35 2.68 
44.53 2.37 
44.51 2.38 
49.96 4.84 
49.63 4.46 
48.95 3.92 
53.32 4.64 
53.31 4.58 
53.31 4.53 
54.72 1.23 
54.96 1.30 
56.25 1.48 
40.90 1.62 
40.57 1.51 
41.02 1.70 
43.66 2.15 
42.63 1.96 
43.32 1.97 
45.89 2.90 
45.73 2.74 
45.76 2.70 
50.28 4.64 
50.45 4.59 
50.64 4.58 
54.17 4.28 
54.35 4.51 
54.67 4.79 
56.19 1.10 
56.53 1.20 
57.88 1.54 
T9(the) - glass transition temperature 
theoretical onset where thermal curve 
leaves the pre-transition baseline 
"/ 
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Appendix 4. DSC data of recovered microsphere residue from release studies performed 
at various temperatures 
Transition 
Batch Medium Tg(the) Tg(on) 1/2 Cp ACp / Onset Peak AH / Jg" 
/°C /°C /°C /°C Jgl *°C /°C /°C 
32 33 46.23 48.94 51.72 0.40 53.13 55.79 2.71 
35 41.69 44.36 48.14 0.44 51.55 55.53 1.61 
37 38.08 40.76 43.43 0.38 45.27 50.08 1.13 
39 39.00 36.27 42.03 0.39 43.99 49.75 0.50 
31 33 44.69 47.91 51.09 0.44 53.38 56.63 2.99 
35 40.13 42.21 46.59 0.48 51.06 53.86 1.32 
37 36.92 39.04 41.56 0.33 45.44 49.32 1.18 
39 36.71 34.64 39.84 0.37 41.99 47.81 1.02 
30 33 44.93 48.68 51.81 0.45 53.53 56.31 3.50 
35 42.55 44.64 50.29 0.46 51.76 54.44 1.45 
37 36.36 39.13 42.01 0.39 45.38 49.57 1.27 
39 37.34 36.34 41.10 0.39 43.07 47.56 1.11 
29 33 45.35 48.91 51.90 0.45 53.37 56.71 3.80 
35 44.48 46.97 50.54 0.44 52.28 55.45 2.39 
37 37.32 40.51 43.59 0.43 45.10 49.75 1.20 
39 39.52 36.60 42.48 0.41 44.78 50.08 2.02 
28 33 45.24 48.80 51.71 0.43 53.88 56.54 3.56 
35 45.40 47.62 50.65 0.36 52.79 56.37 2.77 
37 40.79 37.86 42.86 0.34 45.41 49.92 1.10 
39 40.10 38.99 42.95 0.50 44.82 49.75 1.80 
24 33 44.20 49.40 52.16 0.45 54.23 57.12 3.46 
35 48.284 51.29 54.64 0.51 53.06 56.79 2.62 
37 43.34 46.14 49.82 0.44 51.69 54.87 1.60 
39 43.14 41.47 46.23 0.38 50.97 55.04 1.88 
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Appendix 5. DSC data of selected samples during in vacuo storage at 24 ± 2.0 °C 
Transition 
Batch R104 / Storage Tg(the) Tg(on) 1/2 Cp ECp / Onset Peak OH / Jg' 
%w/w /h /°C /°C /°C /Jg'*°C /°C /°C 
32 31 Coll 47.51 
Cycl 49.71 
1 50.04 
3 49.49 
5 51.72 
24 50.66 
48 51.28 
72 51.64 
168 51.00 
336 50.80 
(100 d) 50.11 
33 30 Coll 48.96 
Cycl 49.07 
1 47.75 
3 50.56 
5 50.68 
24 50.56 
48 50.36 
72 50.86 
168 51.046 
336 50.89 
(100 d) 50.32 
34 29 Coil 45.73 
Cycl 48.66 
1 49.81 
3 50.23 
5 50.45 
24 51.74 
48 50.99 
72 50.61 
168 51.72 
336 51.04 
(100 d) 51.49 
44.29 51.53 0.52 48.31 52.92 0.85 
46.66 52.20 0.36 48.63 53.45 2.52 
46.15 52.87 0.45 51.52 54.45 0.04 
42.47 53.19 0.59 50.98 55.28 1.90 
47.98 53.41 0.35 52.45 56.30 2.49 
45.09 52.59 0.40 53.70 56.80 3.50 
45.58 54.21 0.51 55.56 58.15 3.83 
44.62 52.90 0.45 56.57 58.78 3.86 
44.65 53.69 0.52 57.28 59.47 4.56 
45.66 52.38 0.48 57.80 59.80 4.91 
53.20 55.42 0.42 59.00 61.41 4.20 
42.81 51.09 0.40 47.91 53.61 0.86 
44.70 52.35 0.45 49.03 54.28 1.86 
40.59 50.02 0.41 48.89 53.94 2.27 
44.59 53.68 0.49 51.02 55.62 2.13 
47.40 52.95 0.40 51.52 55.63 2.25 
43.48 53.25 0.50 53.84 56.97 3.22 
41.95 52.68 0.49 55.02 57.47 3.69 
45.73 53.69 0.52 56.17 58.63 3.79 
44.81 54.09 0.53 57.28 59.47 4.57 
45.27 53.50 0.53 58.02 59.92 4.25 
53.60 55.75 0.46 59.55 61.49 4.10 
41.16 49.62 0.46 47.10 53.27 2.28 
41.34 53.12 0.52 49.36 54.79 2.46 
45.88 53.26 0.50 50.19 55.45 2.88 
46.12 53.51 0.51 51.02 55.68 3.02 
46.35 53.46 0.51 51.91 55.94 2.90 
48.94 53.81 0.41 54.05 57.14 2.80 
45.00 53.98 0.53 55.38 57.96 3.26 
42.26 53.57 0.55 55.76 58.29 4.27 
45.81 54.68 0.52 57.29 59.48 4.81 
45.92 53.21 0.46 57.71 59.63 
4.54 
53.72 55.81 0.47 59.60 61.62 
4.40 
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Appendix 6. Effect of storage time on the first order release statistics at 37 ± 0.1 °C and 
100 ±1 rpm using method B. (amount released = ao a bt) 
Release /h 
Batch R104 / Storage ab se 25 % 50 % 75% 
%w/w /d 
32 31 1 102.4 0.408 0.98 4.07 0.76 1.75 3.46 
3 99.5 0.487 0.98 4.68 0.58 1.41 2.83 
7 102.0 0.396 0.98 4.63 0.77 1.79 3.54 
40 103.3 0.361 0.99 2.14 0.88 2.01 3.93 
50 99.1 0.257 0.99 2.54 1.08 2.64 5.34 
33 30 1 108.7 0.243 0.99 3.51 1.52 3.19 6.05 
3 107.8 0.312 0.98 4.17 1.16 2.46 4.68 
7 113.7 0.263 0.98 3.48 1.59 3.13 5.78 
40 105.3 0.221 0.99 1.80 2.01 4.67 9.19 
50 105.7 0.154 0.99 2.19 2.24 4.89 9.43 
34 29 1 111.2 0.218 0.98 4.72 1.78 3.64 6.81 
3 108.9 0.271 0.98 4.27 1.37 2.87 5.43 
7 110.8 0.223 0.98 3.87 1.73 3.55 6.67 
40 101.8 0.074 0.99 1.38 4.10 9.59 18.98 
50 107.3 0.102 0.99 1.58 3.49 7.47 14.25 
2-a 
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Appendix 7. DSC data of microsphere residue during release studies at 37 ± 0.1 °C and 
100 ±1 rpm using method B. 
Transition 
Batch R104 / Time Tg(the) Tg(on) 112 pp ACp/ Onset Peak Area  Onset Peak Areal %w/w /min / °C  °C / °C Jg''*°C / °C / °C Jg'' / °C / °C Jg"' 
30 36 5 46.11 43.55 49.58 
30 43.61 38.29 47.28 
60 40.85 38.33 43.81 
120 39.26 36.15 41.80 
240 41.91 37.22 45.08 
480 41.95 36.01 44.90 
31 32 5 46.88 42.20 49.93 
30 46.05 40.89 48.98 
60 43.07 37.72 46.12 
120 41.98 37.81 44.75 
240 40.94 37.39 43.76 
480 41.67 37.67 44.76 
35 28 5 43.83 37.49 47.43 
30 46.05 40.56 49.13 
60 45.08 39.48 47.83 
120 44.60 39.29 48.39 
240 43.11 37.36 46.47 
480 43.31 38.07 46.99 
36 24 5 48.76 44.44 51.23 
30 48.09 42.30 51.79 
60 47.48 41.15 50.69 
120 47.29 40.98 50.97 
240 46.48 40.51 50.65 
480 46.43 38.31 49.39 
37 20 5 48.13 42.13 51.31 
30 46.80 41.76 49.99 
60 46.32 42.43 49.73 
120 45.61 38.52 48.92 
240 45.73 40.33 48.96 
480 44.24 37.98 47.77 
0.44 50.70 53.48 3.59 58.48 62.52 0.68 
0.48 49.39 52.37 1.84 56.44 61.68 1.14 
0.35 43.62 48.42 2.45 50.24 61.02 1.16 
0.36 41.24 47.20 3.13 52.41 59.72 2.94 
0.43 39.85 46.74 2.58 51.99 58.86 1.77 
0.41 41.63 47.16 2.94 25.44 29.89 1.27 
0.45 51.61 54.20 3.18 59.11 62.99 3.04 
0.47 50.43 53.80 2.79 58.24 62.59 0.99 
0.50 46.53 50.28 2.88 57.62 61.93 0.43 
0.46 43.56 49.12 2.94 55.00 61.72 0.47 
0.41 43.40 49.03 3.15 54.23 64.36 1.86 
0.46 44.69 48.20 2.15 
0.56 50.38 52.76 4.47 58.33 61.70 0.72 
0.48 50.86 53.38 3.93 58.15 63.21 0.74 
0.44 50.80 53.33 3.96 57.94 61.82 0.79 
0.51 50.94 53.33 3.75 57.22 62.19 1.27 
0.50 50.17 52.91 3.81 56.94 61.51 1.04 
0.51 50.54 52.94 2.99 56.34 61.33 1.33 
0.40 53.32 56.00 3.45 59.12 63.72 0.71 
0.54 52.85 55.58 3,34 58.95 63.95 0.98 
0.52 52.39 54.91 2.74 58.58 63.37 0.86 
0.54 52.27 54.9 2.95 58.25 64.19 0.98 
0.53 51.65 54.31 2.62 57.53 63.35 1.25 
0.49 51.34 54.31 2.35 57.01 62.14 0.56 
0.49 52.92 55.65 3.23 60.78 64.10 0.42 
0.47 51.64 54.36 3.53 58.58 63.16 0.81 
0.47 53.13 54.03 2.81 58.16 65.43 0.73 
0.55 51.41 53.96 2.75 57.61 62.93 1.27 
0.47 50.97 53.47 2.52 57.80 62.68 1.08 
0.48 50.43 53.22 1.91 56.83 62.68 1.33 
? 'S 
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Appendix 8a. Effect of medium temperature on the regression statistics of release profiles fitted to the power law using method B. amount released r= a* tb 
released /h 
Batch R104 / Medium lab rz SE 25 50 75 %w/w °c 
4 60 33 
35 
37 
39 
5 56 33 
35 
37 
39 
6 52 33 
35 
37 
39 
7 48 33 
35 
37 
39 
8 44 33 
35 
37 
39 
9 40 33 
35 
37 
39 
31 32 33 
35 
37 
39 
32 31 33 
35 
37 
39 
33 30 33 
35 
37 
39 
34 29 33 
35 
37 
39 
35 28 33 
35 
37 
39 
36 24 33 
35 
37 
39 
29.78 1.647 0.998 
120.77 0.829 0.985 
238.40 0.858 0.992 
124.06 0.321 0.973 
36.16 1.440 0.999 
120.53 0.818 0.987 
183.06 0.741 0.991 
156.66 0.409 0.982 
156.66 0.409 0.932 
12.34 0.661 0.987 
75.58 0.624 0.990 
142.03 0.39 0.985 
10.29 0.377 0.965 
16.35 1.011 0.988 
104.56 1.093 0.995 
185.60 1.296 0.995 
8.74 0.296 0.973 
13.05 0.917 0.990 
30.39 0.516 0.949 
127.55 1.105 0.990 
5.22 0.360 0.956 
6.82 1.104 0.998 
31.84 1.098 0.989 
109.43 0.810 0.995 
no fit 
7.81 0.702 0.981 
23.04 0.733 0.973 
60.21 0.900 0.987 
9.92 0.196 0.988 
14.97 0.561 0.972 
25.44 0.795 0.991 
74.62 0.603 0.991 
8.01 0.171 0.988 
7.94 0.705 0.978 
15.07 0.902 0.993 
55.99 0.738 0.988 
6.40 0.232 0.996 
6.83 0.425 0.979 
11.81 0.958 0.994 
47.02 0.782 0.991 
7.53 0.176 0.998 
9.32 0.414 0.972 
15.87 0.861 0.978 
45.09 0.875 0.992 
5.25 0.191 0.995 
6.74 0.275 0.981 
6.97 0.543 0.978 
11.15 0.853 0.994 
1.24 0.899 
3.87 0.150 
3.44 0.072 
3.63 0.006 
1.00 0.768 
3.79 0.146 
3.29 0.006 
3.50 0.012 
3.50 0.011 
1.93 2.90 
2.75 0.170 
3.032 0.011 
0.952 10.47 
3.23 1.52 
2.28 0.270 
2.41 0.213 
0.803 34.74 
3.26 2.03 
6.59 0.685 
3.64 0.229 
0.777 77.40 
1.12 3.23 
3.06 0.802 
2.22 0.162 
1.60 
6.64 
3.80 
0.344 
2.73 
3.24 
3.06 
0.191 
1.65 
3.56 
3.58 
0.179 
0.803 
2.37 
3.23 
0.129 
1.22 
3.93 
2.94 
0.154 
0.487 
1.10 
1.91 
5.23 
1.11 
0.377 
119.35 
2.49 
0.978 
0.163 
938.58 
5.54 
1.75 
0.335 
360.09 
21.67 
2.19 
0.445 
4837 
10.81 
1.69 
0.509 
3456 
1117 
10.68 
2.57 
1.37 1.75 
0.345 0.563 
0.162 0.260 
0.059 0.209 
1.24 1.64 
0.341 0.560 
0.162 0.286 
0.061 0.165 
0.061 0.165 
8.28 15.29 
0.516 0.988 
0.068 0.194 
65.69 192.25 
3.02 4.51 
0.502 0.738 
0.363 0.497 
361.47 1422 
4.32 6.72 
2.62 5.74 
0.429 0.618 
530.79 1637 
6.06 8.75 
1.50 2.18 
0.380 0.627 
14.06 25.07 
2.87 5.00 
0.815 1.27 
4317 35452 
8.580 17.69 
2.33 3.89 
0.514 1.01 
15.17 
3.77 
0.858 
3036 
110.03 
4.51 
1.08 
44150 
57.64 
3.79 
1.12 
27.93 
5.914 
1.48 
44265 
284.84 
6.88 
1.81 
436552 
153.41 
6.07 
1.79 
4164 6401 
39.12 83.89 
6.07 9.33 
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Appendix 8b. Effect of medium temperature on the linear regression statistics of release profiles using method B. amount releasedt =a+ bt 
% released /h 
Batch R104 Medium ab º'ý SE 25 50 75 %wlw 1 °C 
4 60 33 
35 
37 
39 
5 56 33 
35 
37 
39 
6 52 33 
35 
37 
39 
7 48 33 
35 
37 
39 
8 44 33 
35 
37 
39 
9 40 33 
35 
37 
39 
31 32 33 
35 
37 
39 
32 31 33 
35 
37 
39 
33 30 33 
35 
37 
39 
34 29 33 
35 
37 
39 
35 28 33 
35 
37 
39 
36 24 33 
35 
37 
39 
-21.15 
3.54 
4.28 
21.96 
-7.64 
4.78 
8.20 
15.91 
5.48 
8.02 
11.66 
14.52 
7.08 
2.94 
-1.83 
-4.75 
6.59 
1.12 
17.06 
-2.95 
3.76 
-1.27 
-0.088 
4.55 
4.97 
3.76 
9.32 
2.25 
8.13 
8.58 
7.22 
17.87 
6.73 
7.55 
2.80 
10.81 
4.91 
4.35 
2.28 
8.55 
6.08 
6.04 
3.68 
4.26 
4.38 
4.96 
4.04 
3.10 
52.82 
125.94 
263.06 
228.09 
48.40 
124.25 
227.01 
326.98 
6.03 
109.14 
64.81 
317.83 
2.37 
13.57 
102.18 
154.55 
1.51 
11.05 
10.20 
125.10 
1.06 
8.32 
32.77 
113.14 
0.827 
4.01 
13.56 
57.46 
1.11 
5.61 
17.47 
56.33 
0.77 
4.81 
12.41 
43.29 
0.883 
1.84 
10.51 
36.65 
0.801 
2.4415 
11.85 
39.78 
0.617 
1.13 
2.51 
8.07 
0.992 
0.985 
0.988 
0.882 
0.989 
0.984 
0.978 
0.920 
0.972 
0.976 
0.970 
0.928 
0.942 
0.976 
0.995 
0.991 
0.879 
0.986 
0.894 
0.994 
0.834 
0.997 
0.989 
0.991 
0.891 
0.999 
0.961 
0.987 
0.905 
0.992 
0.990 
0.974 
0.877 
0.991 
0.987 
0.975 
0.847 
0.974 
0.994 
0.982 
0.812 
0.978 
0.983 
0.989 
0.828 
0.934 
0.991 
0.992 
2.56 0.874 1.34 1.82 
5.11 0.170 0.369 0.567 
5.20 0.078 0.174 0.269 
15.20 
4.24 0.674 1.191 1.70 
5.17 0.163 0.364 0.565 
6.66 0.074 0.184 0.294 
13.92 
3.06 3.23 7.37 11.51 
6.21 0.156 0.385 0.614 
6.32 0.206 0.591 0.977 
12.84 
1.77 7.53 18.04 25.55 
6.27 1.62 3.46 5.309 
2.79 0.263 0.507 0.752 
3.81 0.193 0.354 0.516 
1.70 
3.84 2.16 4.42 6.68 
10.61 
3.30 0.223 0.423 0.623 
1.46 
1.29 3.15 6.15 9.15 
3.62 0.765 1.52 2.29 
3.78 0.181 0.402 0.622 
0.877 24.23 54.48 84.74 
0.766 5.28 11.48 17.72 
8.06 1.15 3.001 4.86 
4.09 0,397 0.833 1.26 
1.04 15.11 37.52 59.92 
1.46 2.92 7.37 11.82 
3.53 1.01 2.44 3.87 
5.35 0.126 0.570 1.01 
0.894 21.74 50.35 78.95 
1.36 3.74 9.06 14.37 
4.19 1.78 3.80 5.81 
5.27 0.327 0.905 1.48 
1.14 22.75 51.09 79.43 
0.881 11.27 24.90 38.53 
2.40 2.16 4.54 6.93 
4.57 0.448 1.131 1.81 
1.19 
1.11 9.26 38.09 92.22 
4.60 1.79 3.90 6.01 
3.54 0.521 1.15 1.77 
0.8695 33.40 73.91 114.41 
0.899 17.72 39.85 61.97 
0.719 8.37 18.38 28.38 
2.13 2.71 5.81 8.90 
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Appendix 8c. Effect of medium temperature on the first order release statistics using -bt method B. amount releasedt = ae 
released/ h 
Batch R104 / Medium lab r2 SE 25 50 75 %w/w °c 
4 60 33 
35 
37 
39 
5 56 33 
35 
37 
39 
6 52 33 
35 
37 
39 
7 48 33 
35 
37 
39 
8 44 33 
35 
37 
39 
9 40 33 
35 
37 
39 
31 32 33 
35 
37 
39 
32 31 33 
35 
37 
39 
33 30 33 
35 
37 
39 
34 29 33 
35 
37 
39 
35 28 33 
35 
37 
39 
36 24 33 
35 
37 
39 
112.52 
105.05 
101.97 
91.97 
112.80 
103.93 
99.62 
95.13 
96.39 
102.17 
99.70 
95.22 
93.15 
108.17 
107.77 
107.74 
93.52 
105.24 
96.15 
108.09 
96.30 
103.63 
106.84 
103.28 
95.05 
96.69 
95.08 
121.02 
91.61 
92.45 
112.63 
99.99 
93.06 
96.40 
101.87 
109.33 
95.12 
95.75 
51.59 
109.71 
93.94 
94.15 
104.26 
113.96 
95.63 
95.08 
99.43 
109.35 
0.587 0.938 
2.34 0.991 
4.87 0.992 
7.04 0.974 
0.713 0.947 
2.35 0.993 
4.58 0.997 
8.75 0.989 
0.084 0.982 
2.22 0.996 
1.39 0.999 
7.84 0.988 
0.028 0.947 
0.270 0.987 
1.64 0.976 
2.21 0.961 
0.017 0.884 
0.184 0.993 
0.273 0.973 
1.95 0.973 
0.011 0.839 
0.112 0.986 
0.527 0.987 
2.06 0.996 
0.009 0.894 
0.048 0.993 
0.012 0.937 
1.19 0.990 
0.011 0.971 
0.076 0.988 
0.334 0.994 
1.42 0.999 
0.007 0.934 
0.045 0.988 
0.331 0.983 
0.988 0.996 
0.009 0.851 
0.020 0.977 
0.598 0.989 
0.795 0.992 
0.008 0.8165 
0.028 0.9795 
0.170 0.981 
0.797 0.989 
0.006 0.831 
0.012 0.937 
0.117 0.995 
0.231 0.992 
8.89 
3.98 0.144 0.317 0.613 
4.11 0.063 0.146 0.289 
7.39 0.029 0.086 0.185 
9.32 
3.58 0.139 0.311 0.605 
2.29 0.061 0.150 0.302 
5.19 0.027 0.735 0.150 
2.45 2.974 7.78 15.99 
2.64 0.139 0.321 0.632 
1.35 0.204 0.495 0.993 
5.21 0.030 0.082 0.171 
1.68 7.62 21.84 46.16 
4.61 1.35 2.858 5.42 
6.29 0.220 0.467 0.888 
8.00 0.164 0.350 0.660 
1.66 12.73 36.11 76.09 
2.76 1.83 4.03 7.79 
5.50 0.909 2.39 4.92 
6.80 0.187 0.394 0.749 
1.44 21.42 56.15 115.53 
2.90 2.88 6.50 12.69 
5.19 0.672 1.44 2.75 
2.59 0.155 0.351 0.686 
12.69 49.66 113.23 118.60 
1.02 5.262 13.66 28.01 
0.879 19.02 51.53 107.11 
3.33 0.403 0.744 1.327 
0.536 16.87 51.01 109.40 
1.76 2.72 7.99 17.24 
3.03 1.22 2.43 4.51 
1.25 0.202 0.485 0.970 
0.559 27.21 78.44 166.02 
1.26 5.65 14.70 30.16 
4.49 0.924 2.14 4.24 
2.12 0.381 0.792 1.49 
1.13 24.63 66.56 138.31 
0.855 11.91 31.61 65.32 
3.25 2.46 5.07 9.89 
3.01 0.478 0.989 1.85 
1.18 25.42 71.21 149.46 
1.04 7.96 22.15 46.41 
4.37 1.93 4.32 8.40 
3.68 0.524 1.16 1.90 
0.861 36.60 97.66 202.03 
0.879 19.02 51.53 107.11 
1.52 2.41 5.89 11.84 
3.19 1.63 3.38 6.37 
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Appendix 9a. Effect of oligomer, R104 level on the biexponential coefficients of drug 
release using method 8 from microsphere prepared from RG502 (data fitted to equation 
8.1) 
Biexponential coefficients Quartile release /h 
Medium Batch R104 /A/% al h" B/% ß/ h"' r2 25 % 50 % 75 % /°C %w/w 
33 1 56 86.51 7.108 7.904 0.116 0.956 0.043 0.126 0.284 
33 7 60 66.61 7.031 5.542 0.006 0.916 -0.006 0.057 0.096 
33 13 63.3 79.99 7.791 17.19 0.060 0.997 0.041 0.114 0.302 
33 19 66.6 82.01 6.774 15.13 0.090 0.998 0.046 0.125 0.307 
33 31 75 81.29 7.651 14.16 0.261 0.998 0.037 0.542 0.255 
33 37 80 54.47 3.330 20.73 0.026 0.917 0.0008 0.180 0.719 
33 25 90 31.09 2.463 58.91 0.021 0.976 2.299 0.260 7.984 
35 1 56 71.04 35.00 22.73 3.034 0.991 0.009 0.028 0.077 
35 7 60 75.11 20.51 18.44 1.013 0.993 0.013 0.042 0.114 
35 13 63.3 83.73 9.809 12.37 0.140 0.996 0.029 0.081 0.191 
35 19 66.6 78.25 8.047 16.54 0.209 0.993 0.037 0.109 0.276 
35 31 75 78.15 8.736 17.64 0.283 0.996 0.035 0.100 0.258 
35 37 80 75.42 5.920 20.49 0.069 0.994 0.054 0.156 0.454 
35 25 90 41.12 1.808 52.72 0.029 0.992 1.741 0.329 2.584 
37 1 56 61.63 35.80 
37 7 60 55.49 31.42 
37 13 63.3 78.94 9.195 
37 19 66.6 78.87 10.84 
37 31 75 78.76 11.17 
37 37 80 57.46 5.913 
37 25 90 45.80 1.118 
39 1 
39 7 
39 13 
39 19 
39 31 
39 37 
39 25 
56 57.69 
60 63.73 
63.3 79.90 
66.6 76.00 
75 73.64 
80 88.74 
90 69.17 
13.66 3.334 0.921 0.0004 0.018 0.053 
13.07 2.281 0.949 0.004 0.025 0.069 
13.55 0.382 0.997 0.027 0.083 0.208 
16.71 0.212 0.995 0.027 0.076 0.200 
15.83 0.439 0.997 0.025 0.073 0.181 
13.26 0.037 0.895 -0.013 0.077 0.274 
35.65 0.020 0.918 6.767 0.139 1.013 
16.98 28.04 1.738 0.987 
23.33 27.03 2.037 0.994 
15.11 12.65 0.386 0.994 
15.89 16.44 0.498 0.992 
12.53 19.55 0.374 0.992 
8.554 15.37 0.181 0.995 
3.799 31.88 0.180 0.997 
0.011 0.051 0.168 
0.011 0.040 0.1205 
0.016 0.050 0.124 
0.016 0.050 0.130 
0.023 0.073 0.206 
0.046 0.109 0.252 
1.024 0.124 0.366 
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Appendix 9b. Effect of oligomer, R104 level on the biexponential coefficients of drug 
release using method B from microsphere prepared from RG503 (data fitted to equation 
8.1) 
Biexponential coefficients Quartile release /h 
Medium Batch R104 /A/%a/ h"1 B/%ß/ h"' r2 25 % 50 % 75% /°C %w/w 
33 2 56 81.97 11.05 16.17 1.581 0.981 0.028 0.075 0.169 
33 8 60 91.40 6.280 4.222 -0.060 0.971 0.040 0.110 0.236 
33 14 63.3 68.93 8.045 25.45 0.582 0.998 0.042 0.144 18.66 
33 20 66.6 75.94 7.048 15.95 0.067 0.996 0.035 0.113 0.297 
33 32 75 52.44 3.385 42.04 0.031 0.997 0.135 0.533 16.52 
33 38 80 27.22 20.09 70.19 0.008 0.980 0.085 
33 26 90 13.97 9.842 85.55 0.009 0.956 1.198 13.87 
35 2 56 
35 8 60 
35 14 63.3 
35 20 66.6 
35 32 75 
35 38 80 
35 26 90 
37 2 56 
37 8 60 
37 14 63.3 
37 20 66.6 
37 32 75 
37 38 80 
37 26 90 
39 2 
39 8 
39 14 
39 20 
39 32 
39 38 
39 26 
73.83 28.83 20.82 2.742 0.993 0.010 0.030 0.076 
61.61 23.79 30.52 4.156 0.983 0.012 0.039 0.104 
86.34 5.700 13.35 0.068 0.992 0.061 0.158 0.408 
77.43 5.279 16.85 0.062 0.996 0.053 0.159 0.417 
52.34 4.456 43.24 0.026 0.997 0.111 0.444 20.62 
27.57 16.70 66.71 0.011 0.969 0.071 26.00 
9.743 22.51 88.12 0.002 0.886 1.095 
79.56 24.10 5.536 0.039 0.952 0.002 0.019 0.048 
57.14 38.55 33.01 4.573 0.976 0.0007 0.030 0.093 
68.02 4.137 24.20 0.256 0.996 0.069 0.224 0.663 
76.32 10.44 16.45 0.097 0.995 0.025 0.078 0.207 
50.00 5.458 47.75 0.027 0.996 0.111 0.577 23.34 
23.97 12.53 70.76 0.018 0.964 0.136 19.17 
10.29 33.06 87.14 0.004 0.887 1.158 
56 52.26 36.90 39.36 
60 25.60 31.26 69.96 
63.3 71.72 16.93 21.88 
66.6 78.29 14.29 13.28 
75 49.43 7.433 46.75 
80 32.84 10.32 67.51 
90 11.95 17.50 87.94 
4.383 0.992 0.010 0.036 0.115 
4.629 0.989 0.024 0.084 0.224 
0.271 0.993 0.019 0.061 4.136 
0.228 0.993 0.016 0.052 0.131 
0.029 0.996 0.074 0.365 21.28 
0.022 0.997 0.140 13.23 
0.006 0.990 0.292 
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Appendix 9c. Effect of oligomer, R104 level on the biexponential coefficients of drug 
release using method B from microsphere prepared from RG503H (data fitted to equation 
8.1) 
Biexponential coefficients Quartile release /h 
Medium Batch R104 / A1% a/ h" B1% PIK' 25 50 75 
/ °C l w/w 
33 3 56 90.99 8.137 11.14 0.116 0.989 0.043 0.104 0.229 
33 9 60 89.25 5.944 9.940 0.030 0.99 0.053 0.134 0.299 
33 15 63.3 68.29 4.009 30.39 0.018 0.999 0.106 0.313 11.47 
33 21 66.6 76.90 3.567 21.19 0.039 0.999 0.099 0.273 0.798 
33 33 75 46.20 1.346 51.52 0.027 0.999 0.419 2.269 26.35 
33 39 80 11.78 1.425 82.97 0.013 0.974 7.714 
33 27 90 5.392 30.45 94.00 0.005 0.849 1.021 
35 3 56 81.66 13.99 14.33 0.569 0.991 0.021 0.058 0.138 
35 9 60 77.56 14.24 17.61 1.028 0.995 0.023 0.059 0.015 
35 15 63.3 86.59 4.725 16.35 0.061 0.993 0.082 0.200 0.504 
35 21 66.6 79.31 4.409 17.96 0.063 0.997 0.076 0.209 0.549 
35 33 75 41.35 2.291 53.67 0.038 0.999 0.330 3.050 20.77 
35 39 80 24.16 9.152 69.66 0.015 0.977 0.589 25.64 
35 27 90 15.21 21.53 82.32 0.012 0.997 0.456 
37 3 56 69.16 
37 9 60 55.31 
37 15 63.3 56.62 
37 21 66.6 77.07 
37 33 75 43.58 
37 39 80 25.06 
37 27 90 5.632 
39 3 
39 9 
39 15 
39 21 
39 33 
39 39 
56 51.56 
60 55.84 
63.3 67.05 
66.6 76.66 
75 49.47 
80 33.81 
44.08 15.30 2.029 0.967 0.003 0.016 0.270 
41.18 37.24 2.472 0.980 0.009 0.032 0.165 
7.719 39.71 0.096 0.992 0.077 1.623 6.284 
7.706 20.75 0.114 0.998 0.045 0.124 0.354 
2.399 54.15 0.046 0.998 0.293 1.981 16.35 
2.052 68.36 0.026 0.991 0.732 13.60 
37.10 93.34 0.003 0.867 0.774 
33.44 42.95 2.821 0.995 0.013 0.045 0.199 
11.60 42.73 1.620 0.997 0.044 0.127 0.329 
10.64 30.42 0.081 0.997 0.276 0.140 8.203 
10.38 18.51 0.217 0.995 0.029 0.084 0.226 
2.988 48.73 0.035 0.996 0.195 0.872 18.18 
2.404 64.00 0.015 0.997 0.452 15.55 
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Appendix 9d. Effect of oligomer, R104 level on the biexponential coefficients of drug 
release using method B from microsphere prepared from RG504 (data fitted to equation 
8.1) 
Biexponential coefficients Quartile release /h 
Medium Batch R104 /A/%a/ h"1 B/%ß/ h'1 r2 25 % 50 % 75% 
/°C %w/w 
33 4 56 85.28 11.69 9.894 0.55 0.990 0.022 0.063 0.144 
33 10 60 64.27 9.309 8.090 2.167 0.924 -0.004 0.044 0.133 
33 16 63.3 83.02 12.31 11.23 0.382 0.956 0.036 
33 22 66.6 75.21 13.25 14.23 0.187 0.992 0.087 
33 34 75 49.97 3.749 45.07 0.029 0.997 0.231 1.165 20.51 
33 40 80 12.10 2.628 58.30 0.004 0.524 -0.066 
33 28 90 19.67 26.69 73.83 0.015 0.900 1.798 0.243 6.118 
35 4 56 
35 10 60 
35 16 63.3 
35 22 66.6 
35 34 75 
35 40 80 
35 28 90 
37 4 56 
37 10 60 
37 16 63.3 
37 22 66.6 
37 34 75 
37 40 80 
37 28 90 
39 4 
39 10 
39 16 
39 22 
39 34 
39 40 
39 28 
74.08 11.36 21.10 0.686 0.997 0.040 0.459 0.199 
78.10 27.12 10.02 2.191 0.986 0.006 0.024 0.058 
86.80 5.266 10.71 0.124 0.997 0.060 0.155 0.349 
77.99 8.227 12.96 0.015 0.996 0.165 0.524 0.238 
53.71 6.684 38.91 0.026 0.993 0.059 0.233 16.95 
24.19 8.446 68.37 0.008 0.959 0.152 36.87 
6.568 30.52 91.33 0.001 0.791 1.043 
70.29 27.98 12.95 0.743 0.972 0.005 0.024 0.064 
71.04 32.12 17.43 3.010 1.258 0.006 0.023 0.450 
83.32 9.919 11.00 0.345 0.997 0.026 0.076 0.176 
76.67 11.73 15.44 0.140 0.994 0.023 0.384 0.174 
54.82 6.848 38.91 0.025 0.995 0.050 0.190 18.194 
6.412 1.128 69.08 0.003 0.960 0.039 
4.125 0.952 71.23 0.001 0.941 0.041 
56 42.53 
60 61.90 
63.3 80.95 
66.6 78.24 
75 53.29 
80 25.78 
90 7.323 
42.54 54.10 4.823 0.980 0.0098 0.037 0.141 
33.92 27.37 4.942 0.987 0.008 0.029 0.078 
16.01 10.65 0.782 0.996 0.014 0.044 0.105 
17.37 11.41 0.185 0.991 0.011 0.040 0.099 
13.25 39.73 0.027 0.994 0.031 0.124 16.90 
10.13 74.34 0.010 0.996 1.044 33.72 
13.22 92.39 0.003 0.990 0.176 
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Appendix 9e. Effect of oligomer, R104 level on the biexponential coefficients of drug 
release using method B from microsphere prepared from RG752 (data fitted to equation 
8.1) 
Biexponential coefficients Quartile release /h 
Medium Batch R104 /A/%a/ h-1 B/%ß/ h"1 r2 25 % 50 % 75% / °C %w/w 
33 5 56 83.07 1.735 15.69 0.060 0.997 0.193 0.506 1.256 
33 11 60 80.23 1.234 16.24 0.042 0.995 0.265 0.605 1.356 
33 17 63.3 50.25 2.356 43.58 0.039 0.976 0.150 3.211 
33 23 66.6 43.12 9.231 52.35 0.038 0.983 0.752 5.321 
33 29 70 32.63 15.25 65.45 0.025 0.984 1.034 7.359 10.898 
33 35 75 28.07 17.85 68.86 0.021 0.987 0.083 14.89 
33 41 80 35.71 13.10 58.17 0.020 0.974 0.060 8.152 
35 5 56 80.60 5.416 17.45 0.958 0.998 0.059 0.153 0.339 
35 11 60 73.49 1.018 14.58 0.114 0.994 0.199 0.680 1.674 
35 17 63.3 71.09 3.237 28: 09 0.138 0.973 0.126 0.347 1.239 
35 23 66.6 59.08 4.535 34.56 0.003 0.996 0.083 0.296 
35 29 70 26.59 29.42 70.87 0.009 0.977 1.146 0.076 
35 35 75 22.76 14.95 72.72 0.072 0.994 0.137 5.193 14.80 
35 41 80 34.30 11.42 58.28 0.023 0.969 0.006 7.118 
37 5 56 89.63 7.988 
37 11 60 82.93 1.430 
37 17 63.3 73.62 7.688 
37 23 66.6 56.62 8.531 
37 29 70 34.91 3.869 
37 35 75 17.46 23.78 
37 41 80 35.20 8.558 
39 5 
39 11 
39 17 
39 23 
39 29 
39 35 
39 41 
56 72.56 
60 79.96 
63.3 66.44 
66.6 76.00 
70 72.05 
75 50.88 
80 29.69 
6.288 0.907 0.996 0.033 
7.591 -0.044 0.995 0.145 
21.25 0.272 0.997 0.040 
38.26 0.166 0.995 0.055 
57.06 0.319 0.993 2.577 
77.93 0.2715 0.999 0.162 
57.26 0.292 0.981 0.425 
0.893 0.191 
0.472 1.107 
0.119 0.336 
0.271 2.559 
0.143 0.635 
1.640 4.201 
2.793 17.46 
11.91 23.59 2.024 0.998 0.028 0.497 0.189 
9.005 14.58 0.150 0.997 0.030 0.089 0.221 
10.08 28.11 0.445 0.991 0.033 0.105 0.437 
7.980 19.32 0.309 0.996 0.037 0.110 0.292 
3.279 23.60 0.276 0.997 1.423 0.524 0.287 
2.395 42.13 0.469 0.998 0.148 0.477 1.311 
6.745 69.01 0.055 0.994 0.219 5.880 22.49 
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Appendix 9f. Effect of oligomer, R104 level on the biexponential coefficients of drug 
release using method B from microsphere prepared from RG755 (data fitted to equation 
8.1) 
Biexponential coefficients Quartile release /h 
Medium Batch R1041 A/% (x/h"1 B/% ß/h" 12 25 % 50 % 75 % 
/°C %w/w 
33 6 56 77.43 6.272 19.83 0.119 0.993 0.053 0.149 0.409 
33 12 60 57.13 2.291 32.89 0.045 0.993 0.132 0.516 6.106 
33 18 63.3 47.21 2.841 43.84 0.024 0.965 0.145 
33 24 66.6 35.27 2.541 58.35 0.009 0.989 0.541 
33 30 70 27.92 22.16 70.53 0.008 0.975 1.285 0.082 
33 36 75 20.10 17.00 76.52 0.007 0.981 2.646 
33 42 80 28.29 26.05 68.34 0.007 0.983 0.055 
35 6 56 
35 12 60 
35 18 63.3 
35 24 66.6 
35 30 70 
35 36 75 
35 42 80 
37 6 56 
37 12 60 
37 18 63.3 
37 24 66.6 
37 30 70 
37 36 75 
37 42 80 
39 6 
39 12 
39 18 
39 24 
39 30 
39 36 
39 42 
83.90 5.944 13.44 0.321 0.998 0.051 0.137 0.316 
62.73 4.061 30.97 0.060 0.994 0.079 0.266 2.620 
58.01 3.808 39.50 0.068 0.998 0.129 0.426 6.646 
29.18 9.979 65.51 0.003 0.980 0.112 
26.57 36.86 68.67 0.011 0.977 1.195 0.038 
19.14 24.32 77.81 0.005 0.984 7.090 
24.38 32.99 72.42 0.009 0.972 0.068 
82.07 16.72 10.31 0.723 0.993 0.014 0.043 0.100 
62.04 4.685 31.65 0.097 0.991 0.439 0.256 3.348 
59.86 7.110 34.55 0.105 0.995 0.300 0.185 3.069 
33.70 9.622 62.02 0.102 0.991 0.140 4.432 4.575 
14.50 30.42 83.31 0.012 0.912 1.060 0.138 19.48 
18.54 25.75 77.52 0.004 0.976 7.986 
24.48 49.06 76.00 0.005 0.973 2.480 
56 81.09 13.33 16.33 
60 72.84 10.53 24.15 
63.3 60.12 6.351 32.72 
66.6 36.17 6.906 56.66 
70 29.00 9.354 70.34 
75 15.77 31.63 80.10 
80 19.78 16.55 80.78 
1.698 0.993 0.022 0.060 0.137 
0.151 0.997 0.183 0.097 0.339 
0.150 0.991 0.055 0.204 1.798 
0.107 0.986 0.095 1.168 7.625 
0.035 0.993 0.828 
0.006 0.969 10.20 
0.005 0.989 13.90 
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Appendix 10. DSC statistics for spray-dried microspheres containing 20 % wlw rifampicin 
prepared from blends of Resomero R104 and various lactide-glycolide copolymers 
1st peak 2nd peak 
Transition / °C Transition / °C Transition / °C 
Compl. Batch Polymer/ Tg(on) Tg(the) 1/2 Cp ACp / Onset Peak Area / Onset Peak Areal polymer %w/w Jg 1 '°C J9 sV 'i 
RG502 1 
7 
13 
19 
31 
37 
RG503 2 
8 
14 
20 
32 
38 
RG503H 3 
9 
15 
21 
33 
39 
RG504 4 
10 
16 
22 
34 
40 
RG752 5 
11 
17 
23 
35 
41 
RG755 6 
12 
18 
24 
36 
42 
56 39.68 37.63 40.82 
60 40.42 38.08 41.20 
63.3 41.72 39.59 41.60 
66.6 40.85 39.85 41.38 
75 40.88 39.26 41.71 
80 39.20 36.85 40.40 
56 43.67 41.86 44.71 
60 45.09 42.74 46.06 
63.3 44.90 41.92 45.66 
66.6 44.57 43.05 44.82 
75 46.05 42.71 46.70 
80 44.47 42.13 45.64 
56 45.15 42.40 46.56 
60 45.85 43.84 47.94 
63.3 46.84 46.71 48.70 
66.6 46.01 41.77 47.02 
75 47.16 44.26 47.56 
80 46.95 44.79 48.11 
56 44.28 42.38 45.59 
60 44.67 40.22 44.63 
63.3 45.30 43.59 45.72 
66.6 45.52 42.81 45.44 
75 46.24 43.35 47.68 
80 46.00 44.47 46.53 
56 44.31 42.98 46.41 
60 46.24 45.04 48.04 
63.3 44.98 40.49 46.61 
66.6 44.72 41.50 46.56 
75 46.17 45.04 47.42 
80 44.55 40.11 45.85 
56 
60 49.46 46.75 50.04 
63.3 49.05 43.80 49.80 
66.6 49.57 43.05 50.44 
75 49.95 46.59 50.20 
80 50.05 48.32 50.92 
0.15 46.13 
0.17 46.26 
0.05 45.22 
0.15 47.27 
0.26 50.68 
0.41 47.44 
0.14 50.81 
0.20 54.00 
0.22 49.95 
0.15 52.52 
0.28 54.87 
0.31 53.82 
0.22 51.98 
0.32 54.82 
0.26 50.98 
0.30 55.83 
0.22 55.47 
0.31 53.41 
0.18 51.26 
0.33 54.03 
0.19 52.84 
0.22 55,78 
0.35 55.32 
0.20 55.07 
0.35 55.32 
0.30 56.60 
0.35 55.61 
0.40 54.93 
0.25 55.61 
0.40 53.92 
0.27 
0.51 
0.34 
0.28 
0.29 
48.21 2.67 54.74 57.41 1.61 
48.22 3.09 57.71 60.99 1.24 
47.27 2.83 57.52 60.51 0.86 
49.25 4.18 58.64 62.34 1.30 
52.31 5.17 61.38 63.71 0.52 
49.72 9.70 
52.297 3.55 57.09 59.95 1.53 
55.80 4.33 62.73 65.68 1.55 
51.52 3.21 61.26 64.45 0.89 
54.29 4.95 61.90 64.56 0.96 
56.34 5.28 63.12 65.88 0.40 
55.28 5.58 
53.49 3.16 56.84 59.61 1.46 
56.45 4.11 60.52 63.34 1.25 
53.07 3.47 61.28 64.32 0.94 
57.42 4.81 61.70 64.29 0.66 
57.00 5.22 62.88 65.55 0.19 
54.50 5.89 
52.80 3.59 57.49 60.30 1.57 
55.64 4.44 62.14 64.85 1.20 
54.29 4.52 61.11 64.04 0.91 
57.13 4.21 63.26 64.67 0.39 
56.67 5.09 64.54 66.72 0.08 
56.45 6.54 
56.49 7.21 
58.14 7.24 
57.07 7.46 
56.79 6.60 
57.00 5.62 
55.78 7.07 
58.16 59.26 
57.90 59.28 
58.80 60.15 
57.88 59.18 
58.85 60.13 
5.86 
5.64 
5.71 
4.56 
6.26 
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Appendix 11 a. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with Resomerr various lactide-glycolide 
copolymers at R104 levels of 44 %w/w total polymer containing 20 %w/w rifampicin 
Transition / °C Transition / °C 
Polymer Medium Tg(the) Tg(on) 1/2 Cp ACp / Jg' Onset Peak AH / Jg' 
I °C "°c 
RG502 33 36.12 34.46 38.37 
35 35.54 33.72 37.20 
37 36.23 34.21 37.11 
39 37.34 35.53 39.00 
RG503 33 38.56 36.56 40.85 
35 38.25 36.12 40.35 
37 37.18 36.00 39.23 
39 39.35 36.78 41.53 
RG503H 33 37.09 35.67 39.91 
35 40.21 37.48 43.08 
37 42.22 39.23 44.20 
39 40.83 38.74 42.39 
RG504 33 38.63 35.91 38.63 
35 40.55 38.00 43.15 
37 39.83 37.11 41.99 
39 40.02 35.66 41.31 
RG752 33 37.37 34.73 39.82 
35 40.41 38.01 42.65 
37 39.23 36.23 40.23 
39 38.47 36.83 40.70 
RG755 33 42.71 39.68 44.65 
35 41.07 39.13 44.10 
37 41.82 39.88 43.98 
39 39.29 36.71 42.01 
0.26 45.23 
0.25 43.93 
0.31 44.37 
0.34 44.47 
0.34 45.77 
0.38 47.99 
0.23 47.00 
0.41 48.01 
0.41 44.08 
0.45 48.57 
0.39 46.19 
0.29 47.75 
0.30 45.38 
0.41 48.27 
0.39 47.00 
0.38 46.73 
0.34 44.52 
0.44 47.14 
0.41 44.81 
0.43 44.57 
0.40 50.31 
0.38 48.57 
0.32 47.42 
0.36 47.39 
47.00 3.11 
46.14 3.21 
45.98 3.26 
46.87 4.28 
50.69 3.57 
47.99 1.73 
49.51 2.54 
50.74 2.67 
47.17 2.42 
52.03 2.48 
48.34 1.88 
50.57 2.80 
50.86 3.74 
50.24 1.47 
49.52 2.44 
49.05 2.26 
50.36 2.50 
50.07 2.68 
48.13 2.74 
48.21 3.28 
53.20 4.17 
51.76 1.13 
50.70 1.72 
50.07 0.94 
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Appendix 11b. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with various Resomer® lactide-glycolide 
copolymers at R104 levels of 40 % w/w total polymer containing 20 1 wf'w rifampicin 
Transition / °C Transition / °C 
Polymer Medium Tg(the) Tg(on) 
1/2 
Cp ACp / Jg" Onset Peak AH / Jg 
/ °C aoc 
RG502 33 37.05 34.51 38.80 0.40 
35 38.95 36.59 40.53 0.34 
37 35.84 33.45 36.99 0.31 
39 35.30 32.97 37.28 0.34 
RG503 33 33.20 34.51 36.06 0.24 
35 40.62 36.10 42.45 0.44 
37 38.16 36.29 40.09 0.41 
39 37.93 32.80 39.95 0.43 
RG503H 33 37.77 34.87 40.22 0.35 
35 40.67 37.41 43.44 0.38 
37 35.87 33.87 42.41 0.34 
39 38.71 32.86 41.43 0.32 
RG504 33 40.91 37.98 41.86 0.33 
35 40.52 36.39 41.75 0.30 
37 39.54 34.87 40.76 0.24 
39 38.36 33.00 39.90 0.23 
RG752 33 42.24 37.17 43.73 0.48 
35 39.83 37.82 41.92 0.37 
37 37.24 35.89 39.35 0.38 
39 36.32 33.28 38.69 0.39 
RG755 33 46.09 41.32 48.04 0.56 
35 47.60 45.55 49.43 0.37 
37 41.12 38.99 45.98 0.40 
39 40.27 34.19 42.57 0.40 
43.06 45.96 4.53 
44.16 46.99 3.82 
45.79 48.35 2.23 
41.73 43.85 2.94 
48.19 51.36 4.44 
46.75 51.19 3.10 
46.23 49.19 2.82 
43.80 46.20 1.68 
45.03 49.00 3.24 
46.05 49.36 2.49 
44.20 45.99 2.75 
43.16 44.85 0.60 
47.09 51.53 4.04 
46.87 51.36 2.57 
46.60 49.33 2.22 
42.65 45.36 1.10 
43.85 47.83 5.45 
45.17 47.17 1.58 
44.47 47.69 2.77 
40.95 44.34 0.84 
51.70 55.40 4.08 
50.10 55.73 2.87 
48.00 51.77 1.93 
46.61 48.89 0.35 
Appendices 
Development and characterization of biodegradable microspheres containing selected antimycobacterials David F Bain 
Appendix 11c. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with various Resomer-° lactide-glycolide 
copolymers at R104 levels of 36.6 %w/w total polymer containing 20 %w/w rifampicin 
Transition / °C Transition / °C 
Polymer Medium Tg(the) Tg(on) '/2 Cp ACp / Jg"' Onset Peak OH / Jg" 
/ °C "°c 
RG502 33 31.16 30.98 31.37 26.45 32.02 32.32 2.99 
35 30.25 31.25 31.51 21.21 32.01 32.51 2.21 
37 32.46 32.14 32.75 27.26 32.89 33.15 2.38 
39 31.43 30.95 31.52 26.57 32.25 32.47 2.95 
RG503 33 33.90 33.38 33.86 28.46 34.44 34.85 2.81 
35 32.54 30.11 31.25 26.21 32.14 32.12 2.12 
37 31.27 30.75 31.25 26.32 31.75 31.76 2.18 
39 33.09 32.45 33.00 27.70 33.76 34.06 2.01 
RG503H 33 33.99 33.48 34.30 28.74 34.75 35.29 2.06 
35 33.10 32.57 33.07 27.54 33.28 33.59 2.57 
37 32.99 32.61 33.61 28.10 33.75 34.40 2.58 
39 33.09 32.38 33.16 27.79 33.72 33.98 2.93 
RG504 33 33.82 33.32 33.82 28.42 34.44 34.77 2.63 
35 32.49 32.19 33.07 27.93 33.92 34.24 2.21 
37 32.21 31.81 32.41 27.38 34.03 33.26 2.62 
39 32.89 32.39 33.26 28.23 34.25 34.67 2.60 
RG752 33 34.27 34.12 35.04 29.50 35.59 35.98 3.08 
35 31.10 31.10 31.10 31.10 31.10 31.10 3.10 
37 30.45 29.97 30.50 25.706 31.18 31.55 2.99 
39 31.53 31.00 31.58 26.50 32.06 32.51 2.97 
RG755 33 37.50 36.98 37.60 31.54 38.02 
38.48 3.82 
35 35.24 44.13 44.87 33.76 37.07 39.85 
3.39 
37 35.19 34.79 35.40 29.67 35.78 
36.26 2.88 
39 34.71 34.39 35.13 29.46 35.34 
35.76 2.49 
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Appendix 11 d. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with various Resomer® lactide-glycolide 
copolymers at R104 levels of 33.3 %w/w total polymer containing 20 %w/w rifampicin 
Transition / °C Transition / °C 
Polymer Medium Tg(the) Tg(on) 
1/2 Cp ACp / Jg" Onset Peak AH / Jg' 
1°C 0 
cc 
RG502 33 37.57 35.30 39.22 0.39 
35 37.31 34.60 38.83 0.37 
37 35.64 32.61 37.64 0.38 
39 38.13 35.04 39.65 0.41 
RG503 33 42.81 19.09 44.02 0.44 
35 40.77 38.04 40.93 0.28 
37 42.14 37.88 44.16 0.47 
39 40.56 37.21 42.76 0.36 
RG503H 33 44.60 39.65 45.95 0.46 
35 40.83 37.33 42.62 0.41 
37 44.38 39.04 46.26 0.48 
39 43.89 39.59 44.19 0.31 
RG504 33 41.14 38.25 42.42 0.34 
35 41.12 38.24 42.36 0.37 
37 40.51 36.05 42.35 0.43 
39 42.41 38.70 43.98 0.36 
RG752 33 42.85 39.496 44.38 0.45 
35 39.45 36.27 41.28 0.44 
37 39.70 36.71 40.72 0.39 
39 40.63 36.93 42.32 0.43 
RG755 33 48.50 43.30 49.66 
0.41 
35 44.42 40.33 46.28 0.39 
37 47.17 43.51 48.81 0.46 
39 45.87 41.55 47.26 0.39 
44.72 46.64 4.28 
44.13 46.16 4.13 
41.92 43.76 3.97 
45.48 47.33 4.36 
49.27 51.86 3.66 
46.30 48.64 2.44 
47.34 49.66 3.13 
47.27 49.64 2.60 
49.98 52.95 3.67 
46.16 48.98 1.91 
46.68 49.87 3.40 
46.84 49.57 2.53 
46.97 49.39 2.26 
46.51 49.06 2.29 
46.26 49.0 2.26 
47.51 50.24 2.23 
47.54 50.33 3.60 
44.47 46.95 1.66 
44.61 47.45 2.13 
45.14 48.99 3.10 
51.71 54.45 3.31 
49.38 51.57 1.84 
50.23 52.49 1.88 
48.79 52.84 2.23 
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Appendix 11e. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with various Resomero lactide-glycolide 
copolymers at R104 levels of 25 %w/w total polymer containing 20 %w/w rifampicin 
Transition / °C Transition / °C 
Polymer Medium Tg(the) Tg(on) 112 Cp ©Cp 1 Jg" Onset Peak . \H / Jg 
1 
/ °C '°c 
RG502 33 38.05 36.22 39.55 0.37 
35 38.60 36.53 39.96 0.36 
37 38.82 36.41 40.23 0.41 
39 39.62 36.67 41.01 0.44 
RG503 33 45.54 41.67 46.19 0.36 
35 44.22 41.09 45.65 0.40 
37 45.14 42.84 45.97 0.316 
39 44.56 41.12 46.12 0.44 
RG503H 33 44.90 42.43 46.49 0.41 
35 45.27 42.88 46.90 0.40 
37 45.40 42.45 47.19 0.46 
39 45.32 41.42 46.59 0.43 
RG504 33 44.63 41.59 45.71 0.37 
35 44.59 42.00 46.04 0.40 
37 46.11 42.80 46.57 0.35 
39 45.84 43.74 46.69 0.33 
RG752 33 40.67 38.52 42.90 0.41 
35 43.63 40.94 45.45 0.44 
37 42.46 39.80 43.84 0.40 
39 41.51 38.22 41.90 0.33 
RG755 33 44.57 41.55 46.92 0.41 
35 47.66 44.76 49.08 0.34 
37 48.60 45.50 50.32 0.39 
39 48.43 43.26 48.81 0.38 
43.28 45.36 
44.69 46.61 
44.62 46.61 
44.72 46.78 
47.79 50.16 
47.91 50.16 
48.71 50.92 
48.41 50.49 
47.86 50.59 
48.32 50.82 
49.05 51.51 
48.22 50.58 
47.30 49.64 
47.89 50.16 
48.38 50.50 
47.98 50.07 
47.44 49.74 
47.06 49.91 
47.01 49.41 
46.31 48.90 
49.44 47.25 
50.94 53.34 
51.72 53.77 
51.40 53.35 
4.31 
4.50 
4.65 
4.60 
3.09 
3.16 
3.83 
3.02 
3.43 
3.29 
3.20 
2.72 
2.88 
2.82 
2.54 
2.73 
3.93 
1541 
2.74 
2.53 
1642 
3.15 
3.18 
3.09 
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Appendix 11f. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with various Resomer® lactide-glycolide 
copolymers at R104 levels of 20 %w/w total polymer containing 20 %w/w rifampicin 
Transition / °C Transition / °C 
Polymer Medium Tg(the) Tg(on) 1/2 Cp ACp / Jg' Onset Peak AH / Jg'' 
/ °C "°c 
RG502 33 39.26 35.76 40.51 0.45 44.38 
35 39.51 38.83 42.23 0.38 45.79 
37 38.71 34.23 40.89 0.41 44.22 
39 39.14 35.02 39.97 0.35 43.32 
RG503 33 44.96 41.78 45.61 0.35 51.34 
35 44.32 42.41 46.62 0.39 46.23 
37 40.70 39.81 41.70 0.30 48.11 
39 43.26 35.43 44.57 0.44 46.70 
RG503H 33 46.04 39.90 47.59 0.46 50.83 
35 41.99 39.21 43.11 0.34 44.20 
37 40.31 38.40 42.26 0.31 47.48 
39 41.94 37.53 43.93 0.40 46.10 
RG504 33 45.42 41.04 45.89 0.35 52.01 
35 45.49 42.88 47.20 0.31 46.60 
37 44.63 42.11 46.61 0.29 48.89 
39 44.51 40.49 46.12 0.43 46.03 
RG752 33 48.45 45.04 49.25 0.37 55.65 
35 40.92 39.32 43.20 0.32 44.47 
37 41.23 39.00 43.10 0.30 46.70 
39 40.90 37.55 42.42 0.42 44.74 
RG755 33 42.42 38.03 44.24 0.47 51.70 
35 48.11 45.23 49.23 0.38 48.40 
37 47.97 44.23 48.97 0.34 51.51 
39 47.26 43.18 48.76 0.30 49.80 
47.32 6.29 
48.35 2.23 
45.98 6.24 
45.54 4.91 
53.05 5.29 
49.19 2.82 
49.70 4.24 
48.75 4.81 
53.83 4.91 
45.99 2.75 
50.02 3.54 
48.91 2.89 
53.71 5.37 
49.33 2.22 
50.37 4.13 
47.69 2.43 
57.24 4.98 
47.69 2.77 
49.70 4.17 
47.38 2.05 
53.70 5.98 
51.77 1.93 
53.07 4.04 
51.59 2.89 
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Appendix 11g. DSC data of recovered residue from release studies performed at various 
temperatures. Microspheres prepared with various Resomer® lactide-glycolide 
copolymers at R104 levels of 10 % w/w (batch #25 - 28) and 30 % w/w (batch #29 & 30) 
total polymer containing 20 %w/w rifampicin 
Transition I °C Transition I °C 
Polymer Medium Tg(the) Tg(on) 
/ °C 
RG502 33 39.80 35.80 41.12 0.47 
35 40.58 36.25 41.81 0.46 
37 37.93 36.10 39.83 0.41 
39 42.47 39.80 44.39 0.34 
RG503 33 45.18 40.79 46.51 0.43 
35 47.53 45.31 48.43 0.27 
37 44.72 43.82 46.34 0.26 
39 44.86 41.74 45.20 0.22 
RG503H 33 47.32 44.56 48.39 0.34 
35 45.40 43.12 46.43 0.31 
37 40.12 39.23 44.21 0.34 
39 35.22 35.29 39.08 0.37 
RG504 33 45.70 41.90 46.44 0.33 
35 46.40 43.55 47.66 0.32 
37 43.72 42.80 47.03 0.32 
39 45.84 42.33 46.74 0.30 
RG752 33 42.66 39.87 44.25 0.40 
35 42.98 39.82 44.37 0.40 
37 40.17 37.82 42.11 0.39 
39 38.02 35.99 40.14 0.37 
RG755 33 48.01 43.68 49.40 
0.40 
35 49.20 46.91 50.26 0.27 
37 46.13 44.23 49.11 0.42 
39 44.68 41.58 47.06 0.41 
1/s Cp ACp / Jg" Onset Peak \H / Jg' 
"°C 
44.28 46.99 6.93 
42.00 44.80 1.67 
44.02 45.99 6.44 
47.82 49.57 3.07 
52.41 53.88 6.44 
52.13 53.70 4.79 
48.35 49.68 4.87 
47.18 48.73 4.10 
53.04 54.38 5.85 
51.40 52.86 5.83 
48.90 50.37 4.71 
42.78 44.85 5.57 
52.02 53.53 6.03 
52.38 53.70 5.34 
48.46 49.85 4.63 
46.99 48.73 4.10 
51.00 53.19 4.94 
48.43 50.36 2.81 
48.45 47.23 2.10 
43.31 45.36 1.53 
54.73 56.40 4.41 
55.50 56.90 3.35 
50.72 52.39 3.12 
48.85 50.57 1.62 
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Appendix 12. Effect of polymer composition on the Arrhenius derived activation energies 
of initial drug release using method B from microsphere prepared from various blends of 
Resomere R104 and lactide-glycolide copolymers 
Mean RSD 
Compl. polymer Batch R104 / (%w/w) Ea / kJ In A Ea r2 In A 
RG502 1 44 113.1 0.236 46.99 34.5 
7 40 155.9 0.586 63.57 18.6 
13 36.6 75.92 0.764 31.87 17.1 
19 33.3 113.9 0.932 46.63 6.74 
31 25 66.94 0.847 28.34 23.5 
37 20 111.9 0.846 43.62 5.46 
RG503 2 44 
8 40 
14 36.6 
20 33.3 
33 25 
39 20 
RG503H 3 
9 
15 
21 
33 
39 
RG504 4 
10 
16 
22 
34 
40 
RG752 5 
11 
17 
23 
29 
41 
RG755 6 
12 
18 
24 
36 
42 
44 
40 
36.6 
33.3 
25 
20 
44 
40 
36.6 
33.3 
25 
20 
44 
40 
36.6 
33.3 
25 
20 
44 
40 
36.6 
33.3 
25 
20 
63.1 31.5 
8.04 18.0 
0.94 16.0 
7.06 6.24 
18.4 21.8 
9.45 3.65 
131.3 0.632 54.2 32.2 28.5 30.4 
206.5 0.672 83.4 16.8 28.2 16.3 
74.46 0.156 31.0 5.42 12.3 5.19 
110.9 0.684 45.3 4.13 10.3 3.96 
101.6 0.985 41.1 1.61 1.68 1.52 
90.83 0.971 32.6 5.82 2.58 6.38 
211.3 0.811 85.27 
119.4 0.270 48.94 
135.4 0.962 54.55 
149.4 0.961 59.94 
97.85 0.866 38.86 
71.27 0.986 28.33 
188.4 0.863 
154.4 0.668 
224.8 0.994 
149.3 0.990 
167.3 0.751 
81.31 0.06 
243.8 0.920 
289.9 0.859 
227.3 0.918 
113.0 0.654 
219.5 0.471 
99.84 0.988 
130.9 
127.8 
101.7 
49.64 
76.19 
38.62 
0.781 
0.932 
0.525 
0.770 
0.902 
0.095 
76.33 
63.23 
89.49 
60.41 
67.04 
33.03 
79.14 
169.1 
90.07 
45.77 
83.06 
36.71 
53.09 
74.35 
41.18 
26.50 
32.84 
-11.67 
15.15 5.65 
25.5 69.8 
2.25 0.57 
1.48 4.43 
22.2 0.34 
2.01 0.30 
2.10 
25.4 
14.4 
1.53 
56.9 
17.9 
9.04 
86.4 
1.82 
0.49 
1.92 
14.1 
0.98 
85.4 
56.6 
94.5 
3.96 
64.9 
14.80 
24.8 
2.30 
1.40 
21.6 
2.03 
2.54 1.97 
32.6 24.4 
0.20 13.9 
1.10 1.49 
31.9 55.2 
9.52 16.8 
1.16 
0.40 
0.38 
47.8 
7.42 
1.00 
29.6 
0.36 
1.73 
0.32 
1.92 
14.4 
17.6 
3.39 
63.8 
21.7 
2.78 
107 
0.96 
3.98 
54.2 
29.5 
3.48 
-84.4 
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Appendix 13. Effect of storage time on the biexponential coefficients of drug release 
using method B from microsphere prepared with 25 %w/w R104 and a range of 
Resomer® lactide-glycolide copolymers (data fitted to equation 8.1) 
Biexponential coefficients Quartile release /h 
Batch Polymer Time A/%a/ h"1 B/%0/ h"1 r2 25 % 50 % 75 % 
31 RG502 14 78.76 11.16 15.83 0.439 0.997 0.024 0.073 0.181 
40 80.04 11.55 14.27 0.539 0.995 0.023 0.069 0.166 
120 76.44 7.785 14.96 0.330 0.992 0.030 0.102 0.259 
32 RG503 14 49.97 5.469 47.78 0.027 0.996 0.111 0.581 23.30 
40 55.85 4.940 40.69 0.028 0.997 0.099 0.358 19.73 
120 63.61 4.882 35.20 0.027 0.998 0.096 0.298 13.90 
33 RG503H 14 43.58 2.399 54.15 0.047 0.997 0.293 1.980 16.35 
40 53.61 3.587 43.61 0.033 0.997 0.159 0.627 16.66 
120 62.53 2.117 35.49 0.045 0.989 0.215 0.667 7.781 
34 RG504 14 54.83 8.337 38.91 0.024 0.995 0.050 0.190 18.56 
40 58.81 7.332 35.78 0.017 0.996 0.055 0.192 20.74 
120 62.64 7.077 33.50 0.017 0.998 0.059 0.190 17.87 
35 RG752 14 17.46 23.76 77.93 0.271 0.999 0.162 1.640 4.2015 
40 18.78 23.43 76.65 0.251 0.998 0.134 1.704 4.467 
120 22.53 8.803 72.31 0.342 0.997 0.171 1.086 3.096 
36 RG755 14 18.54 25.75 77.52 0.004 0.976 7.956 
40 18.37 23.24 77.10 0.004 0.969 7.207 
120 18.95 16.71 78.01 0.007 0.984 6.472 
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P2.001 PREPARATION OF RIFAMPICIN-LOADED BIODEGRADABLE MICROSPHERES DF Bain. DL Minday, PJ Cox 
School of Pharmacy, The Robert Gordon Univrrsity, Schoolhip, Aberdftn, A89 1 FR. UK 
Rifampicin is often taken orally over prolonged periods for the treatment of mycobactenal infections. 
p 
However compliance is poor, resulting in treatment failure and drug resistance. To overcome this 
problem, biodegradable polylactide(PLA) and polylactide-co- 
glycolide(PLGA) may be useful in the development of controlled 
release parenterals containing antimycobacterial drugs. Rifampicin- 
loaded microspheres were produced utilising a solvent evaporation 
technique. This work examines the effect of process variables on 
microsphere characteristics and in vitro release. Efforts to maximise 
rifampicin loading included presaturation of continuum, optimisation of 
pH and adjustments to phase volumes and drug: polymer(D: P) ratios. 
A continuum of unbuffered 1% polyvinyl alcohol at pH 5.0 minimised 
partitioning of dispersed rifampicin into the continuum. By adjustment 
of continous: disperse phase volume ratio to 3: 1, loadings of 35%w/w 
were achieved at a D: P ratio of 1: 1. When comparing microspheres 
prepared with drug free continuum, presaturation had a significant 
effect on loading depending on D: P ratio. At D: P 0.2: 1, loading 
increased threefold, whereas at D: P 1: 1 loading paradoxically 
decreased. This. was due to dissolution of crystals formed at the 
surface during evaporation at the stage of microsphere washing. With 
increasing D: P ratio there was an associated sharp increase in both 
initial `burst' and overall release rate. Scanning electron micrographs 
show a porous microsphere surface accounting for these observations. 
After a modest `burst' of 15% loaded nfampicin (D: P ratio 0.2: 1) 
release was sustained for about 30 days. These profiles were 
observed for both PLA and PLGA, release being faster from the latter. 
Microsphere size was largely independent of process variable (30- 
100µm), PLGA prepared microspheres being consistently smaller than 
PLA for comparable conditions. In conclusion, PLGA/PLA 
microspheres with suitable surface characteristics and release profiles 
were prepared using low D: P ratios. Efforts to maximise 
loading in 
order to minimise dose volume have resulted 
in predominantly `burst' 
with little sustained release. 
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EFFECT OF RESIDUAL SOLVENT ON THE CHARACTERISTICS OF BIODEGRADABLE 
MICROSPHERES PREPARED BY SPRAY-DRYING 
D. F. Bain', D. L. Munday' and A. Smith2 
'School of Pharmacy, The Robert Gordon University, Aberdeen, AB10 1FR, United 
Kingdom 
2 Knoll Pharmaceuticals, Pennyfoot Street, Nottingham, NG 11 GF, United Kingdom 
Introduction 
Spray-drying has emerged in recent years as a convenient one-step procedure for producing 
microspheres of predictable drug loading and release characteristics'. Typically, however, 
this procedure results in reduced product yields when compared with traditional 
emulsification-solvent-evaporation as a preparative technique2. We have demonstrated that 
with judicious choice of organic solvent and processing conditions, yields in excess of 66% 
w/w theoretical can be consistently achieved at the expense of high residual solvent loads. 
Reports of residual solvent have considered only the toxicological consequences3' °, using 
USP limits as markers of acceptability4. No reports exist of the influence of residual solvent 
on the physicochemical characteristics of biodegradable microspheres. 
The purpose of this work is to demonstrate the influence of the solvent choice on the 
microsphere characteristics prepared by spray-drying blends of biodegradable poly-(D, L- 
lactide). Blends of polymer have been previously shown to readily modulate rifampicin (RIF) 
release from microspheres thus prepared'. 
Experimental Methods 
Materials, poly(D, L-lactide) Resomer' R104 (MW=2000) and R202H (MW=9000) were 
purchased from Boehringer Ingelheim (Ingelheim, Germany). Rifampicin was gifted by 
Lepetit (Milan, Italy). All other chemicals were of reagent grade or better. Microspheres were 
prepared from co-solutions (3 % w/v total solid) comprising 24 % w/w R104,56% w/w 
R202H and 20% w/w RIF, which were sprayed through the nozzle of a Buchi" Minispray- 
drier (Flawil, Switzerland) according to Table 1 at a constant flow rate of 600 NL. h 1. 
Microspheres were vacuum dessicated and characterized at predetermined intervals as 
follows. Thermal characteristics of the microspheres and residual solvent were examined by 
DSC (Pyris 1, Perkin Elmer, Connecticut, USA) at a scanning rate of 10 °C min-' and 
gravimetrically respectively. Release of RIF was studied using the USP paddle method 
(Sotax AT7, Basel, Sweden) in 500 cm3 Serensens buffer (pH 7.4) (modified) containing 
0.1 % w/v `Tween' 80 at 37 °C at 100 rpm with UV detection at 330 nm (the isobestic point of 
RIF and its major quinone degradation product). 
Table I. Preparation conditions for spray-drying 
Solvents Spray parameters Yield/ g 
Batch Type Ratio Inlet temp / Aspiration / (1.5g 
°C % total) 
1 DCM 100% 40 100 0.93 
2 DCM: ACT 21 40 100 0.32 
3 DCM ACT 2.1 40 50 0.03 
4 ACT 100% 40 100 003 
5 DCM. CFM 11 40 100 0.84 
6 DCMCFM 1.1 50 100 0.62 
7 CFM. ACT 2.1 40 100 0.54 
Key DCM, dichlorornethane: ACT. acetone. CFM. chloroform 
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Results and Discussion 
The release profiles in Figure 1 and Figure 2 of microspheres prepared with compositionally 
identical polymer blends highlight the dramatic influence of solvent and storage period 
respectively on their release characteristics. The results are explained below in terms of the 
mechanism of microsphere formation and the plasticizing action of residual solvent, amounts 
of which are listed in Table 2. Thermograms in Figure 3 revealed no discernable thermal 
events for freshly prepared products, whereas upon dessication an endotherm rapidly 
developed, the magnitude of which was time-dependent. Moreover, the position of this 
endotherm and the underlying glass transition, Tg, shifted upscale as the plasticizing action 
of residual solvent diminished with increased storage time. Residual solvent load, 
determined the magnitude of this shift, which in parallel increased as the boiling point of the 
solvent system increased and, in contrast, the drying temperature decreased. 
2 3 a 5 6 ý 8 
Time' h 
Figure 1. Release profiles of RIF from microspheres freshly prepared from different solvents 
(adjacent legend indicates batch reference) 
The thermal behaviour of blends of low and moderate MW PDLA has been identified as a 
critical determinant of drug release'. Other important factors include matrix hydrophilicity and 
structure. For compositionally identical microspheres, intrinsic hydrophilicity should however 
remain ostensibly constant. Thus, the differences in release of RIF with change in process 
conditions can be attributed to variation in matrix architecture and thermal characteristics. 
Upon incubation, microspheres slowly hydrate. Water ingresses slowly, causing matrix 
softening until the softening temperature corresponds to that of the dissolution medium, 
when water uptake accelerates promoting drug release. This mechanism accounts for the 
sigmoidal release pattern in Figure 2 from microspheres stored for 10 days prepared with 
DCM and DCM: CFM blends. These comprised induction, accelerated and slow terminal 
phases. For drug release in Figure 1, however, from microspheres immediately after 
preparation with high residual solvent (Batch 1& 5), the softening temperature was close, if 
not below that of the dissolution medium, resulting in a rapid burst with a short induction 
period. However, as residual solvent is lost under vacuum, the burst reduces and the 
induction period lengthens as polymer chain rearrangement creates an ordered structure, 
elevating the Tg, which retards RIF release. In contrast, release from microspheres prepared 
from ACT was independent of storage time, release accelerating as the proportion of the 
ACT used in the microsphere preparation increased (batch 2 c. f 4). 
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Figure 2. Effect of storage time on RIF release 
(legend indicates batch reference and period of storage) 
Solvent choice and drying temperature affects the microsphere structure through their influence 
on solvent evaporation rate, which, in turn, affects matrix deposition rate. In general terms, 
highly volatile ACT rapidly evaporates to yield microspheres with a highly porous structure which 
also explains the low solvent residue measurements and the rapid release from these 
formulations irrespective of storage time. In contrast, reduced microsphere formation rate with 
CFM or DCM, particularly at lower inlet temperatures, results in a more coherent matrix. High 
matrix tortuousity thus formed explains their tenacious retention of organic solvent and the 
correspondingly slower release of RIF therefrom. The high solvent residue does however 
facilitate molecular mobility within the matrix allowing greater order to be achieved during 
solvent removal. This feature further attributes for the slower release rate from microspheres 
with high original residual solvent, which accelerates release initially, before dessication, through 
a matrix plasticizing action. Progressive elevation of the softening temperature is paralleled by 
an increase in the induction period. This feature is consistent with the mechanism of drug 
release described above. 
Table 2. Residual solvent analysis 
Batch Residual solvent / ppm x 10-3 
Storage/day 05 10 
1 39.43 19.47 1.022 
2 2.460 1.406 0.626 
3 2.457 1.307 0.507 
4 1.219 0.719 0.456 
5 36.91 8.017 2.697 
6 26.14 7.019 2.180 
7 34.26 9.012 1.483 
Variation in yield of production can be attributed to microsphere architecture, solvent residue 
and the Tg of the microsphere matrix. Rapid solvent evaporation of ACT produces low density 
porous particles with low solvent load which are readily exhausted from the apparatus. High 
solvent residue lowers the Tg which would promote product adherence to the glassware were it 
below that of the drying air. In contrast, high solvent residue is associated with formation of a 
more coherent matrix with a greater density which reduces the proportion of particles exhausted 
from the glassware, whilst promoting particle deposition in the apparatus collector. Considerable 
residue of relatively dense solvents such as CFM and DCM, further contributes to individual 
particle density and promotes high microsphere yields. 
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The results in Table 1 and the release profiles noted in Figure 2 support this pattern of product 
formation and yield which collectively indicate high product yields are promoted at the expense 
of considerable solvent loads. However, prolonged drying can effectively lower these to 
acceptable levels3. 
Figure 3. Thermograms after various storage times 
(legend indicates batch, storage time) Peak temperature in °C 
Conclusion 
Moderate evaporation rates provided by DCM appear to promote the formation of coherent 
microspheres with relatively slow release rate whilst providing high product yield. The effect of 
high solvent residue on microsphere release character might however result in erroneous 
conclusions being drawn where adequate dessication has not been perfomed. Overall, solvent 
choice for spray-drying has a considerable influence on final microsphere characteristics and 
should be carefully considered from both a technological in addition to a traditional toxicological 
view point. 
Acknowledgement 
The financial support of Knoll Pharmaceuticals is gratefully acknowledged. 
References 
1. Bain D. F, Munday D. L., Cox P. J., and Smith A. J. Pharm. Pharmacol., 49, (S4), 29, 
1997. 
2. Pavanetto F., Conti B., Genta I, & Giunchedi P., Int J Pharm, 84,151-159,1992. 
3. Bitz C. & Doelker E. Proc. 1st World Meeting APGI/APV, Budapest, 409-410,1995. 
4. Ratter G. & Jobmann M., Drugs made in Germany, 37(4), 115-119,1994. 
95 
Cbnrnnaiications 302 
Development and characterization of biodegradable microspheres containing selected antimycobacterials 
MECHANISMS OF RIFAMPICIN RELEASE FROM SPRAY-DRIED BLENDS 
OF BIODEGRADABLE POLY(D, L-LACTIDE) 
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Introduction Hydration studies were performed gravimetrically on 
Rifampicin (RIF), in combination with other anti- recovered microspheres. Microsphere granulometry 
mycobacterials, represents the mainstay of effective was determined by Coulter Multisizer (Coulter 
tuberculosis therapy. However, hepatotoxicity can limit Electronics Ltd., Luton, UK). 
its application when administered systemically". 
Biodegradable drug-loaded microspheres have been 
investigated as a technique to target chemotherapeutics to 
the lung whilst providing a sustained release and thus 
therapeutic action12). Spray-drying is emerging as a 
convenient one-step continuous procedure for 
reproducibly preparing large quanitiies of microspheres 
of predictable character and drug loading"'. Moreover, 
the granulometry of these products renders them 
ameniable to alveolar penetration, allowing a reduction in 
dosage and fewer systemic side-effects'21. Previously we 
demonstrated the utility of blends of poly(D, L-lactide) 
(PDLA) as a means to reduce the `burst' of drug release, 
and accelerate the terminal phase characteristic of low 
and high molecular weight PDLA respectively, when 
used individually"'. The mechanism of drug release from 
these hydrophilic matrix systems is considered here. 
Experimental 
Materials 
, 
Poly(D, L-Iactide) Resomer® R104 and R202H were 
purchased from Boerhinger Ingelheim (Ingelheim, 
Germany). Rifampicin was gifted by Lepetit® (Milan, 
Italy). All other chemicals were of reagent grade or 
better. 
Methods 
Microsphere preparation 
Co-solutions in dichloromethane (DCM) of R104 and 
R202H containing 20% w/w dissolved RIF were sprayed 
through the nozzle of a Buchi® Minispray-drier (Flawil, 
Switzerland) according to Table I under the conditions: 
Inlet temp., 40°C; Outlet, 35°C, Aspiration, 100%; flow 
rate, 600 NL h-'. Microspheres were vacuum dessicated 
before characterization. 
Microsphere characterization 
Thermal behaviour of microspheres was examined by 
DSC at a scanning rate of 10°C min-' (Pyris I, Perkin 
Elmer, Connecticut, USA). Release of RIF was studied 
using the USP paddle method (Sotax AT7, Basel, 
Sweden) in 500 cm ' Sorensens buffer (pI1 7.4) 
(modified) containing 0.1% `Tween' 80 between 33-39°C 
at 100 rpm. Residual microspheres post-dissolution were 
recovered by filtration and also thermally characterized. 
Table 1. Composition of 20% w/w RIF-loaded 
microspheres 
Polymeric composition / (% w/w) 
Batch R104 R202H 
1 36 64 
2 32 68 
3 31 69 
4 30 70 
5 29 71 
6 28 72 
7 24 76 
8 20 80 
Results and Discussion 
Particle size distributions typical of the technique were 
relatively monodisperse, with mean diameter, d5o, 
increasing from 2.6-3.3 µm as the proportion of R202H 
increased. In addition, 90% of particles were <10 µm, 
independent of the encapsulating polymer blend. These 
coincided with the target range of 0.5-3.0 µm for alveolar 
deposition [2]. 
Temperature / °C 
Figure 1. DSC thermograms or microspheres (legend 
indicates batch, time of dissolution) 
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The utility of combinations of low and moderate 
molecular weight PDLA to modulate release of RIF 
microspheres has been established 
[3). The criticality of 
matrix composition and other experimental variables on 
drug release within a narrow range of polymer 
composition was, however, highlighted in that work. A 
number of factors have been cited as promoting drug 
release by diffusion including 1) depression of glass 
transition, (Tg), of the polymer network; 2) pore 
formation and; 3) polymer degradation which itself 
promotes 1) and 2) above. Matrix hydration associated 
with these changes accelerates the flux of entrapped drug 
molecules when compared with diffusion through an 
amorphous dehydrated network. 
Figure I shows the thermograms of 
microspheres following 14 days vacuum dessication. 
Typical thermograms registered a glass transition 
underlying an endothermic peak representing formation 
of a structured order within the matrix which developed 
as residual DCM was removed. 
Figure 2 shows the release profiles from 
microspheres at 37°C. Minor changes in polymer 
composition showed a significant effect on drug release 
rate around a critical composition. 
Figure 2. Release profiles for microspheres at 37°C 
The modulation of release rate by this technique was 
attributed to modification of the rate and delay in 
hydration of the matrix with minor variation in matrix 
composition. As water ingresses the thermal character of 
the polymer changes with the plasticizing action of water 
and the matrix softens. Once the softening temperature, 
Tg, of the matrix decreases below the temperature of the 
release medium, water uptake accelerates promoting 
release by diffusion. This proposed mechanism is 
supported by the sigmoidal release patterns, whereby 
after an initial induction period, further water uptake 
propogates water penetration deep into the microsphere 
matrix. In figure 1, the time-dependent destruction of the 
ordered matrix structure is indicative of increased 
hydration. However, with batch 6, the endothermic peak 
persisted indicating partial preservation of matrix 
integrity. These data are corroborated by the hydration 
data in Figure 3. 
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Figure 3. Hydration data for microspheres during 
dissolution at 37°C (batch adjacent to each line) 
The importance of matrix softening and hydration to the 
release mechanism was further supported by the first 
order release rate constants at different dissolution 
medium temperatures listed in Table 2. These data 
showed the anticipated pattern of increased release rate as 
temperature and proportion of low MW PDLA increased. 
The dramatic multi-fold increase in the fractional rate 
constant occurred at higher temperatures as the 
proportion of higher MW and hydrophobic R202H 
increased which is commensurate with increases in 
matrix Tg . 
However, the Tg of the samples assessed did 
not correspond with the temperature of the dissolution 
medium. During dessication, the Tg partially recovered 
upon removal of aqueous plasticizer. Further thermal 
studies of hydrated samples are therefore required to 
confirm the correspondence of accelerated drug release 
with matrix softening. 
Table 2. First order release data for selected 
microsphere blends 
tat order rate constant (xt )/ h- 
Temp /°C 33 35 37 39 
Batch 
1 1.35 11.05 122 505.5 
2 1.19 7.69 32.80 142.8 
3 0.903 4.83 33.40 119.1 
4 0.461 4.55 23.25 98.80 
5 0.942 2.075 21.25 79.55 
6 0.880 2.855 17.00 79.55 
7 0.605 2.19 2.64 11.70 
8 0.237 0.995 1.995 7.87 
*rz>_ 0.980, (10 -< 80% release) 
Conclusion 
Microspheres of the required granulometry for intra- 
pulmonary delivery were readily prepared by spray- 
drying. The auto-hydration mechanism linked to the Tg 
of the hydrophilic microspheres should facilitate and 
provide controlled drug release in the low volume of 
liquid which prevails in the lung. 
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The substitution of dichloromethane and chloroform 
with less toxic acetone (Rafler & Jobmann, 1994) 
and halothane (Guiziou et al, 1996) has been 
proposed for the preparation of biodegradable 
microspheres. However, little consideration has 
been paid to the technological consequences of such 
substitution on drug release. This report describes 
thermal characterization of compositionally 
identical microspheres prepared from different 
organic solvents and its correlation with other 
determined characteristics. 
Microspheres were prepared from solutions of the 
(co)solvents listed in Table 1 (3 % w/v total solid) 
comprising 24,56 and 20 % w/v poly(D, L-lactide) 
Resomer® R104, R202H (Boehringer Ingelheim) 
and rifampicin (Lepetit) respectively. DSC (Pyris 1, 
Perkin Elmer, USA) was performed at various 
scanning rates to compute Arrhenius derived 
activation energies (Ea) of glass transition (Tg). 
Other thermal data in Table I was gathered at a rate 
of 10 °C min 1. Solvent residue and drug release 
were determined as described previously (Bain et 
al., 1998). 
Table 1. Preparative conditions, thermal and residual solvent data 
plasticizing action. This ageing process can be 
followed by the up-scale shift of the Tg and the 
progressive development of an anomalous 
endotherm. These changes marked the loss of 
excess enthalpy generated by rapid microsphere 
formation during spray-drying. After exhaustive in 
vacuo drying, activation energies in Table I for the 
Tg were inversely related to the enthalpy of the 
endotherm. The latter parameter was, in contrast, 
directly related to the level of solvent residue which 
facilitates molecular movement associated with 
relaxation and Tg elevation. 
x 
b 
ý 
ü 
Ti- /n 
Batch Solvent(s) Tg enthalpy E. residue / 
/kJgý /Jg ppm 
zlo' 
nature ratio 
I UCM 100% 58.3 4.15 5.47 60.69 
2 HAL 100% 49.9 5.57 3.50 125.51 
3 ACT 100% 423 3.69 7.59 24.73 
4 DCM: CFM I. I 58.1 560 4.61 93.52 
5 DCM: ACT 2: 1 51.7 5.40 4.11 40.50 
6 CFM: ACT 2: 1 53.5 6.74 3.84 106.29 
Key DCM, d, chloromeih ,, e ACT, -etne (FM, hh, ro/arm, HAL, halothane 
Solvent change led to variation in thermal 
behaviour and release character (see Figure 1) 
which can be related to the microsphere formation 
mechanism (Bain et al, 1998). In general, rapid 
polymer deposition associated with highly volatile 
solvents e. g. ACT produced a porous matrix and 
rapid drug release, whereas other solvents resulted 
in a slower release. However, high and persistent 
solvent residue permitted significant polymer 
enthalpy relaxation upon storage due to its 
161 
Figure 1. Release profiles of microspheres 
Relaxation corresponds to the formation of a more 
stable microsphere matrix. Thus, based on this 
factor, those prepared from HAL (2) and CFM: ACT 
(6) should result in slowest drug release. However, 
related to relaxation, the Tg of the matrices formed 
proved a more reliable indicator of microsphere 
stability, release rate decreasing as Tg increased. 
Clearly, other factors influenced by the drying 
process, such as matrix density, have a role in 
determining the magnitude of the Tg and relaxation 
recovery, which in turn modulate drug release. In 
conclusion, solvent selection for spray-drying has 
significant technological implications in addition to 
toxicological considerations. 
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